




The World Association of Radiopharmaceutical and Molecular Therapy

THE LEGACY



Irene J. Virgolini



“WARMTH is not the domain of one person.

I am happy I was able to realize my dream and create a world-class product.

We all have to move on and so does the WARMTH.

Irrespective who is running it, I am sure it will continue to grow.

Hiccups, we can all have in life, but we all should learn from them and move on.

WARMTH too will overcome its hiccups and will continue to warm our hearts.

And yes, I am very much a part of it - and it's a part of me which will never go away.”

Ajit K. Padhy

(Excerpt of the lecture at the 6th Tyrolean Congress of Nuclear Medicine, June 30 - July 2, 2011)



Dedication

To the Late **Ajit K. Padhy**

(+August 22, 2013)

New Dehli, London, Vienna, Singapore

To All Friends and Members of The WARMTH

To All Friends to Come

Irene Virgolini

Innsbruck, December 2019

Table of Contents – Part I

	Page
Ajit Padhy - in memoriam	6-11
Preface	12-13
The Logos of The WARMTH	14
„Theragnostics“ or „Theranostics“?	15
The Foundation of The WARMTH and the World Journal	16-18
Bylaws of WARMTH Inc.	19-30
Global Distribution of The WARMTH	31-32
The Governing Body of The WARMTH	33-38
The ICRTs of The WARMTH	39-259
The Structure of the ICRTs	39-46
1 st ICRT-2005, Limassol, Cyprus	47-52
2 nd ICRT-2007, Ulaanbaatar, Mongolia	53-60
3 rd ICRT-2008, Goa, India	61-74
4 th ICRT-2009, Cartagena, Colombia	75-90
5 th ICRT-2010, Capetown South Africa	91-98
6 th ICRT-2011, Ho Chi Min City, Vietnam	99-122
7 th ICRT-2012, Levi, Finland	123-140
8 th ICRT-2013, Manila Philippines	141-166
9 th ICRT-2014, Cancun, Mexico	167-174
10 th ICRT-2015, Innsbruck, Austria	175-196
11 th ICRT-2016, Kerala, India	197-212
12 th ICRT-2017, Vienna, Austria	213-224
13 th ICRT-2018, Melbourne, Australia	225-232
14 th ICRT-2019, Nanjing, China	233-256
15 th ICRT-2020, Coxbazar, Bangladesh	257
16 th ICRT-2021, South America	258
17 th ICRT-2022, Kyoto, Japan	259

Table of Contents – Part II

	Page
ISRT's and supported Symposia and Congresses of The WARMTH	260-354
2008 New Delhi, India, 9 th Asia Oceania Congress of Nuclear Medicine and Biology	261-262
2010 Singapore, 19 th Scientific Meeting of the Radiological Society & College of Radiologists	263-273
2011 Singapore, Singapore Nuclear Medicine Update	274-282
2011 Kuwait, WARMTH International Workshop on Radionuclide Therapy & Kuwait Society of Nuclear Medicine	283-288
2011 Bad Berka, Germany, 1 st World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy (PRRNT)	283-302
2013 Yangon, Myanmar, National Symposium in Routine Clinical Practice	303-306
2015 Jeju, Korea, 11 th AOCNMB and 54 th Autumn Meeting of the Korean Society of Nuclear Medicine	307-310
The WARMTH and the Society of Nuclear Medicine and Molecular Imaging	311-323
2016 San Diego, USA, Therapy Center of Excellence	312-314
2017 Denver, USA, Therapy Center of Excellence	315-316
2018 Philadelphia, USA, Therapy Center of Excellence	317-322
2019 Anaheim, California, USA, Therapy Center of Excellence	323
2018 22 nd Annual Scientific Meeting of the Indonesian Society of Nuclear Medicine	324-327
2018 Helsinki, Finland, ISRT	328-338
2019 Novi Sad, Serbia, ISRT and 3 rd Serbian Meeting on Hybrid Imaging and Molecular Therapy	339-345
2019 Limassol, Cyprus, 20 Years Anniversary of Cyprus SNM	346-354
Other Meetings where WARMTH Friends find Each Other	355-356
WARMTH Scientific Projects	357
1. Project: Liver-Targeted Therapy	358-372
2. Project: Thyroid Diseases	373-378
3. Project: PRRT	379-381
4. Project: PRLT	382-387
World Journal of Nuclear Medicine	388-396
The World Theranostics Academy	397-408
The WARMTH and the Patients	409
The WARMTH and the IAEA	410
Addenda - Links	411
The Sponsors of The WARMTH	412



Editorial

Coming of Age as an Organization: WARMTH

World Association of Radiopharmaceutical and Molecular Therapy was inaugurated in Cartagena, Colombia on November 7, 2009 at a glittering ceremony, soon after the dissolution of World Radiopharmaceutical Therapy Council (WRPTC). WARMTH was practically an up-gradation of WRPTC. The members of the governing body of the dissolved WRPTC were requested to continue in the governing body of WARMTH to achieve smooth transition from council to a global association. WARMTH was duly registered as an International Association in India under the Societies Registration Act XXI 1860 (Government of Delhi) on August 25, 2010. Today, after two and half years of its inception, WARMTH has a total Paid Membership of 330 from all over the world, its own constitution, own journal, and a bank account. Our signature scientific activity, the International Conference on Radiopharmaceutical Therapy (ICRT), has become an Annual Global Event and is growing from strength to strength every year. We have held ICRTs at Cyprus, Mongolia, India, Colombia, South Africa, Vietnam, and Finland, covering most major regions of the world. The last ICRT, which was held in Levi, Finland, was a great success—probably one of the rarest of rare occasions when an International Congress in nuclear medicine ever held in an Arctic environment.

World Journal of Nuclear Medicine (WJNM), WARMTH's Official Journal has been making slow but steady progress. The journal has gained enough credibility to be considered good enough for getting indexed in the PubMed.

Within a few years of its creation, WARMTH has grown in stature and respect. We have been able to forge an alliance with the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and, henceforth, WARMTH will join SNMMI in organizing one Annual SNMMI-WARMTH Symposium on Radionuclide

therapy in conjunction with the Annual Meeting of SNMMI.

In the research front, we are in the process of initiating a multi-centre study on Liver Cancer Therapy using Re-188 (AHDD) Lipiodol. This project has the potential to put WARMTH at the forefront of scientific international organizations dealing with nuclear medicine.

WARMTH successfully held its first real elections, where the members voted and elected their own Governing Body (2013–2014) through secret ballots. The members of the new Governing Body are as follows: President - Prof. Richard P. Baum (Germany), Secretary - Dr. Emerita Barrenechea (Philippines), Treasurer - Dr. Parth S. Chaudhary (India), President Elect - Dr. Suresh Srivastava (U.S.A.), Past President - Prof. A. K. Padhy; and Members - Dr. Patricia Bernal Trujillo (Colombia), Dr. Luzmaria Castaneda (Dominican Republic), Prof. A. H. Elgazzar (Kuwait), Dr. Shazia Fatima (Pakistan), Dr. Gopinath Gnanasegaran (U.K.), Dr. Knut Liepe (Germany), Prof. Raihan Hussain (Bangladesh), Dr. Mai Trong Khoa (Vietnam), Prof. J. Harvey Turner (Australia), Prof. Irene Virgolini (Austria), Prof. N. Watanabe (Japan), and Dr. Seyed R Zakavi (Iran).

In keeping with the rising importance as an International Organization, the Members' Assembly of WARMTH voted in Levi (Finland) to appoint the outgoing founding President Prof. A. K. Padhy as its Executive Director to look after its administration and organization aspects.

With a lot of hard work and dedication, we have been able to lay the foundation of WARMTH, which promises to be a great International Organization. As the world moves on, so does WARMTH. We in our organization truly believe that "change" is always for better. Changing is about moving forward for the better. It brings in new ideas, new directions, and with it new results. The new governing body under the leadership of Prof. Richard Baum has taken charge from January 1, 2013. We wish the governing body great success and hope that they will be able to take WARMTH to greater heights with their collective wisdom and efforts.

'Coming of age' is a young organization's transition from childhood to adulthood. The age at which this transition takes place varies, as does the nature of the transition.

Access this article online	
Quick Response Code: 	Website: www.wjnm.org
	DOI: 10.4103/1450-1147.107272

For WARMTH, this has come at the right time and in the most appropriate manner. Today, WARMTH has all the attributes of a credible International Organization. These speak volumes about this new and vibrant organization's strength and character.

Ajit Kumar Padhy

Editor in Chief, World Journal of Nuclear Medicine,

Executive Director, WARMTH, Department of Nuclear
Medicine and PET, Singapore General Hospital,
Singapore, 169608. E-mail: ajitpadhy1@yahoo.co.uk

How to cite this article: Padhy AK. Coming of Age as an Organization:
WARMTH. World J Nucl Med 2013;12:1-2.

Source of Support: Nil. **Conflict of Interest:** None declared.



In Memoriam

Ajit Kumar Padhy



Ajit Kumar Padhy

On the 22nd of August 2013, Professor Ajit Kumar Padhy passed away from massive heart attack. The news that such an energetic and vibrant friend and colleague had been taken from us, caused shock and disbelief to the many people who knew him. Condolences and tributes poured in from around the world.

Ajit Kumar Padhy was born in Orissa, India and on leaving school studied medicine at Berhampur graduating in 1976. He obtained a postgraduate diploma in Radiation Medicine from the University of Bombay in 1987. He obtained membership of the national academy of Medical Sciences after being examined in Nuclear Medicine in 1982. In 1991, he was awarded a Commonwealth Medical Fellowship to study Nuclear Medicine at St Bartholomew's Hospital in London where he worked for 2 years under Keith Britton. In 1992, he returned to India to take up a post in New Delhi where he became Professor and Head of Department. It was whilst working in New Delhi that he was granted leave by the government of India to work at the IAEA in Vienna. Professor Padhy eventually became the Head of the IAEA Nuclear Medicine Division where he served for a period of seven and a half years. It was during this time he excelled in his natural ability for networking

and initiating collaboration. He implemented 22 multinational coordinated research projects, many for the benefit of developing countries such as the use of Re-188-lipiodol and P-32 for radionuclide therapy. He travelled extensively developing close relationships with nuclear medicine professionals throughout the world, establishing close friendships that would last forever. It was these close personal contacts that subsequently enabled him to facilitate educational symposia and congresses in outstanding locations where expert speakers could be attracted for the benefit of those working in developing countries.

In 2005, he took up the post of Senior Consultant in Nuclear Medicine and PET at Singapore General Hospital where he combined his clinical role with educational activities such as the annual Singapore Nuclear Medicine Update meetings and taking on the role of Editor in Chief of the World Journal of Nuclear Medicine.

It was his personal commitment and ability to "make things happen" that resulted in the further promotion and development of nuclear medicine therapy. Firstly, as chairman of the World Radionuclide Therapy Council, and then as its co-founder and president. Subsequently, he took the role as an executive director of the World Association for Radionuclide and Molecular Therapy (WARMTH). WARMTH was inaugurated in 2009 at a ceremony at Cartagena, Colombia. He was instrumental in the rapid growth of WARMTH membership, which now stands at over 390, and he personally signed up most of the members.

During this time he initiated a series of outstanding symposia and congresses in locations such as Goa, Ulaanbaatar, Cartagena, Ho Chi Minh City, and Lapland. He excelled at organizing these meetings by paying meticulous attention to both the educational and social programs for his "nuclear medicine people" from countries throughout the world, paying particular attention to those from the developing countries. His natural charm and easy manner were his personal trademark.

In a recent WARMTH update in July 2013, he was thrilled to announce to the membership that the 1st First WARMTH-SNMMI Continuing Education Program on "Novel Targeted Radionuclide Therapy" was successfully held in Vancouver at the recent 2013 SNMMI Annual Scientific Meeting. He noted that "it was a great beginning to this collaboration between WARMTH

Access this article online	
Quick Response Code: 	Website: www.wjnm.org DOI: 10.4103/1450-1147.119940

Perkins, *et al.*: In Memoriam of Ajit Kumar Padhy

and SNMMI” and that it is planned that this will be a regular feature of every SNMMI Annual Meeting. He was also very proud to be nominated as the WARMTH representative on the Board of the Nuclear Oncology Council of SNMMI.

The news of his sudden death has resulted in stunned disbelief throughout the world, that such a giant force in our Nuclear Medicine community will no longer walk the grounds of the earth. He was a constant source of inspiration and knowledge to all of us, and worked extremely hard to improve the status of Nuclear Medicine around the world, especially in developing countries. His mentorship to those who have been fortunate to learn under him is also not to be underestimated as the tears of shock and sorrow reverberated around the world. His personal qualities were truly unique and inspiring, and we will never forget his penchant for a good joke and his infectious smile. He was a rare individual — the Guru of Nuclear Medicine.

We are sure that you will agree that his spirit will continue to linger within all of us and he will continue to guide us to establish WARMTH as a credible, functional, and vibrant organization as he had dreamt it to be.

Professor Ajit Padhy is survived by his wife and two sons whom he treasured so much. Our deepest condolences and prayers of peace go out to them.

May he attain everlasting happiness in the life beyond!

**Alan Perkins, Emerita Andres- Barrenechea¹,
Richard Baum²**

Immediate Past Honorary Secretary of WARMTH,
¹Secretary of WARMTH, ²President of WARMTH.

How to cite this article: Perkins A, Andres- Barrenechea E, Baum R. Ajit Kumar Padhy. *World J Nucl Med* 2013;12:183-4.

Source of Support: Nil. **Conflict of Interest:** None declared.



To be “Padhied”: A Neologism to Show the Pathos of Prof. Ajit Padhy for Nuclear Medicine

Padhied: The ability to use charm and persuasion to get someone doing something without to have either the person who asked or the other person having any personal benefit.

The word is a neologism to show one of the main and important characteristics of Prof. Ajit Kumar Padhy who died suddenly on August 22, 2013.^[1,2]

He was a person to create thing from nothing. His origin perhaps helps a lot. Innovation is the art of survival in hardship. He was born in Orisha Province in Eastern India one of the poorest states in India. “Impossible is nothing” was his motto. Knowing what he succeeded in achieving over the years - this was true.

He attended Berhampur University passing his MBBS in 1976. He went to Mumbai, India, to train in nuclear medicine and then to the All India Institute of Medical Sciences (AIIMS) in Delhi.

In 1991-1992, he went to St. Bartholomew’s Hospital to work with Prof. Keith Britton. At AIIMS went through the academic ranks to achieve a full chair in 1999 and became a co-founder of the Indian College of Nuclear Medicine. At the same time he became the head of the nuclear medicine section at International Atomic Energy Agency (IAEA) the start of 7 great years for Nuclear Medicine around the world. Many people were “Padhied” during this time. He has this charisma to make someone share his dreams. And, it was a very simple concept. Everything is possible to be done if you give the right spirit in the people.

In his Editorial, “when was the first time that you have done something for the first time” he wrote:^[3] “Life as a nuclear medicine professional can be very exciting and challenging. In my 33 years as a nuclear medicine physician, I have never had a dull moment. Life has not been that easy, but the dynamics of nuclear medicine

keeps you going on and on. As a specialty, nuclear medicine probably offers the possibility of “doing something for the first time,” more often than any other specialty in medicine” and further in this editorial he adds “several years ago when a young nuclear medicine physician friend of mine wrote an E-mail with just the following line: “Wah! single photon emission computed tomography (SPECT) in my country – I cannot believe this,” I could realize my young friend’s happiness and excitement, the feeling of doing or experiencing something for the first time. For some this could be just another SPECT camera, but for some this is “first SPECT” camera and that makes all the difference.”

I was also “Padhied” many times and I am happy that experience this feeling. It made me a better person and add a lot in my professional life.

2002 I have been asked by Ajit to be the publisher of the new World Journal of Nuclear Medicine. “How?” I asked. “You will manage” he answered. And it happens. We bought a special computer program. He send me all the material corrected and English edited by himself and I had the duty in my personal computer using this special program, that I was using for the first time, to create the pdf file to be sent to the local printer for printing the Journal.

Ajit made a lot of things for the first time. Many would say that it was impossible. Some will think is just a dream but somehow he has able to find people who share his vision helping him to make this dream reality.

There are 1000 small or big project that he did in his life. The center of his attention was always nuclear medicine and especially radionuclide therapy. In the same editorial, he wrote: For some, nuclear medicine still remains a diagnostic specialty. This is not true. Ours is a truly clinical specialty. Therapeutic nuclear medicine is growing rapidly and in many nuclear medicine departments it constitutes almost 25-30% of our workload. So what are you waiting for? It doesn’t matter, if you are young or old, junior or senior, wherever you are, if you have not started using radionuclide therapy yet, it is time to do so. It is time to do something for the first time in your life, start with the simplest things, create a small (one small room) “Thyroid Clinic” in a corner of your nuclear medicine unit or department, and treat your

Access this article online	
Quick Response Code: 	Website: www.wjnm.org
	DOI: 10.4103/1450-1147.138566

first thyrotoxicosis patient with 400 MBq of iodine-131. You will feel the difference; you will experience the ecstasy of "doing something for the first time."

Ajit gave during his unfortunately short life much to the worldwide nuclear medicine community. In his time in the IAEA, he was organizing dozen of training courses asking people that never before organized such an event to take the responsibility to their hand. Many people were Padhied and they gave their best for nuclear medicine. After he left the IAEA all of us were thinking this effort without the support of IAEA will stop. Once again all of us were wrong. He started with the International Conference on Radionuclide Therapy. Without budget without any money back in 2005 we organized together the first meeting in Cyprus. The conference then went to Goa, Ulaanbaatar, Cartagena, Ho Chi Minh City and Lapland all of them with a great success. This year in Manila he planned the seventh conference.

To increase the visibility of Nuclear Medicine in Asia he organized the nuclear medicine Updates in Singapore increasing the knowledge base of people in the area.

One of his major achievements was the creation of World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). His dream was that WARMTH will be the umbrella organization for education and to facilitated studies regarding therapy,

especially in the so called developing countries. He used to talk about the headquarters of the Association in New Delhi dreaming about a big building in which all the facilities for education and research can be accommodated.

Ajit Padhy Padhied a lot of people around the world. It will be a blessing if this could continue. If each of us can with charm and persuasion to get someone else doing something without to have any personal benefit.

Savvas Frangos

Department of Nuclear Medicine, Bank of Cyprus
Oncology Centre, 32, Acropoleos Avenue,
2006 Strovolos, Nicosia, Cyprus,
E-mail: savvas.frangos@gmail.com

References

1. Frangos S, Buscombe J. Prof. Ajit Padhy MBBS, MNAMS, FAMS. Eur J Nucl Med Mol Imaging 2014; 41: 185-6.
2. Perkins A, Andres-Barrenechea E, Baum R. Ajit Kumar Padhy. World J Nucl Med 2013;12:183-4.
3. Padhy AK. When was the last time you did something for the first time? World J Nucl Med 2012;11:99-100.

How to cite this article: Frangos S. To be "Padhied": A Neologism to Show the Pathos of Prof. Ajit Padhy for Nuclear Medicine. World J Nucl Med 2014;13:1-2.

Source of Support: Nil. **Conflict of Interest:** None declared.





Preface

May I submit for your consideration that we are a group of people travelling around the world. Most of us are Nuclear Medicine physicians and we meet at various conferences throughout the world. Besides smaller national meetings and larger international congresses the WARMTH people meet once a year at the annual International Congress of Radiopharmaceutical Therapy, the ICRT, which happens to move around the globe with participants from around the globe also. Our meetings not only have an outstanding scientific programme but they are also cosy and warm. Many of us have become best friends over the years and we hold together such as molecules hold the world together.

„Nuclear Medicine“ is a medical speciality that works with chemical isotopes that emit radioactivity for the good of the individual. In fact, nuclear reactions once upon a time not only were the basis for the creation and steadily ongoing evolution of this world, but also in a way the specific nuclear reactions we daily use in our Nuclear Medicine live create atomic reactions used for medical diagnosis and therapy. In a sense the field thus daily carries on with the evolution for the better of the human being. Let`s say that the medical speciality „Nuclear Medicine“ holds the world together and provides a unique basis for the creation of new radioactive molecules. Our group of people is related in the one or other way to this prestigious medical speciality.

Being our own created, our group presents the WARMTH by mixed sexes, nationalities and cultures, and also mixed religious believes, being on the way together, becoming one with God everlasting and thus an ever living being.

The writings of this booklet aim to provide insight into the Nuclear Medicine field not only for The WARMTH members and friends but also for the patient who is either diagnosed or treated by radioactive substances. The booklet basically aims to carry on with the legacy the founder of WARMTH, our late Ajit K. Padhy, has left behind. Ajit K. Padhy demised six years ago on August 22, 2013. He was a special friend to me and many of us. He was trained in Bombay, India, worked then in London, UK, as a Nuclear Medicine consultant and became later Professor and Head of Nuclear Medicine in New Delhi. His global career started as Head of the Division of Nuclear Medicine at the Section of Human Health, IAEA (International Atomic Energy Agency), in Vienna, Austria, where I first met him in 1999.



With the foundation of The WARMTH Ajit K. Padhy wanted to create a Nuclear Medicine Therapy Society which would help our patients far beyond the end of the end of the world. We are so glad that his dream has become reality and that The WARMTH moves with power and strength to places other societies would not take care! That we “keep on moving” is based on strong personal relationships among The WARMTH people, which I personally also call “*friends` club*”. The WARMTH thus exists and extends the work because of You reading this booklet, working with your patients, and reporting your good scientific and clinical work back to us and the community. I want to thank you from my whole heart for all your support and want to encourage you to keep on going the good way of live!

Also I want to handle over to you a simple booklet, easy to read and to understand, full of wonderful pictures of the area we are „training in“.

In fact, I started this booklet over a sleepless night on the train from Chendgu to Lhasa, being on the touristic Chinese highway train to Tibet, prior to our ICRT-2019 in Nanjing, China. We just crossed over the 5400 m height when the „The WARMTH Legacy Booklet“ crossed my brain.

It was an honour for me to serve The WARMTH as Congress President of the 10th ICRT-2015 held in Innsbruck, Austria, under President Richard Baum, Bad Berka, Germany, as President-Elect (2016 – 2017) under President Suresh Srivastava, Brookhaven, USA, as President (2018 – 2019), and I am looking forward to continue serving The WARMTH as Immediate-Past-President under the Presidency of Partha Choudhury, New Delhi, India (2020 – 2021).

I am fortunate to have been part of such an exciting team of the WARMTH and working with exceptional people around the globe.

With this booklet, I want to leave to you an educational and exciting summary of my time as close friend to the late Ajit K. Padhy as well as to all of you, ... and this booklet is yet to continue in a real live time!

Thank you all very much from my deepest heart!



Irene J. Virgolini
President of WARMTH
(2018 – 2019)
Innsbruck, December 2019



The Logos of The WARMTH

The Executive Board of The WARMTH (2016-2017) has decided in the Executive Board Call on February 20, 2016, to use three different templates of WARMTH logos. The main logo in „red“, the logo for the ICRT in „light blue“ and the logo for the WTA (World Theragnostics Academy) in „dark blue“. These logos were kindly supplied by Savvas Frangos, Cyprus.

There has been much debate regarding „**theranostics**“ or „**theragnostics**“. The Executive Board of The WARMTH (2016-2017) has decided to keep the „g“ in theragnostics.



„Theragnostics“ or „Theranostics“? (WARMTH keeps the „g“)

European Journal of Nuclear Medicine and Molecular Imaging (2019) 46:519
https://doi.org/10.1007/s00259-018-4204-z

LETTER TO THE EDITOR



Why should we be concerned about a “g”?

Savvas Frangos¹  · John R. Buscombe²

Received: 18 October 2018 / Accepted: 23 October 2018 / Published online: 6 November 2018
© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Dear Sir,

In recent years there has been much debate regarding whether we should use the term “theranostics” or “theragnostics”. Both have a long history of use [1, 2] and it is generally understood that the both words mean a combination of treatments, being derived from the Greek words *therapia* and *diagnosis*, the latter itself being derived from the Greek word *gnosis* which means knowledge. In a recent review in the *EJNMMI*, Verburg et al. used the term “theragnostics” in the title but acknowledged the term “theragnostics” [3].

Greek is one of the oldest continuously spoken Indo-European languages having been used for 34 centuries [4], and is the language of Hippocrates and Galen. The writings of Hippocrates date back to the fifth and fourth centuries BC. At that time Greek was not just a national language but was the universal language of scholarship, not only in Europe but also in North Africa and western Asia.

During the period of the Roman Empire Greek words may have been latinized, for example the words *stomachus* and *brachium* in *De Medicina* by Aulus Cornelius Celsus [5]. In modern medicine the Greek language continues to be mined to provide terms we use every day in our practice, sometimes to the confusion of non-medically trained Greeks. After all, patients with leukaemia do not have blood that is white. However, the use of Greek words has not always been as sympathetic to the original language as it should have been, often to our detriment as the essential meaning of the original words may have been lost.

As always when there is a dispute it is good to seek the help of an expert. Therefore, we turned to Prof. George Babinotis who is Emeritus and Honorary Professor of Linguistics and former Rector (2000–2006) of the University of Athens. He

has compiled the definitive lexicon of modern Greek [6]. Following our correspondence concerning the “theragnostics” versus “theragnostics” dispute these are his thoughts:

Theragnostics is the better term. In theragnostics the second part of the word nostics refer more to the disease than diagnostics. Linguistically the better approach is a synergy of the two words therapo-gnostics because ther alone does not refer to therapy and could be confused with the Greek word for hunting.

Although we may feel that we do indeed hunt down the tumour, it would seem then that “theragnostics” is the better term with its emphasis on knowledge. Also it is important to understand that the key to the term “theragnostics” is “gnosis”, not “agnosis” that is derived from the Greek word *agnosia* which is a lack of knowledge, because nuclear medicine with its combination of molecular imaging and molecular radiotherapy does indeed offer knowledge-based precision medicine.

Compliance with ethical standards

Conflicts of interest None.

Ethical approval This article does not describe any studies with human participants or animals performed by any of the authors.

References

1. Kelkar SS, Reineke TM. Theragnostics: combining imaging and therapy. *Bioconjug Chem*. 2011;22:1879–903.
2. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. *Lancet Oncol*. 2005;6:112–7.
3. Verburg FA, Heinzel A, Hlinscheid H, Mottaghy FM, Luster M, Giovanella L. Nothing new under the nuclear sun: towards 80 years of theragnostics in nuclear medicine. *Eur J Nucl Med Mol Imaging*. 2014;41:199–201.
4. Newton B. Greek language. In: *The New Encyclopaedia Britannica*. 15th ed. Chicago: Encyclopaedia Britannica; 2010.
5. Wulff HR. The language of medicine. *J R Soc Med*. 2004;97:187–8.
6. Babinotis G. *Lexicon of the new Greek language*. Athens: Lexicology Center; 1998.

✉ Savvas Frangos
savvas.frangos@gmail.com

¹ Nuclear Medicine Department, Bank of Cyprus Oncology Center, Nicosia, Cyprus

² Department of Nuclear Medicine, Cambridge University Hospitals, Cambridge, UK



The Foundation of The WARMTH and the World Journal

My story with Ajit Padhy starts in 1999 when I was hired by the IAEA as an officer at the Division of Nuclear Medicine. G. Nair just had retired and Ajit Padhy had recently taken over the position of heading the Division. At the University of Vienna Rudolf Höfer had retired after a life-long dedication to Nuclear Medicine had taken over the Department of Nuclear Medicine. I had applied for the Director call of the Institute of Nuclear Medicine at the Lainz Hospital in the South of the City of Vienna, and was in a waiting position for the appointment. My former head Rudolf Höfer had always kept close contact to the IAEA, especially to G. Nair and in this changing situation I was a proper and optimal young scientist for IAEA recruitment. In fact, in the half year when I part-time worked at the IAEA Ajit Padhy was starting to settle the Division of Nuclear Medicine at the IAEA onto a new level. Ajit Padhy was travelling a lot and mostly I remained alone with the other staff of the Division. My time at the office consisted basically in reviewing research applications from around the world within the established CRPs (Consented Research Projects), sending experts from one country to the other. Ajit started to settle the „¹⁸⁸Re-Lipiodol liver project“ which, for many years, was one of his many major Nuclear Medicine projects, and which will be discussed later on in this booklet. Applications came from developing countries around the globe, but Ajit Padhy supported the colleagues from Asia the most. Ajit was working all day around, even at night, and sometimes his wife with the two small boys came to his office at the IAEA in the afternoon.

Once a day Ajit came into my room and enthusiastically said „Irene, we have to do the World Journal of Nuclear Medicine. You should be on the board, give me some ideas!“ We were talking about his world vision on Nuclear Medicine and, in his point of view, the lack of vision of the World Federation of Nuclear Medicine and Biology (WFNMB). We were discussing the different features of going to this or that country as IAEA representatives, and who should be on the Editorial Board of the World Journal from his many friends around the globe. A journal that would provide a unique publication platform for those colleagues who would not easily be able to publish their results in higher-ranked journals. Subsequently, he founded the World Journal of Nuclear Medicine (WJNM) which was launched in 2002. Since then the WJNM was registered and produced in New Dehli, India, and indexed under his name.



The problems of governmental and industrial supply in many developing countries of the world bothered him a lot. Ajit Padhy was a Nuclear Medicine therapy man despite of being an all-in-through Nuclear Medicine physician. Thyroid disease projects, especially thyroid cancer throughout the world were of his primary interest. Bringing people together from around the world was his goal and to implement the Nuclear Medicine therapy worldwide. The WFNMB was moving around the world with congresses but did not provide much support for the younger colleagues from developing countries. Ajit's goal was to train the younger colleagues, encourage them and educate them for a better future. Make things possible where there is no way, give them a little hand, a bit of money from the own pocket. Engage them into research projects, encourage them to prepare an abstract. Give them a bit, they would be so happy and proud and make something out of nothing, have a step and start moving towards a better world. The WARMTH indeed has many testimonies that this concept works for the individual and certainly may subsequently affect families and friends.

Quickly Ajit Padhy had decided that he would dedicate his work at the IAEA to nuclear therapy, that there is a lack of training facilities and education in the field especially for people of the developing world. Subsequently, the 1st ICRT was soon assigned and took place in Limassol, Cyprus in 2005, which was then followed by many other meetings – more the less annually – until today. Clearly, the separation from The WFNMB was performed successfully and many members of the WFNMB also became members of The WARMTH later on, attending the annual ICRT's and making friendships in The WARMTH network.

Ait Padhy in his congress invitation letter for the 2nd ICRT-2007 in Ulaanbaator, Mongolia mailed to me *"The meetings organized by the World Radiopharmaceutical Therapy Council (WRPTC) are clearly conceptually different from all other conferences. There is no registration fee. Everyone pays for himself or herself to attend the congress. We try to keep the expenses as low as reasonably possible so that professionals from all parts of the world and from all levels of nuclear medicine practice can attend. All participants stay in the same hotel. There are no parallel sessions. All participants participate in all scientific activities of the conference. All participants participate in all social activities as well. All in all these meetings are the "meetings of friends", belonging to the global nuclear medicine family"*.



While the ICRT's were the major meetings of the increasing number of participants the idea of founding a separate scientific society took a while. In fact, the WRPTC under the chair of Ajit Padhy (Co-Chairmen were Alan Perkins, UK and Richard Baum, Germany) met in Cartagena, Colombia, for the 4th ICRT-2009 during the ALASBIMN congress chaired by Patricia Bernal, Colombia. Some considerations were the existing larger societies and industrial support for a new society, and also that the time of Ajit Padhy at the IAEA was ending in 2006 after a duration of seven years as officers at the IAEA are not easily contracted for live-long. This meeting in Cartagena was only later renamed by me as "ICRT-2009".

Ajit Padhy noted in his invitation letter for Cartagena emailed to me: *"Upon the second Members' Assembly of WRPTC, which was held during the First International Symposium on Radiopharmaceutical Therapy (ISRT-2008) in Goa, India, on 30th October 2008; approval was given for the formation of a larger and more democratic International Organization to replace World Radiopharmaceutical Therapy Council (WRPTC). The new organization will be called **World Association of Radionuclide & Molecular THERapy (WARMTH)**; it will be inaugurated at Cartagena during the ICRT-2009. I would invite you to participate in the next Members' Assembly of our organization and **witness the historic event of "birth of WARMTH"**.*

The constitution of The WARMTH was subsequently approved by the (1) General Assembly of the WRPTC, held on 4th November 2009 at Cartagena, Colombia, and was then (2) subsequently approved and adopted by the 1st General Assembly of WARMTH, which was held on 7th November 2009 at Cartagena, Colombia.

The WARMTH was then subsequently registered in New Dehli, India (Registration No:/S 84634, registered under the Societies' Registration Act of 1860). The immediate address of WARMTH in 2009 was the Department of Nuclear Medicine & PET, Max Devki Devi Heart & Vascular Institute, Saket, New Delhi, India.

A revised version of the Constitution of The WARMTH was presented to, and subsequently approved and adopted by, the General Assembly of WARMTH, which was held on the 6th May 2015 during the 10th ISRT at Innsbruck, Austria.

Following ongoing discussions on the Indian tax system, under the presidency of Suresh Srivastava, USA (2017 - 2018), the move of The WARMTH from India to the USA was finally adopted and approved by The WARMTH General Assembly during the ICRT-2017 held in Vienna, Austria. Following the agreement all members of The WARMTH society registered in India became members of the WARMTH society registered in the State of Delaware, USA, The „**WARMTH Inc**“!

BYLAWS
of
WARMTH, INC.
March 5, 2018



**Members Assembly at the ICRT-2017 Vienna, Austria
Discussion on „WARMTH Inc.“**



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

Table of Contents

	Page
Article 1. General Provisions	1
1.1 Name	1
1.2 Offices	1
1.3 Fiscal Year	1
1.4 Members	1
Article 2. Statement of Purposes	1
Article 3. Members	
3.1 Members	2
3.2 Additional Terms	2
3.3 Meetings	2
3.4 Quorum and Voting	2
3.5 Proxy Voting	3
3.6 Action without a Meeting	3
3.7 Waiver of Notice for Meetings	3
3.8 Resignation and Removal	3
Article 4. Board of Directors	2
3.1 Authority	2
3.2 Composition	2
3.3 Terms of Office	2
3.4 Meetings	2
3.5 Quorum and Voting	2
3.6 Meetings By Remote Communication	2
3.7 Action Without a Meeting	3
3.8 Waiver of Notice for Meetings	3
3.9 Committees	3
3.10 Compensation	3
3.11 Resignation	3
3.12 Removal	3
3.13 Vacancies	3
3.14 Advisory Board	3
Article 5. Officers	4
4.1 Officers	4
4.2 Election	4
4.3 Vacancies	4
4.4 Removal	4
4.5 President	4
4.6 Treasurer	4
4.7 Clerk	4
Article 6. Corporate Transactions	5
5.1 Contracts	5
5.2 Indebtedness	5
5.3 Deposits	5
5.4 Contributions	5
Article 7. Books and Records	5
Article 8. Restrictions on Activities	6
Article 9. Dissolution	6
Article 10. Conflicts of Interest	6
Article 11. Personal Liability	7
Article 12. Indemnification	7
Article 13. Amendment to Bylaws	7



BYLAWS

of

WARMTH, INC.

March 5, 2018

ARTICLE 1

General Provisions

Section 1.1 Name. The name of this Corporation is WARMTH, Inc., and shall herein be referred to as "the corporation."

Section 1.2 Offices. The Corporation shall have a registered agent at 1521 Concord Pike #303, Wilmington, Delaware 19803. The corporation may also have offices at such places as the Corporation may require.

Section 1.3 Fiscal Year. The fiscal year of the Corporation shall begin on January 1 and end on the following December 31 of each year.

ARTICLE 2

Statement of Purposes

The Corporation is dedicated to charitable, educational, scientific purposes including, but not limited to, advancing the science and education of therapeutic nuclear medicine and radiopharmaceutical therapy including dosimetry, treatment evaluation, radiation physics, radiation biology and radiation protection for the benefit of public health and humanity; working toward worldwide access to radionuclide therapy by harmonizing good practice; and educating nuclear medicine professionals in the use of radionuclide therapies and to facilitate research in this area. The Corporation may, as permitted by law, engage in any and all activities in furtherance of, related to, or incidental to these purposes which may lawfully be carried on by a corporation formed under the laws of Delaware and which are not inconsistent with the corporation's qualification as an organization described in Section 501(c)(3) of the Internal Revenue Code or corresponding section of any future tax code.

ARTICLE 3

Members

Section 3.1 Members. In conformity with the aims of WARMTH and the universal nature of scientific research and human rights, membership is irrespective of any one country, language area, ethnic group, gender or religion. All members shall promote and embrace the objective of WARMTH as set out in the Certificate of Incorporation and Article 2 of these

WARMTH, Inc
Bylaws of March 5, 2018
Page 2

Bylaws. Membership shall consist of the following three [3] categories with voting privileges as noted for each category:

Section 3.1.1 Electing Members. An Electing Member is physician, scientist, or person committed to the objectives of WARMTH with a completed university or equivalent education who is mainly engaged in nuclear medicine or related fields. Electing members may be individuals or corporate members. Corporate members are companies whose employees include persons with the individual qualifications described above interested in promoting the aims of WARMTH.

Admission and Term: Electing members shall complete and submit an online application. The application shall be reviewed and approved by the Executive Committee, in its sole discretion. The term of membership shall be the calendar year or such other period as the Board of Directors may from time to time determine. An Electing Member's membership shall terminate at the end of the membership period unless the membership fees for the succeeding period, as determined by the Board of Directors in accordance with Section 4.1, following, shall have been paid in full.

Voting and other Rights: Each Electing Member shall have one vote at meetings of the Membership. Each Corporate Members shall designate one representative to vote on its behalf. Electing members shall have the following voting and other rights:

1. to attend member meetings and to serve on WARMTH committees;
2. to be informed and participate in the activities of WARMTH, receive the Annual Report of the Board of Directors, to provide feedback to the Board of Directors regarding policies under consideration and other corporate affairs;
3. to elect the President, Treasurer, Clerk, and President Elect, who shall also be voting members of the board.
4. to approve ICRT venues recommended by the Board of Directors up to four (4) years in advance;
5. to propose in writing to the Board of Directors nominees for honorary membership and to elect Honorary Members;
6. to be eligible to serve on the Board of Directors after two years of membership;
7. to approve amendments to the Certificate of Incorporation and to Article 3 of these Bylaws
8. to approve dissolution of WARMTH;



WARMTH, Inc
Bylaws of March 5, 2018
Page 3

Section 3.1.3 Associate Members. An Associate Member is a non-physician and non-scientist, such as a nuclear medicine technologist, working in the field of nuclear medicine or related fields.

Admission and Term: Associate members shall complete and submit an online application. The application shall be reviewed and approved by the Executive Board, in its sole discretion. The term of membership shall be the calendar year or such other period as the Board of Directors may from time to time determine. An Associate Member's membership shall terminate at the end of the membership period unless the membership fees for the succeeding period, as determined by the Board of Directors in accordance with Section 3.11, following, shall have been paid in full.

Voting Rights: Associate Members do not have voting rights in the Corporation.

Section 3.1.3 Honorary Members: An Honorary Member is a person of outstanding distinction who has provide great service to WARMTH.

Admission and Term: Honorary Members shall be nominated by the Board of Directors and elected by a 2/3rds vote of the members at the Annual Meeting. Honorary Members shall serve for life, unless their membership is otherwise concluded as specified in Section 3.8 following. Honorary Members are not responsible for paying membership fees.

Voting Rights: Honorary Members do not have voting rights in the Corporation.

Section 3.2 Additional Terms of Membership. The Board of Directors shall establish membership fees, additional classes of membership, and additional conditions of membership.

Section 3.3 Meetings and Notice.

Annual Meeting. An Annual Meeting of the membership shall be held each year at a date, time and place specified by the Board of Directors. The Annual Meeting shall normally be held during the WARMTH International Conference on Radiopharmaceutical Therapy (ICRT).

Extraordinary Meetings. Extraordinary meetings of the members may be called by Board of Directors or if at least 20% of the ordinary members propose this in a writing delivered to the President.

Notice. Notice of the Annual Meeting, together with an agenda, shall be given such that members shall reasonably be expected to receive notice six (6) weeks before the Annual Meeting. Items may be added to the agenda and discussed at the Annual Meeting under "Other Items" if approved by a majority of the Members present or by the Executive Board of WARMTH. Notice of an Extraordinary Meeting, together with an agenda, shall be given such that members shall reasonably be expected to receive notice twelve (12) weeks before the meeting. Notice may be made by mail, in person, or by electronic means.

Section 3.4 Quorum and Action at Meetings. A quorum for transaction of business at the Annual Meeting or an Extraordinary Meeting shall consist of 20 Electing Members. At any



WARMTH, Inc
Bylaws of March 5, 2018
Page 4

meeting of the Electing Members at which a quorum is present, the vote of a majority of those present shall decide any matter, unless a different vote is specified by law, the Articles of Organization, or these Bylaws.

Section 3.5 Proxy Voting. At all meetings of the members the vote of each Electing Member may be cast by written proxy. Proxies shall be filed with the clerk of the meeting before being voted. A proxy purporting to be executed by or on behalf of a member shall be deemed valid unless challenged at or prior to its exercise, in which event the burden of proving invalidity shall rest on the challenger.

Section 3.6 Action Without a Meeting. Any action required or permitted to be taken at any meeting of the members may be taken without a meeting if a consent in writing, setting forth the action to be taken, shall be signed by all persons comprising the membership with respect to such subject matter. Such consent, which may be signed in counterparts, shall have the same force and effect as a vote of the member.

Section 3.7 Waiver of Notice for Meetings. Whenever any notice of a meeting is required to be given to any member under the Certificate of Incorporation, these Bylaws, or the laws of Delaware, a waiver of notice in writing signed by the member, whether before or after the time of the meeting, shall be equivalent to the giving of such notice.

Section 3.8 Resignation and Removal. Any member may resign as such at any time by written notice to the clerk of the Corporation. Any member may be removed from the Corporation, with or without assignment of cause, by a vote of three-fourths of the members voting at a duly called meeting. No member shall be removed from the Corporation unless the notice of the meeting at which removal is to be considered states such purpose and opportunity to be heard at such meeting is given to the member whose removal is sought.

ARTICLE 4

Board of Directors

Section 4.1 Authority and Functions. The business and affairs of the Corporation shall be controlled and governed by the board of directors, which shall have the right to exercise all powers of the Corporation as permitted by law. In furtherance thereof, without limitation, the Board of Directors shall:

- establish policy and engage in strategic planning
- provide financial oversight of the Corporation
- formulate and approve the WARMTH annual budget
- approve the membership application process, annual membership fees and member qualifications
- appoint 'at large' directors to the board
- appoint the ICRT Chair and Chair Elect
- hire, evaluate, approve compensation for, offer guidance to, and take any other employment actions as they regard the senior manager and other key employees of WARMTH
- convene the Annual Meeting and report the activities of the Corporation to the members annually



WARMTH, Inc
Bylaws of March 5, 2018
Page 5

- carry out actions approved by the members
- carry out any and all other functions as may be required by law or in the best interests of the Corporation

Section 4.2 Composition and Election. The Initial Board of Directors shall be those directors elected by the Sole Incorporator and shall hold office until the first Annual Meeting of the Corporation and until their successors have been elected and qualified. Thereafter, the Board shall be comprised of the President, Treasurer, Clerk, President Elect, Immediate Past President, Current ICRT Chair, ICRT Chair Elect, and two (2) at large directors and the senior manager of the Corporation who shall sit on the Board ex officio, without a vote. Elections for the President, Treasurer, Clerk, President-Elect, shall be held at the Annual Meeting utilizing an electronic voting process determined by the Board. Votes shall be cast in person or by proxy during the Annual Meeting. At large directors having skills and experience which can contribute to the purposes and mission of the Corporation are appointed by the Board. The ICRT Chair and Chair Elect are appointed by the Board after an application process determined by the Board. The Board shall appoint the ICRT Chair, ICRT Chair Elect and at large members a meeting convened immediately following the Annual Meeting of the members

Section 4.3 Terms of Office. With the exception of the initial directors' initial terms, the term of all directors shall be two years and shall commence at the end of the meeting at which they are elected. Terms shall be staggered so that approximately one-half of the total number of directorships shall be elected each year. The board of directors shall determine the limit, if any, on the number of terms to be served by directors.

Section 4.4 Meetings. The board of directors shall hold regular meetings each year and may hold special meetings at dates and times selected by the board. No notice of regular meetings shall be required provided the board has adopted a regular meeting calendar for the year and all directors have received a copy of the calendar. Special meetings of the board of directors may be called by the president or by a majority of the directors then in office by delivering notice in writing of the date, time, place, and purpose of such meeting to all directors at least three (3) days in advance of such meeting.

Section 4.5 Quorum and Voting. A majority of the board of directors shall constitute a quorum for the transaction of business at any meeting of the board. At any meeting of the board of directors at which a quorum is present, a majority of those directors present shall decide any matter, unless a different vote is specified by law, the Certificate of Incorporation, or these bylaws.

Section 4.6 Meetings by Remote Communication. One or more directors may attend any annual, regular, special, or committee meeting of the board through telephonic, electronic, or other means of communication by which all directors have the ability to fully and equally participate in all discussions and voting on a substantially simultaneous basis. Such participation shall constitute presence in person at such meeting.



WARMTH, Inc
Bylaws of March 5, 2018
Page 6

Section 4.7 Action Without a Meeting. Any action required or permitted to be taken at any board meeting may be taken without a meeting if a consent in writing, setting forth the action to be taken, shall be signed by all of the directors with respect to such subject matter. Such consent, which may be signed in counterparts, shall have the same force and effect as a vote of the board of directors.

Section 4.8 Waiver of Notice for Meetings. Whenever any notice of a meeting is required to be given to any director under the Certificate of Incorporation, these bylaws, or the laws of Delaware, a waiver of notice in writing signed by the director, or sent by electronic mail by the director from an email address belonging to the director, whether before or after the time of the meeting, shall be equivalent to the giving of such notice.

Section 4.9 Executive Committees and Other Committees.

Executive Committee. The Executive Committee shall be a standing committee of the Board. The Initial Executive Committee shall be comprised of the President, Treasurer and Clerk and the Committee shall be so comprised until the first Annual Meeting of the Corporation. Thereafter, the Committee shall be comprised of the President, President-Elect, Clerk, Treasurer and Immediate Past President. The Executive Committee shall meet as necessary and, generally, once a month and shall be responsible for:

- approving membership applications through a membership application process;
- recommending ICRT Chairs selected through an application process for appointment to the board;
- providing continuity between board meetings;
- screening and recommending proposed projects and policies for deliberation by the Board;
- formulating Board and Annual Meeting agendas;
- offering interim guidance to senior management, if needed,
- taking rapid action on behalf of the board;
- handling, either directly or by appropriate delegation, confidential or sensitive matters relating to members of the Corporation
- any such other matters as may be requested by the Board

Actions taken by the executive committee and all matters deliberated before it shall be reported to the full board at its next meeting, if not sooner. The full board shall have the right to ratify, comment, approve, and if necessary, modify those decision made on its behalf.

Other Committees. The board of directors may create such other standing and special committees as it determines to be in the best interest of the Corporation. The board of directors shall determine the duties, powers, and composition of such committees, except that the board shall not delegate to such committees those powers which by law may not be delegated. Each such committee shall submit to the board of directors at such meetings as the board may designate, a report of the actions and recommendations of such committees for consideration and approval by the board of directors. Any committee may be terminated at any time by the board of directors.

Section 4.10 Compensation. Directors as such shall not receive any compensation for their services on the board or on committees of the board, but directors shall not be precluded from serving the Corporation in any other capacity and receiving reasonable compensation.



WARMTH, Inc
Bylaws of March 5, 2018
Page 7

Section 4.11 Resignation. Any director may resign by delivering a written resignation to the Corporation at its principal office or to the president or clerk. Such resignation shall be effective upon receipt unless it is specified to be effective at some later time.

Section 4.12 Removal. Any director may be removed, with or without assignment of cause, by a vote of two-thirds of the entire board of directors at any meeting of the board of directors. No member of the board shall be removed from office unless the notice of the meeting at which removal is to be considered states such purpose and opportunity to be heard at such meeting is given to the director whose removal is sought. Notwithstanding the notice provision of Section 4.4 above, written notice shall be delivered to all directors at least fourteen (14) days in advance of a meeting at which removal is sought.

Section 4.13 Vacancies. Any vacancy occurring in the board of directors shall be filled by the board of directors. A director elected to fill a vacancy shall be elected for the unexpired term of his or her predecessor in office.

Section 4.14 Advisory Board. There shall be an advisory board to the board of directors which shall be comprised wholly as the board of directors determines. The advisory board shall provide advice to the board of directors and perform such duties as the board from time to time may request. Advisory board members as such shall not be entitled to vote at or attend board of director meetings or hold any other powers of the Corporation. However, advisory board members shall not be precluded from serving simultaneously on the board of directors or in any other capacity as the board may request.

ARTICLE 5

Officers

Section 5.1 Officers. The Initial Officers of the Corporation shall be a president, treasurer and clerk who shall hold office until the first Annual Meeting of the Corporation and until their successors have been elected and qualified. Thereafter, the officers of the Corporation shall be a president, treasurer, clerk and president elect of the board of directors and such other officers as may be elected in accordance with the provisions of this Article.

Section 5.2 Election. The officers of the Corporation shall be elected by the Members at the Annual Meeting. Each officer shall hold office until a successor shall have been elected and qualified.

Section 5.3 Vacancies. A vacancy in any office because of death, resignation, disqualification, or otherwise may be filled by the board of directors for the unexpired portion of the term.

Section 5.4 Removal. Any officer may be removed, with or without assignment of cause, by a vote of a majority of the entire board of directors at any meeting of the board of directors. No officer shall be removed from office unless the notice of the meeting at which removal is to be considered states such purpose and opportunity to be heard at such meeting is given to the officer whose removal is sought. Notwithstanding the notice provision of Section 4.4 above, written notice shall be delivered to all directors at least fourteen (14) days in advance of a meeting at which removal is sought.



WARMTH, Inc
Bylaws of March 5, 2018
Page 8

Section 5.5 President. The president shall preside at all meetings of the board of directors, meetings of the members and shall convene the ICRT. The president, or other proper officer or agent of the Corporation authorized by the board of directors, may sign any checks, deeds, mortgages, bonds, contracts, or other instruments which the board of directors has authorized to be executed. The president shall perform all duties incident to the office of president and such other duties as may be prescribed by the board of directors from time to time.

Section 5.6 President Elect. The president shall perform such duties as may be prescribed by the board of directors from time to time. In the case of early retirement or incapacity of the president, the president elect shall take office immediately and shall hold office until the end of his/her term as president elect and as president. In the absence of the president, the president-elect shall preside at all meetings of the board of directors, meetings of the members and shall convene the ICRT.

Section 5.7 Treasurer. The treasurer, or other proper officer or agent of the Corporation authorized by the board of directors, shall have charge and custody of and be responsible for all funds and securities of the Corporation; receive and give receipt for moneys due and payable to the Corporation from any source whatsoever, and deposit all such moneys in the name of the Corporation in such banks, trust companies, or other depositories as shall be selected by the board of directors; and in general perform all of the duties incident to the office of treasurer and such others as may from time to time be assigned by the board of directors.

Section 5.8 Clerk. The clerk shall keep the minutes of the meetings of the board of directors in one or more books provided for that purpose; ensure that all notices are given in accordance with the provisions of these bylaws; be custodian of the corporate records; and in general perform all such duties as may from time to time be assigned by the board of directors.

ARTICLE 6

Corporate Transactions

Section 6.1 Contracts. The board of directors may authorize any officer or officers, agent or agents of the Corporation in addition to the officers so authorized by these bylaws, to enter into any contract or execute and deliver any instrument in the name of and on behalf of the Corporation, and such authority may be general or confined by specific instances.

Section 6.2 Indebtedness. All checks, drafts, or orders for the payment of money, notes, or other evidence of indebtedness issued in the name of the Corporation, shall be signed by the president or treasurer, or such other officer or agent of the Corporation as from time to time may be determined by the board of directors. In the absence of such determination of the board, such instruments shall be signed by the president or treasurer of the Corporation.

Section 6.3 Deposits. All funds of the Corporation shall be deposited from time to time to the credit of the Corporation in such banks, trust companies, brokerages, or other depositories as the board of directors shall select.



WARMTH, Inc
Bylaws of March 5, 2018
Page 9

Section 6.4 Contributions. The board of directors or any authorized officer or agent may accept on behalf of the Corporation any contribution, gift, bequest, or devise for the general purposes or for any special purpose of the Corporation.

ARTICLE 7

Books and Records

The Corporation shall keep at the principal office of the Corporation correct and complete books and records of account; minutes of the proceedings of board of directors; and a register of the names and addresses of the directors of the Corporation. All books and records of the Corporation may be inspected by any director, or agent or attorney thereof, for any proper purpose at any reasonable time.

ARTICLE 8

Restrictions on Activities

No part of the net earnings of the Corporation shall inure to the benefit of, or be distributable to its members, directors, officers, or other private persons, except that the Corporation shall be authorized and empowered to pay reasonable compensation for services rendered and to make payments and distributions in furtherance of the purposes of the Corporation. Except to the extent permitted by the Internal Revenue Code, whether pursuant to an election under Section 501(h) or otherwise, no substantial part of the activities of the Corporation shall be the carrying on of propaganda, or otherwise attempting, to influence legislation, and the Corporation shall neither participate nor intervene in (including by publishing or distributing statements) any political campaign on behalf of any candidate for public office. Notwithstanding any other provision of these bylaws, neither the Corporation nor any director, officer, employee, agent, or any other representative of the Corporation shall carry on any other activities not permitted to be carried on (a) by a Corporation exempt from federal income tax under Section 501(c)(3) of the Internal Revenue Code, or corresponding section of any future federal tax code, or (b) by a Corporation, contributions to which are deductible under Section 170(c)(2) of the Internal Revenue Code, or corresponding section of any future federal tax code.

ARTICLE 9

Dissolution

In the event of the liquidation, dissolution or winding up of the Corporation (whether voluntary, involuntary or by operation of law), the Corporation's property or assets shall not be conveyed or distributed to any director, officer, employee or member of a committee of, or person connected with, the Corporation, or any other private individual, nor to any organization created or operated for profit; but, after deducting all necessary expenses of liquidation, dissolution or winding up, as the case may be, all the remaining property and assets of the Corporation shall be distributed in furtherance of the corporate purposes of the Corporation to one or more organizations as shall then qualify under Section 501(c)(3) of the Internal Revenue Code, or to the federal government, or a state or local government, for a public purpose, in each case as the board of directors of the Corporation shall determine.



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2008

WARMTH, Inc
Bylaws of March 5, 2018
Page 10

ARTICLE 10

Conflicts of Interest

The Board of Directors shall adopt a Conflict of Interest policy and procedures consistent with the requirements of state and federal law and best practices governing 501(c)(3) public charities incorporated in Delaware.

ARTICLE 11

Personal Liability

No officer or director of the Corporation shall be personally liable to the Corporation for monetary damages for or arising out of a breach of fiduciary duty as an officer or director notwithstanding any provision of law imposing such liability; provided, however, that the foregoing shall not eliminate or limit the liability of an officer or director to the extent that such liability is imposed by applicable law (i) for a breach of the officer's or director's duty of loyalty to the Corporation, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of the law, or (iii) for any transaction from which the officer or director derived an improper personal benefit.

ARTICLE 12

Indemnification

The Corporation shall, to the extent legally permissible, indemnify each person who may serve or who has served at any time as an officer or director of the Corporation against all expenses and liabilities, including, without limitation, counsel fees, judgments, fines, excise taxes, penalties and settlement payments, reasonably incurred by or imposed upon such person in connection with any threatened, pending or completed action, suit or proceeding in which he or she may become involved by reason of his or her service in such capacity; provided that no indemnification shall be provided for any such person with respect to any matter as to which he or she shall have been finally adjudicated in any proceeding not to have acted in good faith in the reasonable belief that such action was in the best interests of the Corporation; and further provided that any compromise or settlement payment shall be approved by a majority vote of a quorum of directors who are not at that time parties to the proceeding.

The indemnification provided hereunder shall inure to the benefit of the heirs, executors and administrators of persons entitled to indemnification hereunder. The right of indemnification under this Article shall be in addition to and not exclusive of all other rights to which any person may be entitled.

This Article constitutes a contract between the Corporation and the indemnified persons. No amendment or repeal of the provisions of this Article which adversely affects the right of an indemnified person under this Article shall apply to such person with respect to those acts or omissions which occurred at any time prior to such amendment or repeal.

ARTICLE 13

Amendments to Bylaws

These bylaws may be amended, restated, or repealed by a majority vote of the Board of Directors. Notwithstanding the foregoing sentence, Article 3 of these bylaws and this Article 13, may not be amended, restated, or repealed unless approved by a 2/3 vote of the members present in person or by proxy at any meeting of the members.


(End of Bylaws)

Global Distribution of The WARMTH

„According to our mailing list The WARMTH has touched people in 83 countries (either members or conference participants)“ (Josh Mailman, USA, December 2019).

Honoray Memberships

- Hossein Jadvar
- Stanely Goldsmith
- Mathew L. Thakkur
- Steven M. Larson



The map is a „heat map“.

Global Distribution of The WARMTH

Countries	N
Albania	1
Argentina	3
Armenia	1
Australia	44
Austria	27
Bahrain	1
Bangladesh	44
Belgium	5
Bosnia and Herzegovina	6
Brazil	8
Bulgaria	5
Cambodia	1
Canada	12
Chile	2
China	16
Colombia	2
Croatia	3
Cyprus	3
Domanian Republic	3
Estonia	5
Ethiopia	1
Finland	24
France	4
Germany	44
Ghana	8
Greece	5
Hungary	4
India	114
Indonesia	34
Iran	15
Israel	3
Italy	6
Japan	12
Jordan	4
Kazakhstan	1

Countries	N
Kenya	2
Republic of Korea	10
Kuwait	10
Kyrgyzstan	2
Latvia	4
Lebanon	1
Libya	1
Republic of Macedonia	1
Malaysia	17
Mali	1
Mexico	2
Mongolia	3
Morocco	1
Myanmar	14
Nepal	3
Netherlands	4
Nigeria	1
Norway	5
Oman	3
Pakistan	14
Peru	1
Philippines	68
Poland	11
Portugal	9
Romania	7
Russian Federation	21
Saudi Arabia	2
Serbia	11
Singapore	28
Slovakia	1
Slovenia	4
South Africa	25
Spain	7
Sri Lanka	2

Countries	N
Switzerland	9
Syria	1
Taiwan	2
Thailand	2
Tunisia	1
Turkey	13
Ukraine	3
United Arab Emirates	2
United Kingdom	32
United States	53
Uruguay	3
Uzbekistan	3
Vietnam	16



Mariela Agolti, Argentina, and Josh Mailman, USA, working on WARMTH member recruitment.

Over the years The WARMTH reached >1.000 members. Around 400 members are in „good standing“ (i.e. members who paid / renewed payment after WARMTH was integrated in WARMTH Inc.).



The Governing Body of The WARMTH

The Presidents 2009 – 2023

Harvey Turner, Perth, Australia	2009 - 2010
Ajit Padhy, Singapore	2011 - 2013
Richard Baum, Bad Berka, Germany	2014 - 2015
Suresh Srivastava, Brookhaven, USA	2016 - 2017
Irene Virgolini, Innsbruck, Austria	2018 - 2019
Partha Choudhury, Delhi, India	2020 - 2021
Mike Shatekge, Bretonia, South Africa	2022 - 2023



Editorial

Greetings from the New President of the World Association of Radiopharmaceutical and Molecular Therapy



Dear Friends and Members of World Association of Radiopharmaceutical and Molecular Therapy (WARMTH),

First of all, I want to thank my predecessors, the Immediate Past President of WARMTH, Suresh Srivastava, Brookhaven, USA (2016–2017) and the Past President of WARMTH Richard Baum, Bad Berka, Germany (2014–2015), who both have contributed significantly in different ways to our success after the sudden demise of our dear WARMTH Founding President Ajit Padhy, Singapore, on August 22, 2013. Furthermore, I am also very grateful to all of our Executive and Governing Board Members all of whom have continuously served and contributed to the success of WARMTH over the past years.

Within only a few years of our creation, WARMTH has grown in status and respect, with presently approaching 500 members from all over the world. As the President of WARMTH, it is my privilege and pleasure to congratulate all the new selected members of the Executive and Advisory Board of WARMTH (2018–2019). The current version of our WARMTH Constitution was presented to, and subsequently approved and adopted by, the General Assembly of WARMTH, which was held on May 7, 2015, during the 10th ICRT-2015 at Innsbruck, Austria.

The Governing Board Structure of World Association of Radiopharmaceutical and Molecular Therapy 2018-2019

The Executive Board

- | | |
|----------------------------|----------------------------|
| • President | Irene Virgolini, Austria |
| • President-Elect | Partha Choudhury, India |
| • Immediate Past President | Suresh Srivastava, USA |
| • Secretary | Butch Magsombol, Singapore |
| • Treasurer | Aviral Singh, Germany. |

Elected Advisory Board

- Sze Ting Lee, Australia.
- Kalevi Kairemo, Finland.
- Mike Sathekge, South Africa.
- Patricia Bernal Trujillo, Colombia.
- Raihan Hussain, Bangladesh.
- Knut Liepe, Germany.

Adopted Advisory Board

- | | |
|--------------------------------|-------------------|
| • Chief Operating Officer | Josh Mailman, USA |
| • ICRT 2019 Congress President | Feng Wang, China. |

World Journal of Nuclear Medicine

- | | |
|-------------------------|-----------------------|
| • Editor-in-Chief | John Buscombe, UK |
| • Editor-in-Chief-Elect | Qaisar Siraj, Kuwait. |

I want to thank all of the new Governing Board Members for taking up leadership with me and on my side and helping me in the continuation of our WARMTH's Friends Club! I am sure that in my presidency period and thereafter under our new President-Elect Partha Choudhury, WARMTH will grow even stronger and reach even greater heights with our collective wisdom and efforts. Welcome in the Ajit Padhy's Friends Club, the WARMTH!

WARMTH initiatives comprise of the advances in science and education in therapeutic nuclear medicine and radiopharmaceutical therapy including dosimetry, treatment evaluation, radiation physics, radiation biology, and radiation protection. WARMTH is the only worldwide organization founded to promote the use of radionuclide molecular therapy and of the relatively novel paradigm of "*Thera (g) nostics*" worldwide. WARMTH experts in nuclear medicine belong to more than fifty countries from around the globe, and all of our experts dedicate their time in the implication of new therapeutic methods and they do this almost always on a charity basis. The success of nuclear therapy in the global sphere will depend on all of you, dear WARMTH members from around the world!



Virgolini: World association of radiopharmaceutical and molecular therapy

I have known Ajit Padhy since his time at the IAEA in Vienna, and also working also with him on different projects over almost 20 years. After Ajit Padhy's sudden demise, we all have continuously endeavored towards our collective goal of making WARMTH grow into a great international organization. During one of his many lectures, Ajit Padhy had stated *"WARMTH is not the domain of one person. I am happy I was able to realize my dream and create a world-class product. We all have to move on and so does the WARMTH. Irrespective who is running it, I am sure it will continue to grow. Hiccups, we can all have in life, but we all should learn from them and move on. WARMTH too will overcome its hiccups and will continue to warm our hearts. And yes, I am very much a part of it-and it's a part of me which will never go away."*

Today, WARMTH has all the attributes of a credible international organization, and our young organization is transitioning from its "childhood" to its "adulthood."

WARMTH is duly registered as an international association in India under the Societies Registration Act XXI, Government of Delhi, on August 25, 2010. In order to facilitate and streamline our finances, the Governing Board of WARMTH 2016–2017 has decided to newly register WARMTH's new registration as a nonprofit scientific entity in the USA. The constitution has been adapted and the Assembly of WARMTH in the 2018 Annual Meeting in Melbourne shall be solicited to agree on this action.

WARMTH official journal, the World Journal of Nuclear Medicine, has gained enough credibility to be indexed in the PubMed. We are very grateful to our Editor-in-Chief John Buscombe, UK (2014–2018), and our Senior Editor, Savvas Frangos, Cypress. We look forward to continued growth of our journal under its incoming new Editor-in-Chief Qaisar Siraj, Kuwait (from 2019). Based on our financial limitations, the Governing Board has decided that we maintain the journal online only, and that both paper submission and access remain free. Savings should help towards increasing the number of issues from three to four a year and also reducing the time from acceptance to publication.

WARMTH's main scientific activity, the ICRT (International Conference on Radiopharmaceutical Therapy), has become an annual global event with unforgettable meetings in Limassol, Cyprus (2005), Ulaanbaatar, Mongolia (2007), Goa, India (2008), Cartagena, Colombia (2009), South Africa (2010), Ho Chi Minh City, Vietnam (2011) and Kuwait (2011), Levi, Finland (2012), Manila, the Philippines (2013), Cancun, Mexico (2014), Innsbruck, Austria (2015), Kochi, India (2016), Vienna, Austria (2017), Melbourne, Australia (2018). The "Ajit Padhy Memorial Oration"

was implemented during the ICRT-2015 in Innsbruck and its first presentations were delivered by Hossein Jadvar, USA (ICRT-2016, Kochi) and Stanley Goldsmith, USA (ICRT-2017, Vienna).

WARMTH has been able to forge an alliance with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and hence, in conjunction with the Annual Meeting of the SNMMI, WARMTH has co-sponsored a number of joint sessions in the Continuing Medical Education program during both the SNMMI Mid-Winter and SNMMI Annual Meetings since 2013, as well as by participation in the Categorical Seminars on Theranostics during the SNMMI Annual Meetings in Baltimore (2015), San Diego (2016), Denver (2017) as well as Philadelphia (2018). Great beginnings of WARMTH's collaboration with the new SNMMI "Therapy Center of Excellence" have been implemented by the Immediate Past President of WARMTH Suresh Srivastava who also served as President of the "Therapy Center of Excellence."

In addition, WARMTH members have served and continue to serve in a number of international and national societies and organizations such as the WFNMB, AOFNMB, SNMMI, or the IAEA. We hope to continue our collaborations for everybody's mutual success.

WARMTH's research activities over the last years concentrated on liver cancer therapy using Re188-Lipiodol, with its availability in generator form and similar chemistry to Tc99m. With more than 70% of the world's liver cancer in Asia—where the vast majority of patients do not have any health insurance—it is imperative that a cost-effective palliation procedure would be available. During the Manila ICRT-2013, Ajit Shinto, India, took lead of this project which had started in summer 2013 in Coimbatore shortly before the sudden demise of Ajit Padhy, resulting also in the WARMTH-sponsored World Rhenium Congress in Coimbatore 2016 and 2017, along with the WARMTH Theranostic Academy. With the help of many faculties, further development in radiochemistry, pharmacy, and dosimetry for Re188 was achieved, resulting also in projects for pain palliation, synoviorthesis, neuroendocrine tumor therapy (NET), and even prostate-specific membrane antigen (PSMA) labeling. Lined-up centers for the Re188 projects include India, China, Mongolia, Pakistan, the Philippines, Vietnam, South Africa, and Myanmar. I like Ajit Shinto's quotation of Saint Francis of Assisi *"We started by doing what is necessary, we are doing what is possible and then with your continued support we will be soon doing the impossible!"*

Recent years have brought up a number of very promising data on PSMA Theranostics. Hojjat Ahmadzadehfar, Germany, took lead of organizing a retrospective WARMTH-sponsored study on the currently available



Virgolini: World association of radiopharmaceutical and molecular therapy

response data after treatment of prostate cancer patients with Lu117-PSMA-ligand, and a couple of WARMTH centers have already accepted to participate in this evaluation.

Furthermore, under the lead of Sabina Dizdarevic, UK, a WARMTH multicentric study on thyroid cancer therapy has been proposed and will be presented soon.

A multicentric retrospective evaluation on the role of F18-FDG-PET in somatostatin receptor PET-positive NET patients is currently initiated under the supervision of WARMTH.

WARMTH's educational endeavors include the WARMTH Theranostic Academy. There are many ways that WARMTH may participate in the global health work. Offering training programs for doctors, medical physicists, and technicians is one way. Universities can invite and sponsor health workers for training. Such training courses can also be in the online distant learning mode of the WARMTH website. Sending "visiting professors" to train local doctors in developing countries or continued support through "Telenuclear Medicine" is another possibility.

IAEA's support for WARMTH was repeatedly ensured by Diana Paez, Section Head of Nuclear Medicine at the Division of Human Health, IAEA. In collaboration with the IAEA, WARMTH's participation in IAEA projects – or vice versa – our educational program have to be imparted need to be thoroughly discussed *de novo*.

What will be new and how will we proceed?

I will continue, and kindly ask all of you to help to obtain sponsorship of as many industrial companies as possible to support our scientific and educational activities. We should attract additional WARMTH Corporate Members who can support our needs. We have to set aside some kind of "Educational Fund" in order to support our young scientists to present their results, network and interact with fellow nuclear medicine members at our future ICRTs. We also have to appoint a new permanent WARMTH secretariat, following the old one in Singapore, and express our thanks for the devotion of our Chief Operational Officer Josh Mailman, whose help has been inestimable, and also acknowledge the continued assistance by my own secretaries Gertraud Buchberger

and Anna Meister since then. We are constantly taking steps to improve our website to provide relevant information and facilitate communication.

On behalf of the members of the Organizing Committee and the Scientific Committee of the WARMTH and the WFNMB, I would like to extend my cordial invitation to all of you to attend and participate in our 13th ICRT-2018, which will take place on April 20, 2018, in Melbourne, Australia, held as pre-congress meeting of the 12th WFNMB Congress. The ICRT-2018 reflects WARMTH's mission with the goal of providing the best treatment and care for our patients, and as in the past, there is no registration fee for the members of WARMTH!

I am looking forward to your active participation in the 13th ICRT-2018 and all other activities of WARMTH and to meet and interact with friends and colleagues from all over the world.

At last, I would like to thank each and every one of you, WARMTH members, for your continued support and for your help in ensuring a brilliant future for WARMTH!

Yours warm(th)ly.

Irene Virgolini

Department of Nuclear Medicine, Medical University Innsbruck, 6020 Innsbruck, Austria.
E-mail: warmth-icrt@i-med.ac.at

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online	
Quick Response Code: 	Website: www.wjnm.org
	DOI: 10.4103/wjnm.WJNM_27_18

How to cite this article: Virgolini I. Greetings from the new president of the world association of radiopharmaceutical and molecular therapy. World J Nucl Med 2018;17:67-9.



The Executive Board Members 2011 - 2019

2011 – 2013	
Ajit Kumar Padhy (Singapore)	President
Alan Perkins (UK)	Secretary
Pankaj Dougall (India)	Treasurer
Richard Baum (Germany)	President Elect
Harvey Turner (Australia)	Past President
Emerita Barrenechea (Philippines)	Congress President ICRT-2013
2013 – 2015	
Richard Baum (Germany)	President
Emerita Barrenechea (Philippines)	Secretary
Partha Choudhury (India)	Treasurer
Suresh Srivastava (USA)	President Elect
Irene Virgolini (Austria)	Congress President ICRT-2015
Josh Mailman (USA)	Chief Operational Officer
2016 – 2017	
Suresh Srivastava (USA)	President
Irene Virgolini (Austria)	President Elect
Partha Choudhury (India)	Secretary, Congress President ICRT-2017
Emerita Barrenechia (Philippines)	Treasurer
Richard Baum (Germany)	Past President
Josh Mailman (USA)	Chief Operational Officer
2018 – 2019	
Irene Virgolini (Austria)	President
Partha Choudhury (India)	President Elect
Butch Magsombol (Singapore)	Secretary
Aviral Singh (Germany)	Treasurer
Suresh Srivastava (USA)	Immediate Past President
Josh Mailman (USA)	Chief Operational Officer
Feng Wang (China)	Congress President ICRT-2019

Large Governing Board Members 2009 - 2019

2009 – 2012

Abdelhamid Elgazzar (Kuwait)
Annare Ellmann (South Africa)
Haddia Bererhi (Oman)
Horacio Amaral (Chile)
Patricia Bernal Trujillo (Colombia)
John Buscombe (United Kingdom)
Kalevi Kairemo (Finland)
Savvas Frangos (Cyprus)
Frank Roesch (Germany)
Peljee Onkhuudai (Mongolia)
Gregory Wiseman (USA)
N Watanabe (Japan)
Suresh Srivastava (USA)

2013 – 2014

Patricia Bernal Trujillo (Colombia)
Luzmaria Castaneda (Dom. Republic)
Abdelhamid Elgazzar (Kuwait)
Shazia Fatima (Pakistan)
Gopinath Gnanasegaran (UK)
Knut Liepe (Germany)
Raihan Hussain (Bangladesh)
Mai Trong Khoa (Vietnam)
Harvey Turner (Australia)
Irene Virgolini (Austria)
N. Watanabe (Japan)
Seyed Rasoul Zakavi (Iran)
Sze Ting Lee (Australia)
Cornelis Hoefnagel (The Netherlands)

2014 – 2018

Patricia Bernal Trujillo (Colombia)
Gopinath Gnanasegaran (UK)
Raihan Hussain (Bangladesh)
Sze Ting Lee (Australia)
Jasna Mihailovic (Serbia)
Mike Sathekge (South Africa)
Ajit Shinto (India)
Harvey Turner (Australia)

2018 – 2019

Sze Ting Lee (Australia)
Kalevi Kairemo (Finland)
Mike Sathekge (South Africa)
Patricia Bernal Trujillo (Colombia)
Raihan Hussain (Bangladesh)
Knut Liepe (Germany)
Qaisar Siraj (Kuwait)

2020 – 2021



The ICRTs of The WARMTH

ICRT	LOCATION	CONGRESS PRESIDENT
1 st ICRT-2005	Limassol, Cyprus	Ajit Padhy, Savvas Frangos
2 nd ICRT-2007	Ulaanbaatar, Mongolia	Ajit Padhy, Sereegotov Erdenechimeg
3 rd ICRT-2008 = ISRT	Goa, India	Ajit Padhy
4 th ICRT-2009 = ISRT	Cartagena, Colombia	Ajit Padhy, Patricia Bernal
5 th ICRT-2010 =ISRT+WFNMB	Capetown, South Africa	Ajit Padhy, Annare Ellmann
6 th ICRT-2011	Ho Chi Min City, Vietnam	Ajit Padhy, Nguyen Chau
7 th ICRT-2012	Levi, Finland	Ajit Padhy, Kairemo Kalevi
8 th ICRT-2013	Manila, Philippines	Emerita Barrenechia
9 th ICRT-2014 +WFNMB	Cancun, Mexico	Richard Baum, Horacio Amaral
10 th ICRT-2015	Innsbruck, Austria	Irene Virgolini
11 th ICRT-2016	Kochi, India	Partha Choudhary
12 th ICRT-2017 +IAEA	Vienna, Austria	Irene Virgolini, Diana Paez
13 th ICRT-2018 +WFNMB	Melbourne, Australia	Irene Virgolini, Sze Ting Lee
14 th ICRT-2019	Nanjing, China	Feng Wang
15 th ICRT-2020	Coxbasar, Bangladesh	Raihan Hussain
16 th ICRT-2021 + ALASBIMN	South America	Partha Choudhary, Juliano Cerci Mariela Agolti?
17 th ICRT-2022 +WFNMB	Kyoto, Japan	Mike Sathekge, Seigo Kinuya



The Principle Structure of a „Typical“ ICRT

The scientific programme of a typical ICRT is usually conducted over 2 to 3 days on all aspects of radionuclide therapy. In the past it also became usual to have a pre-congress meeting on nuclear cardiology and nuclear neurology. These pre-congress symposia are mostly in the interest of the local nuclear institution for general training purpose and give the opportunity to hold organizational meetings (such as Executive Board Meetings or Governing Board Meetings) prior the scientific programme on nuclear therapy commences. Thus, participants/delegates arrive on this **„Pre-Congress Day“**.

The **„Welcome Reception“** in the evening is basically a social gathering with local food, drinks and music. During the **„Opening Ceremony“**, on the next day in the morning, the Congress President introduces the scientific programme. Local representatives from the Politics / University / Hospital welcome the delegates, mostly accompanied by local traditional music or performances. The WARMTH President acknowledges the hard work of the Congress President and the local organization team. The opening speeches are followed by a **„Candle Light Ceremony“** which was first introduced by Ajit Padhy. The last speech of the Opening Ceremony is the **„Ajit Padhy Oration“** which is by nomination and subsequent approval by the WARMTH Executive Board.

Each day, the scientific programme consists of several planary (invited) lectures within specific symposia in the various fields of nuclear therapy. Usually, the lunch is taken together at the conference location. In the evening of each scientific day, the WARMTH dinners are exceptional **„WARMTH Gala Dinners“**. The **„Oenophilus Dinner“** on the last day of the scientific programme has become very famous as it has become the habit that all delegates bring one or two bottles of wine from their countries. In addition, a **dresscode** for the evening was implemented, and the evening was always full of a plentitude of food, wine, dance and music. For instance, the dresscode for Manila was „violet“, for Innsbruck „red“, for Kochi „green“, for Nanjing „blue“.

The friends of WARMTH enjoyed a one-day post-congress local touristic tour in the area. Many also came with their families to other continents and had post- or pre-ICRT social tours.



The Ajit Padhy Orations

Innsbruck, Austria	ICRT2015	Patricia Bernal, Bogotá, Colombia: Video Presentation in memoriam of Ajit Padhy
Kochi, India	ICRT2016	Hossein Jadvar, NY, USA Title: „Recent Advances in Prostate Cancer Theragnostics“
Vienna, Austria	ICRT2017	Stanley Goldsmith, NY, USA Title: „Searching for the Magic Bullet: History of Targeted Radionuclide Therapy“
Helsinki, Finland	ISRT2018	Steven M. Larson, NY; USA Title: „New Insights in Theragnostics“
Nanjing, China	ISRT2019	Mathew L. Thakur, Philadelphia, USA: „Oncologic Urology“



Patricia Bernal, 2015



Hossein Jadvar 2016




Stanley Goldsmith 2017



Steven Larson 2018



Mathew L. Thakur 2019



The Life-Time Achievement Awards

Innsbruck, Austria	2015	Georg Riccabona, Austria
Kochi, India	2016	not presented
Vienna, Austria	2017	Suresh Srivastava, Brookhaven, USA
Helsinki, Finland	2018	M. Juhani Knuuti, Turku, Finland
Nanjing, China	2019	Xiujie Liu, Beijing, China



Executive Board
President
Irene Virgili (AT)
President Elect
Pavla S. Choudhury (IN)
Secretary
Belen Miquel (SG)
Treasurer
Avin Singh (DE)
Chief Operational Officer
Josh Maiman (US)
Governing Board
Sue Ting Lin (AU)
Kateri Kallene (FI)
Mike Sathkuge (SA)
Patricia Derral Tsouko (GD)
Radwan Hussien (BD)
Raul Lopez (DE)

Past Presidents
Suresh Srivastava (US)
Richard Evans (DE)
Ari Pachy (RU)
Harvey Turner (AU)

WJRM:
Chief Editor
John Basciano (GB)
Chief Editor Elect
Gerald Song (KR)
<http://www.warmth.org>

Email:
info@warmth.org

In Recognition of
His Continued Role in the Global Advancement
of Clinical and Basic Sciences in
Nuclear Medicine
this
Lifetime Achievement Award
is presented to
Professor M. Juhani Knuuti,
Turku, Finland
on the occasion of this
International Symposium on Radiopharmaceutical Therapy (ISRT)
under the auspices of WARMTH
(World Association of Radiopharmaceutical and Molecular Therapy)
Helsinki, Finland November 18-20, 2018

WORLD ASSOCIATION OF RADIOPHARMACEUTICAL AND MOLECULAR THERAPY

Awards

The WARMTH Lifetime Achievement Award




WARMTH
WORLD ASSOCIATION OF RADIOPHARMACEUTICAL & MOLECULAR THERAPY
Registered office: 10140141 - Registered under the Austrian Companies Act 1989 in the state of Austria

Governing Body (2009-2014)

President:
Prof. Richard Baum (Germany)
richard.baum@innsbruck.ac.at

Secretary:
Dr. Erika Barmann (Austria)
erika.barmann@innsbruck.ac.at

Treasurer:
Dr. P. S. Choudhary (India)
pschoudhary@innsbruck.ac.at

Honorary Chair:
Dr. J. Schmider (USA)
jschmider@innsbruck.ac.at

Members:
Dr. Patricia Barakat (Colombia)
Dr. Carmela Cordero (Spain, Retired)
Prof. Ali Elgazzar (Tunisia)
Dr. Anne Hesse (Germany)
Dr. Dorothea Krenn (Germany)
Dr. Klaus Lippert (Germany)
Prof. Rainer Müller (Austria)
Dr. Marc Thewissen (France)
Prof. J. H. van der Meer (Netherlands)
Prof. J. H. van der Meer (Netherlands)
Prof. J. H. van der Meer (Netherlands)
Prof. J. H. van der Meer (Netherlands)
Prof. J. H. van der Meer (Netherlands)
Prof. J. H. van der Meer (Netherlands)
Prof. J. H. van der Meer (Netherlands)
Prof. J. H. van der Meer (Netherlands)

Address for Communications:
WARMTH Secretariat
secretariat@innsbruck.ac.at
warmth.org

In Recognition of
His Continued Role in the Global Advancement
of Clinical and Basic Sciences in
Nuclear Medicine
this
Lifetime Achievement Award
is presented to
Professor Dr. GEORG RICCABONA
on the occasion of this
Tenth International Conference of Radiopharmaceutical
Therapy (ICRT)
Convened in Innsbruck, Austria, May 3 – 8, 2015
under the auspices of WARMTH
(World Association of Radiopharmaceutical and Molecular
Therapy)

May 7, 2015 Medical University of Innsbruck, Austria



Awards

The WARMTH Recognition Award



Director Zhang, Nanjing Hospital
ICRT 2019, Nanjing / China





Awards

The WARMTH Organisation Award



1st ICRT-2005, Limassol, Cyprus

Window on World Radiopharmaceutical Therapy

INTERNATIONAL CONFERENCE ON
RADIOPHARMACEUTICAL THERAPY (ICRT-2005)



Organized by:
World Radiopharmaceutical Therapy Council (A Subsidiary body of WFNMB&B)
Limassol, Cyprus, 11-14 October 2005

You are most cordially invited

Important Information

Dates: 11-14 October 2005

Venue:

St. Raphael Resort

Limassol, Cyprus

Conference web address:

<http://www.nucleardiagnostics.com.cy/>
and follow the link: ICRT-2005

For Details Please Contact:

Secretariat:	Local Host in Cyprus:
Prof. A.K. Padhy	Dr. S. Frangos
Professor & Head	Department of Nuclear Medicine
Department of Nuclear Medicine	KF Nuclear Diagnostics
Gujarat Cancer & Research Institute	Filiou Zannetou 10
Ahmedabad, Gujarat, India-380016	CY-3021 Lemesos, Cyprus
Tel: 00-91-79-22681451	Tel.: +357 25878725
Fax: 00-91-79-22685490	Fax: +357 25871747
Cell: 00-91-9879621757	Cell: 00-357-99589100
ajitpadhy1@yahoo.co.uk	frangos@nucleardiagnostics.com.cy

World Journal of Nuclear Medicine, Volume 4, Number 2, April 2005













2nd ICRT-2007, Ulaanbaatar, Mongolia

Congress Invitation Letter

Dear Friends,

Greetings from World Radiopharmaceutical Therapy Council.

I am happy to inform you that the preparations for the 2nd International Conference on Radiopharmaceutical Therapy (ICRT-2007) are progressing well. The conference is being organised in collaboration with International Atomic Energy Agency (IAEA), World Federation of Nuclear Medicine & Biology (WFNM&B), European Association of Nuclear Medicine (EANM), Asia Oceania Confederation of Nuclear Medicine & Biology (AOCNMB), Asia Regional Cooperative Council of Nuclear Medicine (ARCCNM), Mongolian Nuclear Medicine Society and Mongolian Radiological Society. We are getting tremendous response from prospective participants from all over the world. This early we have been able to obtain the confirmation from a large number of highly distinguished International experts for their participation in the congress as Plenary Speakers. We also have an excellent and highly functional congress website (www.icrt-07.com), where people can register on-line, submit abstracts on line and get all relevant information about the conference on line.

The local organisers in Mongolia are working very hard to host a memorable conference in Ulaanbaatar . The scientific programme is under construction. Your inputs are most welcome. Please do not hesitate to send us your suggestions and recommendations for the scientific and other programmes of the conference. We need your inputs, suggestions and recommendation to formulate an outstanding scientific and social programme.

As you are aware, the meetings organised by WRPTC are conceptually different from all other conferences. There is no registration fee. Every one pays for himself or herself to attend the congress. We try to keep the expenses as low as reasonably possible so that professionals from all parts of the world and from all levels of nuclear medicine practice can attend. All participants stay in the same hotel. There are no parallel sessions. All participants participate in all scientific activities of the conference. All participants participate in all social activities as well. All in all these meetings are the "meeting of friends", belonging to the "global nuclear medicine family".



At this point of time I would like to inform you that we have booked the entire Chinggis Khaan Hotel in Ulaanbaatar for the conference. There are about 280 rooms. Since we are having tremendous response for the meeting, the room reservations and allocations will be done on a "first come first serve" basis. I would therefore request you to kindly register yourself (Registration is free) for the conference on-line and remit your lumpsum to the ICRT bank account in Mongolia at your earliest convenience.

Please note that September is the peak tourist season in Mongolia . I would therefore request you to kindly make your airline bookings from now itself. Otherwise it may be difficult (and also may be more expensive) to obtain the tickets at a reasonable price. The conference lumpsum covers your stay in Ulaanbaatar for six nights and 7 days starting from 2nd September (Sunday) 2007. The conference ends on Friday (7th September) noon time. There is no need for you to leave Ulaanbaatar in a hurry on Friday itself. Friday night accommodation is included in the lumpsum. So you should depart on Saturday. I hope that the Mongolian congress will provide you the right mix of academics and social activities and you will have enough opportunities to relax and relish the hospitality of the Mongolian people, experience the vibrant Mongolian culture and enjoy the serene beauty of nature at its best. Please note the deadlines:

Deadline for Registration: 5 March 2007

Deadline for submission of abstracts: 5 April 2007

Deadline for lump-sum payment: 5 May 2007

I am looking forward to your active participation in the ICRT-2007 and contributions to all other activities of the World Radiopharmaceutical Therapy Council.

I would also take this opportunity to wish you, your friends and family HAPPY NEW YEAR, filled with happiness, health and prosperity.

Kind regards,

Ajit Padhy

The 2nd International Conference on Radiopharmaceutical Therapy (ICRT-2007), Ulaanbaatar, Mongolia, September 2-7, 2007

Dr. Emerita Barrenechea
Regional Editor (Asia), WJNM

World J Nucl Med 2008;7:199-221

Mongolia is a country of spectacular landscape, pristine nature and friendly people. In Mongolia, you will experience a rich and ancient nomadic cultural heritage. You will encounter an awesome landscape which varies from the spectacular Altai mountain peaks to mysterious Gobi desert, to the untouched wildlife of the steppes. The 2nd International Conference on Radiopharmaceutical Therapy (ICRT-2007) was held in the picturesque city of Ulaanbaatar, the capital of the great land-locked country Mongolia. The meeting was a great success, truly a feat for the World Radiopharmaceutical Council. One can say that there is some direction now with the high turnout of people who signed up for membership. The response of the participants was very encouraging as seen in their active participation and extending assistance in whatever way they could contribute, whether academically or socially.

Where else in the world can you find a more active group of people who do things with utmost zeal and great dedication, majority of which are young participants, who for the first time in their lives were given a chance to be heard, seen and become ambassadors of good will of their respective countries, enabling others to know more about their region and the field of Nuclear Medicine as a whole. The pageantry and noise along with the whirlwind of academic and social activities; as well as dinners accompanied by lights and sounds from different corners of the world made the event absolutely unique and extraordinary. But what made the ICRT-2007 truly memorable was the genuine spirit of camaraderie felt amongst all the participants.

The event was organized by the WRPTC in collaboration with the First State Central University Hospital of Ulaanbaatar, which has the only NM center in far-away Mongolia, serving as host. The meeting was also made possible through the joint collaborative efforts of several regional and international organizations like, ARCCNM, DOE-USA, EANM, AOFNMB, ANZSNM, Mongolian NMS and the Mongolian Radiological Society. This whole event from its very conceptualization, planning and implementation was made possible under the absolute and dynamic leadership of the Chairman of the WRPTC Prof. Ajit Padhy.

A total of 210 participants coming from 67 countries attended the conference. The 5-day event was divided into 17 scientific sessions. A total number of 45 invited lectures and 218 proffered scientific papers (25 oral and 193 poster

presentations) were presented. The topics covered in the conference included the current trends in almost all areas of radionuclide therapy including clinical applications, radiation protection, radiation dosimetry, medical physics, radiopharmacy and molecular therapy. Radionuclide treatment of thyroid disorders, metastatic bone pain, liver cancer, lymphoma, neuroendocrine tumours, rheumatoid arthritis, hemophilic haemarthropathy formed the main bulk of the scientific presentations.

Several important scientific presentations which are of great importance for the practice of radionuclide therapy in the developing countries, were made using relatively new radiopharmaceuticals involving Lutetium 177, Tin-117m and Re-188. Newer and innovative concepts like Aptamers in therapy were discussed. One of the most exciting presentations in the conference came from Prof. Alan Perkins of UK, was based on the highly controversial topic of Plutonium poisoning. This was an extremely informative and useful presentation and hopefully served its purpose of creating awareness on the medical, social and legal implications of this extremely toxic and dangerous radionuclide.

These discussions and lectures came from established names in nuclear medicine from highly sophisticated NM facilities and from experiences of the developing countries that only have the very basic NM departments. So there was great sharing of simple things and advances in NM. It was nice to learn from each other.

The other highlights were feasts for the soul and senses. Nice food, nice scenery, wine, music and dancing. The nature tour was exhilarating. The mountain climbing amidst the natural splendor of this God's own country was something to behold. We were made to spend an afternoon in the ger, a tent made of lattice wood covered by felt. The ger is the most important possession of a herder. It is amazing that this dwelling place looks so small from the outside but actually can fit a family with all the basic amenities. In winter they add layers of felt to protect them from the cold. Also they can pack this tent in an hour should they decide to transfer places and wander in the desert and can be carried easily on camel back. Here we were able to experience the Mongolian chill, and as I have mentioned the organizers foreseeing this provided immediate heat through a huge bonfire where there were fireworks, dances to drive the evil spirits and wish us good luck and of course

Window on ICRT

singing and dancing. The other dinners provided healthy cuisine plus a variety of entertainment consisting of local dances, songs, contortionists and fashion shows.

All in all, the Mongolian experience was something like an experience of “once in a life time”. As a perfect blend of high scientific content and great social and cultural interaction, this meeting at Ulaanbaatar will probably remain as “gold standard” for all future congresses and conferences. The Mongolia conference has also confirmed that one does not need millions of dollars to organize a successful congress. This meeting, like all other meetings organized by the WRPTC had no registration fee. All participants had to pay a modest amount of lump sum to cover their hotel, food etc. during the conference. This meeting has also proven that simple people with hard work, dedication and honesty can do wonders given the right opportunity and encouragement.

We salute the efforts of Prof. A.K. Padhy, Prof. P.

Onkhuudai, Dr. E. Sereegotov, Dr. B. Enkhtuya and all other colleagues from the WRPTC and Mongolia for organizing such a wonderful congress under such wonderful surroundings.

The WRPTC, which was conceptualized in 1994, taken shape in 1998 (Berlin) and formally established in 2002 – has come of age in Mongolia within such a short span of only 5 years. It is soon going to be upgraded to World Association of Radionuclide and Molecular Therapy (WARMTH), which will be inaugurated in Cartagena, Colombia in November 2009. With the support and efforts of each and every individual belonging to the global nuclear medicine community the future “WARMTH” should be able to promote radionuclide therapy throughout the world in such a way that would provide cure and relieve pain in millions of people suffering from diseases and sickness.

Let us keep this spirit alive!



Figure 1. ICRT-2007, Ulaanbaatar, Mongolia. 210 participants from 67 countries from all over the world attended the conference.





Pic of the day !






Figure-4. Alan Perkins (UK), Suresh Srivastava (USA), Russ Knapp (USA) and Eko Purnomo (Indonesia) during a coffee break.



Figure-13. The ARCCNM delegates from all Asian Member States along with the ARCCNM Chairman, Prof. June Key Chung (Sitting fourth from left).



Figure-10. The Philippine delegation with their magnificent Barongs seen with the President of PSNM Dr. Obmerga (Standing fourth from left). Also seen are Drs. San Luis, Emerita Barrenechea and Resty Monzon along with their other colleagues. Philippine had the largest delegation at the conference.



Figure-15. A section of the audience during a Scientific Session.



Figure-18. Dr. Raihan Hussain with two of his charming colleagues from Bangladesh.



Figure-17. Dr. Sidney Yu (Singapore) and Prof. Joachim Kropp (Germany) chairing a scientific session.



Figure-25. Delegates from Vietnam, Indonesia, Philippines and Mongolia during a sight-seeing tour of Ulaanbaatar



Figure-22. Participants from Cyprus, Indonesia, UK and Vietnam



Figure-51. Prof. Richard Baum (Germany) addressing the participants during the Oenophilous dinner. Dr. Rena Demetriadou the President of world nuclear oenophilous society is in the middle



Figure-53. Savvas Frangos (Cyprus) all smiles



Figure-54. Morteza (Iran) with Aisyah Elliyanti (Indonesia) and Anca Zamfirescu (Romania).



Figure-55. Dancing around the fire. It was a wonderful evening full of joy, friendship and camaraderie.



3rd ICRT-2008, Goa, India





WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2008



PROGRAMME

INTERNATIONAL SYMPOSIUM ON RADIOPHARMACEUTICAL THERAPY (ISRT-2008)
Goa, India, 27-30 October 2008

Monday: 27 October 2008

0900-1600 Participants start arriving
Registration
Basically the participants will have a free morning and afternoon - relaxing in the hotel, strolling on the beach, shopping in the local markets or sightseeing.

1800-1900	Executive Council Meeting of WRPTC	
1700-1900	Pre-congress CME on Nuclear Cardiology	
	Chairpersons: Prof. R.D. Lele (India), Prof. Diwakar Jain (USA)	
	Invited Lectures	
1700-1730 113	Nuclear cardiovascular imaging for the evaluation of patients with heart failure	Prof. Diwakar Jain (USA)
1730-1800 114	Myocardial Ischaemia Imaging	Prof. Zuo-Xiang He (China)
1800-1830 115	Prognostic value of Myocardial Perfusion Imaging	Dr. Felix Keng (Singapore)
1830-1900 116	Is there a life beyond Myocardial Perfusion Imaging?	Prof. Diwakar Jain (USA)
1900-2200	Pre-congress get-together and Dinner	

Tuesday: 28 October 2008

0800-1600	Registration continues	
0815-0900	Abstract No	Scientific Session-1
	Chairpersons: Prof. Annare Ellmann (President, WFNMB), Prof. M.L. Thakur (USA)	
0815-0830	Opening Remarks	
	Prof. A.K. Padhy (Singapore), Chairman, WRPTC	
	Prof. A. Ellmann (South Africa), President, WFNMB	
	Prof. A. Malhotra (India), President, AOFNMB	
	Dr. P. Dougall (India) Chairman, Local Organizing Committee	
	Prof. A. Perkins (UK), Chairman, Scientific Committee	
	Invited Lectures	
0830-0850	Radiopharmaceutical Therapy: A perspective	Prof. R.D. Lele (India)



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

0850-1030 Scientific Session-2

Thyroid:I

Chairpersons: Dr. Arpan Bhattacharya (India), Prof. Myung C. Lee (Korea)

Invited Lectures

0850-0915	81	Radioiodine Treatment of Hyperthyroidism: A review	Dr. Wai Yin Wong (Singapore)
0915-0935	94	Long-Term outcome: Radioiodine ablation of Toxic AFTN	Prof. C.S. Bal (India)
0935-0955	95	Radioiodine treatment of hyperthyroidism in the male patient	Prof. Annare Ellmann (South Africa)

0955-1045

Proffered Presentations

Oral Presentation

0955-1003	47	Is prior ATD treatment necessary before radioiodine therapy in Graves' Disease?	Prof. B.K. Das (India)
-----------	----	---	------------------------

1003-1045 Posters, Networking & Coffee

19	Transient Hypothyroidism after I-131 Therapy	Dr. F. Saddadi (Iran)
22	The effect of antithyroid drugs pretreatment on the efficacy of radioactive iodine therapy in Graves' Disease	Dr. Z. Rajkovaca (Bosnia and Herzegovina)
31	The feasibility of 131I treatment in patient with nodular goiter : Effect on thyroid function and size	Dr. Hosne Ara Rahman (Bangladesh)
32	Evaluation of TSH as a sole first line test for the detection of thyroid disorders in the Philippines setting	Dr. Joe Ryan Agga (Philippines)
45	Toxic Intrathoracic Goitre: A case Report	Dr. Jefferson Pagsisihan (Philippines)
48	Our experience with Radioiodine Therapy of very large goitre	Dr. Antra Berzina (Latvia)
55	Definitive I-131 treatment in patients with hyperthyroid diseases	Dr. Margarita Radeva (Bulgaria)
17	Management of Differentiated Thyroid Cancer with available facilities for Radioiodine Therapy	Dr. Damayanthi Nanayakkara (Sri Lanka)
27	Follow up of treatment with I-131 in patients with Thyroid Cancer and Pulmonary metastases	Dr. Daniel Santos (Peru)
35	Serial Thyroid Stimulating Hormone (TSH) estimation after Thyroidectomy in well-differentiated thyroid cancer	Dr. Nurun Nahar (Bangladesh)
37	Influence of antithyroglobulin antibodies on thyroglobulin concentration measured by immunoradiometric assay	Dr. Snezana Zivancevic Simonovic (Serbia)
38	Effect of furosemide and potassium chloride adjuvant therapy on radioiodine retention in patients with differentiated thyroid carcinoma treated with I-131	Dr. Milovan Matovic (Serbia)
42	Radioiodine treatment of paediatric thyroid cancer: An institutional experience	Dr. Kaouthat Chatti (Tunisia)



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

67	Efficacy of I-131 Therapy in Hyperthyroid Children	Prof. Sahana Afroz (Bangladesh)
59	Pregnancy outcome after treatment with radioiodine for differentiated thyroid carcinoma	Dr. Armaghan Fard-Esfahani (Iran)
66	Adenomas Behave Aggressively During Follow-up: a Padang Experience	Dr. Aisyah Elliyanti (Indonesia)
63	Outcome of radioiodine therapy in toxic diffuse goiter and toxic nodular goitre	Dr. Sayedur Rahman Miah Sayedur (Bangladesh)

1045-1315 Scientific Session-3

Thyroid-II

Chairpersons: Dr. Shabber Zaveri (India), Dr. Rasoul Zakavi (Iran)

Invited Lectures

1045-1105	91	Guidelines, standard setting and standard operating procedures in the treatment of Thyroid Cancer	Dr. Susan Clarke (UK)
1105-1125	77	Current Practice of I-131 Therapy of Differentiated Thyroid Cancer: An Overview	Dr. Jasna Mihailovic (Serbia)
1125-1145	96	Treatment and Management of Differentiated Thyroid Cancer in the Paediatric Population	Dr. Isabel Roca (Spain)
1145-1205	97	Sporadic Thyroid Cancer in Children: Indian Scenario	Prof. C.S. Bal (India)
1205-1225	98	Various protocols to use in the primary treatment and follow up of thyroid carcinomas	Prof. Joachim Kropp (Germany)
1225-1245	99	Use of rhTSH in the Treatment of Differentiated Thyroid Cancer: A Review	Dr. Haddia Bererhi (Sultanate of Oman)

1245-1315 Preferred Presentations

1245-1315 Oral Presentation

73	Pregnancy after Therapeutic Doses of I-131 for Differentiated Thyroid Carcinoma: A Sultan Qaboos University Hospital experience	Dr. Haddia Bererhi (Sultanate of Oman)
75	A randomized clinical trial for the evaluation of the efficacy of 30 mCi versus 100 mCi ¹³¹ I for ablation of residual thyroid tissue	Dr. Abbas Takavar (Iran)
62	The usefulness of serum thyroglobulin in monitoring therapy for thyroid cancer	Dr. Emerita Barrenechea (Philippines)
71	Detection of I-131-negative recurrent/ metastatic papillary thyroid cancer on 18F-FDG-PET/CT – our experience	Dr. Eve Kelk (Estonia)
61	Epidemiology of Differentiated Thyroid Cancer in Morocco	Prof. Nozha Ben Rais (Morocco)

1315-1400 Lunch

1400-1530 Scientific Session-4

Neuroendocrine Tumours

Chairpersons: , Dr. A.M. Samuel (India), Prof. M. Sathakge (South Africa)

Invited Lectures



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

1400-1425	100	An update on our experience with Peptide Receptor Radiotherapy (PRRT) in Neuroendocrine Tumours (NETs)	Prof. R. P. Baum (Germany)
1425-1445	92	MIBG Therapy: An Overview	Dr. Susan Clarke (UK)
1445-1505	101	Radiopeptide control of endocrine cancer: A Phase IIA study of Lu-177 octreotate/ capecitabine therapy of disseminated neuroendocrine tumours	Prof. Harvey Turner (Australia)
1505-1525	10	Therapy of metastatic NET with in house radiolabelled somatostatin analogues	Dr. Jure Fettich (Slovenia)
1525-1545	102	Technetium-99m labeled somatostatin analogues and their role in the management of patients with	Dr. Renata Mikolajczak (Poland)
1545-1602	82	Innsbruck Experience with Peptide Related radionuclide Therapy (PRRT) in Patients with Somatostatin Receptor Positive (SSTR) Tumours 1) Long-term Follow-Up of Clinical Response 2) Effects of Architecture, Music and Prayer on Quality of Life Parameters and Treatment Response Criteria – „Healing is Release from Fear“	Prof. Irene Virgolini, Claudia Schumm, Gertraud Jestl-Horngacher, Margot Staudinger, Remigius O, Dirk Heute, anders, Martin Jeller (Austria)

1605-1620		Posters, Networking & Coffee	
18	Comparative Evaluation of Samarium-153, Holmium-166, Yttrium-90 and Lutetium-177 labeled EDTMP for bone pain palliation	Dr. Azra Parveen (Pakistan)	
26	In vivo Localization of a New 90Y-based Phosphonate Chelate: Bone Metastases Treatment	Dr. Nadežda Nikolic (Serbia)	
39	Efficacy of Strontium-89 Chloride in Patients with Painful Bone Metastases. Is There Any Reason to Be Afraid of Toxicity?	Dr. Raluca Mititelu (Romania)	
41	Strontium-89 Chloride in the palliation of painful bone metastases	Dr. Ljiljana Jaukovic (Serbia)	
43	First experience of utilizing of Sm-153 EDTMP in palliative treatment of multiple skeletal bone metastases in Uzbekistan	Dr. Nigora Rasulova (Uzbekistan)	
58	Rhenium-88 tin microparticles for Radiosynovectomy: An in-house preparation	Dr. Jaya Shukla (India)	
70	Prevalence of bone metastases from female breast cancer in Central Sudan	Dr. Suliman Salim (Sudan)	
23	90Y- labeled antimony trisulfide and tin colloid as promising agents for therapy: preparation and biodistribution	Dr. Drina Jankovic (Serbia)	

1620-		Scientific Session-5	
		Radiosynovectomy & Bone Pain Palliation	
		Chairpersons: Prof. J.H. Turner (Australia), Prof. Abdelhamid Elgazzar (Kuwait)	
		Invited Lectures	



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2008

1620-1640	103	Radionuclide Therapy with high LET Electron emitters	Dr. S. Srivastava (USA)
1640-1700	78	Radionuclide treatment of Haemophillic haemarthopathy	Dr. E. Barrenechea (Philippines)/ Dr. Shrikant Solav (India)
1700-1720	24	Diagnostic and therapeutic applications of "core peptide" and Tc-99m labelled Glucosamine in the management of rheumatoid arthritis	Dr. Vijay Kumar (Australia)
1720-1740	89	Radiation Synovectomy of Chronic Knee Synovitis	Prof. Izac Garty (Israel)
1740-1810		Proffered Presentations	
		Oral Presentation	
1740-1748	40	Evaluation of ^{99m} Tc-HMPAO labelled PEG-liposomes as drug delivery vehicle to target rheumatoid arthritis lesions	Dr. Anne Vanniasinghe (Australia)
1748-1756	56	Comparison of potential bone pain palliation agents—Lu-177-EDTMP and Lu-177-DOTMP	Dr. Dinesh Shetty (Korea)
1756-1804	65	Low Dose I-131 MIBG Therapy as an Adjunct for Bone Pain Palliation in Pediatric Patients with End-Stage Neuroblastoma: A Pilot Study	Dr. Thomas Neil Pascual (Australia/ Philippines)
1804-1812	15	^{99m} Tc-DOTMP: A Multidentate Skeletal Imaging and Therapeutic Agent for Bone Metastase	Dr. A. Dutta (India)
1812-1930		Break	

1930-2300

Formal opening ceremony:

Speeches by representatives of:
WFNMB, WRPTC, SNM, EANM, ALASBMN, AOFNMB, ARCCNM, ASNM,
Entertainment & Dinner

Celebration of Diwali with Lights and Fireworks. Incidentally Diwali, one of the greatest Indian Festivals falls on this date.

Wednesday: 29 October 2008

0730-0830

Scientific Session-6

Miscellaneous & General Nuclear Medicine

Chairpersons: Prof. Birendra Kishore Das (India), Prof. Azu Owunwanne (Kuwait)

Invited Lectures

0730-0750	104	Targeted drug delivery systems for Imaging Purposes	Prof. Kalevi Kairemo (Finland)
0750-0810	80	PET/CT studies in children, including some preliminary results in oncology	Dr. Judith M Ash (Canada)
0810-0830		Proffered Presentations	
		Oral Presentation	
	14	The Value of Three-Phase Bone Scintigraphy in the Assessment of Stress Fracture	Dr. Marlon Fetalvo (Philippines)

Poster Presentations

- | | | |
|-----|--|--|
| 105 | Scintigraphy and modelling time activity curves of salivary glands after IMRT for Head & Neck Cancer | |
| 12 | Localization of ectopic parathyroid adenoma by double phase technetium ^{99m} - Sestamibi scintigraphy | Dr. Nouzha Ben Rais (Morocco) |
| 13 | Effectiveness of Thermoluminescent Crystals for diagnostic radiology Dose at 70 to 120 kvp | Dr. Seyed Ali Rahimi (Iran) |
| 20 | Paget's disease of the pelvis: A case report | Dr. Irene Bandong (Philippines) |
| 21 | Radioimmuno=detection with Tc-99m Labeled Anti-CEA Fragments in patients with Colorectal Carcinoma | Dr. Moidrag Lacie (Croatia) |
| 30 | ^{99m} Technicium- IgG- HYNIC preparation and its Bio distribution in experimental animals. | Dr. Saeed Rajabifar (Iran) |
| 33 | A comparative study of TSH levels of neonates's cord blood and mother's serum just after delivery and estimation of norms | Dr. Dil Ara Taslima Begum Taslima (Bangladesh) |
| 34 | Preference of "Michrom" over Conventional ITLC Method For The determination of Radiochemical purity of ^{99m} Tc- Labeled Radiopharmaceuticals | Dr. Anwar Ul Azim (Bangladesh) |
| 44 | Reliability of detection and biopsy of Sentinel lymph node in patients with breast cancer | Dr. Marina Vljakovic (Serbia) |
| 49 | The value of stress myocardial perfusion scintigraphy (MPS) in the detection of coronary artery disease (CAD) in women, experience in a tertiary hospital in the Philippines | Dr. Morteza Bahri Iraii (Philippines) |
| 50 | Multi-organ Visualization in a DMSA Renal Scan of a 9-year-old male with Reflux Nephropathy | Dr. Jasmine De Jesus (Philippines) |
| 54 | Scintigraphic Lymph Node Mapping in Malignant Vulvar Melanoma | Dr. Maria Lira Poscablo (Philippines) |
| 69 | SPECT Image Quality Improvement by Attenuation Correction Using Chang Method | Dr. Sassan Saber (Iran) |
| 64 | Findings in the follow-up DMSA Renal Scintigraphy in patients with Urinary Tract Infection | Dr. Apolinario jr de Gracia (Philippines) |
| 84 | Status of nuclear medicine in Azerbaijan. | Dr. Farida Nasirova (Azerbaijan) |
| 76 | Sentinel lymphnode biopsy (SLNB) in malignant melanoma patients – influence of limphoscintigraphy on extent of surgical treatment. | Dr. Bozena Birkenfeld (Poland) |

0815-0930

Scientific Session-7

Radioimmunotherapy

Chairpersons: Prof. Richard P. Baum, Prof. Franklin C Wong (USA)

Invited Lectures



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

0815-0845	106	An update on Nuclear Medicine Therapy	Prof. Markus Luster (Germany)
0845-0915	107	Radioimmunotherapy of Non-Hodgkin's Lymphoma	Prof. Harvey Turner (Australia)

Preferred Presentations

Oral Presentation

0915-0930	60	Radioimmunotherapy (RIT) with ¹³¹ I-anti-CD52 Monoconal Antibody (MoAb) for Stem Cell Support in a Patient with Acute Lymphoblastic Leukemia (ALL) following ¹²⁴ I-anti-CD52 MoAb	Dr. Daniel Putzer (Austria) (To be presented by Prof. I. Virgolini)
-----------	----	---	--

0930-1100 Scientific Session-8

Liver Cancer

Chairpersons: Dr. Russ Knapp (USA), Prof. C.S. Bal (India)

Invited Lectures

0930-0950	108	Development of Re-188 Labelled Radiopharmaceuticals	Prof. Jae Min Jeong (Korea)
0950-1020	83	Natural History of HCC and Current Treatment Options	Prof. Jean-Luc Raoul (France)
1020-1040	85	A perspective on the palliative treatment of inoperable HCC with Re-188 Lipiodol	Prof. A.K. Padhy (Singapore)
1040-1100	74	How to analyze survival data when cause of death is unreliable or missing	Prof. Janez Stare (Slovenia)

Preferred Presentations

1100-1120 Posters, Networking & Coffee

86	Re-188 Lipiodol Therapy of HCC: Experience in Mongolia	Dr. E. Sereegotov (Mongolia)
7	Preparation and Biological Evaluation of [¹¹¹ In]-DTPA-Buserelin for Breast Cancer Therapy	Dr. AR Jalilian (Iran)
8	Preparation and Biodistribution of [¹¹¹ In]-rHuEpo for Erythropoietin Receptor Positive Tumor Therapy	Dr. AR Jalilian (Iran)
28	Monte Carlo and Experimental measurements of dosimetric parameters of a new Pd-103 source	Dr. Mahdi Sadeghi (Iran)
52	Labeling of Mab PR81 with ¹⁷⁷ Lu to Produce a New Biologic Radiopharmaceutical for Radioimmunotherapy of Breast Cancer	Dr. Mojtaba Salouti (Iran)
57	Dose Responsive In-Vitro Cytotoxicity Assessment and Biodistribution Studies of Re(V)DMSA Microspheres for Tumor	Dr. Jaya Shukla (India)

1120-1300 Scientific Session-9

Development of New Radiopharmaceuticals, Production, Dosimetry and Regulatory aspects of Therapeutic Radiopharmaceuticals

Chairpersons: Dr. Sidney Yu (Singapore), Prof. Irene Virgolini (Austria)

Invited Lectures

1120-1140	16	Constraints and limitations in the development of new radiopharmaceuticals: Short-term solutions	Dr. Richard Zimmermann (France)
1140-1200	46	The important role of Research Reactors for Production of Therapeutic Radiopharmaceuticals	Dr. Russ F. Knapp (USA)
1200-1200		Radiopharmaceutical production and regulatory compliance	Dr. Uday Bhonsle (UK)
1200-1220	93	Locoregional Radionuclide Therapy	Prof. Franklin C Wong (USA)
1220-1240		To be announced	
1240-1300		Proffered Presentations	
		Oral Presentations	
1240-1250	11	Potential imaging and Therapeutic Agents for Malignant Melanoma	Dr. Alummoottil Joshua (Canada)
1250-1300	51	Use of surface applicators in Nuclear Medicine: Institutional Experience	Prof. Sahana Afroz (Bangladesh)
1315-1400		Lunch	
1400-1600		Scientific Session-10	
		Development of new radiopharmaceuticals, Molecular Imaging in Radionuclide Therapy, Approaches to stem cell therapy	
		Chairpersons: Prof. Daya Kishore Hazra (India), Dr. Suresh Srivastava (USA)	
		Invited Lectures	
1400-1420	109	Preparation of ⁶⁸ Ga-labelled tumor imaging tracers	Prof. Frank Roesch (Germany)
1420-1440	110	An overview of Metabolic and Molecular Imaging of NET using PET	Prof. Richard Baum (Germany)
1440-1500	25	Is Tc-99m Hynic-Annexin V a useful imaging tool for early detection of apoptosis in Tumour Therapy and Transplant Rejection	Assoc. Prof. Vijay Kumar (Australia)
1500-1520	90	Approaches to Stem-cell Therapy	Prof. Mathew L. Thakur (USA)
1520-1540	87	Nuclear imaging in drug delivery: Radiolabelling and biodistribution of Tc-99m preformed Doxorubicin liposomes in breast cancer	Prof. Alan C. Perkins (UK)
1540-1600	88	Intratumoral P-32 Radionuclide Therapy for Pancreatic Cancer	Dr. Anthony Goh (Singapore)
1600-1620		Posters, Networking & Coffee	
	72	Effect of ¹¹¹ In-Oxine labeling on the survival of human mesenchymal stem cells	Dr. Mohammad Eftekhari (Iran)
	29	Irradiation and dosimetry of Nitinol Stent for Renal Artery Brachytherapy	Dr. Mahdi Sadeghi (Iran)
	68	Role of myocardial perfusion scan in the evaluation of coronary artery disease in diabetic patients.	Dr. Sharmin Quddus (Bangladesh)
	36	Blood Volume and Red Cell Volume Measurement Using Single Tag ⁵¹ Cr-Sodium Chromate	Dr. I Hossain Ansari (Bangladesh)



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

- 53 The correlation of TID (Transient Ischemic Dilation) with HbA1c concentration in type 2 Diabetes Mellitus patients who also present the Metabolic Syndrome Dr. Hendra Budiawan (Indonesia)

1620-1800 Scientific Session-11

Radionuclide Therapy in diseases of haemopaetic and Cardiovascular System,
Chairpersons: Prof. Zuo Xiang He (China), Prof. Bozena Birkenfeld (Poland)

Invited Lectures

- 1620-1640 111 Intravascular radionuclide therapy using Re-188 Prof. Joachim Kropp (Germany)
Perrhenate
- 1640-1700 112 Potential of Tin-117m for the Molecular Imaging and Therapy of Atherosclerotic Disease Dr. Suresh Srivastava (USA)
- 1700-1730 116 Cardiotoxicity of Cancer Chemotherapy: Mechanism, Early Detection and Prevention Prof. Diwakar Jain (USA)

1730-1830 World Radiopharmaceutical Therapy Council Assembly

Chairpersons: Prof. A.K. Padhy, Prof. A.C. Perkins

* Provisional Agenda:

1. Annual Report by the Hon Secretary Prof. A.C. Perkins
2. Discussions on the formation of World Association of Radionuclide and Molecular Therapy (WARMTH)
3. Adoption of WARMTH Constitution
4. Information about ICRT-2009 at Cartagena, Colombia (3-7 November 2009)
5. Any other matter with permission of the Chair

* This is provisional agenda. The final agenda will be provided by Prof. Perkins, the Hon. Secretary of WRPTC in due course

1830-1900 Closing Ceremony

Break

1930-2300 Oenophilous Dinner

Hosted by: World Nuclear Oenophilous Society

Thursday: 30 October 2008

- 0700-1000 Breakfast and Beach Activities
- 1100-1300 Tour
- 1300-1400 Lunch
- 1400-1600 Tour continues
- 1700 Return to the Hotel
- 1700-1900 Beach activities
- 1900-2200 Dinner


Friday: 31 October 2008

Early morning departure to Delhi or to the respective destinations
Inauguration of AOFNMB Meeting at New Delhi starts at 18.00 hrs











4th ICRT-2009, Cartagena, Colombia

Congress President: Patricia Bernal Trujillo



„The organisation of the ICRT-2009 in Cartagena was a group work with Dr. Ajit Padhy in which a fine mix between the scientific activities of the highest quality on the novel, current and praxis of diagnosis and therapy in Nuclear Medicine was sought. It was a gathering of friends, who discover new countries, customs, flavors and music. An exquisite mix, not achieved by any other scientific event! We worked shoulder to shoulder and continuously for more than 18 months resulting in a successful meeting that merged with the meeting of the Latin American Association of Nuclear Medicine Societies (ALASBIMN) and the Colombian Congress of Nuclear Medicine attracting more than 757 representatives from 53 countries around the world.“ (Patricia Bernal Trujillo, November 2019)





WORLD RADIOPHARMACEUTICAL THERAPY COUNCIL (WRPTC)
A Subsidiary Body of World Federation of Nuclear Medicine & Biology (WFNMB)



**3rd INTERNATIONAL CONFERENCE ON
 RADIOPHARMACEUTICAL THERAPY (ICRT-2009)**
Cartagena, Colombia, 3-7 November 2009



**World
 Radiopharmaceutical
 Therapy Council
 (WRPTC)**

Executive Council:

Chairman:

A.K. Padhy (Singapore)

Honorary Secretary:

A.C. Perkins (UK)

Treasurer: J.

Buscombe (UK)

Past Chairman:

J.H. Turner (Australia)

Members

Amaral H(Chile)

Baum R (Germany)

Behr T (Germany)

Britton KE (UK)

Divgi C (USA)

Ellmann A (S. Africa)

Frangos S (Cyprus)

McEwan AJB (Canada)

Raoul J-L (France)

Srivastava S (USA)

Sundram F X (Malaysia)

Wong F (USA)

**3rd International Conference
 on Radiopharmaceutical
 Therapy**

Cartagena, Colombia 3-7
 November 2009

www.icrt-09.warmolth.org

**Secretariat & Address for
 communication:**

Prof. A.K. Padhy MD
 Chairman – WRPTC &
 Senior Consultant,
 Department of Nuclear
 Medicine & PET,
 Singapore General Hospital,
 Singapore-169603
 Tel: (65)81287726 Fax:
 (65)62240938
ajitpadhy1@yahoo.co.uk

Local Organiser in Colombia

Dr. Patricia Bernal Trujillo
 Department of Nuclear
 Medicine & PET
 Fundacion Santa Fe de Bogota
 Bogota
 Colombia
 Tel: +57 1 6030303 -ext 5489
 Mob: +57- 3134224267
 Fax: +57- 1- 2104214
 E-mail:
patriciabernalt@yahoo.com

www.icrt-09.warmolth.org

To

1 January 2009

Prof. Dr. Irene Virgolini
 Department of Nuclear Medicine
 University of Innsbruck
 Anichstrasse 35, A-6020, Innsbruck
 Austria

Sub: Invitation to participate in the 3rd International Conference on Radiopharmaceutical Therapy (ICRT-2009) and deliver Plenary Lecture(s)

Dear Prof. Virgolini,

Greetings from World Radiopharmaceutical Therapy Council.

We would like to wish you and your family a very happy, meaningful and prosperous New Year.

We are pleased to inform you that the World Radiopharmaceutical Therapy Council, which is a subsidiary body of the World Federation of Nuclear Medicine & Biology, is holding its Third International Conference on Radiopharmaceutical Therapy (ICRT-2009) at Cartagena, Colombia from 3-7 November 2009. The previous two meetings were held at Cyprus (2005) and Mongolia (2007).

The objectives of the conference are to evaluate the current status of radiopharmaceutical therapy in the world in general and in the developing countries in particular, to exchange information on the current advances in the field between scientists from developed and developing countries; to interact with user groups (clinicians, oncologists, surgeons, radiopharmacists, medical physicists, etc.) and to bring them the most important information in the field, and to define future directions. The major emphasis of the symposium will be to involve the end-users and stake holders of radionuclide therapy, e.g., oncologists, endocrinologists, radiation oncologists, rheumatologists, haematologists, physicians and surgeons.

The Conference will cover topics and discuss issues on all aspects of radiopharmaceutical therapy through a number of plenary lectures, papers, posters, panel discussions and interactive audiovisual sessions. The topics to be addressed at the symposium include the following:

1. Reviews in therapeutic radiopharmaceuticals
2. Development of new radiopharmaceuticals
3. Clinical overviews of the current trends in radionuclide therapy
4. Radionuclide therapy: Treatment of primary cancer, Treatment of metastatic disease, Pain palliation. Treatment of benign diseases (Rheumatoid arthritis, hyperthyroidism etc.)
5. Prognostication in cancer therapy.
6. Dosimetry 7. Monitoring.
8. Molecular methods in radiopharmaceutical therapy
9. Approaches to Stem-cell Therapy
10. Treatment planning



11. Use of new instruments (PET/CT, dedicated cameras, hand held cameras, etc.) in radiopharmaceutical therapy planning
12. Drug resistance.
13. Radioimmuno-detection and therapy.
14. Infrastructure development, Training & Education.

Keeping in view your international standing and contributions to science in the field of nuclear medicine, we, on behalf of the WRPTC would like to invite you to this conference as a "Cost-free expert" to deliver one or more plenary lectures in one or more of its scientific sessions. Due to paucity of funds, it will not be possible for WRPTC to provide any financial support for your participation in the conference. It is hoped that you will be able to generate funds from your own sources to participate in this conference. With regard to the choice of topics of your talk(s), WRPTC would like to leave that to your discretion. We will be grateful if you can inform me at your earliest convenience if it would be possible for you to participate in the conference as a "cost-free" expert. In case of an affirmative answer, we would also request you to kindly provide us the title(s) of your lecture(s). Please note that time allocated for each invited lecture is 25 minutes, followed by five minutes discussion.

After finalization of the programme, you will be requested to provide extended abstract(s) of your presentation(s) latest by 7th September 2009. The abstracts will be published in a supplementary issue of World Journal of Nuclear Medicine.

Further, it may be noted that in the second Members' Assembly of WRPTC, which was held during the First International Symposium on Radiopharmaceutical Therapy (ISRT-2008) in Goa, India on 30th October 2008; approval was given for the formation of a larger and more democratic International Organization to replace World Radiopharmaceutical Therapy Council (WRPTC). The new organization will be called **World Association of Radionuclide & Molecular THERapy (WARMTH)**; it will be inaugurated at Cartagena during the ICRT-2009. I would invite you to participate in the next Members' Assembly of our organization and witness the historic event of "birth of WARMTH".

As a valued Member and a dynamic leader of the World Nuclear Medicine community, we expect your active support and enthusiastic collaboration in the organization of this historic meeting.

For further details about the congress, we would request you to kindly visit our congress web-site: www.icrt-09.warmth.org. Registration is now open and you may register now on-line. As usual WRPTC does not charge any registration fee to the participants. Registration is free.

With kind regards.

Yours sincerely,

Prof. A.K. Padhy
Chairman, World Radiopharmaceutical Therapy Council (WRPTC) &
Chairman, International Organizing Committee, ISRT-2008

Prof. A.C Perkins
Hon. Secretary, World Radiopharmaceutical Therapy Council (WRPTC) & Co-
Chairman, Scientific Committee, ISRT-2008
Prof. R.P. Baum
Co-Chairman, Scientific Committee, ISRT-2008



PROGRAMME

INTERNATIONAL CONFERENCE ON RADIOPHARMACEUTICAL THERAPY (ICRT-2009)

CARTAGENA, COLOMBIA, 3-7 NOVEMBER 2009

THE POSTERS WILL BE ON DISPLAY ON ALL DAYS. THE PARTICIPANTS ARE REQUESTED TO FIX THEIR POSTERS ON 3RD NOVEMBER AND REMOVE THEM ON 7th NOVEMBER 2009

Tuesday: 3 November 2009

Whole Day	Participants start arriving
0900-2100	Registration
2000-2100	Executive Council Meeting of WRPTC
2000-2300	Informal get-together and Dinner

Wednesday: 4 November 2009

0800-1600 Registration continues

0800-1015 Abstract No Scientific Session-1

Opening & Thyroid I

Chairpersons: Prof. JH Turner (Australia), Prof. A. Ellmann (South Africa)

0800-0815	Opening Remarks:	Dr.
	Patricia Bernal Trujillo, Chairman, Organizing Committee	
	Prof. Richard Baum, Chairman, Scientific Committee	
	Prof. Ajit Kumar Padhy, Chairman, WRPTC	

0815-1015 Invited Lecture

0815-0845	1	Creativity and motivation: A Necessity for Advancing Research and Healthier Life	Prof. AH Elgazzar (Kuwait)
0845-0925	2	I-131 Therapy of Thyroid Cancer	Prof. Stanley Goldsmith (USA)
0925-0955	3	Equivalence randomised stratified control Trial in Remnant Ablation of DTC	Prof. C.S. Bal (India)
0955-1015	4	Thyroid antibodies and Differentiated Thyroid Cancer	Prof. J. Mihailovic (Serbia)

Proffered Presentations

Poster Presentations

(To be viewed and discussed during the coffee break at 1015-1100 am on 04/11/09)

5	Clinical experience with recombinant human thyrotrophin in the radioiodine treatment of patients with differentiated thyroid cancer on L-thyroxine	Dr. Zvezdana Rajkovaca (Bosnia and Herzegovina)
---	--	---

- | | | |
|----|--|---|
| 6 | Use of recombinant TSH (r-TSH) stimulation for treatment of bone metastasis & follow-up in differentiated thyroid carcinoma : work in progress. | Dr. Partha S Choudhury, et al (India) |
| 7 | The level of carcinogenic risk after radioiodine ablation for low risk group papillary thyroid cancer | Dr. Tatiana Hadjieva, et al (Bulgaria) |
| 8 | Effect of low dose radioiodine therapy in differentiated thyroid carcinoma | Dr. Farid Alam, et al. (Bangladesh) |
| 9 | Enhanced sensitivity of lesion detection by performing delayed I-131 whole body scanning beyond the standard 48 hr scan protocol in patients of metastatic differentiated thyroid cancer treated with rhTSH (Thyrogen) intervention | Dr. Kelvin Loke, et al (Singapore) |
| 10 | FRAX assessment of Osteoporotic fracture probability in patients of differentiated thyroid cancer on Thyroid hormone suppressive therapy | Dr. Butch Magsombol, Dr. Kelvin Loke, et al (Singapore) |
| 11 | Scintigraphic profile of thyroid diseases in Yaounde | Dr. Joseph Francis Nwatoek, et al (Cameroun) |
| 12 | Thyroid cancer imaging: Are we missing nodules with high resolution collimator and limiting pinholes studies to anterior view only? | Prof. AH Elgazzar, et al (Kuwait) |
| 13 | The influence of treatment of Subclinical Hyperthyroidism with radioiodine on achievement of euthyroid state, thyroid volume and level of Sex Hormone Binding Globulin. | Dr. Grzegorz Kaminski, et al (Poland) |
| 14 | Radioiodine therapy in childhood thyroid cancer | Dr. Abu-Taher Muhammad (Bangladesh) |
| 15 | The role of high resolution neck ultrasound in combination with thyroglobulin measurement in the wash-out fluid from the fine needle aspiration of neck lesions (FNAB-Tg) in patients with differentiated thyroid carcinoma and positive or negative Iodine-131 whole body scintigraphy. | Dr. S. Frangos, et al. (Cyprus) |
| 16 | Effect of Levothyroxine suppressive therapy on bone mineral density in patients with well-differentiated thyroid carcinoma | Dr. Faria Nasreen, et al (Bangladesh) |
| 17 | Thyroid cancer in Latvia: Review of statistical data and some management problems | Dr. Antra Bergina, et al. (Latvia) |
| 18 | Is Measuring of 131I Thyroid Uptake Using Gamma Camera Reliable Enough? | Dr. Milovan Matovic, et al (Serbia) |
| 19 | Persistent and unusual combination of negative thyroglobulin levels and positive I-131 avid metastases in a patient with metastatic follicular carcinoma of thyroid | Dr. Butch Magsombol, et al (Singapore) |

- | | | |
|----|--|---------------------------------------|
| 20 | Clinical Significance of Serial Measurements of Serum Thyroglobulin & Thyroglobulin Antibodies In Differentiated Thyroid Cancer Patients | Dr. Shazia Fatima, et al. (Pakistan) |
| 21 | Radioiodine Treatment Complications in Mother and Child in Patients with Differentiated Thyroid Carcinoma | Dr. Abbas Takavar, et al. (Iran) |
| 22 | Evaluation of the efficacy of low and high dose radioiodine therapy for ablation | Dr. Abbas Takavar, et al. (Iran) |
| 23 | Predictive value of TSH levels after 131-I treatment of patients with Grave's disease | Dr. Pavel Bochev (Bulgaria) |
| 24 | Diagnostic Value of Serum Thyroglobulin in Differentiated Thyroid Carcinoma Patients to Monitor Persistence or Recurrence Disease | Dr. Aisyah Elliyanti (Indonesia) |
| 25 | Umbilical cord blood TSH values in neonates for screening of congenital hypothyroidism | Dr. Ansari M.I.H, et al. (Bangladesh) |

1015-1100

Networking, Posters & Coffee Break

Poster Coordinators: Dr. Mohd. Aleem Khan, Dr. Nigora Rasulova

ALL POSTERS FROM SCIENTIFIC SESSION-1 & 4 WILL BE VIEWED AND DISCUSSED

1100-1300

Scientific Session-2

Thyroid:II

Chairpersons: Dr. Omar Alonso (Uruguay), Dr. E. Barrenechea (Philippines)

Invited Lectures

- | | | | |
|-----------|----|--|--------------------------------|
| 1100-1125 | 26 | Radioiodine-negative, Somatostatin-Receptor PET-Prof. Roy Moncayo (Austria) negative Thyroid Cancer: Current Status and Developments | |
| 1125-1150 | 27 | Paediatric Thyroid Cancer | Prof. Isabel Roca (Spain) |
| 1150-1215 | 28 | rhTSH stimulated radioiodine therapy of metastatic differentiated thyroid cancer, an off-label use: Initial experience | Prof. C.S. Bal (India) |
| 1215-1240 | 29 | Radioiodine Therapy of Benign Thyroid Disorders | Prof. A. Klissarova (Bulgaria) |
| 1240-1300 | 30 | Targeted Radiotherapy and Radiobiology | Dr. Maria Neves (Portugal) |

1300-1400

Lunch

1400-1550

Scientific Session-3

Neuroendocrine Tumours-1

Chairpersons: , Dr. Savvs Frangos (Cyprus), Prof. G. Wiseman (USA)

Invited Lectures

- | | | | |
|-----------|----|--|----------------------------------|
| 1400-1425 | 31 | Chemical aspects of labelling octreotides | Dr. Mikolajczak Renata (Poland) |
| 1425-1450 | 32 | The Targeting of G-protein Coupled Receptors with Radiopeptides for Imaging and Internal Radionuclide Therapy. | Prof. H. R. Maecke (Switzerland) |
| 1450-1520 | 33 | An update on our experience with Peptide Receptor Radiotherapy (PRRT) in Neuroendocrine Tumours (NETs) | Prof. R. P. Baum (Germany) |



1520-1550	34	Lanreotide-based Diagnosis and Treatment of Cancer Patients: Current Status, Indications, Future Directions".	Prof. Roy Moncayo (Austria)
1550-1610		Coffee Break	
1610-1800		Scientific Session-4 Neuroendocrine Tumours-2 Chairpersons: Prof. R. Moncayo (Austria), Dr. N. Watanabe (Japan)	
		Invited Lectures	
1610-1635	35	Concomitant chemotherapy, radioimmunotherapy of lymphoma and radiopeptide control of endocrine cancer.	Prof. J.H. Turner (Australia)
1635-1700	36	Bisphosphonates conjugated to macrocyclic ligands: 68Ga-based PET/CT imaging tracers vs. 177Lu-based therapy.	Prof. Dr. Frank Roesch (Germany)
1700-1720	37	Treatment of neuroendocrine tumors with radiolabeled peptide: The Chilean Experience	Prof. Horacio Amaral (Chile)
		Proffered Papers (Oral Presentations)	
1720-1800		Oral Presentations	
	38	Survival benefits and efficacy of Peptide Receptor Radionuclide Therapy (PRRT) using Y-90/Lu-177 DOTA-TATE in Pancreatic Neuroendocrine Tumors (pNET)	Prof. R. P. Baum, et al. (Germany)
	39	Comparison between clinical results of PRRT with 90Y-DOTA TATE and 90Y/177Lu- DOTATATE	Dr. Jolanta Kunikowska, et al (Poland)
	40	Ensayos preclínicos del 177lu-dota-minigastrina para su potencial uso en prrt (<i>Preclinical trial of Lu-177-dota-minigastrin for potential use in prrt</i>)	López Bularte A.C, Puerta Yepes N, Nevares N, Zapata M, Rojo A.M, Crudo J (Argentina).
	41	Tratamiento de tumores neuroendocrinos (tne) con péptidos análogos de la somatostatina marcados con radionucleidos (<i>Treatment of neuroendocrine tumors (TNE) with peptides of somatostatine labelled with radionuclides</i>)	Horacio Amaral, Rossana Pruzzo, Cecilia Gil, Irene Coudeu, Hugo Lavados, Francisca Redondo, Bárbara Morales (Chile)
	42	Effectivness of treatment of gastroenteropancreatic non-functioning neuroendocrine tumours consisted of Sandostatin LAR® after 90Y - and/or 177Lu - DOTA-TATE therapy.	Dr. Norbert Szalus, et al. (Poland)
		Poster Presentation (To be viewed and discussed during the coffee break at 1015-11 am on 04/11/09)	
	43	Peptide receptor radionuclide therapy in neuroendocrine tumors: preliminary results in 18 cases treated with 90Y-DOTATOC	Dr. Lutfun Nisa, et al (Bangladesh)
	44	Preparation of [18F] containing neurotensine-derived peptides	Dr. Horvath Geza, et al (Denmark)
	45	I-131 MIBG Imaging in the Diagnosis of Pheochromocytoma: 'Philippine Setting'	Dr. Erik Cruz, et al. (Philippines)



1800-1900		WRPTC Members' Assembly	
All participants of ICRT-2009 and ALASBIMN Congress are defacto members of WRPTC and are welcome to attend this Assembly and contribute to the proceedings			
1900-2000		FREE TIME	
2000-2300		Oenophilous Dinner	Cartagena Club
Thursday: 5 November 2009			
		Scientific Session-5 (Plenary with ALASBIMN Congress) ALASBIMN Opening & Combined Plenary with ALASBIMN Chairpersons: , Prof. I. Mena (Chile), Prof. S. Goldsmith (USA)	
0800-0815		ALASBIMN Opening	Dr. Patricia Bernal (Colombia)
0815-0850	46	Contribution of nuclear medicine in early breast cancer: from ROLL (Radioguided Occult Lesion Localization) to IART® (Intra-operative Avidination for Radionuclide Therapy	Prof. Giovanni Paganelli (Italy)
0850-0930	47	PET/CT in Lung Cancer and Oncology Guidelines - Has it Become a Must?	Prof. R. Baum (Germany)
0930-1030		Networking, Posters & Coffee Break Poster Session Coordinator: Dr. Shazia Fatima (Pakistan), Dr. Antra Berzeina (Latvia)	
		ALL POSTERS FROM SCIENTIFIC SESSIONS-5, 6,7and 8 WILL BE VIEWED AND DISCUSSED	
1030-1300		Scientific Session-6 Radiosynovectomy & Bone Pain Palliation Chairpersons: Dr. S. Srivastava (USA), Prof. AH Elgazzar (Kuwait)	
		Invited Lectures	
1030-1055	48	Radionuclide therapy of bleeding joints in Haemophilia: A review	Dr. E. Barrenechea (Philippines)
1055-1120	49	Radiosynoviorthesis (RSO): influencing factors and therapy monitoring	Dr. K. Liepe (Germany)
1120-1145	50	Treating bone metastases use of radionuclides in combination with other therapies	Dr. J. Buscombe (UK)
1145-1210	51	Results of autoradiographic uptake of Re-188-HEDP	Dr. K. Liepe (Germany)
1210-1235	52	Metabolic Radionuclide Therapy of Metastatic Bone Pain Using 89 SrCl (Metastron) - Review and Perspectives	Prof. A. Klissarova (Bulgaria)
		Proffered Presentations	
1235-1300		Oral Presentation	
	53	Metabolic Radionuclide Therapy in Painful Bone Metastases with 89SrCl : Better Patients' Selection for Therapy	Dr. Zhivka Dancheva (Bulgaria)
	54	Knowing people, caring for persons, not just treating pain: 15 years delivering radionuclides to palliate bone pain.	Morales R, Cano R, Mendoza G (Peru)

- | | | |
|----|---|--|
| 55 | Radiosynoviolitis (rsnv) con Re188-coloide en sinovitis villonodular (svn) recidivante de rodilla. Experiencia clinico terapeutica (<i>Radiosynoviolitis (rsnv) with Re 188 colloid in synovitis villonodular (snv) recidivant of knee. Experience clinical and therapeutical</i>) | Alvaro Calderon, Augusto Llamas Olier, Humberto Varela, Amelia de los Reyes, Maria Cristina Martinez, Emperatriz Angarita, Nidia Delgado, Javier Rada, César Villamil. Camilo Soto Alejandro Estévez(Colombia) |
| 56 | Estudio biocinético y dosimétrico de un kit de producción local de 177lu-edtmp para su uso como agente paliativo del dolor. (<i>Biokinetic study and dosimetry evaluation of Lu-177 EDTMP for use in the palliative treatment of bone pain</i>) | Nancy Puerta Yepes, Juan Horacio Pérez, Noemí Nélide Nevares, Alfredo Miguel Zapata, Ana Clarisa López Bularte, Ana Maria Rojo, Sebastián Gossio, José Luis Crudo (Argentina) |

Poster Presentations

be viewed and discussed during the coffee break at 9.30-10.30 am on 5/11/09)

(To

- | | | |
|----|--|--|
| 57 | 153Sm-oxabiphore radionuclide therapy combined with external beam radiation therapy (8Gy) in breast cancer patients with bone metastases | Prof. Valeriy Krylov, et al. (Russia) |
| 58 | Therapeutic Response of Radiosynovectomy with 32P Colloid in Haemophilic Synovitis of Adolescents | Dr. Pei-yong LI (China, PR) |
| 59 | Development of a New 131I-Labelled Bisphosphonic Acid for Palliative Therapy of Metastatic Bone-Pain. | Dr. Alejandro Perera (Cuba) |
| 60 | Radionuclide Therapy in Patients with Painful Bone Metastases due to prostate Carcinoma. Efficacy of Strontium-89 Chloride | Dr. R. Mititelu (Romania) |
| 61 | Is radiosynoviorthesis of medium and small joints in patients with rheumatoid arthritis effective? | Dr. Otakar Kraft, et al. (Czech Republic) |
| 62 | Effect of combined Samarium-153 and adjuvant analgesic therapy for pain palliation in patients with skeletal metastases | Dr. S. Barai (India) |
| 63 | The duration of pain free period after Sm-153 EDTPM palliative treatment of skeletal bone MTS in patient moderate severity of bone pain in comparison to group of patient with severe to intolerable pain. | Dr. N. Rasulova (Uzbekistan) |
| 64 | Possibility of using Tc99m (V) DMSA in assessment to treatment response of patients with gastro intestinal stromal tumor. | Dr. Vladimir Lyubshin, et al. (Uzbekistan) |
| 65 | Bone pain from osteoblastic metastases | Dr. Fahid Ibrar, Dr. Baber Juniad (Pakistan) |

1300-1400

Lunch

1400-1600		Scientific Session-7 Liver Cancer & Miscellaneous Chairpersons: Prof. Azu Owunwanne (Kuwait), Prof. Keon Wook Kang (S. Korea)	
Invited Lectures			
1400-1430	66	Statistics don't lie – do people?	Prof. J. Stare (Slovenia)
1430-1450	67	Recent advances in radioconjugate targeting	Prof. D.K. Hazra (India)
1450-1520	68	Targeted Liver Tumor Therapy with Radioembolization	Prof. G. Wiseman (USA)
1520-1550	69	A perspective on WRPTC: We may not change the world, but we can make a small difference	Prof. A.K. Padhy (Singapore)
Oral Presentations			
1550-1600	70	Evaluación de la eficacia terapéutica de un complejo mixto 188re(v)-oxo como potencial agente para terapia de melanoma (<i>Evaluation of the therapeutic efficacy of Re-188(V) - oxo like potential agent for melanoma therapy</i>)	S. Fernández, J. Giglio, M. Terán, M. Incerti, C. Agorio, A. Chabalgoity, A. Rey (Uruguay)
1600-1615		Coffee Break	
1615-1745		Scientific Session-8 Radioimmunotherapy Chairpersons: Prof. Horacio Amaral (Chile), Prof. Kalevi Kairemo (Finland)	
Invited Lectures			
1615-1645	71	Radioimmunotherapy of Lymphoma	Prof. Stanley Goldsmith (USA)
1645-1715	72	Radioimmunosintigraphy and Radioimmunotherapy: Summary of 20 years of experience and the state of the art".	Prof. I. Garty (Israel)
1715-1745	73	Radioimmunotherapy of Prostate Carcinoma	Prof. Stanley Goldsmith (USA)
Proffered Presentations			
Poster Presentations (To be viewed and discussed during the coffee break at 0930-1030 am on 05/11/09)			
	74	Development of 177Lu- Dendrimer-Anti-CD20 : preliminary studies	Dr. Marcos Tassano, et al. (Uruguay)
	75	Development of 153Sm-DTPA-Rituximab for radioimmunotherapy	Dr. Amir R Jalilian, et al (Iran)
	76	177-Lu-Anti-CD20 monoclonal antibody: A potential radiopharmaceutical for treatment of non-Hodgkin's lymphoma	Dr. Paola Audicio, et al (Uruguay)
	77	Sterically stabilized 177Lu de DTPA-Liposomes and 177Lu DTPA-Liposomes: development of labeling procedure and biologic evaluation	Dr. Mirel Cabrera, et al. (Uruguay)
	78	177Lu –Bevacizumab: a novel therapeutic radiopharmaceutical	Dr. Ximena Camacho, et al (Uruguay)



- | | | |
|----|--|---|
| 79 | In vivo characterization of a Lu-177 Bombesin-based radiopharmaceutical for GRP Positive tumours - Diagnosis & Treatment | Dr. Priscilla Brunelli Pujatti, et al. (Brazil) |
| 80 | 177Lu-DOTA-TATE and Sandostatin LAR as a promising therapy of Esthesioneuroblastoma – case report | Dr. Zbigniew Podgajny, et al (Poland) |
| 81 | 177 Lu - Dendrimer PAMAM G4: Evaluation in a murine melanoma model | Dr. Marcos Tassano, et al. (Uruguay) |

1930-2300	Formal opening ceremony of ICRT & 22nd ALASBIMN Congress: Conference Banquet
------------------	---

Friday: 6 November 2009

0900-1700	Sight-seeing tour with Lunch (Details are being worked out)
------------------	--

1930	Dinner at Hilton
-------------	-------------------------

Saturday: 7 November 2009

0830-1100	Scientific Session - 9 Molecular Imaging in Therapy Chairpersons: Dr. Isabel Roca (Spain), Prof. D.K. Hazra (India)
------------------	--

Invited Lectures

- | | | | |
|-----------|----|---|------------------------------|
| 0815-0845 | 82 | Road Map to Molecular Imaging: Historic and Basic Considerations | Prof. AH Elgazzar (Kuwait) |
| 0845-0915 | 83 | PET/CT and Radiotherapy Planning | Dr. Subramaniam Rathan (USA) |
| 0915-0945 | 84 | The Importance of Quantitative Molecular Imaging: From MORE (Molecular Response) to PERCIST (PET Response Criteria in Solid Tumors) | Prof. R. Baum (Germany) |
| 0945-1010 | 85 | Use of PET/CT imaging with 68Ga DOTATATE in the evaluation of patients with neuroendocrine tumors" | Dr. Horacio Amaral (Chile) |
| 1010-1035 | 86 | The limitations of CT to monitor radionuclide therapy in Neuro-endocrine tumours | Dr. John Buscombe (UK) |
| 1035-1100 | 87 | In the current world of PET/CT for therapeutic monitoring, who needs Tc-99m and the other non-positron emitting radiopharmaceuticals? | Prof. Azu Owunwanne (Kuwait) |

Proffered Papers

Poster Presentations:
(To be viewed and discussed during the coffee break at 1100-1145 am on 07/11/09)

- | | | |
|----|---|---|
| 88 | Effects of external beam irradiation on Radioimmunotargeting | Dr. Padmamalika Khanna-Hazra, et al (India) |
| 89 | Rapid guide for drug interaction with radiopharmaceutical | Ralph Santos-Oliveira, et al (Brazil) |
| 90 | Targeted imaging with 64Cu trastuzumab PET in non small cell lung cancer | Dr. Bishnuhari Paudyal, et al. (Japan) |
| 91 | Evaluation of risk of increased cerebral blood flow by intravenous adenosine-tri-phosphate: A PET study with 15O-labeled water. | Dr. Raihan Hussain (Bangladesh) |

	92	Phase I Clinical Trial and Pharmacokinetics of the anti-CEA single chains fragment (scFv)2 M3	Dr. Gilmara Pimentel, et al (Cuba)
	93	Experience of Radiopharmaceutical Therapy in a Developing Country	Dr. Hasan Mizanul, et al (Bangladesh)
1100-1145	Networking, Posters & Coffee Break Poster Session Coordinator: Dr. R Mititelu (Romania), Dr. Ana Ugrinska (Macedonia) ALL POSTERS FROM SCIENTIFIC SESSIONS-9 and 10 WILL BE VIEWED AND DISCUSSED		
1145-1300	Scientific Session - 10 Miscellaneous Chairpersons: Dr. J. Buscombe (UK), Prof. H. R. Maecke (Switzerland) Invited Lectures		
1145-1210	94	Molecular Radiotherapy for Human Neuroblastoma Cells with Auger Electrons of In-111-labeled N-myc Antisense Oligonucleotides in Combination with Chemotherapy	Dr. N. Watanabe (Japan)
1210-1235	95	Molecular Imaging and Therapy of Cancer using Radiolabeled Nanoparticles	Dr. Keon Wook Kang (S. Korea)
1235-1300	96	PBPK modeling for dosimetry of nonclinical and clinical radioimmunotherapy	Prof. Kalevi Kairemo (Finland)
	Posters (To be viewed and discussed during the coffee break at 1100-1145 am on 07/11/09)		
1225-1245	97	Architecture & Music in the Light of Healing of Cancer Patients	Dr. Gertraud Jestl-Horngache (Austria)
	98	Primary Tumor Size, Can It Predict the Histopathologic Outcome of an Identified Sentinel Node?	Dr. Susan Gironella-Camomot, et al (Philippines)
	99	Evaluation of sentinel lymph nodes in patients with cutaneous malignant melanoma	Dr. M. Lacic (Croatia)
	100	SPECT imaging in the diagnosis of pulmonary embolism, comparison with planar V/Q scan and CTPA	Dr. Fatima Shazia, et al (Pakistan)
	101	Evaluation of Performance of Rest Gated Myocardial Perfusion Imaging in Emergency Room Patients with Suspected Acute Coronary Syndrome presenting with Acute Chest Pain and Non-diagnostic ECG - Preliminary results from the PREMIER trial	Dr. Arzoo Fatima (Pakistan)
	102	Myocardial infarction, scar or ischemia at rest?	Maruf Pirnazarov (Uzbekistan)
	103	Carcinoma of Unknown Primary: Initial Experience with 18F FDG PET-CT	Madhur Kumar Srivastava (India)
	104	Prediction of response to neoadjuvant chemotherapy in locally advanced breast cancer with scintimammography and its correlation with p-glycoprotein levels	Dr. Muhammad Aleem Khan (Pakistan)



1300-1400		Lunch	
1400-1600		Scientific Session - 11 Closing Session Chairpersons: Prof. Richard P. Baum (Germany), Dr. Patricia Bernal (Colombia) Invited Lectures	
1400-1425	105	Alpha therapies present practice and future prospects	Dr. John Buscombe (UK)
1425-1450	106	our experience comparing Bi-213 with Lu-177 in a prostate cancer model if you would like.	Prof. H. R. Maecke (Switzerland)
1450-1600		Inauguration of WARMTH Introduction to ICRT-2010 (Bali): Address by the Organizing Chairman Closing Remarks Highlights and closing remarks	
		Dr. Hussein Kartamihardja (Indonesia) Dr. Patricia Bernal, Chairperson - Organizing Committee (ICRT-2009) A.K. Padhy (Singapore)	
1600-1630		Coffee Break	
1630-2000		FREE TIME A few interesting Scientific Sessions of ALASBIMN will still be continuing in other Lecture Halls. Those who are interested may attend and participate in them also (Please refer to the ALASBIMN Programme).	
2000-onwards		Closing Ceremony of ICRT-ALASBIMN Congress Dinner Latin Music & Dance and Celebrations	
DRESS CODE FOR CLOSING CEREMONY : ALL WHITE			



La alcaldesa (e) de Cartagena, Alicia Saenz, entregó las llaves de la ciudad a los médicos nucleares Ajit Kumar Padhy, de Singapur; Annare Ellmann, de Sudáfrica; y Patricia Bernal Trujillo, de Colombia, en el marco del Congreso de Biología y Medicina Nuclear.



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009






WARMTH
WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY
FOUNDED 2009





5th ICRT-2010, Capetown South Africa





WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009



W A R M T H

World Association of Radiopharmaceutical and Molecular Therapy

2ND INTERNATIONAL SYMPOSIUM ON RADIOPHARMACEUTICAL THERAPY ISRT-2010

IN CONJUNCTION WITH THE 10th WORLD CONGRESS OF WFNMB
CAPE TOWN, SOUTH AFRICA

PART-1

21 September 2010 (08.00-13.00 hrs)

VENUE	CAPE TOWN INTERNATIONAL CONVENTION CENTRE, CAPE TOWN
MEETING ROOM	Auditorium 2
DATE	21 September 2010
08.00 – 08.05	Opening Remarks – Prof. A. Ellmann, Prof. A.K. Padhy
08.05 – 09.30	Scientific Session-1: Revisiting the Fundamentals Chairpersons: Prof. J.H. Turner (Australia), Dr. H. Amaral (Chile)
08.05 – 08.25	Creativity and motivation: A Necessity for Advancing Practice and Research in Nuclear Medicine Therapy. Prof. AH Elgazzar, University of Kuwait, Kuwait
08.25 – 08.50	Radioiodine Therapy of Thyroid Cancer: Controversies, Challenges and New Possibilities. Prof. C.S. Bal, AIIMS, New Delhi, India.
08.50 – 09.10	Therapeutic effect of radiosynovectomy and side effects, Dr. Knut Liepe, Kassel, Germany
09.10 – 09.30	Local Treatment of Liver Cancer. Dr. John Buscombe, UK
09.30 – 10.00	Coffee/Tea Break
10.00 – 11.30	Scientific Session-2: Plenary Lectures Chairpersons: Prof. G. Wisemann (USA), Prof. Kalevi Kairemo (Finland)
10.00 – 10.30	An Overview of Radioimmunotherapy: Principles, Current Status & Future Directions. Prof. Stanley Goldsmith, USA
10.30 – 11.00	Quantitative molecular imaging in oncology using PET/CT – where are we now with regard to radionuclide therapy and what are the perspectives. Prof. R.P. Baum, Germany
11.00 – 11.30	Development of new molecular targets/peptides for NM therapy. Prof. Helmut Maecke, Germany.
11.30 – 13.00	Scientific Session-3: Radionuclide Therapy: Looking Beyond Chairpersons: Dr. Leonard Mausner (USA), Prof. I. Virgolini (Austria)
11.30 – 11.40	New solutions to develop radionuclides for therapy: Dr. R. Zimmermann (Germany)
11.40 – 12.00	Bone Pain Palliation Therapy: What Lies Ahead? Dr. S. Srivastava, USA
12.00 – 12.20	Radiolabelled Aptamers as novel radiopharmaceuticals: Prof. A.C. Perkins, UK
12.20 – 12.40	Molecular cancer therapy with radio- labeled antisense: Prof. N. Watanabe, Japan.
12.40 – 13.00	Peptide Receptor Radionuclide Therapy (PRNT) of neuroendocrine tumors using Lu-177 and Y-90 labeled SSTR targeting peptides: clinical indications, practical guidelines and long- term results. Prof. Richard P Baum, Germany



PART-2

21 September 2010 (1430-1730)

VENUE	CAPE TOWN INTERNATIONAL CONVENTION CENTRE, CAPE TOWN
MEETING ROOM	Room 1.61-2
DATE	21 September 2010

14.30 – 16.00	Scientific Session- 4: Radionuclide Therapy – Developing Country Perspective <i>Chairpersons: Dr. Enrique Estrada (Mexico), Prof. Milovan D. Matovic (Serbia)</i>
14.30 – 14.50	WARMTH Perspectives on Radionuclide Therapy: <i>Prof. A.K. Padhy, President, WARMTH, Singapore</i>
14.50 – 15.10	Radionuclide Treatment of Bleeding Joints in Haemophiliacs. <i>Dr. E. Barrenechea, St Luke's Hospital, Manila, Philippines</i>
15.10 – 15.25	Use of Re-188 Colloid in Radiosynovectomy. <i>Dr. Rakesh Kumar. AIIMS, New Delhi, India.</i>
15.25 – 15.45	Bone Pain Palliation – From Theory to Practice: A Developing Country Perspective. <i>Prof. V. Rangarajan, Head, Division of Nuclear Medicine & PET, Tata Memorial Cancer Centre, Mumbai, India</i>
15.45 – 16.00	Y-90 SIRT – SGH Experience. <i>Dr. Yung Hsiang KAO, Singapore General Hospital, Singapore</i>
16.00 – 17.00	Scientific Session-5: Round Table: Global Harmonization of Radionuclide Therapy <i>Chairpersons: Prof. R.P. Baum, Prof. A.H. Elgazzar</i> <i>Panellists: To be drawn from SNM, EANM, AOFNMB, ALASBIMN, GSNM, Industry, International Organizations like IAEA, WFNMB, National Societies</i>
17.00 – 17.30	WARMTH Members' Assembly <i>Chairpersons: Prof. A.K. Padhy (President), Prof. A.C. Perkins (Secretary)</i>

Agenda:

WARMTH Registration

Membership

WARMTH Bank Account

WARMTH Auditors

WARMTH Relationship with WFNMB

WARMTH Headquarters in New Delhi

Forthcoming Meetings/ Seminars/Workshops:

1. WARMTH support to Romanian Society of Nuclear Medicine Annual Meeting
2. International Workshop on Radionuclide Therapy (IWRT), Kuwait
3. 4th International Conference on Radiopharmaceutical Therapy (ICRT), Muscat, Oman, 28 November-2 December 2011
4. 3rd International Symposium on Radiopharmaceutical Therapy (ISRT), Lapland, Finland, ... November 2012

WARMTH Support to ALASBIMN Congress (November 2011)

Any other item with the permission of the Chair



WARMTH

**WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY**

FOUNDED 2009



WFNMB 2010 PLENARY SESSIONS

PLENARY 1: SUNDAY 19 September 2010

Quality Assurance and Quality Control

Organised by the International Atomic Energy Agency

Chairperson: Ravi Kashyap, IAEA

- | | |
|----------------------|---|
| 10:00 – 10:15 | Quality Management in Nuclear Medicine Practice: IAEA Perspective
<i>Ravi Kashyap, IAEA</i> |
| 10:15 – 10:35 | Radiopharmacy
<i>Kishor Salanki, UK</i> |
| 10:35 – 10:55 | Instrumentation
<i>Mario Marengo, Italy</i> |
| 10:55 – 11:15 | Clinical Audit
<i>Angelika Bischof-Delaloye, Switzerland</i> |
| 11:15 – 11:30 | Discussion
<i>Ravi Kashyap, IAEA</i> |

PLENARY 2: TUESDAY 21 September 2010

Therapy

Organised by the World Association of Radiopharmaceutical and Molecular Therapy

Chairpersons: Prof Gregory Wisemann (USA), Prof Kalevi Kairemo (Finland)

- | | |
|----------------------|---|
| 10:00 – 10:30 | An Overview of Radioimmunotherapy: Principles, Current Status and Future Directions
<i>Stanley Goldsmith, USA</i> |
| 10:30 – 11:00 | Quantitative molecular imaging in oncology using PET/CT – where are we now with regard to radionuclide therapy and what are the perspectives
<i>Richard Baum, Germany</i> |
| 11:00 – 11:30 | Development of new molecular targets/peptides for NM therapy
<i>Helmut Maecke, Germany</i> |

PLENARY 3: WEDNESDAY 22 September 2010

Inflammation and Infection: Novel Agents and Applications

Organised by ISORBE

Chairpersons: Victoria Soria (Argentina), and Mathew Thakur (USA)

- | | |
|----------------------|---|
| 10:00 – 10:10 | Positron Emitters for Labeling Leukocytes
<i>CJ Palestro, USA</i> |
| 10:10 – 10:20 | Gallium-68
<i>V Kumar, Australia</i> |
| 10:20 – 10:30 | Molecular Imaging and Therapy of Inflammatory Atheromatous Disease
<i>S Srivastava, USA</i> |
| 10:30 – 10:40 | Radiolabeled Vitamins
<i>E Lazzeri, Italy</i> |
| 10:40 – 10:50 | Molecular Imaging of Autoimmune Diseases
<i>A Signore, Italy</i> |
| 10:50 – 11:00 | Neutrophil Trafficking
<i>CJ Palestro, USA</i> |
| 11:00 – 11:10 | Radiolabeled Stem Cells
<i>M Thakur, USA</i> |
| 11:10 – 11:30 | Discussion |





WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

WFNMB 2010 SCHEDULE OF MEETINGS



SUNDAY 19 September 2010

SASNM Council	11:30 – 13:30	Meeting Room 2.61
WFNMB Governing Council	14:00 – 16:00	Meeting Room 2.61
SASNM General Members' Meeting	16:30 – 18:30	Roof Terrace Room

TUESDAY 21 September 2010

SA Association of Nuclear Physicians	11:00 – 12:30	Meeting Room 2.64-6
WARMTH Members' Assembly	17:00 – 17:30	Meeting Room 1.61-2

WEDNESDAY 22 September 2010

WFNMB Delegates Assembly	15:00 – 17:30	Meeting Room 1.61-2
--------------------------	---------------	---------------------











6th ICRT-2011, Ho Chi Min City, Vietnam



4th INTERNATIONAL CONFERENCE ON RADIOPHARMACEUTICAL THERAPY (ICRT-2011)

www.icrt-2011.warmolth.org

In Conjunction with the 10th Annual General Meeting of ARCCNM
(Asia Regional Cooperative Council for Nuclear Medicine)
In Collaboration with
Vietnam Society of Radiology and Nuclear Medicine
Nuclear Medicine Society Singapore

28 November -2 December 2011

Venue:
New World Hotel
76 Le Lai Street, District 1, Ho Chi Minh City (Saigon), Vietnam
www.newworldhotels.com

After many highly successful congresses in Cyprus, Mongolia, India, Colombia, South Africa and Kuwait WARMTH Goes to Vietnam

For Registration & Other Details please visit our website:

www.icrt-2011.warmolth.org







4th International Conference on Radiopharmaceutical Therapy

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 1: MONDAY, 28 NOVEMBER 2011		
0800 – 1600	REGISTRATION	Ben Thanh Hall Foyer, Level 1
0900 – 1700	NATIONAL COORDINATORS' MEETING OF AN IAEA REGIONAL TECHNICAL COOPERATION PROJECT	Ben Thanh Hall 1 & 2, Level 1
1200 – 1300	LUNCH / TRADE EXHIBITION	Parkview Restaurant, Ground Level
1300 – 1445	PRE-CONGRESS NUCLEAR CARDIOLOGY SYMPOSIUM: SESSION I	Ben Thanh Hall 1 & 2, Level 1
	Session Chairpersons: 1. Prof Vo Thanh Nhan, Vietnam 2. Prof Henry Bom, CNU Medical School, Korea	
1300 – 1330 (O-6)	Myocardial Perfusion Imaging as a Gatekeeper for Coronary Angiography Dr Carlos D Libhaber, Nuclear Cardiology, University of the Witwatersrand, Johannesburg, South Africa	
1330 – 1400 (O-2)	Clinical Roles of Myocardial Viability Assessment Prof Zuo-Xiang He, Nuclear Medicine, Fu Wai Hospital & Cardiovascular Institute, Beijing, China	
1400 – 1430 (O-3)	Nuclear Medicine in Heart Failure Dr Raffaele Giubbini, Chair of Nuclear Medicine, University of Brescia, Italy (IAEA Expert)	
1430 – 1450	ORAL PRESENTATIONS	Ben Thanh Hall 1 & 2, Level 1
1430 – 1440 (O-4)	A Custom-Built Software Tool for Data Storage and Analysis of Acquisition and Processing Parameters For Tc-99m and Tl-201 MPI with Different Imaging Systems Dr Charalambos Yiannakkaras, Medical Physics, Nicosia General Hospital, Nicosia, Cyprus	
1440 – 1450 (O-5)	Construction of a Dynamic Cardiac Phantom to Optimize the Diagnostic Value in SPECT Myocardial Perfusion Imaging Dr Yiannis Parpottas, General Department (Physics-Math), Frederick University, Nicosia, Cyprus	
1450 – 1500	COFFEE / TEA / TRADE EXHIBITION	Ben Thanh Hall Foyer Pre-Function Area, Level 1
1500 – 1700	PRE-CONGRESS NUCLEAR CARDIOLOGY SYMPOSIUM: SESSION II	Ben Thanh Hall 1 & 2, Level 1
	Session Chairpersons: 1. Dr Bùi Diệu Hằng, Vietnam 2. Dr Vikram Lele, Nuclear Medicine & PET-CT, Jaslok Hospital & Research Centre, Mumbai, India	
1500 – 1530 (O-1)	Direct Myocardial Ischemia Imaging Prof Zuo-Xiang He, Nuclear Medicine, Fu Wai Hospital & Cardiovascular Institute, Beijing, China	
1530 – 1600 (O-7)	Multimodality Assessment of Myocardial Ischemia and Viability – Part 1 (CT/MRI/Echo) Dr Felix Keng, Nuclear Cardiology, National Heart Centre, Singapore	
1600 – 1630 (O-8)	Multimodality Assessment of Myocardial Ischemia and Viability – Part 2 (SPECT & PET) Prof Henry Bom, CNU Medical School, Korea	
1630 – 1700	Discussions	
1730 – 1830	WARMTH GOVERNING BODY MEETING (GOVERNING BODY MEMBERS ONLY)	
1930 – 2200	WELCOME DINNER	Grand Mekong Ballroom, Level 1
2200	END OF DAY 1	



4th International Conference on Radiopharmaceutical Therapy

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 2: TUESDAY, 29 NOVEMBER 2011		
0730 – 1600	REGISTRATION	Ben Thanh Hall Foyer, Level 1
0800 – 0815	OPENING REMARKS	Ben Thanh Hall, Level 1
0815 – 0955	SCIENTIFIC SESSION I: THYROID I	Ben Thanh Hall, Level 1
Session Chairpersons: 1. Prof Adil Al-Nahhas, Nuclear Medicine, Imperial College, London, United Kingdom 2. Dr Tran Van Thiep, Vietnam		
0815 – 0840 (O-9)	Radioiodine Therapy of Thyroid Cancer at Seoul National University (SNU) Hospital Prof June-Key Chung, Nuclear Medicine, Seoul National University Hospital, Seoul, Korea	
0840 – 0905 (O-10)	Thyroid Cancer and the Benefit of rhTSH in Treatment Dr Knut Liepe, Nuklearmedizin, Klinikum Kassel, Germany	
0905 – 0930 (O-11)	Thyroid Cancer: Anything New? Prof Irene Virgolini, Nuclear Medicine & PET, Medical University of Innsbruck, Innsbruck, Austria	
0930 – 0955 (O-12)	Eurasian Federation of Oncology: Ventures for Collaboration with WARMTH Dr Somasundaram Subramanian, Director, Eurasian Federation of Oncology, Surgeon (Head & Neck, Melanoma), Department of Biotherapy, N. N. Blokhin Russian Cancer Research Center, Moscow, Russia	
0955 – 1015	ORAL PRESENTATIONS	Ben Thanh Hall, Level 1
0955 – 1005 (O-13)	Effect of Short Term Metformin Therapy Associated with Levothyroxin Dose Decrement on TSH and Thyroid Hormone Levels in Patients with Thyroid Cancer Dr Seyed Rasoul Zakavi, Nuclear Medicine Research Center, Emam Reza Hospital / Mashhad University of Medical Sciences, Mashhad, Iran	
1005 – 1015 (O-14)	Breast Cancer and Autoimmune Thyroiditis: Does the Sodium Iodide Symporter Play a Role? Dr Jefferson Pagsisihan, Nuclear Medicine, St. Lukes Hospital, Quezon City, Philippines	
1015 – 1100	COFFEE / TEA / TRADE EXHIBITION	Ben Thanh Hall Foyer Pre-Function Area, Level 1
1015 – 1100	POSTER PRESENTATIONS: THYROID DISEASES	Ben Thanh Hall Foyer Pre-Function Area, Level 1
Session Coordinators: 1. Dr Ngo Thuy Trang, MD, The Nuclear Medicine and Oncology Center, Hanoi, Vietnam 2. Dr Duong Duc Binh, Nuclear Medicine, Danang Hospital, Danang City, Vietnam		
(P-1)	Is 99Tcm Thyroid Planar Imaging Suitable for Evaluating Residue Thyroid after Thyroidectomy: Comparing with I131 Scan after Radioiodine Therapy Dr Shuqi Wu, Nuclear Medicine, Xinhua Hospital, Shanghai Jiaotong University, Shanghai, China	
(P-2)	Tc-99m MIBI Scintigraphy For Post-Therapy Differentiated Thyroid Carcinoma Patients Follow Up Dr Ryan Yudistiro, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia	
(P-3)	Effect of I-131 Large Dose Thyroid Carcinoma Therapy on Sub Mandibular & Parotid Gland. Quantitative Analysis of Salivary Excretion Pre and Post Therapy Dr Om Prakash Sinha, Nuclear Medicine, Gujrat Cancer & Research Institute, Ahmedabad, India	
(P-4)	Serum Thyroglobulin Level Alone is not Enough to Monitor Persistence or Recurrence Disease of Differentiated Thyroid Carcinoma Dr Aisyah Eliyanti, Radiology / Nuclear Medicine, Dr M Djamil Hospital / Faculty of Medicine Andalas University, Padang, Indonesia	
(P-5)	Pattern of Metastases in Well Differentiated Thyroid Microcarcinoma Dr Fithriany Syamsuddin, Nuclear Medicine, Dr Hasan Sadikin Hospital / Padjajaran University, Bandung, Indonesia	
(P-6)	Outcome of Pregnancy after Radioactive Iodine Treatment Dr Dessie Yulistiawaty, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia	
(P-7)	Radioactive Iodine Ablation in Young Adults With Differentiated Thyroid Carcinoma Dr Yustia Tuti Jelani, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia	

Page 2 of 17
Please note that the programme is correct at time of update and is subject to change without prior notice

ICRT 2011

4th International Conference on Radiopharmaceutical Therapy

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 2: TUESDAY, 29 NOVEMBER 2011 (CONT'D)

(P-8)	Applications of Nuclear Medicine Techniques in Diagnosis and Treatment of Differentiated Thyroid Carcinoma: Results in Vietnam Dr Phan Sy An An, Nuclear Medicine & Oncology, Bach Mai, Hanoi, Vietnam
(P-9)	Differentiated Thyroid Cancer Ablation: 5 Years Experience in Limassol General Hospital Dr Ourania Demetriadou, Nuclear Medicine, Limassol General Hospital, Limassol, Cyprus
(P-10)	Efficiency Predictive Factors of Radio-Iodine Ablation in Differentiated Thyroid Cancer Dr Chatti Kaouthar, Nuclear Medicine, Sahloul University Hospital, Sousse, Tunisia
(P-11)	Lymph Node Metastasis of Differentiated Thyroid Cancer More Frequently Develops into Non-Iodine-Avid Than Lung or Bone Metastasis Dr Fang Feng, Nuclear Medicine, Xinhua Hospital, Shanghai, China
(P-12)	The Outcome of 23 Patients Differentiated Thyroid Carcinoma with Lung Metastase After Radiothyroablation with Iodine-131 Dr Gani Gunawan, Nuclear Medicine, Hasan Sadikin General Hospital, Bandung, Indonesia
(P-13)	Head Mass with Radioactivity Uptake in Patient with Thyroid Carcinoma Dr Nopriwan Agamawan Salam, Nuclear Medicine, Hasan Sadikin Hospital, Bandung, Indonesia
(P-14)	Recent Status of Radioiodine Therapy for Patients with Primary Hyperthyroidism and Differentiated Thyroid Carcinoma in Bangladesh Dr Shahana Afroz, Biological Science, Bangladesh Atomic Energy Commission, Dhaka, Bangladesh
(P-15)	Role of Ultrasonography (USG), Radionuclide Scan (RNS) and Fine Needle Aspiration Cytology (FNAC) in Thediagnosis of Malignancy in Solitary Thyroid Nodule Dr Akhter Nahid, Nuclear Medicine, Centre for Nuclear Medicine & Ultrasound, Dinajpur, Dhaka, Bangladesh
(P-16)	Unusual Metastasis in Papillary Thyroid Carcinoma: A Case Report Dr Hapsari Indrawati, Nuclear Medicine, Hasan Sadikin Hospital, Bandung, Indonesia
(P-17)	Effect of Low Dose Radioiodine Therapy in Respect to Amount of Post-Operative Thyroid Tissue (With Metastasis or Not) Dr AKM Fazlul Bari, Thyroid Medicine, Institute of Nuclear Medicine and Ultrasound, Dhaka, Bangladesh
(P-18)	I-131 Therapy for Pediatric Hyperthyroid; A Clinical Experience in Nuclear Medicine Department, Dr Hasan Sadikin Hospital, Indonesia Dr Erwin Affandi Soerjadi, Nuclear Medicine, Dr Hasan Sadikin Hospital, Indonesia
(P-19)	Quantitative Study of the Different Protocols Analysis for Excess Radiation Absorbed Doses from Radioiodine Treatment of Hyperthyroidism in Bangladesh Dr Md Nahid Hossain, Institute of Nuclear Medicine & Ultrasound, Dhaka, Bangladesh
(P-20)	Thyroid Functional Status in Chronic Kidney Disease (CKD) Dr Mosharruf Hossain, Nuclear Medicine, Rajshahi Medical College Hospital, Rajshahi, Bangladesh
(P-21)	Effect of Single Dose of Radioiodine Therapy on Volume Reduction of Thyroid Gland in Hyperthyroidism Dr Shamrukh Khan, Institute of Nuclear Medicine & Ultrasound, Dhaka, Bangladesh
(P-22)	Graded Empirical I-131 Therapy in Differentiated Thyroid Cancer – Is There an Ideal Dose? Dr Ajit Shinto, Nuclear Medicine and PET, KMCH, Coimbatore, India
(P-23)	Role of Tc-99m Perchnetate Thyroid Scintigraphy in Detecting Etiology of Congenital Hypothyroidism Dr Aulia Huda Buchori, Dr Hasan Sadikin Hospital / Padjadjaran University, Bandung, Indonesia
(P-24)	Incremental Value of 131I-SPECT/CT Fusion Imaging Over 131I-WBS in the Management of Patients with Differentiated Thyroid Carcinoma Dr Ye Zhi-Yi, Nuclear Medicine, Xinhua Hospital, Shanghai Jiaotong University, Shanghai, China
(P-25)	Empirical Dual Dose Iodine-131 Therapy for Graves' Disease Dr Khalid Makhdomi, Radiology, Aga Khan University Hospital, Nairobi, Kenya

ICRT 2011

4th International Conference on Radiopharmaceutical Therapy

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 2: TUESDAY, 29 NOVEMBER 2011 (CONT'D)

(P-26)	Complications to the Mother and Child with Thyroid Cancer after the Treatment with I-131 Prof Sassan Saber, Nuclear Medicine, Shariati Hospital, Tehran, Iran
(P-27)	Lacrimal Duct Obstruction after Iodine-131 Therapy in Patients with Differentiated Thyroid Cancer Prof Abbas Takavar, Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
(P-28)	Comparison of Different Techniques for Assessment of Thyroid Functional Status in Patients with Hyperthyroidism Dr Qaisar Siraj, Nuclear Medicine, Farwania Hospital Kuwait, Kuwait
(P-29)	The Advantages of Routine Radiothyroablation in Well Differentiated Thyroid Carcinoma Patients Dr Hapsari Indrawati, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia
(P-30)	Electrolyte Imbalance in Patients During Radioablation Na I-131 Dr Aulia Huda Buchori, Nuclear Medicine, Dr Hasan Sadikin Hospital / Padjadjaran University, Bandung, Indonesia
(P-31)	Therapeutic Response Evaluation on Hyperthyroidism Using a Fixed Dosed of I-131 Dr Yulia Kurniawati Burhanuddin, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia
(P-32)	Influence of Metastases Characteristic to Survival Rate in Papillary Thyroid Carcinoma Dr Nopriwan Agamawan Salam, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia
(P-33)	Pattern of Lung Metastases and its Influence to DTC Treatment Outcome Dr Gani Gunawan, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia
(P-34)	Assessment of Organification Defect in Thyroid Gland in Children with Goitrous Hypothyroidism Dr Anirudhan Narasimhan, Nuclear Medicine, G.K.N.M Hospital, Coimbatore, India
(P-35)	NaI-131 Radio Ablation for Well Differentiated Thyroid Cancer at Dr Hasan Sadikin General Hospital Dr Dodi Nugraha, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia
(P-36)	Significance of Raised Anti Thyroglobulin Antibody Levels in Differentiated Thyroid Cancer Patients Dr Javaid Irfan, Nuclear Medicine Oncology and Radiotherapy Institute (NORI), Islamabad, Pakistan
(P-37)	Rare Case of Metastasis to Pituitary from Follicular Thyroid Carcinoma Dr Butch Magsombol, Nuclear Medicine and PET, Singapore General Hospital, Singapore
(P-38)	Efficacy of I-131 Therapy in the Treatment of Differentiated Thyroid Carcinoma: Results in 655 Patients Treated at the Nuclear Medicine Department of Bach Mai Hospital, Hanoi Prof Mai Trong Khoa, Nuclear Medicine, Bach Mai Hospital, Hanoi, Vietnam Dr Trang Ngo, Nuclear Medicine, Bach Mai Hospital, Hanoi, Vietnam
(P-39)	Radionuclide Therapy in Russia. A Status Report from the Largest Radionuclide Therapy Centre in Russia Prof Valeriy Krylov, Radionuclide Therapy Department, Medical Radiological Research Center, Obninsk, Russia
1100 – 1240	SCIENTIFIC SESSION 2: THYROID II Ben Thanh Hall, Level 1
Session Chairpersons: 1. Dr Nguyen Thi Bich Dao, Vietnam 2. Prof Leszek Krolicki, Nuclear Medicine, Medical University of Warsaw, Poland	
1100 – 1120 (O-15)	Radioiodine Therapy of Differentiated Thyroid Cancer: A Review Dr Savvas Frangos, Nuclear Medicine, Bank of Cyprus Oncology Center, Strovolos, Nicosia, Cyprus
1120 – 1140 (O-16)	Guidelines for Treatment of Differentiated Thyroid Carcinoma: A Critical Appraisal Prof Jasna Mihailovic, Nuclear Medicine, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia
1140 – 1200 (O-17)	Radioiodine Treatment of Hyperthyroidism: A Review Dr Emerita Barrenechea, Nuclear Medicine, Veterans Memorial Medical Centre, Quezon City, Philippines
1200 – 1220 (O-18)	Graves' Ophthalmopathy Dr Wong Wai Yin, Nuclear Medicine, Singapore General Hospital, Singapore
1220 – 1240 (O-19)	Thyromimetics Dr A Velumani, Thyrocare Technologies Ltd, Turbhe, Navi Mumbai, India



ICRT 2011

4th International Conference on Radiopharmaceutical Therapy

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)
28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 2: TUESDAY, 29 NOVEMBER 2011 (CONT'D)

1240 – 1300	ORAL PRESENTATIONS	Ben Thanh Hall, Level 1
1240 – 1250 (O-20)	The Assessment of Oxidative Stress and Hematological Changes in Patients with Differentiated Thyroid Carcinoma Treated with Radioiodine Prof Milovan Matovic, Nuclear Medicine, Clinical Centre Kragujevac, Kragujevac, Serbia	
1250 – 1300 (O-21)	Relationship Between Radiation Absorbed Dose to the Blood and Successful Ablative Treatment in Thyroid Cancer Patients Dr Shazia Fatima, Nuclear Medicine, Oncology & Radiotherapy Institute Islamabad, Islamabad, Pakistan	
1300 – 1400	LUNCH / TRADE EXHIBITION	Parkview Restaurant, Ground Level
1400 – 1505	SCIENTIFIC SESSION 3: BONE PAIN & RADIOSYNOVECTOMY	Ben Thanh Hall, Level 1
Session Chairpersons: 1. Dr Emerita Barrenechea, Nuclear Medicine, Veterans Memorial Medical Centre, Quezon City, Philippines 2. Dr Qaisar Siraj, Nuclear Medicine, Farwania Hospital Kuwait, Kuwait		
1400 – 1425 (O-22)	Radiosynovectomy in the Treatment of Arthritis Dr Knut Liepe, Nuklearmedizin, Klinikum Kassel, Germany	
1425 – 1445 (O-23)	Use of Re-188 Colloid in Radiosynovectomy: Experience at AIIMS Prof Rakesh Kumar, Nuclear Medicine & PET, All India Institute of Nuclear Medicine, India	
1445 – 1505 (O-23A)	Radiosynoviorthosis (Radiation Synovectomy): State of the Art 2011 Prof Gynter Moedder, German Centre for Radiosynoviorthosis, Cologne, Germany	
1505 – 1545	ORAL PRESENTATIONS	Ben Thanh Hall, Level 1
1505 – 1515 (O-25)	Intra-Articular Evaluation of Lu-177 Hydroxyapatite in Animal Model Dr Muhammad Sohaib, Medical Sciences, Pakistan Institute of Engineering and Applied Science (PIEAS), Islamabad, Pakistan	
1515 – 1525 (O-26)	Development of Colloidal Samarium Phosphate [32P] Injection for Radiation Synovectomy-A New Therapeutic Radiopharmaceutical Agent For The Treatment Of Joint Disorders Dr Prabhakar Ganti, Department of Atomic Energy (DAE), Board of Radiation & Isotope Technology, Navi Mumbai, India	
1525 – 1535 (O-27)	Optimal Timing of Biphosphonate Therapy in Combination with Samarium-153 Therapy in Metastatic Bone Disease Dr Nigora Rasulova, Nuclear Medicine, Republic Specialized Center of Surgery, Tashkent, Uzbekistan	
1535 – 1545 (O-28)	Evaluation of P-32 for Bone Pain Palliation in Prostate Cancer with Skeletal Metastases Dr Muhammad Aleem Khan, Nuclear Medicine, Nuclear Medicine Oncology and Radiotherapy Institute (NORI), Islamabad, Pakistan	
1545 – 1600	COFFEE / TEA / TRADE EXHIBITION	Ben Thanh Hall Foyer Pre-Function Area, Level 1
	POSTERS PRESENTATION: BONE PAIN PALLIATION / RADIOSYNOVECTOMY	Ben Thanh Hall Foyer Pre-Function Area, Level 1
Session Coordinators: 1. Dr Vo Khac Nam, Vietnam 2. Dr Tran Song Toan, Nuclear Medicine, Cho Ray Hospital, Ho Chi Minh, Vietnam		
(P-40)	Detection of Bone Metastases by Planer Bone Scintigraphy and SPECT Bone Scintigraphy Dr MD Sayedur Rahman Miah, Centre for Nuclear Medicine & Ultrasound, Bangladesh Atomic Energy Commission, Comilla, Bangladesh	
(P-41)	Our First Experiences in Palliative Treatment of Painful Bone Metastases with Sm-153 Dr Zvezdana Rajkova, Nuclear Medicine, Clinical Center Banja Luka, Banja Luka, Bosnia & Herzegovina	

Page 5 of 17

Please note that the programme is correct at time of update and is subject to change without prior notice

ICRT 2011

4th International Conference on Radiopharmaceutical Therapy

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 2: TUESDAY, 29 NOVEMBER 2011

(P-42)	Evaluation of Prostate Cancer with Serum Prostate Specific Antigen, Alkaline Phosphatase Level and Bone Scintigraphy Dr Afroz Shirin, Scintigraphy, Institute of Nuclear Medicine & Ultrasound, Dhaka, Bangladesh
(P-43)	Bone Scintigraphy Findings of Multiple Osteoblastic Lesions in a Child with Primitive Neuroectodermal Tumor Dr Karina Michaela Dela Cruz, Nuclear Medicine, University of Santo Tomas, Manila, Philippines
(P-44)	Bone-Seeking Radiopharmaceuticals for Pain Palliation in Prostate Cancer Metastasis Dr Raluca Mititelu, Nuclear Medicine, Central University Military Hospital Bucharest, Bucharest, Romania
(P-45)	Present Day Utility of Whole Body Bone Scan in Evaluating Silent Skeletal Metastases in Apparently Operable Non Small Cell Lung Cancer when PET is not Available Dr Ajit Shinto, Nuclear Medicine and PET, KMCH, Coimbatore, India
(P-46)	⁸⁹Sr Bremsstrahlung Lung SPECT Imaging in Bone Metastases Dr Masanobu Ishiguro, Section of Radiology Division of Nuclear Medicine, Fujita Health University Hospital, Toyoake, Japan
(P-47)	Comparison of the Value of 18 F-FDG PET And 99 Tcm-MDP Bone Scan in the Detection of Bone Metastases Dr Shuqi Wu, Nuclear Medicine, Xinhua Hospital, Shanghai Jiaotong University, Shanghai, China
(P-48)	Current Status of Radionuclide Therapy in Indonesia Dr Alvita Dewi Siswoyo, Nuclear Medicine, RS Dr Hasan Sadikin, Bandung, Indonesia
(P-49)	Effectiveness of Bone Metastases Treatment by Sm-153 Oxalofore in Combination with Monoclonal Antibody Denosumab (Xgeva) Dr Nigora Rasulova, Nuclear Medicine, Republic Specialized Center of Surgery, Tashkent, Uzbekistan
1600 – 1730	SCIENTIFIC SESSION 4: RADIOPHARMACY / GENERAL NUCLEAR MEDICINE Ben Thanh Hall, Level 1
Session Chairpersons: 1. Prof Alan Perkins, Radiological and Imaging Sciences, Nottingham University Hospital, Nottingham, United Kingdom, 2. Prof Azu Owunwanne, Nuclear Medicine, Faculty of Medicine, Kuwait University, Safat, Kuwait	
1600 – 1625 (O-29)	Theragnostic Radiopharmaceuticals: An Emerging Paradigm Empowering Personalized Medicine Dr Suresh Srivastava, Collider-Accelerator Department, Brookhaven National Laboratory, Upton, NY USA
1625 – 1640 (O-30)	ONCIDIUM Foundation: A Perspective Dr Richard Zimmermann, IBA, Molecular, IBA, Louvain-La-Neuve, Belgium
1640 – 1700 (O-31)	Regulatory Aspects of Therapeutic Radiopharmaceuticals Dr Maung Maung Saw, Clinical Imaging Research Centre, National University of Singapore, Singapore
1700 – 1720 (O-32)	Clinical Applications of SPECT/CT in Oncology Dr Sonia Sergieva, Nuclear Medicine, Sofia Cancer Centre, Sofia, Bulgaria
1720 – 1800 (O-33)	Radiopharmaceutical And Molecular Therapy Quiz (Three Prizes for 3 Participants Scoring Highest Scores) Dr Gopinath Gnanasegaran, Nuclear Medicine, Guys & St Thomas' Hospital NHS Foundation Trust, St Thomas Hospital, London, United Kingdom
1900 – 2300	FORMAL INAUGURATION OF THE CONFERENCE & GALA DINNER Grand Mekong Ballroom, Level 1
2300	END OF DAY 2

ICRT 2011

4th International Conference on Radiopharmaceutical Therapy

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 3: WEDNESDAY, 30 NOVEMBER 2011

0800 – 1020	SCIENTIFIC SESSION 5: GI TRACT CANCER / LIVER CANCER	Ben Thanh Hall, Level 1
Session Chairpersons: 1. Dr Patricia Bernal Trujillo, Fundacion Santa Fe, Bogota, Colombia 2. Prof Harvey Turner, University of Western Australia, Fremantle Hospital, Australia		
0800 – 0825 (O-34)	Targeted Chemoradiation in Metastatic Colorectal Cancer: A Phase I Trial of 131I-Hua33 with Concurrent Capecitabine Prof Andrew Scott, Centre for PET, Austin Hospital, Heidelberg, Australia	
0825 – 0850 (O-35)	Targeted Radionuclide Therapy of Liver Tumors Prof Gregory Wiseman, Radiology, Mayo Clinic, Rochester, USA	
0850 – 0915 (O-36)	Radiological and Clinical Efficacy of Radio-embolization (Re) Using 188Re HSA-microspheres in Patients with Advanced, Primary or Metastatic Liver Cancer Dr Jaroslaw Cwikla, Radiology and Diagnostic Imaging, Postgraduate Medical Centre and Central Clinical Hospital, Warsaw, Poland	
0915 – 0935 (O-37)	PET is Superior to CT in Assessing Response to SIRT in Liver Tumours Prof Adil Al-Nahas, Nuclear Medicine, Imperial College, London, United Kingdom	
0935 – 0955 (O-38)	Molecular Radiotherapy in the UK: The Current Status Prof John Buscombe, Nuclear Medicine, Royal Free Hospital, Cambridge, United Kingdom	
0955 – 1020 (O-39)	Statistics – OR, RR and HR Prof Janez Stare, Faculty of Medicine, University of Ljubljana, Slovenia	
1020 – 1030	ORAL PRESENTATIONS	Ben Thanh Hall, Level 1
1020 – 1030 (O-40)	Does Clinical Outcome In Hepatic Y-90 Microsphere Therapy Depends On Correlation Between Y-90 and Tc-99m MAA Distributions? Dr Karin Knesaurek, Radiology / Nuclear Medicine, Mount Sinai Medical Center, New York, USA	
1030 – 1100	COFFEE / TEA / TRADE EXHIBITION	Ben Thanh Hall Foyer Pre-Function Area, Level 1
1030 – 1100	POSTER PRESENTATIONS: MOLECULAR IMAGING, RADIOPHARMACY	Ben Thanh Hall Foyer Pre-Function Area, Level 1
Session Coordinators: 1. Dr Butch Magsombol, Nuclear Medicine and PET, Singapore General Hospital, Singapore 2. Dr Nigora Rasulova, Nuclear Medicine, Republic Specialized Center of Surgery, Tashkent, Uzbekistan		
(P-50)	Normal Uptake Value of C-11 Acetate in Some Organs Dr Thi Minh Chau Trinh, Nuclear Medicine, University Medical Center, Ho Chi Minh City, Vietnam	
(P-51)	Development of Nanoradiopharmaceuticals Dr Ralph Santos-Oliveira, Laboratory of Nanoradiopharmaceuticals, University Hospital Clementino Fraga Filho, Rio de Janeiro, Brazil	
(P-52)	Nanoradiopharmaceuticals: Development of Labeling Process Dr Ralph Santos-Oliveira, Laboratory of Nanoradiopharmaceuticals, University Hospital Clementino Fraga Filho, Rio de Janeiro, Brazil	
(P-53)	Synthesis, Radio Labeling and Biological Evaluation of [67Ga]- 5,10,15,20-Tetrakis(Pentafluorophenyl) Porphyrin Complex as an Imaging Agent Dr Mohammad Reza Aboudzadeh Rovals, Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School, Karaj, Iran	
(P-54)	Synthesis, Radiolabeling and Biological Evaluation of [111In]-Maltolate Complex as an Imaging Agent Prof Yousef Fazaeli, Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School (AMIR), Karaj, Iran	
(P-55)	Production, Quality Control and Imaging of 64Cu-ATSM in Healthy Rabbits for Clinical Applications Prof Yousef Fazaeli, Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School (AMIR), Karaj, Iran	

Page 7 of 17

Please note that the programme is correct at time of update and is subject to change without prior notice

ICRT 2011

4th International Conference on Radiopharmaceutical Therapy

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 3: WEDNESDAY, 30 NOVEMBER 2011 (CONT'D)

(P-56)	Synthesis, Radiolabeling and Biological Evaluation of [67Ga]-Maltolate Complex as an Imaging Agent Prof Yousef Fazaeli, Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School (AMIR), Karaj, Iran
(P-57)	Preparation and Evaluation of [67Ga]-Tetra Phenyl Porphyrin Complexes as Imaging Agents Prof Yousef Fazaeli, Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School (AMIR), Karaj, Iran
(P-58)	Radiosynthesis and Biological Evaluation of [111In]-5,10,15,20-Tetrakis(Pentafluorophenyl) Porphyrin Complex as a Possible Imaging Agent Dr Mohammad Reza Aboudzadeh Rovais, Nuclear Medicine Research Group, Agricultural, Medical And Industrial Research School, Karaj, Iran
(P-59)	Emergency Handling in a Medical Cyclotron Facility Dr Rajeev Kumar, PET Scan Centre , Medical Cyclotron Facility, Army Hospital Research And Referral, New Delhi, India
(P-60)	Development and Evaluation of New Protocol for Synthesis of 6-(18F) Fluoro-L-DOPA Dr Rajeev Kumar, PET Scan Centre , Medical Cyclotron Facility, Army Hospital Research And Referral, New Delhi, India
(P-61)	AFP-Combined 18F-FDG PET/CT Detection of HCC and its Recurrence Dr Wu Shuqi, Nuclear Medicine, Xinhua Hospital, Shanghai Jiaotong University, Shanghai, China
(P-62)	Simple, Reliable and Cost Effective Radiochemical Purity Test Technique for N-13 Ammonia Dr Dhananjay Kumar Singh, Nuclear Medicine, Army Hospital Research And Referral, New Delhi, India
(P-63)	99mTc-Doxorubicin Labeling and its Pre-Clinical Evaluation as a Potential Scintigraphic Probe For Tumor Imaging Dr Baljinder Singh, Nuclear Medicine, PGIMER, Chandigarh, India
(P-64)	Engineering Salmonella Typhimurium to Become a Dual Purpose-Probe for Therapeutic and in Vivo Monitoring Applied in Cancer or Myocardial Infarction Dr Vu Hong Nguyen, Nuclear Medicine, CNU Hwasun Hospital, Hwasun, South Korea
(P-65)	Preliminary Results of Various Pegylated I-RGD Peptides for Animal PET-Imaging Prof Aapo Ahonen, Physiology And Nuclear Medicine, HUSLAB/HUCH, Helsinki, Finland
(P-66)	Medical Cyclotron: Accidental Scenarios and Analysis Dr Nguyen Tan Chau, Unit of PET-CT & Cyclotron, Cho Ray Hospital, Ho Chi Minh, Vietnam
(P-67)	To Establish a Synthesis Protocol of 68Gallium-DOTANOC Using 0.05MHCl as Eluant of 68Ge/68Ga Generator for PET Imaging of Neuroendocrine Tumors (NETS) Dr Snehlata Lata, Nuclear Medicine & PET, All Institute of Medical Sciences, New Delhi, India
(P-68)	Production of Radiopharmaceutical F-18 FDG and C-11 Acetate Using Cyclotron 11 Mev at Cho Ray Hospital Dr Truong Ka My Dang, PET-CT & Cyclotron, Cho Ray Hospital, Ho Chi Minh, Vietnam
(P-69)	Radionuclide Imaging for Neuroendocrine Tumours: Experience of Singapore General Hospital (SGH), The Largest Acute Tertiary Hospital in Singapore Dr Thang Sue Ping, Nuclear Medicine and PET, Singapore General Hospital, Singapore
(P-70)	Cyclotron Production of 99mTc in Canada Dr Erik Van Lier, Targetry and Radiochemistry, Advanced Cyclotron Systems Inc, Richmond, Canada
(P-71)	Diagnosis of Pulmonary Neuroendocrine Tumors with 99mTc-Tectrotide (99mTc-HYNIC -TOC) SPECT/CT and 18F-FDG PET-CT in the Selection of the First Line of Treatment and Determining Staging and Restaging Dr Norbert Szalus, Nuclear Medicine, Military Institute of Medicine, Warsaw, Polska
(P-71A)	Peptide Receptor Radionuclide Therapy (PRRT): Colombia Experience Dr Patricia Bernal Trujillo, Nuclear Medicine, Fundacion Santa fe de Bogota, Bogota, Colombia



ICRT 2011

4th International Conference on Radiopharmaceutical Therapy

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)
28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 3: WEDNESDAY, 30 NOVEMBER 2011 (CONT'D)

1100 – 1230	SCIENTIFIC SESSION 6: NEUROENDOCRINE TUMORS I	Ben Thanh Hall, Level 1
Session Chairpersons: 1. Prof John Buscombe, Nuclear Medicine, Royal Free Hospital, Cambridge, UK 2. Prof Andrew Scott, Centre For PET, Austin Hospital, Heidelberg, Australia		
1100 – 1125 (O-41)	Peptide Receptor Radionuclide Therapy – The Innsbruck Experience Prof Irene Virgolini, Nuclear Medicine & PET, Medical University Of Innsbruck, Innsbruck, Austria	
1125 – 1150 (O-42)	Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors – The Bad Berka Experience After 10 Years in Over 1000 Patients Prof Richard Baum, Department of Nuclear Medicine, Center for PET/CT, Bad Berka, Germany	
1150 – 1205 (O-43)	PRRT-Experience at Jaslok Hospital Dr Vikram Lele, Department of Nuclear Medicine & PET-CT, Jaslok Hospital & Research Centre, Mumbai, India	
1205 – 1220 (O-44)	Ga-68 DOTATATE Imaging & PRRT in South Africa Dr Carlos D Libhaber, Nuclear Cardiology, University of the Witwaterstrand, Johannesburg, South Africa	
1220 – 1235 (O-24)	New DOTA-Based Bisphosphonate Ligands for PET/CT and Endoradiotherapy of Bone Metastases Dr Achim Reibel, University of Mainz, Institute of Nuclear Chemistry, Mainz, Germany	
1235 – 1300	ORAL PRESENTATIONS	Ben Thanh Hall, Level 1
1235 – 1245 (O-45)	90Y And 177Lu – Radionuclides for Peptide Receptor Radionuclide Therapy Dr Dariusz Pawlak, Research and Development, Institute of Atomic Energy POLATOM, Otwock, Poland	
1245 – 1255 (O-46)	Early Prediction of Tumor Response in GEP NET by the Sequential Change of Absorbed Doses During Treatment with Lu177-Octreotate Dr Ezziddin Samer, MD, Nuclear Medicine, University Bonn, Bonn, Germany	
1255 – 1305 (O-47)	Effect of Peptide Receptor Radionuclide Therapy (PRRT) with Tandem Isotopes- 90Y/ 177Lu-DOTATATE in Patients with Disseminated Neuroendocrine Tumors Depending on Qualification PET/CT with 18FDG Dr Jolanta Kunikowska, Medical University Of Warsaw, Nuclear Medicine Department, Medical University Of Warsaw, Warsaw, Poland	
1305 – 1400	LUNCH / TRADE EXHIBITION	Dynasty Restaurant, Level 1
1400 – 1510	SCIENTIFIC SESSION 7: NEUROENDOCRINE TUMORS II	Ben Thanh Hall, Level 1
Session Chairperson: 1. Prof Sobhan Vinjamuri, Nuclear Medicine, Royal Liverpool University Hospital, Liverpool, United Kingdom 2. Dr Cornelis Hoefnagel, Division of Diagnostic Oncology, The Netherlands Cancer Institute, The Netherlands		
1400 – 1425 (O-48)	Combined Modality Radiopeptide Therapy of Neuroendocrine Tumours Prof Harvey Turner, University Of Western Australia, Fremantle Hospital, Australia	
1425 – 1450 (O-49)	PRRT: The Italian Experience Prof Giovanni Paganelli, Divisione Di Medicina Nucleare, IEO Istituto Europeo Di Oncologia, Milano, Italy	
1450 – 1510 (O-50)	Meta-Analysis of Radionuclide Therapy in NETs Dr Shaunak Navalkissoor, Nuclear Medicine, Royal Free Hospital NHS Trust, London, United Kingdom	
1510 – 1530	ORAL PRESENTATIONS	Ben Thanh Hall, Level 1
1520 – 1530 (O-51)	Tc-Carbonyl Based Octreotide Derivatives Dr Gohlke Stefan, Nuclear Medicine, University of Bonn, Bonn, Germany	

ICRT 2011

4th International Conference on Radiopharmaceutical Therapy

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)
28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 3: WEDNESDAY, 30 NOVEMBER 2011 (CONT'D)

1530 – 1600	POSTERS PRESENTATIONS: GENERAL NUCLEAR MEDICINE & MISCELLANEOUS (ARCCNM)	Ben Thanh Hall Foyer Pre-Function Area, Level 1
Session Coordinators: 1. Dr Marika Vereb, Nuclear Medicine Department, Klinikum Kassel, Kassel, Germany 2. Ms Nguyen Thi Kim Dung, Vietnam		
(P-72)	Gamma Camera Based GFR Measurement as an Alternative to 24 Hours Urinary Creatinine Clearance in Healthy Kidney Donors Dr Tania Ahmed Ahmed, Nuclear Medicine & Ultrasound, Centre For Nuclear Medicine & Ultrasound, Chittagong, Chittagong, Bangladesh	
(P-73)	Differences in Decline in GFR with Age Between Males and Females. Reference Data on 24 Hours Urinary Creatinine Clearance and DTPA Clearance Dr Tania Ahmed Ahmed, Nuclear Medicine & Ultrasound, Centre For Nuclear Medicine & Ultrasound, Chittagong, Chittagong, Bangladesh	
(P-74)	Preparation and Bio Distribution of 99mtechnetium-Annexin V for In Vivo Detection of Apoptosis Dr Saeed Rajabifar, Nuclear Medicine, AMIRS, Karaj, Iran	
(P-75)	Ciprofloxacin Labeling by 99mtechnetium and its Bio Distribution in Normal and Infected Animals Dr Saeed Rajabifar, Nuclear Medicine, AMIRS, Karaj, Iran	
(P-76)	Production and Quality Control of 99mtechnetium-Igg-Hynic for Infection Imaging in Experimental Rats Dr Saeed Rajabifar, Nuclear Medicine, AMIRS, Karaj, Iran	
(P-77)	Diagnosing Multifocal Tuberculosis in Children with Tc-99m Ethambutol Scintigraphy: A Case Report Dr Alvita Dewi Siswoyo, Nuclear Medicine, RS Dr Hasan Sadikin, Bandung, Indonesia	
(P-78)	A Comparative Study of Dobutamine Stress Myocardial Perfusion Imaging and Dobutamine Stress Echocardiography in the Detection of Coronary Artery Disease in Female Patient – Initial Experience Dr Nasreen Sultana Nasreen, Nuclear Medicine, Institute of Nuclear Medicine And Ultrasound, BSMMU Campus Block, Dhaka, Bangladesh	
(P-79)	I-131 Meta-Iodobenzylguanidine and Tc99m Sestamibi Parathyroid SPECT Scintigraphy in Diagnosis of Multiple Endocrine Neoplasia 2A Syndrome Dr Jamilla Gomez, Nuclear Medicine, St Lukes Hospital, Quezon City, Philippines	
(P-80)	Myocardial Perfusion Imaging and Calcium Scoring as Coronary Artery Disease Predictors Dr Jamilla Gomez, Nuclear Medicine, St Lukes Hospital, Quezon City, Philippines	
(P-81)	Comparison of Tc-99m Ethambutol Scintigraphy and Scoring System in Diagnosing Pediatric Tuberculosis Dr Ivana Dewi Mulyanto, Department of Nuclear Medicine, Universitas Padjadjaran/RS Hasan Sadikin, Bandung, Indonesia	
(P-82)	Clinical Utility of F-18 FDG PET/CT & Tc-99m MDP Bone Scintigraphy in Ewing's Sarcoma and Other Sarcomaas Dr Judy Nguyen, Nuclear Medicine, Stanford University Medical Center, Stanford, USA	
(P-83)	Castleman's Disease on18F-FDG PET-CT Dr Jamilla Gomez, Nuclear Medicine, St Lukes Hospital, Quezon City, Philippines	
(P-84)	Correlation Between Bone Scintigraphy and Tumour Markers in Patients with Breast Cancer Dr Mohshi Um Mokaddema, Nuclear Medicine, Institute of Nuclear Medicine and Ultrasound, Dhaka, Bangladesh	
(P-85)	Impact of F-18 FDG PET/CT in Staging of Carcinoma Cervix Dr Zaheer Chirag, Nuclear Medicine, BINO Cancer Hospital, Bahawalpur, Pakistan	
(P-86)	Clinical Implications of PSA Level & Gleason Score in Predicting Possible Metastatic Bone Disease in Patients of Carcinoma Prostate Dr Zaheer Chirag, Nuclear Medicine, BINO Cancer Hospital, Bahawalpur, Pakistan	

ICRT 2011

4th International Conference on Radiopharmaceutical Therapy

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)
28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 3: WEDNESDAY, 30 NOVEMBER 2011 (CONT'D)

(P-87)	Role of FDG PET/CT in Diagnostic Evaluation of Carcinoma Urinary Bladder: Comparison with CT Dr Dhritiman Chakraborty, Department of Nuclear and Experimental Medicine, IPGME & R, Kolkata, Kolkata, India
(P-88)	Role of Tc99m MIBI Lower Limb Muscle Perfusion SPECT: In Diagnosis and Follow Up of Peripheral Arterial Diseases (PAD) Dr Rashid Rasheed, Nucler Medicine, GINUM, Gujranwala, Pakistan
(P-89)	Carotid Intima-Media Thickness (CIMT) as a Predictor of Hemodynamically Significant Coronary Artery Disease (CAD) Detected by Myocardial Perfusion Imaging (MPI) Dr Tapati Mandal, Nuclear Medicine, Institute Of Nuclear Medicine And Ultrasound, Dhaka, Bangladesh
(P-90)	Hepatobiliary Scintigraphy in the Non-Invasive Assessment of Early Hepatic Dysfunction in Patients with Risk Factor for Metabolic Syndrome Dr Ajit Shinto, Nuclear Medicine and PET, KMCH, Coimbatore, India
(P-91)	Tc 99m HIDA Diagnoses Early Hepatic Dysfunction in Type II Diabetics Dr Ajit Shinto, Nuclear Medicine and PET, KMCH, Coimbatore, India
(P-92)	Early and Delayed F-18 FDG PET in Assessment of Disease Activity in Tuberculosis Dr Ajit Shinto, Nuclear Medicine and PET, KMCH, Coimbatore, India
(P-93)	Vision of Nuclear Medicine in Bangladesh – A Road Map Prof Mizanul Hasan, Nuclear Medicine, Institute Of Nuclear Medicine & Ultrasound, BSMMU, Dhaka, Bangladesh
(P-94)	Technetium-99m-Sestamibi Scintigraphy on Patient with Nasopharyngeal Carcinoma and Lymphadenopathy Tuberculosis: A Case Report Dr Yulia Kurniawati Burhanuddin, Nuclear Medicine, Hasan Sadikin Hospital, Bandung, Indonesia
(P-95)	Evaluation of Low Grade Gliomas Using F-18 FDOPA and F-18 FDG PET/CT Dr Abhinav Jainini, Department of Clinical PET, Institute of Nuclear Medicine and Allied Sciences, Delhi, India
(P-96)	Case Report: Tc-99m-Ethambuthol Uptake in Case of Leprosy Dr Andika Hananto Gunawan, Department Of Nuclear Medicine, Hasan Sadikin Hospital / Universitas Padjadjaran, Bandung, Indonesia
(P-97)	Role of Tc-99m Ethambuthol Scintigraphy in Diagnosing Tuberculosis in Children with Scoring Systems as Diagnostic Approach Dr Alvita Dewi Siswoyo, Nuclear Medicine, Rs Dr. Hasan Sadikin, Bandung, Indonesia
(P-98)	Role of Dobutamine Stress Myocardial Perfusion Imaging (DS MPI) for the Detection of Myocardial Viability (MV) in Significantly Stenosed Coronary Artery Disease (CAD) Dr Sarwat Ara Sultana Khandaker, Nuclear Medicine, Institute Of Nuclear Medicine & Ultrasound, Dhaka, Bangladesh
(P-99)	Optimization of SPECT MPI Using a Prototype Dynamic Heart Phantom Dr Ourania Demetriadou, Nuclear Medicine, Limassol General Hospital, Limassol, Cyprus
(P-100)	Outcome of Patients with Positive Exercise Test and Normal Exercise Myocardial Perfusion SPECT A/Prof Faria Nasreen, Nuclear Medicine, Institute Of Nuclear Medicine & Ultrasound, Dhaka, Bangladesh
(P-101)	Usefulness Of Dacryoscintigraphy in the Management of Patients with Epiphora Dr Madhur Kumar Srivastava, Nuclear Medicine, Apollo Hospitals, Chennai, India

ICRT 2011

4th International Conference on Radiopharmaceutical Therapy

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 3: WEDNESDAY, 30 NOVEMBER 2011 (CONT'D)

(P-102)	Noninvasive Rest and Acetazolamide 99mTc-HM-PAO Brain Perfusion SPECT Imaging with One Day Protocol Using SPECT/CT System Dr Dang An Binh, Nuclear Medicine, Cho Ray Hospital, Ho Chi Minh, Vietnam
(P-103)	Differentiating Benign and Malignant Lesions of Uterus by FDG and FES PET Imaging Dr Raihan Hussain, Thyroid Division, Institute of Nuclear Medicine and Ultrasound, Dhaka, Bangladesh
(P-104)	Illustration of a Single Anomalous Coronary Artery with Myocardial Ischemia by Fusion of N-13 Ammonia PET/CT with CT Coronary Angiography – Case Report Prof Bom Hee-Seung Henry, Nuclear Medicine, CNU Medical School, Hwasun, S. Korea
(P-105)	Comparative Study of Exercise Tolerance Test (ETT) and SPECT-Myocardial Perfusion Imaging (MPI) in the Diagnosis of Coronary Artery Disease in Bangladeshi Women Dr Akhter Nahid, Nuclear Medicine, Centre For Nuclear Medicine & Ultrasound, Dinajpur, Dhaka, Bangladesh
(P-106)	Radiation Exposure of Patients Undergoing Whole-Body Dual-Modality 18F-FDG PET/CT Examinations at Choray Hospital – Vietnam Dr Le Tran Tuan Kiet, Radiation Safety, Cho Ray Hospital, Ho Chi Minh, Vietnam
(P-107)	The Role of 99mTc-MIBI Pinhole Scintigraphy in Preoperative Parathyroid Localization in Era of SPECT/CT Dr Lucia Kaliska, Nuclear Medicine, Institute Of Nuclear Medicine & Molecular Medicine, Banska Bystrica, Slovakia
(P-108)	Langerhans Cell Histiocytosis. Imaging Findings and Utility of FDG PET/CT in an Adult Patient with Multi-Organ Involvement Dr Xie Wanying, Nuclear Medicine, Singapore General Hospital, Singapore
(P-109)	Juxtapapillary Dieulafoy Lesion: An Obscure Case of G.I. Bleeding Localized Using Tc-99m RBC Scintigraphy Dr Millicent Grace De Guzman, Nuclear Medicine, University of Santo Tomas Hospital, Manila, Philippines
(P-110)	Utility of Delayed Imaging in Evaluating Common Bile Duct Obstruction with Tc-99m Mebrofenin Hepatobiliary Scanning Dr Nand Relan, Radiology, Stony Brook University Medical Center, Stony Brook, USA
(P-111)	Role of 18F-Fluoro-Deoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging (18F-FDG PET/CT) for Preoperative Axillary Staging in Primary Breast Cancer: A Prospective Analysis Dr Ankur Pruthi, Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
(P-112)	Role of FDG in Primary Lesion Identification (A Preliminary Result) Dr Hendra Budiawan, Nuclear Medicine, MRCCC - Siloam Hospitals, Jakarta Indonesia
(P-113)	PET/CT and Contrast Enhanced CT in the Detection of Malignant Lesions: A Prospective Study Dr Susan Gironella-Camomot, Nuclear Medicine, Cagayan de Oro Medical Center, Cagayan de Oro City, Philippines
1600 – 1630	SCIENTIFIC SESSION 8: EDUCATION & TRAINING, MOLECULAR IMAGING Ben Thanh Hall, Level 1
	Session Chairpersons: 1. Prof Lee Jae-Tae, Nuclear Medicine, Kyungpook National University Hospital, Daegu, Korea 2. Prof Jun Hatazawa, Japan
1600 – 1630 (O-52)	Training Nuclear Medicine Physicians Foundation and Ideal Model Prof Abdelhamid Elgazzar, Nuclear Medicine & PET, Medicine University of Kuwait, Kuwait

ICRT 2011

4th International Conference on Radiopharmaceutical Therapy

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)
28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 3: WEDNESDAY, 30 NOVEMBER 2011 (CONT'D)

1630 – 1710	ORAL PRESENTATIONS (ARCCNM)	Ben Thanh Hall, Level 1
1630 – 1640 (O-53)	Detection of Activated Microglia with Translocator Protein (18 Kda) Ligand, [18F]FEPPA PET Prof Hiroshi Toyama, Radiology, Fujita Health University, Toyoake, Japan	
1640 – 1650 (O-54)	FDG Uptake, Glucose Transporter Type-1 and KI-67 Expressions Dr Xuan Canh Nguyen, Unit Of Pet/Ct And Cyclotron, Cho Ray Hospital, Ho Chi Minh, Vietnam	
1650 – 1700 (O-55)	Early Response Assessment in Gastrointestinal Stromal Tumors with FDG PET Scan 24 Hours after a Single Dose of Imatinib Dr Ajit Shinto, Nuclear Medicine and PET, KMCH, Coimbatore, India	
1710 – 1800	ARCCNM NATIONAL DELEGATES' ASSEMBLY	To Be Advised
1745 – 1900	WARMTH MEMBERS' ASSEMBLY ALL MEMBERS OF WARMTH TO ATTEND THE MEETING	Ben Thanh Hall, Level 1
1930 – 2300	DINNER & 10 YEARS OF ARCCNM CELEBRATION	Grand Mekong Ballroom, Level 1
2300	END OF DAY 3	



Page 13 of 17

Please note that the programme is correct at time of update and is subject to change without prior notice

ICRT 2011

4th International Conference on Radiopharmaceutical Therapy

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARGCCNM)

28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 4: THURSDAY, 1 DECEMBER 2011

0800 – 1030	SCIENTIFIC SESSION 9: DOSIMETRY, MOLECULAR IMAGING, GENERAL	Ben Thanh Hall, Level 1
Session Chairpersons: 1. Prof Lee Myung Chul, Nuclear Medicine, Seoul National University, Seoul, Korea 2. Dr Pankaj Dougall, Nuclear Medicine Services, Nuclear Medicine And PET-CT, Max Super Speciality Hospitals, New Delhi, India		
0800 – 0825 (O-56)	Usefulness of SPECT/CT for Radionuclide Therapy Dr Cornelis Hoefnagel, Division of Diagnostic Oncology, The Netherlands Cancer Institute, The Netherlands	
0825 – 0850 (O-57)	The Utility of PET in Intensity Modulated Radiotherapy Planning Dr Lee Sze Ting, Centre For PET, Austin Hospital & Ludwig Institute For Cancer Research, Heidelberg, Australia	
0850 – 0910 (O-58)	Prognostication in Radionuclide Therapy Prof Sobhan Vinjamuri, Nuclear Medicine Dept, Royal Liverpool University Hospital, Liverpool, UK	
0910 – 0930 (O-59)	The 3-D Dosimetry in Radionuclide Therapy Based on 4D SPECT/CT Acquisition Prof Kalevi Kairemo, Molecular Radiotherapy & Nuclear Medicine, International Comprehensive Cancer Center Docrates, Helsinki, Finland	
0930 – 0950 (O-60)	Dosimetry in Solid Tumours – Does it have Any Use Prof John Buscombe, Nuclear Medicine, Royal Free Hospital, Cambridge, UK	
0950 – 1010 (O-61)	Current Knowledge of FET use in PET Dr Malkowski Bogdan, Department of Nuclear Medicine, Oncology Centre, Bydgoszcz, Poland	
1010 – 1030 (O-62)	The Tracer Principle: From De Hevesy's Cup of Tea to the Secret Services? Prof Alan Perkins, Radiological And Imaging Sciences, Nottingham University Hospitals, Nottingham, United Kingdom	
1030 – 1100	COFFEE / TEA / TRADE EXHIBITION	Ben Thanh Hall Foyer Pre-Function Area, Level 1
	POSTER PRESENTATIONS: MISCELLANEOUS	Ben Thanh Hall Foyer Pre-Function Area, Level 1
Session Coordinators: 1. Ms Dang Truong Ka My, PET-CT and Cyclotron, Cho Ray Hospital, Ho Chi Minh, Vietnam 2. Dr Nguyen Thi Thuy Hang, Vietnam		
(P-114)	Plasma Therapy: A New Era of Therapeutic Techniques Dr Tanvir Ahmed Biman, Scintigraphy Division, Nuclear Medicine, Institute of Nuclear Medicine & Ultrasound, Dhaka, Bangladesh	
(P-115)	Early Outcome of Chemotherapy in Lymphoma Patients Using Tc-99m Tetrofosmin Scintigraphy Dr Muhammad Asif Rafique, Nuclear Medicine, Nuclear Medicine, Oncology And Radiotherapy Institute (NORI), Islamabad, Pakistan	
(P-116)	Preparation of In-111 Oxine for Labeling of Stem Cell Prof Ali Sattari, Nuclear Medicine, Agriculture And Medicine Research School, Karadj, Iran	
(P-117)	Sentinel Lymph Node Biopsy In Malignant Melanoma – Role of Lymphoscintigraphy in the Detection of Unpredictable Lymphatic Drainage Dr Zamfirescu Anca, Metabolic Radiotherapy, Bucharest Oncology Institute, Bucharest, Romania	
(P-118)	Dual-Phase Tc99m-MIBI Scintigraphy in Lymphoma as a Predictor of Response to Chemotherapy Dr Zaheer Chirag, Nuclear Medicine, BINO Cancer Hospital, Bahawalpur Pakistan	
(P-119)	Review of Utilization of Surveillance Scans in Lymphoma Patients – A Pilot Study Dr Judy Nguyen, Nuclear Medicine, Stanford University Medical Center, Stanford, USA	

ICRT 2011

4th International Conference on Radiopharmaceutical Therapy
In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)
28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 4: THURSDAY, 1 DECEMBER 2011 (CONT'D)

1100 – 1245	SCIENTIFIC SESSION 10: BREAST CANCER, LYMPHOMA, RADIOIMMUNOTHERAPY (RIT)	Ben Thanh Hall, Level 1
	Session Chairpersons 1. Prof Hiroshi Toyama, Radiology, Fujita Health University, Toyoake, Japan 2. Dr Felix Sundram, Nuclear Medicine, Wijaya International and Sime Darby Medical Centres, Kuala Lumpur, Malaysia	
1100 – 1130 (O-63)	IART in Breast Cancer Prof Giovanni Paganelli, Divisione Di Medicina Nucleare, IEO Istituto Europeo Di Oncologia, Milano, Italy	
1130 – 1150 (O-64)	Positron Emission Tomography in Breast Cancer Dr Patricia Bernal Trujillo, Nuclear Medicine, Fundacion Santa Fe B Ogot, Colombia	
1130 – 1210 (O-65)	Radioimmuno-Scintigraphy and Radioimmuno-Therapy. A State of the Art Prof Izak Garty, Nuclear Medicine, Haemek Medical Centre, Afula, Israel	
1210 – 1230 (O-66)	Radioimmunotherapy of Non-Hodgkin Lymphoma with 131I-Rituximab Prof Harvey Turner, University Of Western Australia, Fremantle Hospital, Australia	
1230 – 1245 (O-67)	Use of PET to Monitor the Results of I-131 CHT25 RIT Dr Ewa Nowosinska, Nuclear Medicine Department, Royal Free Hospital, London, UK	
1245 – 1315	ORAL PRESENTATIONS	Ben Thanh Hall, Level 1
1245 – 1255 (O-68)	Potential Use of 177Lu In Radioimmunotherapy as Targeting Tracers on Monoclonal Antibodies Dr Choi Sun-Ju, Radioisotope Research Division, Korea Atomic Energy Research Institute, Daejeon, Korea	
1255 – 1305 (O-69)	Effect of Molecular Imaging on Evaluation of the Therapeutic Efficacy of VEGFR2 Blocking Antibody in a Sodium-Iodide Symporter Gene Expressed Tumor Model Dr Cheong Su-Jin, Nuclear Medicine, Chonbuk National University Medical School and Hospital, Jeonju, Korea	
1305 – 1315 (O-70)	Diagnostic Efficacy of Scintimammography for Detection of Malignant Tissue in the Breast Performed with Tc-99m MDP and Tc-99m Sestamibi Prof Birendra Kishore Das, Nuclear Medicine, Utkal Institute of Nuclear Medicine, Bhubaneswar, India	
1315 – 1400	LUNCH / TRADE EXHIBITION	Parkview Restaurant, Ground Level
1400 – 1530	SCIENTIFIC SESSION 11: RADIONUCLIDE THERAPY & QUALITY OF LIFE	Ben Thanh Hall, Level 1
	Session Chairpersons: 1. Prof Irene Virgolini, Nuclear Medicine & PET, University Of Innsbruck, Innsbruck, Austria 2. Prof Abdelhamid Elgazzar, Nuclear Medicine & PET, Faculty of Medicine University of Kuwait, Kuwait	
1400 – 1425 (O-71)	The Value of Life and the Concept of QOL: A Critical Examination of the Basic Principles for Clinical Measurement of QOL Dr Remigius Orjiukwu, Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria	
1425 – 1450 (O-72)	QOL from A Doctor's Perspective : Review of Actual Clinical Data Prof Irene Virgolini, Nuclear Medicine & PET, University Of Innsbruck, Innsbruck, Austria	
1450 – 1515 (O-73)	QOL from A Patient Perspective Mr William Claxton, CNETS, Singapore	
1515 – 1525	COFFEE / TEA / TRADE EXHIBITION	Ben Thanh Hall Foyer Pre-Function Area, Level 1

ICRT 2011

4th International Conference on Radiopharmaceutical Therapy

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)
28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 4: THURSDAY, 1 DECEMBER 2011 (CONT'D)

1525 – 1550	SCIENTIFIC SESSION 12: RADIONUCLIDE THERAPY – FUTURE PERSPECTIVES & CLOSING CEREMONY	Ben Thanh Hall, Level 1
	Session Chairpersons: 1. Prof Ajit Kumar Padhy, Nuclear Medicine, Singapore General Hospital, Singapore (President-WARMTH) 2. Prof Henry Bom Hee-Seung, Nuclear Medicine, CNU Medical School, Hwasun, South Korea	
1525 – 1550 (O-74)	THERANOSTICS: From Molecular Imaging Using PET/CT with Ga-68 Labeled Tracers to Personalized Therapy Prof Richard Baum, Department of Nuclear Medicine, Center For PET/CT, Bad Berka, Germany	
1550 – 1700	CLOSING CEREMONY	Ben Thanh Hall, Level 1
1550 – 1600	AWARDS: ▪ BEST ORAL PRESENTATION – 3 PRIZES ▪ BEST POSTER – 3 PRIZES	
1600 – 1607	NEXT CONFERENCE ▪ 3rd International Symposium on Radiopharmaceutical Therapy (ISRT-2012), Levi, Finland Prof Kalevi Kaieremo (Finland)	
1607 – 1615	5th International Conference on Radiopharmaceutical Therapy (ICRT-2013) (Selection of Venue)	
1615 – 1620	Closing Remarks Prof Henry Bom (ARCCNM)	
1620 – 1625	Closing Remarks Dr Nguyễn Trường Sơn (Cho Ray Hospital)	
1625 – 1630	Vote of Thanks Dr Nguyễn Xuân Cảnh (Local Organizing Secretary)	
1630 – 1700	Highlights & Closing Remarks Prof Ajit Kumar Padhy, President, WARMTH	
1710	SHUTTLE TRANSFER TO OENOPHILOUS DINNER	
1730 – 2300	ENTERTAINMENT & OENOPHILOUS DINNER	
2300	END OF DAY 4	





ICRT 2011

4th International Conference on Radiopharmaceutical Therapy

In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)
28 Nov – 2 Dec 2011

New World Saigon Hotel, Ho Chi Minh City, Vietnam

DAY 5: FRIDAY, 2 DECEMBER 2011

0730	Departure to Cu Chi Tunnels for Sight-Seeing Tour
0930 – 1130	Cu Chi Tunnel Tour
1130 – 1230	Ho Chi Minh Memorial
1230 – 1500	LUNCH
1600	Return to Hotel

Last Evening in Ho Chi Minh City

All Participants Will Have A Free Evening. This Evening's Dinner Is Not Included In The Lump-Sum. Participants Are Free To Go Out For Sight Seeing In The City With Friends Or Do Shopping; And Later For A Change Should Try Out Some Of The Delicious Vietnamese Cuisine For Dinner.

DAY 6: SATURDAY, 3 DECEMBER 2011

Post-Congress Tour of Siem Reap, Cambodia





“Nuclear Therapy” Song **(Fr. Dr. Remigius Orjiukwu)**

We Yah (=God) people we are born to be therapists. Our life is meaningless unless it gives meaning to the other,

Yeesh, human relationship is fairly like a nuclear therapy **uuh, uuh**
human relationship is fairly like a nuclear therapy **uuh, uuh**
I say, human relationship is fairly like a nuclear therapy **uuh, uuh**
Do you know human relationship is fairly like a nuclear therapy **uuh, uuh**
Together we are stronger, like nuclear therapy, **uuh, uuh**
The receptor invites the peptide to a hunting companionship **uuh, uuh**
Eeeh, it is a love and affair, like nuclear therapy

(Refrain)

It's like nuclear therapy, **theeraaapy**
It's like nuclear therapy **theeraaapy**
Therapy, therapy, therapy, therapy **theeraaapy**
Therapy, therapy, therapy therapy **theeraaapy**

Human relationship is fairly like a nuclear therapy **uuh, uuh**
Human relationship is fairly like a nuclear therapy **uuh, uuh**
I say, human relationship is theeeeeeraaapy, **uuh, uuh**

Hear me now!

I and you we are receptors
We are sitting on rotten cells of worries and troubles and
Everyone is a peptide and got to be carrier of powerful isotope, which can kill to create
life, powerful love
it is a love and affair, like nuclear therapy

(Refrain)

When you love, you are a therapist and when you give therapy to others you give it to yourself.
Oh, Yah (=God) strengthen you!



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009











7th ICRT-2012, Levi, Finland

Congress-President: Kalevi Kairemo

"The idea of having WARMTH conference in the Cold was presented first time in Cartagena 2009. This idea got a great welcome. Anyhow, final decision was made in Capetown 2010. The original plan was to arrange it in November 2011, but it was postponed until 2012 because of a higher probability for Northern Lights. The time in November 2012, was chosen because of full moon, beginning of dark season and guaranteed snow. The practical limiting factor was the alpine skiing season, because World cup typically starts in Levi, also in 2012/2013. Additionally European Alpine cup has competitions in Levi, but we succeeded in finding the one week time slot.

In the Levi facility, winter is a guaranteed success. In November 2012, there was more than 150 cm snow, and the first snow brought light and new energy after the autumn darkness. The conference venue Levi Summit Conference and Exhibition Center, is located on the fell, in the leading winter holiday resort in Finland, which is located in the Northern part of the country, in the so called Fell-Lapland, about 170 km north from the Arctic Circle in the middle of pure and wild nature. All the multiple and high quality facilities, from luxury accommodation to high-class restaurants and souvenir shops, are within walking distance from each other and the unspoiled nature is just around the corner. The population density in Lapland is approximately 1 person per 2 km², meaning that all the equipment had to be brought from Helsinki or other cities.

In the Levi conference, the temperature varied from +1 – - 24 C, and there was 1-1.5 m snow everywhere. The best transportation from the conference center down to the village was by ski lift"

Candle Lighting Ceremony

26.11.2012 in Levi.

Watanabe (JPN),
Elgazzar (EGY/KUW),
Padhy (IND/SIN),
Turner (AUS),
Kairemo (FIN), Baum
(GER), Bernal (COL),
Srivastava (USA) and
Dougal (IND)





Preparations for me as congress president included three visits to Lapland, in 2011-2012, 1½ h flight one way to/from Helsinki, 4-digit number of e-mails between various contributors in Lapland, 4-digit number of phone calls to various individuals in Finland. In Finland I got help from Docrates Cancer Center and MAP Medical Technologies, especially with the logistics (car-train, trips to Lapland); Pro-doit from Oulu arranged the poster walls to Levi (400 km one way) and Event Works from Tornio arranged most of the AV techniques (300 km one way). We also brought AV/ IT equipment from Helsinki (1100 km, station wagon in the train (900 km) + 200km by car). Polar Meetings arranged the local trips in Lapland in coordination with the Levi Summit Conference Center. I also owe special thanks to Singapore, secretarial help by Ee Sia Tan and co-workers (Events 360) who all travelled to Lapland and to the soul of WARMTH, prof. Dr. Ajit K. Padhy. This was Ajit Padhy's last WARMTH Conference. There was a lack of sponsors, but without the help of Lee Foundation, MAP Medical Technologies, Advanced Accelerator Applications, Polatom, ANSTO, ANZNMS, Genzyme, Imagin, University of Lapland, Municipality of Kittilä, Academy of Finland, the event would not have been possible. The Congress made deficit by approximately 20 000 EUR.

Anyway, the Congress was a real success otherwise. There were 312 registered participants from 72 countries. There was an extensive program, consisting of 85 posters and 65 oral presentations in 18 sessions (attachment). The abstracts were published in World Journal of Nuclear Medicine. Multiple high quality presentations were given. The most exotic, however, was the first nonmedical session on Sunday arranged in collaboration with University of Lapland. The session dealt with research about northern lights, ice & snow sculptures, glacier melting (climate changes), tourism, cold exposures and love as sociological concept. The Conference was opened on Monday by a Candle lightning ceremony (picture), and Minister of Health greeting.

"In the Inaugural Dinner in the Levi village Life-Time Awards were given to three persons from Norway, three persons from Finland and two persons from Sweden.

On Thursday, there was an excursion to Rovaniemi, situated in the heart of Lapland on the Arctic Circle, the Arktikum House, a museum as well as a popular exhibition and congress centre, excursions to Santa Claus Village and Oenophilous dinner in Kaukonen, wine/liqueur from 37 countries.

In Kaukonen, there was a competition between continents in skiing on tandem skis. Antarctica (presented by people who visited the continent) won before Europe and North America, all teams Australia, South America, Africa and Asia finished the competition. The color of the Congress was blue. We arranged a dinner everybody wearing blue in the Conference Center. The group photo was taken after the last lecture on Wednesday evening. The last congress day was Friday, one of the three flights was cancelled (-24 C). Fortunately, I had ordered bigger plane for Finnair (just in case) with 80 extra seats; thus only approximately 10 people had to stay extra night in Kittilä (volunteers for this were easy to find). I personally took the Friday morning flight to Helsinki in order preparing a short visit in Helsinki, before participants moved to their connections." (Kalevi Kairemo)



ICRT 2012

7th International Conference on Radiopharmaceutical Therapy

Levi, Finland
25 – 29 November 2012

Venue: Levi Summit Conference Centre, Levi, Finland

DAY 1: SUNDAY, 25 NOVEMBER 2012

0900 – 1600	REGISTRATION	
1430 – 1605	SCIENTIFIC SESSION 1: PRE-CONFERENCE SYMPOSIUM ON NUCLEAR CARDIOLOGY	Auditorium, Ground Floor
	Session Chairpersons: 1. Dr Pankaj Dougal, Nuclear Medicine and PET-CT, Max Super Speciality Hospitals, New Delhi, India 2. Dr Kok Tian Yue, Nuclear Medicine and PET, Singapore General Hospital, Singapore	
1430 – 1455 PC-1	Myocardial Viability – Implications for Clinicians Dr Carlos D Libhaber, Nuclear Medicine, University of the Witwatersrand, Chris Hani Baragwanath Hospital, Johannesburg, South Africa	
1455 – 1520 PC-2	Role of Radionuclide Imaging in Heart Failure Prof Zuo-Xiang He, Nuclear Medicine, Fu Wai Hospital & Cardiovascular Institute, Beijing, China	
1520 – 1540 PC-3	New Experimental Tracers for Myocardial Ischemia Prof Henry Bom, Nuclear Medicine, Chonnam National University Hospital, Jeonnam, Korea	
1540 – 1605 PC-4	Assessment of Cardiac Dyssynchrony: A Nuclear Approach Prof Chetan Patel, Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India	
1605 – 1630	COFFEE / TEA / TRADE EXHIBITION	
1630 – 1830	SCIENTIFIC SESSION 2: PRE-CONFERENCE SYMPOSIUM ON ARCTIC ENVIRONMENT	Auditorium, Ground Floor
	Session Chairpersons: 1. Prof Mauri Ylä-Kotola, University of Lapland, Finland 2. Prof Kalevi Kairemo, Molecular Radiotherapy & Nuclear Medicine, International Comprehensive Cancer Center Docrates, Helsinki, Finland	
1630 – 1655 PC-5	Hospitals, Hospitality and Hosting Health – An Arctic Avenue Prof Johan Edelman, Multidimensional Tourism Institute, University of Lapland, Rovaniemi, Finland	
1655 – 1705 PC-6	Human Thermal Responses During Reindeer Safaris in Cold Dr Susanna Paakkola, Arctic Centre, University of Lapland, Rovaniemi, Finland	
1705 – 1730 PC-7	Northern Lights Through the Eyes of a Space Scientist Prof Thomas Ulich, Director, Sodankylä Geophysical Observatory, University of Oulu, Oulu, Finland	
1730 – 1745 PC-8	Glaciological Research in Svalbard Dr Martina Schäfer, Arctic Centre, University of Lapland, Rovaniemi, Finland	
1745 – 1805 PC-9	Arctic Sculptures, Snow & Ice Prof Timo Jokela, University of Lapland, Rovaniemi, Finland	
1805 – 1830 PC-10	Many Faces of Love Prof Kaarina Maatta, University of Lapland, Rovaniemi, Finland	
1930 – 2200	WELCOME DINNER	Restaurant Okta, Ground Floor Hotel Levi Panorama
2200	END OF DAY 1	

ICRT 2012

7th International Conference on Radiopharmaceutical Therapy

Levi, Finland
25 – 29 November 2012

Venue: Levi Summit Conference Centre, Levi, Finland

DAY 2: MONDAY, 26 NOVEMBER 2012

0800 – 1600	REGISTRATION	
0830 – 0900	SCIENTIFIC SESSION 3: OPENING	Auditorium, Ground Floor
Welcome Prof Kalevi Kairemo, Local Organising Chairman, ICRT 2012		
Opening Remarks Prof Ajit Kumar Padhy, International Organising Chairman, ICRT 2012 & President-WARMTH		
WARMTH Candle Lighting Ceremony Prof Harvey Turner, Prof Ajit Kumar Padhy, Prof Richard P Baum, Prof Alan Perkins, Prof Kalevi Kairemo & Other Members of WARMTH Governing Body		
0900 – 1100	SCIENTIFIC SESSION 4: THYROID DISEASES I	Auditorium, Ground Floor
Session Chairpersons: 1. Prof Mike Sathekge, Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa 2. Prof Ralph McCready, Nuclear Medicine, Royal Sussex County Hospital, Brighton, United Kingdom		
0900 – 0920 S-1	Subclinical Hyperthyroidism – To Treat or Not to Treat with Radioiodine A/Prof Grzegorz Kaminski, Endocrinology & Radioisotope Therapy, Military Institute of Medicine, Warsaw, Poland	
0920 – 0940 S-2	Graves' Ophthalmopathy & Radioiodine Therapy Dr Emerita Barrenechea, Nuclear Medicine, Veterans Memorial Medical Centre, Quezon City, Philippines	
0940 – 1000 S-3	Thyroid Cancer and Nuclear Accident Prof Naoyuki Watanabe, Radiological Sciences, Gunma Prefectural College of Human Health, Maebashi, Japan	
1000 – 1020 S-4	Use of Rh-TSH (Thyrogen) in Thyroid Cancer – A Review Dr Sze Ting Lee, Nuclear Medicine & PET, Ludwig Institute for Cancer Research, Heidelberg, Australia	
1020 – 1040 S-5	Modern Imaging in Detection of Iodine Negative-Tg Positive Differentiated Thyroid Cancer Prof Jasna Mihailovic, Nuclear Medicine, Oncology Institute of Vojvodina, Novi Sad, Serbia	
	ORAL PRESENTATIONS	Auditorium, Ground Floor
1040 – 1050 O-1	Efficacy of Different Protocols of Radioiodine Therapy for Treatment of Toxic Nodular Goiter: Systematic Review and Meta-Analysis of the Literature Dr R Zakavi, et al (Iran)	
1050 – 1100 O-2	Early Radioiodine Ablation Post Thyroidectomy with Recombinant TSH (r-TSH) Stimulation and its Impact on Performance Status, Versus Thyroxine Abstinence Protocol in Differentiated Thyroid Carcinoma : Initial Results of a Randomized Prospective Clinical Trial Dr P Choudhary, et al (India)	
1100 – 1130	COFFEE / TEA / TRADE EXHIBITION	
1100 – 1130	POSTER PRESENTATIONS	
Session Coordinators: 1. Dr Ruben Ogbac, Nuclear Medicine, St Luke's Medical Center, Quezon City, Philippines 2. Dr Erdenechimeg Sereegotov, Nuclear Medicine, First Central Hospital, Ulaanbaatar, Mongolia		
P-1	What is the Alternative to Radioiodine Therapy in Diffuse Pulmonary Metastasis from Papillary Thyroid Carcinoma in Children Dr Kaouthar Chatti, et al (Tunisia)	
P-2	Thyroid Cancer Treated at the Clinical Center Banja Luka. A Review of 5 Years Experience Dr Zvezdana Rajkovic, et al (Serbia)	
P-3	Optimization of 90Y-antiCD20 Preparation for Radioimmunotherapy Dr Amir R Jalilian, et al (Iran)	
P-4	Optimized Preparation of [64Cu]-DOTA-Trastuzumab for PET Applications Dr Amir R Jalilian, et al (Iran)	
P-5	Significance of Post-Therapy SPECT-CT Scan in Differentiated Thyroid Cancer Dr Rajesh Kumar, et al (India)	
P-6	Patient's Specific Dosimetry for Radioiodine Therapy of Thyroid Cancer and Comparison with Fixed Doses Dr Noreen Marwat, et al (Pakistan)	

Page 2 of 14

Please note that the programme is correct at time of update and is subject to change without prior notice

ICRT 2012

7th International Conference on Radiopharmaceutical Therapy

Levi, Finland
25 – 29 November 2012

Venue: Levi Summit Conference Centre, Levi, Finland

DAY 2: MONDAY, 26 NOVEMBER 2012

P-7	Bone Metastases from Differentiated Thyroid Carcinoma: Clinical Features and Long Term Follow Up Dr Nurun Nahar, et al (Bangladesh)
P-8	Salivary Gland Tumor After Radioiodine Therapy for Well Differentiated Thyroid Carcinoma: A Case Report Prof Lutfun Nisa, et al (Bangladesh)
P-9	Radioactive Iodine Ablation in Children and Adolescents with Differentiated Thyroid Carcinoma Dr Yustia Tuti Jelani, et al (Indonesia)
P-10	The Advantages of Routine Radiothyroablation in Well Differentiated Thyroid Carcinoma Patients Dr Hapsari Indrawati, et al (Indonesia)
P-11	Clinical Outcome of Differentiated Thyroid Carcinoma with Lymph Node Metastasis : A Retrospective Analysis of Patients Treated at a Single Institute Dr Faria Nasreen, et al (Bangladesh)
P-12	Papillary Thyroid Carcinoma after Maximum Radioiodine Therapy with Persistent Disease (A Case Study) Dr Ryna Z Martiana, et al (Indonesia)
P-13	Clinical Behavior of Follicular Variant of Papillary Thyroid Carcinoma at INMU Dr Sadia Sultana, et al (Bangladesh)
P-14	Detection and Treatment of Lung Metastases in Differentiated Thyroid Carcinoma Dr Zeenat Jabin, et al (Bangladesh)
P-15	Clinical Significance of Thyroglobulin Antibody Pattern in Patients with Differentiated Thyroid Carcinoma: Preliminary Study Dr Ivana Dewi Mulyanto, et al (Indonesia)
P-16	Two Cases with Unusual Uptake in the Whole Body Scan with Radioiodine 131: Textiloma; Miliary Tuberculosis Dr Ben Rais Aouad Nozha, et al (Moroco)
P-17	A Rare Pediatric Case of Metastatic Papillary Thyroid Carcinoma in the Brain Dr Karina Michaela Dela Cruz, et al (Philippines)
P-18	Diagnostic Difficulty Due to Incidental Fibrous Dysplasia in a Patient with Metastatic Follicular Thyroid Cancer and the Possible Association of these Entities with McCune Albright Syndrome Dr Sumbul Zaheer, et al (Singapore)
P-19	The Value of PET/CT in the Diagnosis and Therapy of Thyroid Cancer Dr Emerita Barrenechea, et al (Philippines)
P-20	Radioiodine Treatment for Thyrotoxicosis in Childhood and Adolescence: Treatment and Outcome Dr Sirianong Namwongprom, et al (Thailand)
P-21	Follow-up of High Risk Thyroid Cancer Patients with Bone and Lung Metastases Dr Rosanna Morales, et al (Peru)
P-22	Low Dose Radioiodine Ablation for Differentiated Thyroid Carcinoma (DTC) - A Retrospective Analysis Dr Damayanthi KK Nanayakkara, et al (Sri Lanka)
P-23	Clinical Outcome of Radioactive Iodine Therapy Among Patients with Hyperthyroidism in St. Luke's Medical Center-Philippines Dr Irene Bandong, et al (Philippines)
P-24	Hürthle Cell Carcinoma – The Nuclear Medicine Specialist Point of View Dr Ana Ugrinska, et al (Macedonia)
P-25	Role of Thyroglobulin (Tg) Level and Whole-Body Scan (WBS) After I-131 Therapy in Patients with Differentiated Thyroid Cancer Dr Shankar Biswas, et al (Bangladesh)
P-26	Potential Response of Grave's Disease Associated with Thymic Hyperplasia After Radioactive Iodine 131 Therapy: A Case Report Dr Bonan A. Mendoza, et al (Philippines)
P-85	Experience with 30 mCi Iodine-131 Ablation Therapy for DTC in Sarawak General Hospital Dr Dahlia Saidin, et al (Malaysia)



WARMTH
 WORLD ASSOCIATION
 OF RADIOPHARMACEUTICAL
 AND MOLECULAR THERAPY
 FOUNDED 2009

ICRT 2012

7th International Conference on Radiopharmaceutical Therapy
 Levi, Finland
 25 – 29 November 2012

Venue: Levi Summit Conference Centre, Levi, Finland

DAY 2: MONDAY, 26 NOVEMBER 2012

1130 – 1305	SCIENTIFIC SESSION 5: BONES & JOINTS / METASTATIC BONE PAIN PALLIATION	Auditorium, Ground Floor
	Session Chairpersons: 1. Prof Izak Garty, Nuclear Medicine, Central Emek Hospital, Afula, Israel 2. Dr Sze Ting Lee, Nuclear Medicine & PET, Ludwig Institute for Cancer Research, Heidelberg, Australia	
1130 – 1150 S-10	Intermittent Pneumatic Compression: Effect on MDP Uptake – A Potential Method to Facilitate Therapy Prof Abdelhamid Elgazzar, Medical Faculty, University of Kuwait, Safat, Kuwait	
1150 – 1210 S-11	Radionuclide Imaging of Bone Metastases: Science & Practice Dr Gopinath Gnanasegaran, Nuclear Medicine, Guy's & St Thomas Hospital NHS Foundation Trust, London, United Kingdom	
1210 – 1225 S-60	Radiosynovectomy-Procedure Review and Description of A Multicentre Study to Measure the Safety and Efficacy of Radiosynovectomy Performed with Y-90 Citrate Colloid and Re-186 Sulfide Dr James Warrington, Nuclear Medicine, London Health Sciences Centre, London, Canada	
1225 – 1245 S-12	Radiosynovectomy in the Treatment of Arthritis Dr Knut Liepe, Nuclear Medicine, GH Kassel, Kassel, Germany	
1245 – 1305 S-19	Assessing Tuberculosis Response to Therapy Prof Mike Sathkege, Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa	
1305 – 1400	LUNCH / TRADE EXHIBITION	Restaurant Okta, Ground Floor Hotel Levi Panorama
1400 – 1600	WARMTH GOVERNING BODY MEETING (GOVERNING BODY MEMBERS ONLY)	
1400 – 1613	SCIENTIFIC SESSION 6: THYROID DISEASES II	Auditorium, Ground Floor
	Session Chairpersons: 1. Dr Knut Liepe, Nuclear Medicine, GH Kassel, Kassel, Germany 2. Dr Achmad Hussein Sundawa Kartamihardja, Nuclear Medicine, Dr Hasan Sadikin General Hospital, Bandung, Indonesia	
1400 – 1425 S-7	Clinical Role of F-18 FDG PET/CT for Differentiated Thyroid Cancer Before and After High Dose I-131 Therapy Prof Henry Bom, Nuclear Medicine, Chonnam National University Hospital, Jeonnam, Korea	
1425 – 1445 S-8	Role of SPECT-CT in Diagnosis, Staging and Follow Up of Patients with Thyroid Diseases Dr Sonya Sergieva, Nuclear Medicine, Sofia Cancer Center, Sofia, Bulgaria	
1445 – 1500 S-9	Management of Differentiated Thyroid Cancer: A Single Centre Experience & Lessons Learnt in the Last 20 Years Dr Shazia Fatima, Nuclear Medicine, Nuclear Medicine, Oncology & Radiotherapy Institute, Islamabad, Pakistan	
1500 – 1525 S-6	Therapeutic Approaches in Thyroid Cancer – What is Next to Standard Treatment? Dr Daniel Putzer, Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria	
	ORAL PRESENTATIONS	Auditorium, Ground Floor
1525 – 1533 O-3	Clinical Significance of Measurement of Serum Anti Thyroglobulin Antibodies (ATgAb) in the Follow Up of Differentiated Thyroid Carcinoma Dr Javaid Irfan, et al (Pakistan)	
1533 – 1541 O-4	Consequences of Misadministration in Handling of Radiopharmaceuticals Prof Ajai Kumar Shukla (India)	
1541 – 1549 O-5	Experience with 177Lu-EDTMP Regarding Improvement in Quality of life and Bone Pain Palliation Dr Ghazal Jameel, et al (Pakistan)	
1549 – 1557 O-6	Hydroxyapatite Particles Labelled with Beta-Emitting Lanthanoids for Radiosynovectomy Dr Mohammad Sohaib, et al (Pakistan)	
1557 – 1605 O-7	The Pilot Study To Evaluate the Effectiveness of Radiosynoviorthesis (RSO) of Sacro-iliac Joints with Re-186 Dr Marika Vereb, et al (Germany)	
1605 – 1613 O-8	Radiation synovectomy with Yttrium (90Y) Citrate in rheumatoid arthritis patients- 5 years of follow up Dr Ljiljana Jaukovic, et al (Serbia)	

Page 4 of 14

Please note that the programme is correct at time of update and is subject to change without prior notice

ICRT 2012

7th International Conference on Radiopharmaceutical Therapy

Levi, Finland
25 – 29 November 2012

Venue: Levi Summit Conference Centre, Levi, Finland

DAY 2: MONDAY, 26 NOVEMBER 2012

1613 – 1630	COFFEE / TEA / TRADE EXHIBITION / TRADE EXHIBITION
1613 – 1630	POSTER PRESENTATIONS
	<p>Session Coordinators:</p> <ol style="list-style-type: none"> 1. Dr Ana Ugrinska, Institute of Pathophysiology and Nuclear Medicine, Skopje, Macedonia 2. Dr Anne Poksi, Nuclear Medicine Centre, East-Tallinn Central Hospital, Tallinn, Estonia
P-27	<p>Effectiveness of Radiation Synovectomy with Yttrium (90Y) Citrate Related to Preexisting Radiological Damage in Rheumatoid Arthritis Patients Dr Boris Ajdinovic, et al (Serbia)</p>
P-28	<p>Treatment Efficacy of Sm-153 Lexidronate for Pain Management of Bone Metastases: The First Experience in Iran Dr Narjess-Khatoun Ayati, et al (Iran)</p>
P-29	<p>Clinical Characteristics, Efficacy of I-131 Therapy and Outcome of Patients with Differentiated Thyroid Cancer having Bone Metastases – A Retrospective Study Dr Sadaf Butt, et al (Pakistan)</p>
P-30	<p>Production, Quality Control and Biological Evaluation of 153Sm-isoPDTPM and 153Sm-TTHMP as a Possible Bone Palliation Agent Dr Zohreh Naseri, et al (Iran)</p>
P-31	<p>Effectiveness of Strontium -89 Therapy in Multiple Bony Metastases Patient with CA. Breast and CA.Prostate Dr Om Prakash Sinha, et al (India)</p>
P-32	<p>A Study on Strontium-90 Irradiation for Treatment of Post-Operative Conjunctival Squamous Cell Carcinoma Prof Raihan Hussain, et al (Bangladesh)</p>
P-33	<p>The Synthesis, Radiolabeling and First Biological Evaluation of a New 166Ho-Complex for Radiotherapy of Bone Metastases Dr Samaneh Zolghadri, et al (Iran)</p>
P-34	<p>Post- Therapy Precautions and Imaging Properties of Samarium 53 vs Strontium-89 Mr Rey Martin Jr Goco, et al (Philippines)</p>
P-35	<p>Semi-Quantitative Estimation of Samarium-153 Oxabifore Therapy Results of Metastatic Bone Disease in Mono - Regime and in Combination with Bisphosphonates Dr Nigora Rasulova, et al (Uzbekistan)</p>
P-36	<p>Preparation and Biodistribution of 99mTc and 188Re Labeled Zoledronic Acid Dr Olga Klementyeva, et al (Russia)</p>
P-37	<p>Radiopharmaceutical Based on Monopotassium Salt of Hydroxyethylendiphosphonic Acid Labeled with 188Re for Therapy of Bone Metastases Dr Vasily Petrie, et al (Russia)</p>
P-38	<p>Potential Role of Semi-Quantitative Analyses of Bone Metastases in Evaluation of Radionuclide Therapy Response Dr Nigora Rasulova, et al (Uzbekistan)</p>



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

ICRT 2012

7th International Conference on Radiopharmaceutical Therapy

Levi, Finland

25 – 29 November 2012

Venue: Levi Summit Conference Centre, Levi, Finland

DAY 2: MONDAY, 26 NOVEMBER 2012

1630 – 1830	SCIENTIFIC SESSION 7: MOLECULAR IMAGING & RADIONUCLIDE THERAPY	Auditorium, Ground Floor
	Session Chairpersons: 1. Dr Michael Tomblin, Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, USA 2. Dr William Macdonald, Nuclear Medicine, Royal Perth Hospital, Perth, Australia	
1630 – 1650 S-14	Potentially required number of PET apparatus in Asia and Latin America including Mexico Prof Naoyuki Watanabe, Radiological Sciences, Gunma Prefectural College of Human Health, Maebashi, Japan	
1650 – 1710 S-15	Treatment Response Evaluation using current imaging modalities Prof Rakesh Kumar, Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India	
1710 – 1730 S-16	Avibodies – A Novel Approach for Targeting Prostate and Ovarian Cancer Prof Andrew Scott, Nuclear Medicine & PET, Ludwig Institute for Cancer Research, Heidelberg, Australia	
1730 – 1750 S-17	Percutaneous Radionuclide Therapy (PERTH) Prof Ralph McCready, Nuclear Medicine, Royal Sussex County Hospital, Brighton, United Kingdom	
1750 – 1810 S-18	Current Status of PET Radiopharmaceuticals in PET/CT Guided Radiotherapy Treatment Planning Dr Antonija Balenovic, PET/CT Center, Poliklinika Medikol, Zagreb, Croatia	
1810 – 1830 S-13	Development of New Radiopharmaceuticals for Diagnosis and Treatment of Arthritis Prof Vijay Kumar, Nuclear Medicine & PET, Westmead Hospital, Sydney, Australia	
1930 – 2300	FORMAL INAUGURAL CEREMONY	Restaurant Taivas
	<ul style="list-style-type: none">WARMTH AwardsDinner	
2300	END OF DAY 2	

World Association of Radiopharmaceutical & Molecular Therapy (WARMTH)

7th International Conference on Radiopharmaceutical Therapy (ICRT-2012)

Levi Summit Conference and Exhibition Centre, Kittilä, Finland

Nov 25-29, 2012



UNIVERSITY OF LAPLAND
LAPIN YLIOPISTO

MAP MEDICAL
TECHNOLOGIES

DocuMates



Please note that the programme is correct at time of update and is subject to change without prior notice



WARMTH
 WORLD ASSOCIATION
 OF RADIOPHARMACEUTICAL
 AND MOLECULAR THERAPY
 FOUNDED 2009

ICRT 2012

7th International Conference on Radiopharmaceutical Therapy
 Levi, Finland
 25 – 29 November 2012

Venue: Levi Summit Conference Centre, Levi, Finland

DAY 3: TUESDAY, 27 NOVEMBER 2012

0810 – 0930	SCIENTIFIC SESSION 8: WARMTH: HISTORY, FUTURE PERSPECTIVES & INTERNATIONAL COLLABORATIONS	Auditorium, Ground Floor
	Session Chairpersons: 1. Prof Harvey Turner, Nuclear Medicine, Fremantle Hospital, Fremantle, Australia 2. Dr Suresh Srivastava, Collider-Accelerator Department, Brookhaven National Laboratory, New York, USA	
0810 – 0830 S-20	History of WARMTH Prof Ajit Kumar Padhy, Nuclear Medicine & PET, Singapore General Hospital, Singapore	
0830 – 0850 S-21	IAEA Perspectives on Radionuclide Therapy Prof Adriano Duatti, Nuclear Applications, IAEA, Vienna, Austria	
0850 – 0910 S-22	WFNMB Perspectives on Radionuclide Therapy Prof Andrew Scott, President Elect, WFNMB (2014-2018), Australia	
0910 – 0930 S-23	Future Prospects of Radionuclide Therapy in Korea Prof Dong Soo Lee, Nuclear Medicine, Seoul National University Hospital, Seoul, Korea	
0930 – 1105	SCIENTIFIC SESSION 9: NEURO-ENDOCRINE TUMORS I	Auditorium, Ground Floor
	Session Chairpersons: 1. A/Prof Grzegorz Kaminski, Endocrinology & Radioisotope Therapy, Military Institute of Medicine, Warsaw, Poland 2. Dr Vikram Lele, Director, Nuclear Medicine, Jaslok Hospital & Research Centre, Mumbai, India	
0930 – 0955 S-24	Personalized Radionuclide Therapy of Cancer – Will It Remain a Dream or Become Reality? Prof Richard P Baum, THERANOSTICS Center for Molecular Radiotherapy/Imaging, Zentralklinik Bad Berka, Bad Berka, Germany	
0955 – 1020 S-25	Innsbruck Medical University: Long-term Results in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) Prof Irene Virgolini, Nuclear Medicine & PET, Medical University of Innsbruck, Innsbruck, Austria	
1020 – 1045 S-26	NETs: Labeled Somatostatin Analogues in Therapy Dr Chiara Grana, Nuclear Medicine, European Institute of Oncology, Milano, Italy	
1045 – 1105 S-27	Clinical Trial Evaluation of Radiopeptide Therapy of Neuroendocrine Tumours Prof Harvey Turner, Nuclear Medicine, Fremantle Hospital, Fremantle, Australia	
1105 – 1130	COFFEE / TEA / TRADE EXHIBITION / TRADE EXHIBITION	
1105 – 1130	POSTER PRESENTATIONS	
	Session Coordinators: 1. Dr Marika Vereb, Nuklearmedizin, Klinikum Kassel, Kassel, Germany 2. Dr Masha Maharaj, Nuclear Medicine, Polokwane Provincial Hospital, University of Limpopo, Pietersburg, South Africa	
P-39	Selective Internal Radiation Therapy using Yttrium-90 Microspheres: A Practical Demonstration of Personalised Artery Specific Dosimetric Modeling Ms Toh Ying, et al (Singapore)	
P-40	Production and Quality Control of [166 Ho]-DOTA-Bevacizumab for Therapeutic Applications Dr Alireza Khorrami, et al (Iran)	
P-41	Assessment of Human Effective Absorbed Dose of 67Ga-ECC Based on Biodistribution Rat Data Dr Hassan Yousefina, et al (Iran)	
P-42	Radiation Safety Consideration in 90Y- Microsphere Therapy Dr Ashish Jha, et al (India)	
P-43	SPECT/CT & PET/CT in Imaging Neuroendocrine Tumours: Pearls and Patterns Dr Sadia Salam, et al (Bangladesh)	
P-44	Fast Preparation of 131I-MIBG for Therapy Purposes in Nuclear Medicine Dr Ali Sattari, et al (Iran)	
P-45	Ga-68 DOTATATE PET/CT in Tumour-Induced Osteomalacia Dr Ammad Al Tamimi, et al (Singapore)	



WARMTH
WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY
FOUNDED 2009

ICRT 2012

7th International Conference on Radiopharmaceutical Therapy

Levi, Finland
25 – 29 November 2012

Venue: Levi Summit Conference Centre, Levi, Finland

DAY 3: TUESDAY, 27 NOVEMBER 2012

P-46	Safety and Efficacy of Peptide Receptor Radionuclide Therapy after Liver Transplantation in Progressive Neuroendocrine Neoplasms Dr Harshad Kulkarni, et al (India)
P-47	Role of Ga-68 Somatostatin Receptor PET/CT in the Determination of Molecular Response to Radiofrequency Ablation of Hepatic Metastases from Neuroendocrine Neoplasms Dr Harshad Kulkarni, et al (India)
P-48	Believe it or Not! Renal Function can Actually Improve after Peptide Receptor Radionuclide Therapy Dr Harshad Kulkarni, et al (India)
1130 – 1310	SCIENTIFIC SESSION 10: NEURO-ENDOCRINE TUMORS II / LYMPHOMA Auditorium, Ground Floor
	Session Chairpersons: 1. Prof Richard P Baum, THERANOSTICS Center for Molecular Radiotherapy/Imaging, Zentralklinik Bad Berka, Bad Berka, Germany 2. Prof Bozena Birkenfeld, Nuclear Medicine, Uni Lubelskiej, Szczecin, Poland
1130 – 1150 S-28	An Update on PRRT in India Dr Vikram Lele, Nuclear Medicine, Jaslok Hospital & Research Centre, Mumbai, India
1150 – 1210 S-29	Somatostatin Analogs as Possible Theragnostic Molecules for Advanced Prostate Cancer Prof Omar Alonso, Nuclear Medicine, Clinical Hospital, University of Uruguay, Montevideo, Uruguay
1210 – 1230 S-30	Phase II Study of First-Line Iodine-131-Rituximab Radioimmunotherapy of Follicular Non-Hodgkin Lymphoma: The INITIAL Study Dr William Macdonald, Nuclear Medicine, Royal Perth Hospital, Perth, Australia
1230 – 1250 S-31	Low-Dose, Involved Field Radiotherapy Just Prior to Radioimmunotherapy for Relapsed/Refractory B-Cell Lymphoma Dr Michael Tomblyn, Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, USA
1250 – 1310 S-32	Radioimmunotherapy (RIT) of Follicular Non Hodgkin's Lymphoma (FNHL). The State of the Art Prof Izak Garty, Nuclear Medicine, Central Emek Hospital, Afula, Israel
1310 – 1400	LUNCH / TRADE EXHIBITION Restaurant Okta, Ground Floor Hotel Levi Panorama
1400 – 1540	SCIENTIFIC SESSION 11: DOSIMETRY / RADIOPHARMACY Auditorium, Ground Floor
	Session Chairpersons: 1. Prof Frank Roesch, Institute of Nuclear Chemistry, University of Mainz, Mainz, Germany 2. Prof Vijay Kumar, Nuclear Medicine & PET, Westmead Hospital, Sydney, Australia
1400 – 1420 S-3	Paving the Way to Personalized Medicine for Treatment of Cancer and Inflammatory Disorder Dr Suresh Srivastava, Collider-Accelerator Department, Brookhaven National Laboratory, New York, USA
1420 – 1430 S-61	Tin-117m-DOTA-Annexin for Imaging and Treating Vulnerable Plaque Dr Gilbert Gonzales, Collider-Accelerator Department, Brookhaven National Laboratory, New York, USA
1430 – 1440	What it takes to Build a Radiopharmaceutical Product in the Age of Dwindling Financial support Dr Immanuel Thangaraj, Essex Woodlands Health Ventures (EWHV), USA
1440 – 1500 S-34	Personalized Image-Based Dosimetry for Radionuclide Therapies Prof Anna Celler, Radiology, UBC, VGH Research Pavilion, Vancouver, Canada
1500 – 1520 S-35	A New Approach of Individual Dosimetry Dr Matthias Blaukner, Health & Environment Department, Biomedical Systems, AIT Austrian Institute of Technology, Vienna, Austria
1520 – 1540 S-36	New Options to Label Biomolecules with Trivalent Radiometals Adding Non-Aqueous Solvents Prof Frank Roesch, Institute of Nuclear Chemistry, University of Mainz, Mainz, Germany



WARMTH
WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY
FOUNDED 2009

ICRT 2012

7th International Conference on Radiopharmaceutical Therapy

Levi, Finland
25 – 29 November 2012

Venue: Levi Summit Conference Centre, Levi, Finland

DAY 3: TUESDAY, 27 NOVEMBER 2012

1540 – 1600	COFFEE / TEA / TRADE EXHIBITION / TRADE EXHIBITION
1540 – 1600	POSTER PRESENTATIONS
P-49	Evaluation and Calculation of Human Absorbed Dose of Tl(III)-201F -DTPA-HlgG based on Biodistribution Data in Rats Dr Alireza Khorrami, et al (Iran)
P-50	Assessment of Human Effective Absorbed Dose of 111In-DTPA-Buserelin Based on Biodistribution Rat Data Dr A Lahooti, et al (Iran)
P-51	Biodistribution of an Ultra Small Super Paramagnetic Iron Oxide Nano Particles in Balb/c Mice Dr Saeed Shanehsazzadeh, et al (Iran)
P-52	Development of a Radiolabeled Glucagon for SPECT Imaging Ms Mahdokht Joulaei, et al (Iran)
P-53	Biological and Dosimetry Studies of Four Radiolabeled of Rituximab for Human Based on Distribution Data in Rats Dr Edalat Radfar, et al (Iran)
P-54	Investigating the Effectiveness of Low Dose and High Dose Radioiodine Ablation for Post Surgical Thyroid Remnants in Patients with Differentiated Thyroid Carcinoma at Kuala Lumpur Hospital Dr Nor Salita Ali, et al (Malaysia)
P-55	Evaluation and Dosimetry Studies of Human Absorbed Dose of Various Age Groups of 90Y-DOTA-Cetuximab Based on Distribution Data in Rats Dr Ariandokht Vakili, et al (Iran)
P-56	Development of Ho-166 Chitosan for Hepatocellular Carcinoma Dr Hassan Yousefnia, et al (Iran)
P-57	Development and Characterization of Clinical-Grade 64Cu-DOTA-Trastuzumab for HER2/Neu Oncology Imaging Using Dual Head SPECT Dr Behrooz Alirezapour, et al (Iran)
P-58	In-Vitro and In-Vivo Evaluations of a Novel Potential Folate Receptor Imaging Agent Dr Esmail Mollarazi, et al (Iran)
P-59	Synthesis, Quality control, Biological Evaluation by a Kinetic Model of [90Y]-DOTA-Cetuximab for Radioimmunotherapy Purpose Dr Ariandokht Vakili, et al (Iran)
P-60	Development of a New In-111 Quinolate Complex as a Possible Imaging Agent Dr Yousef Fazaeli, et al (Iran)
P-61	Development of In-111 and Ga-67 Maltolate Complexes as Imaging Agents Dr Yousef Fazaeli, et al (Iran)
P-62	Synthesis, Radiolabeling and Biological Evaluation of a New 111Indium-Porphyrin Complex as an Imaging Agent Dr Yousef Fazaeli, et al (Iran)
P-63	Synthesis, Characterization and Biological Evaluation of a new 131Iodo porphyrin complex as an imaging agent Dr Yousef Fazaeli, et al (Iran)
P-64	Synthesis, labeling optimization and Biological Evaluation of 111Indium 5,10,15,20-Tetrakis (3,5-di Hydroxyphenyl) Porphyrin Complex as an Imaging Agent Dr Yousef Fazaeli, et al (Iran)
P-65	Our Experience in the Safe and efficient delivery of Radionuclide Therapy for Neuroendocrine Tumors with Lu-177 DOAT-TATE Mr S Somanesan, et al (Singapore)
P-66	Preparation and Quality Control of Lutetium-177 Bleomycin as a Possible Therapeutic Agent Dr Hassan Yousefnia, et al (Iran)
P-67	Development of [177Lu]-Tetra Phenyl Porphyrin Complexes as Possible Imaging Agents Dr Hassan Yousefnia, et al (Iran)

Page 9 of 14

Please note that the programme is correct at time of update and is subject to change without prior notice

ICRT 2012

7th International Conference on Radiopharmaceutical Therapy

Levi, Finland
25 – 29 November 2012

Venue: Levi Summit Conference Centre, Levi, Finland

DAY 3: TUESDAY, 27 NOVEMBER 2012

1600 – 1740	SCIENTIFIC SESSION 12: DEVELOPMENTS IN THERAPEUTIC RADIOPHARMACEUTICALS	Auditorium, Ground Floor
	Session Chairpersons: 1. Prof Alan Perkins, Radiological & Imaging Sciences, Nottingham University Hospital, Nottingham, United Kingdom 2. Prof Irene Virgolini, Nuclear Medicine & PET, Medical University of Innsbruck, Innsbruck, Austria	
1600 – 1620 S-38	Nanostructures and Their Multiplex Labeling with Targeting Ligands and Radioisotopes Prof Jae Min Jeong, Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea	
1620 – 1640 S-39	Prospects of Lu-177/Y-90 Production and Future Radionuclide Therapy in Korea Dr Sun-Ju Choi, Director, Radioisotope Research Division, Korea Atomic Energy Research Institute, Daejeon, Korea	
1640 – 1700 S-40	Experience of Platform Construction and Clinical Trial of New Radionuclide Therapy in Korea Dr Gi Jeong Cheon, Nuclear Medicine, Korea University, Seoul, Korea	
1700 – 1720 S-41	Introducing the Animal Models for Evaluation of New or/and Already Existing Radiopharmaceuticals Prof Emilija Janevik-Ivanovska, University "Goce delcev", Faculty of Medical Sciences, Stip, Republic of Macedonia	
1720 – 1740 S-37	Review of Available and Future Radionuclides Useful for Radiotherapeutics: Industrial and Regulatory Limitations Dr Richard Zimmermann, Chrysalium Consulting, France	
1740 – 1815	SCIENTIFIC SESSION 13: RADIONUCLIDE THERAPY QUIZ	Auditorium, Ground Floor
	Session Chair & Moderator: 1. Dr Gopinath Gnanasegaran, Nuclear Medicine, Guy's & St Thomas Hospital NHS Foundation Trust, London, United Kingdom	
1815 – 1930	WARMTH MEMBERS' ASSEMBLY ALL MEMBERS OF WARMTH TO ATTEND THE MEETING	Auditorium, Ground Floor
1930	END OF DAY 3	
1930	FREE EVENING (Participants to plan their own activities)	



Please note that the programme is correct at time of update and is subject to change without prior notice

ICRT 2012

7th International Conference on Radiopharmaceutical Therapy
Levi, Finland
25 – 29 November 2012

Venue: Levi Summit Conference Centre, Levi, Finland

DAY 4: WEDNESDAY, 28 NOVEMBER 2012

0800 – 0910	SCIENTIFIC SESSION 14: ALPHA THERAPY	Auditorium, Ground Floor
	Session Chairpersons: 1. Prof Richard P Baum, THERANOSTICS Center for Molecular Radiotherapy/Imaging, Zentralklinik Bad Berka, Bad Berka, Germany 2. Prof Naoyuki Watanabe, Radiological Sciences, Gunma Prefectural College of Human Health, Maebashi, Japan	
0800 – 0825 S-42	Radium-223 (Alpharadin) in The Treatment Of Skeletal Metastases in Prostate Cancer Patients Prof Øyvind S Bruland, Oncology, University of Oslo, Norwegian Radium Hospital, Oslo, Norway	
0825 – 0850 S-43	Glioblastoma Therapy with Substance P labelled with Bismuth-213 – Initial Experience Prof Leszek Królicki, Dr Jolanta Kunikowska, Dr Henryk Kozłara, Dr Alfred Morgenstern, F Bruchertseifer, Maciej Jakucinski, Dr Dariusz Pawlak, Dr Renata Mikołajczak, Dr Bartosz Królicki and Dr Sławomir Barszcz Nuclear Medicine Department, Medical University of Warsaw, POLAND; European Commission, Joint Research Centre, Institute for Transuranium Elements; Institute of Oncology, Maria Skłodowska-Curie Memorial Cancer Center, Warsaw Branch, Warsaw, Poland; Nuclear Medicine Department Brodowski Hospital, Warsaw, Poland; National Centre for Nuclear Research, Radioisotope Centre POLATOM, Otwock-Swierk Poland (To be presented by Dr Jolanta Kunikowska)	
	ORAL PRESENTATIONS	Auditorium, Ground Floor
0850 – 0900 O-9	Cis-Diamminedichloroplatinum (II) Enhancement of Antitumor Effect of In-111-Labeled N-Myc Antisense Oligonucleotides in Nude Mouse-Grown Human Neuroblastoma Prof Naoyuki Watanabe, Radiological Sciences, Gunma Prefectural College of Human Health, Maebashi, Japan	
0900 – 0910 O-10	Ki67 or/and 18FDG PET/CT? Which Do We Need for Qualification Patients to Peptide Receptor Radionuclide Therapy (PRRT) ? Dr Jolanta Kunikowska, Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland	
0910 – 1100	SCIENTIFIC SESSION 15: BREAST CANCER & MISCELLANEOUS	Auditorium, Ground Floor
	Session Chairpersons: 1. Dr Gregory Wiseman, Mayo Clinic, Minnesota, USA 2. Dr Nei Wen Long, Radiation Oncology, National Cancer Centre Singapore, Singapore	
0910 – 0935 S-44	Contribution of Nuclear Medicine in Early Breast Cancer: From Sentinel Node to IART® (Intra-Operative Avidination For Radionuclide Therapy) Dr Chiara Grana, Nuclear Medicine, European Institute of Oncology, Milano, Italy	
0935 – 0955 S-45	Positron Emission Mammography (PEM): A Perspective Dr Patricia Bernal, Nuclear Medicine, Fundacion Santa Fe de Bogota, Bogota, Colombia	
0955 – 1020 S-62	Oncolytic Viral Therapy Prof Akseli Hemminki, University of Helsinki / Docrates Cancer Center, Finland	
1020 – 1040 S-46	Statistics – Interesting and Useful Prof Janez Stare, Biostatistics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia	
1040 – 1100 S-47	Role of Nuclear Medicine in Oncological Surgery Prof Bożena Birkenfeld, Nuclear Medicine, Uni Lubelskiej, Szczecin, Poland	
1100 – 1130	COFFEE / TEA / TRADE EXHIBITION / TRADE EXHIBITION/ POSTER VIEWING	

ICRT 2012

7th International Conference on Radiopharmaceutical Therapy
Levi, Finland
25 – 29 November 2012

Venue: Levi Summit Conference Centre, Levi, Finland

DAY 4: WEDNESDAY, 28 NOVEMBER 2012

	POSTER PRESENTATIONS
	Session Coordinators: 1. Dr Butch Magsombol, Nuclear Medicine & PET, Singapore General Hospital, Singapore. 2. Dr Lucia Kaliska, Nuclear Medicine, Institute of Nuclear Medicine & Molecular Medicine, Banská Bystrica, Slovakia
P-68	Role of PET/CT in Initial Staging of Lung Cancer Dr Xuan Canh Nguyen, et al (Vietnam)
P-69	Pleuroperitoneal Communication Detected by Technetium 99m-tagged Macroaggregated Albumin (MAA) Radionuclide Peritoneal Scintigraphy in a Chronic Kidney Disease Patient on Peritoneal Dialysis: A Case Report Ms Carla Mari Macaísa, et al (Philippines)
P-70	Significant Impact of a Single End of Treatment F-18 FDG PET/CT Study as a Prognostic Indicator and Predictor of Final outcome in Non-Metastatic Squamous Cell Carcinoma of Head and Neck Region Dr Partha Choudhury, et al (India)
P-71	SPECT-CT for the Diagnosis of Primary Hyperparathyroidism Dr Marina Garcheva, et al (Bulgaria)
P-72	Variations of Gates' GFR Among Different Work Stations Mr Rey Martin Jr Goco (Philippines)
P-73	Measurement of Non-Uniformity in Gamma Cameras: Effect of Crystal Hydration Dr Milena Dimcheva, et al (Bulgaria)
P-74	Correlation of Wall Motion Score and Left Ventricular Ejection Fraction by Gated SPECT Myocardial Perfusion Imaging Prof Raihan Hussain, et al (Bangladesh)
P-75	PET/CT & SPECT/CT in Imaging Prostate Cancer: Tracers, Advantages & Limitations Dr Sadia Salam, et al (Bangladesh)
P-76	Clinical Interest of Hybrid Imaging in Lung Cancer Prof Ben Rais Aouad Nozha, et al (Morocco)
P-77	The Clinical Impact of 18-F Fluorocholine PET/CT in the Management of Prostate Cancer Dr Anbalagan Kannivelu, et al (Singapore)
P-78	The Role of Sentinel Lymph Node Biopsy in the Prediction of Metastatic Spread of Malignant Melanoma Dr Anca Zamfirescu, et al (Romania)
P-79	Role of Contrast Enhanced 18F- FDG PET- CT in Restaging of Pancreatic Carcinoma Dr Arun Gandhi, et al (India)
P-80	Controversy over Dense Breast Imaging: Are We Using All the Armaments in Our Arsenal; A Review of Molecular Breast Imaging's Potential Role in the Battle Against Breast Cancer Dr S Krishna Kumar, et al (Singapore)
P-81	Site Specific Radiolodination of HER2-Targeting Affibody Molecules Using Iodophenetylmaleimide Decreases Renal Uptake of Radioactivity Strand J, Nordeman P, Honarvar H, Altai M, Larhed M, Orlova A, Tolmachev V Uppsala University, Uppsala, Sweden
P-82	Is PET and PET/CT useful in Pediatrics? De Leon D, Dr Emerita Barrenechea (Philippines)
P-83	Developing a Nuclear Medicine Outreach Program. The Polokwane Experience Dr Masha Maharaj (South Africa)
P-84	Tc-99m MIBI Scan in Multiple Myeloma Dr Raluca Mititelu, et al (Romania)

ICRT 2012

7th International Conference on Radiopharmaceutical Therapy
Levi, Finland
25 – 29 November 2012

Venue: Levi Summit Conference Centre, Levi, Finland

DAY 4: WEDNESDAY, 28 NOVEMBER 2012		
1130 – 1310	SCIENTIFIC SESSION 15: LIVER AND GI CANCER	Auditorium, Ground Floor
	Session Chairpersons: 1. Dr Patricia Bernal, Nuclear Medicine, Fundacion Santa Fe de Bogota, Bogota, Colombia 2. Prof Jae Min Jeong, Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea	
1130 – 1150 S-48	Clinical use of Rhenium-188 from the Tungsten-188/Rhenium-188 Generator Dr Knut Liepe, Nuclear Medicine, GH Kassel, Kassel, Germany	
1150 – 1210 S-49	SIR-Spheres in HCC Dr Jaroslaw Cwikla, Nuclear Medicine, Faculty of Medical Science, University of Varmia and Masuria Olsztyn Poland	
1210 – 1230 S-50	Re-188 Lipiodol Therapy for HCC – A New Approach and Perspective from the Rhenium Users' Group Prof Ajit Kumar Padhy, Nuclear Medicine & PET, Singapore General Hospital, Singapore	
1230 – 1250 S-51	I-131-Lipiodol Therapy in Local Disease Control and Survival in Patients with Advanced Hepatocellular Carcinoma and Metastatic Liver Disease from other Primary Tumors: Our Initial Experience Dr Kumarwamy Kallur, Nuclear Medicine, Healthcare Global Enterprises Pvt Ltd, Bangalore, India	
1250 – 1310 S-52	Therapy of Colorectal Cancer Tumours with an Agonist DR5 Antibody Prof Andrew Scott, Nuclear Medicine & PET, Ludwig Institute for Cancer Research, Heidelberg, Australia	
1310 – 1410	LUNCH / TRADE EXHIBITION	Restaurant Okta, Ground Floor Hotel Levi Panorama
1410 – 1550	SCIENTIFIC SESSION 16: MISCELLANEOUS/NEW THERAPIES/ FUTURE TRENDS	Auditorium, Ground Floor
	Session Chairpersons: 1. Dr Chiara Grana, Nuclear Medicine, European Institute of Oncology, Milano, Italy 2. Dr Emerita Barrenechea, Nuclear Medicine, Veterans Memorial Medical Centre, Quezon City, Philippines	
1410 – 1430 S-53	Outside the Box: Challenging Cases for Radioimmunotherapy Dr Michael Tomblin, Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, USA	
1430 – 1450 S-54	Ancient Features of Personalizing Cancer Treatment; Learning from Radionuclide Therapy in the Era of Targeted Therapies Dr So Won Oh, Nuclear Medicine, Seoul National University Boramae Hospital, Seoul, Korea	
1450 – 1510 S-55	Quantitative Imaging of Radiotracer Biodistributions Prof Anna Celler, Radiology, UBC, VGH Research Pavilion, Vancouver, Canada	
1510 – 1530 S-56	Quality of Life (QOL) Assessment in Neuroendocrine Tumor (NET) Patients Prof Irene Virgolini, Nuclear Medicine & PET, Medical University of Innsbruck, Innsbruck, Austria	
1530 – 1550 S-57	Quality of Life in Oncological patients and Radionuclide Therapy Mr William Claxton, Carcinoid & Neuroendocrine Tumor Society, Singapore	
1550 – 1615	COFFEE / TEA / TRADE EXHIBITION / TRADE EXHIBITION	
1615 – 1645	SCIENTIFIC SESSION 17: RADIONUCLIDE THERAPY QUIZ	Auditorium, Ground Floor
	Session Chair & Moderator: 1. Dr Gopinath Gnanasegaran, Nuclear Medicine, Guy's & St Thomas Hospital NHS Foundation Trust, London, United Kingdom	
1645 – 1725	SCIENTIFIC SESSION 18: FINAL SESSION	Auditorium, Ground Floor
	Session Chairpersons: 1. Prof Andrew Scott, Nuclear Medicine & PET, Ludwig Institute for Cancer Research, Heidelberg, Australia 2. Prof Abdelhamid Elgazzar, Medical Faculty, University of Kuwait, Safat, Kuwait	
1645 – 1705 S-58	Radionuclide Therapy: From Radium to Radium Prof Alan Perkins, Radiological and Imaging Sciences, Nottingham University Hospital, Nottingham, United Kingdom	
1705 – 1725 S-59	Outpatient Therapeutic Oncology Prof Harvey Turner, Nuclear Medicine, Fremantle Hospital, Fremantle, Australia	

DAY 4: WEDNESDAY, 28 NOVEMBER 2012

Page 13 of 14
Please note that the programme is correct at time of update and is subject to change without prior notice



WARMTH
WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY
FOUNDED 2009

ICRT 2012

7th International Conference on Radiopharmaceutical Therapy
Levi, Finland
25 – 29 November 2012

Venue: Levi Summit Conference Centre, Levi, Finland


1725 – 1815	WARMTH MEMBERS' ASSEMBLY ALL MEMBERS OF WARMTH TO ATTEND THE MEETING		Auditorium, Ground Floor
1815 – 1930	CLOSING		Auditorium, Ground Floor
Awards: Best Oral presentations & Posters			
Impressions from Participants			
Welcome to ICRT 2013 (Cairo, Egypt) Prof Abdelhamid Elgazzar, Local Organising Chairman, ICRT 2013			
Declaration of Results of WARMTH Elections for The Next Governing Body (2013 – 2014)			
Impressions Prof Richard P Baum, THERANOSTICS Center for Molecular Radiotherapy/Imaging, Zentralklinik Bad Berka, Bad Berka, Germany			
Impressions Prof Alan Perkins, Radiological and Imaging Sciences, Nottingham University Hospital, Nottingham, United Kingdom			
Impressions Prof Kalevi Kairemo, Local Organising Chairman, ICRT 2012			
Closing Remarks Prof Ajit Kumar Padhy			
1930	END OF SCIENTIFIC PROGRAM		
2000	DINNER: Theme "Blue Dress" Participants are requested to wear something blue (Any shade of blue)	Restaurant Okta, Ground Floor Hotel Levi Panorama	
2300	END OF DAY 3		

DAY 5: THURSDAY, 29 NOVEMBER 2012

	SIGHT-SEEING TOUR & OENOPHILOUS DINNER
0830	Departure from Hotel
0830 – 1200	Whole Day Excursion To Rovaniemi: Part I <ul style="list-style-type: none">▪ Arctic Circle▪ Santa Claus Village▪ Arctic Science Museum
1200 – 1400	LUNCH
1400 – 1800	Whole Day Excursion To Rovaniemi: Part II <ul style="list-style-type: none">▪ Arctic Circle▪ Santa Claus Village▪ Arctic Science Museum
1800 – 2200	Oenophilous Dinner & Closing

DAY 6: FRIDAY, 30 NOVEMBER 2012

Departure to respective countries



Ski lift during the Levi conference, and a picture from the conference center outside (afternoon)



Oenophilous dinner in Kaukonen, wine/liqueur from 37 countries.



Santa Claus Village





8th ICRT-2013, Manila Philippines

Congress-President: Emerita Barrenechea



FREE REGISTRATION FOR MEMBERS OF WARMTH



W A R M T H



WORLD ASSOCIATION OF RADIOPHARMACEUTICAL & MOLECULAR THERAPY

ICRT-2013

8th INTERNATIONAL CONFERENCE ON RADIOPHARMACEUTICAL THERAPY

www.icrt-2013.warmth.org

Manila, Philippines: 17-21 November 2013

HOST: PHILIPPINE SOCIETY OF NUCLEAR MEDICINE (PSNM)



Venue

SOFITEL PHILIPPINE PLAZA MANILA

CCP Complex, Roxas Blvd, Pasay City, 1300 Manila, Philippines

Become a Member of WARMTH: 5 Years Membership Fee only a Nominal Amount of USD 100





WARMTH
WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY
FOUNDED 2009

ICRT 2013

8th International Conference on Radiopharmaceutical Therapy

Manila, Philippines
17 – 21 November 2013

Sofitel Philippine Plaza Manila, Philippines

DAY 1: SUNDAY, 17 NOVEMBER 2013

0900 – 1600	REGISTRATION
1330 – 1800	PRE-CONFERENCE INTERNATIONAL SYMPOSIUM ON NUCLEAR CARDIOLOGY (Auditorium, St. Luke's Medical Center, Global City)
1330 – 1345	Welcome Address
1345 – 1525	SCIENTIFIC SESSION 1: NUCLEAR CARDIOLOGY I (Auditorium, St. Luke's Medical Center, Global City)
Session Chairs	1. Prof Henry Bom, Nuclear Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea 2. Dr Jerry Obaldo, Division of Nuclear Medicine, Philippine Heart Center, Quezon City, Philippines
1345 – 1410 PC-01	Imaging in Non Acute Chest Pain: Choosing The Right Test Dr Pushan Bharadwaj, Nuclear Medicine and PET, Apollo Gleneagles Hospital, Kolkata, India
1410 – 1435 PC-02	The Challenge of Diagnosing Coronary Heart Diseases in Women. The Special Role of ECG-Gated SPECT Myocardial Scintigraphy Prof Izak Garty, Nuclear Medicine, Central Emek Hospital, Afula, Israel
1435 – 1500 PC-03	Reporting of Gated MPI Dr Jerry Obaldo, Division of Nuclear Medicine, Philippine Heart Center, Quezon City, Philippines
1500 – 1525 PC-04	Artifacts and Pitfalls in Myocardial Perfusion SPECT Imaging Dr Qaisar Hussain Siraj, Nuclear Medicine, Farwania Hospital Kuwait, Kuwait
1525 – 1555	COFFEE & TEA BREAK
1555 – 1800	SCIENTIFIC SESSION 2: NUCLEAR CARDIOLOGY II (Auditorium, St. Luke's Medical Center, Global City)
Session Chairs	1. Dr Qaisar Hussain Siraj, Nuclear Medicine, Farwania Hospital Kuwait, Kuwait 2. Dr Teofilo O.L. San Luis, Jr, Nuclear Medicine, St. Luke's Medical Center, Quezon City, Philippines
1555 – 1620 PC-05	Role of Nuclear Cardiology in Cardiac Resynchronization Therapy Dr Felix Keng, Nuclear Cardiology, National Heart Centre, Singapore
1620 – 1635 PC-06	Regional Myocardial Blood Flow Quantification Using Dynamic SPECT: A Clinical Study Dr Uttam Shrestha, Biomedical Imaging, University of California, San Francisco, USA
1635 – 1650 PC-07	Construction of A Respiratory Phantom to Study SPECT MPI Under The Influence of Respiratory Motion Dr Yiannis Parpottas, Frederick Research Center and Frederick University, Nicosia, Cyprus
1650 – 1710 PC-08	SPECT MPI Mechanical Phantom with Cardiac and Respiratory Motion: First Results in Clinical Settings Dr Ourania Demetriadou, Nuclear Medicine, Limassol General Hospital, Limassol, Cyprus
1710 – 1800	Interactive Case-based Discussion Dr Edward-Bengie Magsombol, Philippines
1900 – 2230	WELCOME DINNER (Grand Sunset Pavilion, Sofitel Philippine Plaza Manila)
2230	END OF DAY 1



WARMTH
WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY
FOUNDED 2009

ICRT 2013

8th International Conference on Radiopharmaceutical Therapy
Manila, Philippines
17 – 21 November 2013

Sofitel Philippine Plaza Manila, Philippines

DAY 2: MONDAY, 18 NOVEMBER 2013

0800 – 1600 REGISTRATION

0830 – 0915 OPENING CEREMONY

(Luzon Ballroom, Lobby Level)

0830 – 0835 Welcome Address

Dr Emerita Barrenechea, Local Organising Chairman, ICRT 2013

0835 – 0840 Opening Remarks

Prof Richard P Baum, President, WARMTH

0840 – 0910 Tribute to Prof Ajit Padhy

0910 – 0915 WARMTH Candle Lighting Ceremony

0915 – 1100 CONCURRENT SESSIONS

SCIENTIFIC SESSION 3: THYROID I / ORAL PRESENTATIONS

0915 – 1100 SCIENTIFIC SESSION 3: THYROID I

(Luzon Ballroom, Lobby Level)

Session Chairs

1. Prof Harvey Turner, Nuclear Medicine, Fremantle Hospital, Fremantle, Australia
2. Dr Suresh C Srivastava, Medical Isotope Research and Production Program, Brookhaven National Laboratory, New York, USA

0915 – 0935 Present State of Nuclear Medicine Practice in Japan with Emphasis on Radiopharmaceutical Therapy

S-01 Prof Yasuhiro Sasaki, Clinical Research Center, Shonankamakura General Hospital, Kamakura, Japan

0935 – 1000 Updates in the Management of Graves' Disease

S-02 Dr Wai Yin Wong, Nuclear Medicine & PET, Singapore General Hospital, Singapore

1000 – 1020 Recent Advances in the Management of Thyroid Cancer

S-03 A/Prof Nemencio Jr Nicodemus, Biochemistry and Molecular Biology, University of the Philippines, College of Medicine, Philippines

1020 – 1040 Radioiodine Therapy Protocols Revisited: Patient Preparations and Medications During Therapy

S-04 Dr Ana Ugrinska, Institute of Pathophysiology and Nuclear Medicine, Medical Faculty, UKIM, Skopje, Republic of Macedonia

1040 – 1100 Thyroid Remnant Ablation Using 1,110 MBq of I-131 for Outpatients with Thyroid Cancer in Japan

S-05 Prof Naoyuki Watanabe, Radiological Sciences, Gunma Prefectural College of Human Health, Maebashi, Japan

Page 2 of 16

Please note that the programme is correct at time of update and is subject to change without prior notice

ICRT 2013

8th International Conference on Radiopharmaceutical Therapy
Manila, Philippines
17 – 21 November 2013

Sofitel Philippine Plaza Manila, Philippines

DAY 2: MONDAY, 18 NOVEMBER 2013

(continued)

0930 – 1100	ORAL PRESENTATIONS (Mindoro Room, Lobby Level)
Session Chairs	<ol style="list-style-type: none"> 1. Dr Ruben Ogbac, Nuclear Medicine, St Luke's Medical Center, Quezon City, Philippines 2. Dr Sze Ting Lee, Nuclear Medicine & Centre for PET, Austin Health, Victoria, Australia
0930 – 0945	Newer Pretargeting Techniques For Radiobioconjugate Therapy Prof Daya Kishore Hazra, Nuclear Medicine, Boston Medical Centre, Agra, India
0945 – 1000	Differentiated Thyroid Carcinoma in Young Patients Treated with I-131: Recurrent Disease and Outcome A/Prof Marina Vljakovic, Nuclear Medicine, Clinical Center Nis, Nis, Serbia
1000 – 1015	Level of Thyroglobulin (Tg) in Patients with Papillary Thyroid Carcinoma (PTC) Received Radio Iodine (RAI) Ablation Therapy Dr Savvas Frangos, Nuclear Medicine, Bank of Cyprus Oncology Center, Strovolos- Nicosia, Cyprus
1015 – 1030	Well-Differentiated Thyroid Carcinoma of Childhood And Adolescence – A Long Term Experience at A Single Institute Dr Faria Nasreen, Nuclear Medicine, Institute of Nuclear Medicine & Ultrasound, Dhaka, Bangladesh
1030 – 1045	Sensitivity of Preparation with rhTSH or Thyroid Hormone Withdrawal Using 131I Whole Body Scans to Identify Metastases of Differentiated Thyroid Cancer Dr Knut Liepe, Nuclear Medicine, GH Kassel, Kassel, Germany
1045 – 1100	Click Chemistry For Design of Oncopharmaceuticals For Theragnostics: Radiolabels For Imaging and Therapy, Nonradioactive Labels For Imaging A/Prof Padmamalika Hazra, Chemistry, St Johns College, Agra, India
1100 – 1130	COFFEE & TEA BREAK / TRADE EXHIBITION (Pre-Function Area / Visayas Ballroom, Lobby Level)
1100 – 1130	POSTER PRESENTATIONS (Pre-Function Area / Visayas Ballroom, Lobby Level)
P-01	Dual-Phase Tc99m MIBI Scintigraphy in Lymphoma as a Predictor of Response to Chemotherapy Z. Chiragh, et al (Pakistan)
P-02	Post Synthesis of a new [64Cu]- Porphyrin Complex on Silica MCM-41 as a New Radiopharmaceutical Delivery System Y Fazaeli, et al (Iran)
P-03	Radio Synthesis of a New [201Tl]- Porphyrin Complex as an Imaging Agent Y Fazaeli, et al (Iran)
P-04	Indium-111 Maltolate Complex as a Cell Labeling Agent for SPECT Imaging Y Fazaeli, et al (Iran)
P-05	SPECT Imaging of Blood Pool in Rabbits, Using PEG-Nano Liposomes Labeled with 99mTc-HMPAO K Sadri, et al (Iran)

ICRT 2013

8th International Conference on Radiopharmaceutical Therapy
Manila, Philippines
17 – 21 November 2013

Sofitel Philippine Plaza Manila, Philippines

DAY 2: MONDAY, 18 NOVEMBER 2013

(continued)

P-06	Prognostic Value of FDG Uptake of Primary Tumor and Metastatic Lesions in Advanced Non-Small Cell Lung Cancer XC Nguyen, et al (Vietnam)
P-07	Feasibility Study for Neodymium-140 (140Nd) Radioisotope Production and its Purification Using Nano-resin M Aboudzadeh, et al (Iran)
P-08	Production of Industrial Zinc-62/Copper-62 Generator for PET Purposes Y Fazaeli, et al (Iran)
P-09	Radioiodine Ablation of Thyroid Remnants in Patients with Differentiated Thyroid Carcinoma SR Miah, et al (Bangladesh)
P-10	Preparation of 99mTc-labeled methotrexate by a Direct Labeling Technique as a Potential Diagnostic and Response Monitoring Agent for Breast Cancer Rashid Rasheed, et al (Pakistan)
P-11	Bone Metastasis from Differentiated Thyroid Carcinoma: Diagnosis, Treatment And Outcome Experience of A Tunisian Centre K Chatti, et al (Tunisia)
P-12	Effectiveness and Thyroid Functional Status after Radioiodine Therapy for Thyrotoxicosis – A Retrospective Study M Hossain, et al (Bangladesh)
P-13	Details Of Histopathology in Patients with One or More First Degree Relatives who have Well Differentiated Thyroid Cancer (WDTC) S Frangos, et al (Cyprus)
P-14	Utility of 99mTc HYNIC–TOC in evaluation of Neuroendocrine Tumor (NET): A Pictorial Review A Shinto, et al (India)
1130 – 1300	SCIENTIFIC SESSION 4: THYROID II & RADIOPHARMACY, DOSIMETRY, RADIOLOGICAL AND NUCLEAR EMERGENCY (Luzon Ballroom, Lobby Level)
Session Chairs	<ol style="list-style-type: none"> 1. Prof Naoyuki Watanabe, Radiological Sciences, Gunma Prefectural College of Human Health, Maebashi, Japan 2. A/Prof Cecilia Jimeno, Medicine Section of Endocrinology & Diabetes, Philippine General Hospital, Manila, Philippines
1130 – 1155 S-09	To Ablate or Not To Ablate: An Evidence Based Approach Dr Savvas Frangos, Nuclear Medicine, Bank of Cyprus Oncology Center, Strovolos- Nicosia, Cyprus
1155 – 1215 S-07	An Overview of Our Specially-Developed Online Remote Radiation Monitoring System for Patients with Differentiated Thyroid Carcinoma Treated with Radioiodine Prof Milovan Matovic, Nuclear Medicine, Clinical Center Kragujevac, Kragujevac, Serbia
1215 – 1240	Tyrosine Kinase Therapy in Patients Refractory to Radioiodine Dr Haluk B Sayman, Nuclear Medicine, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey
1240 – 1300 S-29	Alpha-Therapy: Which Radionuclide, Which Carrier Molecule, Which Clinical Indication? Prof Jean-Francois Chatal, Arronax Cyclotron, GIP Arronax, Nantes-Saint-Herblain, France

ICRT 2013

8th International Conference on Radiopharmaceutical Therapy
Manila, Philippines
17 – 21 November 2013

Sofitel Philippine Plaza Manila, Philippines

DAY 2: MONDAY, 18 NOVEMBER 2013

(continued)

1300 – 1400	LUNCH SYMPOSIUM (SPONSORED BY GENZYME, A SANOFI COMPANY) (Luzon Ballroom, Lobby Level)
Session Chairs	<ol style="list-style-type: none"> 1. Dr Emerita Barrenechea, Nuclear Medicine, Veterans Memorial Medical Center, Quezon City, Philippines 2. Dr Partha S Choudhury, Nuclear Medicine, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India
1315 – 1345 S-10	Radioiodine for Thyroid Cancer: Less is More Findings from A Multicenter, Randomized Non-Inferiority Trial and Its Applicability in Practice Dr B K Yap, Clinical Oncology, The Christie NHS Trust, Manchester, United Kingdom
1400 – 1520	SCIENTIFIC SESSION 5: MOLECULAR IMAGING IN THERAPEUTIC NUCLEAR MEDICINE I (Luzon Ballroom, Lobby Level)
Session Chairs	<ol style="list-style-type: none"> 1. Dr Savvas Frangos, Nuclear Medicine, Bank of Cyprus Oncology Center, Strovolos- Nicosia, Cyprus 2. Dr Gopinath Gnanasegaran, Nuclear Medicine, Guy's & St Thomas Hospital NHS Foundation Trust, London, United Kingdom
1400 – 1420 S-11	The Ups-And-Downs of MIBG; A Historical Perspective Dr Cornelis Hoefnagel, Nuclear Medicine, AvL-NKI, Badhoevedorp, The Netherlands
1420 – 1440 S-12	SPECT-CT in Post Therapy Imaging Prof John Buscombe, Nuclear Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom
1440 – 1500 S-14	Role of PET/CT in Radiotherapy Planning Dr Sze Ting Lee, Nuclear Medicine & Centre for PET, Austin Health, Victoria, Australia
1500 – 1520 S-08	Recent Advances in the Imaging and Therapy of Active Atheromatous Disease Using Theragnostic High-LET Electron Emitters Dr Suresh C Srivastava, Medical Isotope Research and Production Program, Brookhaven National Laboratory, New York, USA
1520 – 1545	COFFEE & TEA BREAK / TRADE EXHIBITION / POSTER VIEWING (Pre-Function Area / Visayas Ballroom, Lobby Level)

ICRT 2013

8th International Conference on Radiopharmaceutical Therapy

Manila, Philippines
17 – 21 November 2013

Sofitel Philippine Plaza Manila, Philippines

DAY 2: MONDAY, 18 NOVEMBER 2013

(continued)

1520 – 1545	POSTER PRESENTATIONS (Pre-Function Area / Visayas Ballroom, Lobby Level)
Session Coordinator	Dr Michele Ogbac, Nuclear Medicine, Philippine Heart Center, Quezon City, Philippines
P-15	Biodistribution Imaging Study in Rats after Intra-articular Administration of 90Y-Labeled Tin Fluoride Colloid L Jaukovic, et al (Serbia)
P-16	I-131 Capsule versus Liquid: A Comparative Study and Clinical Usefulness in Thyroid carcinoma patient. Quantitative and Dosimetric Evaluation Om Prakash, et al (India)
P-17	Perspectives of Availability of Therapeutic Radioisotopes VR Hernan, et al (Bolivia)
P-18	Life Quality Evaluation in Patients with Differentiated Thyroid Cancer: Is SF-36 Appropriate for this Purpose? NK Ayati, et al (Iran)
P-19	Thyroid Volume Changes on Ultrasonography as A Predictor of Radioiodine Therapy Outcome in Hyperthyroidism NK Ayati, et al (Iran)
P-20	Undesirable Effects after Remnant Ablation with Radioactive Iodine in Patients with Differentiated Thyroid Carcinoma – Our Experience M Agolti, et al (Argentina)
P-21	Experimental Study of Targeting Glioma with 131I-CH12 McAb P Li, et al (China)
P-22	Expansion of Radionuclide Therapy in a Developing Country: Experience of Bangladesh Mizanul Hasan (Bangladesh)
P-23	Value of Baseline Thyroglobulin Level in Post-Thyroidectomy Patients with Differentiated Thyroid Cancer FAH Hussain, et al (Bangladesh)
P-24	The Most Common Complaints of Thyroid Cancer Patients Post-Thyroidectomy and Radioiodine Therapy (A Preliminary Report) S Shafiei, et al (Iran)
P-25	Accuracy Study of Sentinel Node Biopsy by 99mTc Phytate in Patients with Non-Small Cell Lung Carcinoma (A Preliminary Report) S Shafiei, et al (Iran)
P-26	Characteristics of Differentiated Thyroid Carcinoma Patients with Low Serum Thyroglobulin-off level but Positive Post-therapy 131I -WBS in First Six Months Follow-Up D Yulistawaty (Indonesia)
P-27	Remnant Ablation using 1 GBq (30 mCi) I-131 in High Risk Differentiated Thyroid Carcinoma Patients Fithriany S, et al (Indonesia)
P-28	Clinical Significance of Thyroglobulin Antibody Pattern in Patients with Differentiated Thyroid Carcinoma F Hutomo, et al (Indonesia)

Page 6 of 16

Please note that the programme is correct at time of update and is subject to change without prior notice

ICRT 2013

8th International Conference on Radiopharmaceutical Therapy
Manila, Philippines
17 – 21 November 2013

Sofitel Philippine Plaza Manila, Philippines

DAY 2: MONDAY, 18 NOVEMBER 2013

(continued)

1545 – 1750	CONCURRENT SESSIONS
	SCIENTIFIC SESSION 6: MOLECULAR IMAGING IN THERAPEUTIC NUCLEAR MEDICINE II / WARMTH GOVERNING BODY MEETING (GOVERNING BODY MEMBERS ONLY)
1545 – 1800	SCIENTIFIC SESSION 6: MOLECULAR IMAGING IN THERAPEUTIC NUCLEAR MEDICINE II (Luzon Ballroom, Lobby Level)
Session Chairs	<ol style="list-style-type: none"> 1. Dr Aviral Singh, Intensive Care Medicine, The Canberra Hospital, Canberra, Australia 2. Dr Jonas Francisco Santiago, Nuclear Medicine, St. Luke's Medical Center, Taguig, Philippines
1545 – 1610 S-15	<p>Choline PET/CT in Staging and Restaging at Biochemical Recurrence for Prostate Cancer: A Systematic Review and A Meta-Analysis of Cohort Studies (Approx. 6000 Patients)</p> <p>Prof Kalevi Kairemo, Molecular Radiotherapy & Nuclear Medicine, Docrates Cancer Center, Helsinki, Finland</p>
1610 – 1635 S-17	<p>Alpha Therapy and PET/SPECT Imaging of Metastatic Bone Disease</p> <p>Prof Homer A. Macapinlac, Nuclear Medicine, UT M. D. Anderson Cancer Center, Houston, USA</p>
1635 – 1700 S-18	<p>Molecular Imaging of Neuroendocrine Tumours</p> <p>A/Prof Grzegorz Kaminski, Endocrinology & Radioisotope Therapy, Military Institute of Medicine, Warsaw, Poland</p>
1700 – 1725 S-20	<p>SIRT: A Decade of Experience</p> <p>Prof Adil Al-Nahhas, Nuclear Medicine, Hammersmith Hospital/ Imperial College, London, United Kingdom</p>
1725 – 1800	<p>Radionuclide Therapy Quiz</p> <p>Dr Gopinath Gnanasegaran, Nuclear Medicine, Guy's & St Thomas Hospital NHS Foundation Trust, London, United Kingdom</p> <p>Prof Kavitha Nallapareddy, Nuclear Medicine, Nizams Institute of Medical Sciences, Hyderabad, India</p>
1600 – 1730	WARMTH GOVERNING BODY MEETING (GOVERNING BODY MEMBERS ONLY) (Mindoro Room, Lobby Level)
1900 – 2300	<p>GALA DINNER</p> <p>(Luzon Ballroom, Lobby Level)</p> <ul style="list-style-type: none"> ▪ WARMTH Awards ▪ Gala Dinner ▪ Entertainment
2300	END OF DAY 2



WARMTH
WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY
FOUNDED 2009

ICRT 2013

8th International Conference on Radiopharmaceutical Therapy
Manila, Philippines
17 – 21 November 2013

Sofitel Philippine Plaza Manila, Philippines

DAY 3: TUESDAY, 19 NOVEMBER 2013

0830 – 1100	CONCURRENT SESSIONS
	SCIENTIFIC SESSION 7: NEURO-ENDOCRINE TUMOURS I / ORAL PRESENTATIONS
0830 – 1100	SCIENTIFIC SESSION 7: NEURO-ENDOCRINE TUMOURS I (Luzon Ballroom, Lobby Level)
Session Chairs	1. Prof John Buscombe, Nuclear Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom 2. A/Prof Nemencio Jr Nicodemus, Biochemistry and Molecular Biology, University of the Philippines, College of Medicine, Philippines
0830 – 0855 S-21	PRRT of Neuroendocrine Neoplasms (NEN) – The Bad Berka Experience after More than 4,000 Treatment Cycles in NEN Patients Prof Richard P Baum, THERANOSTICS Center for Molecular Imaging and Therapy, Zentralklinik Bad Berka, Bad Berka, Germany
0855 – 0920 S-22	Design of An International Multicentre Randomised Controlled Phase II Clinical Trial of ¹⁷⁷Lu-Octreotate/Capecitabine/Temozolomide, Radiopeptide Chemotherapy of Gastro-Entero-Pancreatic Neuroendocrine Tumours: The CONTROL – NET Study Prof Harvey Turner, Nuclear Medicine, Fremantle Hospital, Fremantle, Australia
0920 – 0945 S-23	Targeting Tumor Heterogeneity to Improve Outcomes of Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumours A/Prof Michael Hofman, Medicine, University of Melbourne, Melbourne, Australia
0945 – 1010 S-24	Quality of Life: From a Patient Perspective Mr William Claxton, Carcinoid & Neuroendocrine Tumor Society , Singapore
1010 – 1035 S-25	Nuclear Medicine: A Patient's Viewpoint – Understanding Patient Education / Advocacy Mr Josh Mailman, NorCal CarciNET Community, Oakland, CA USA
1035 – 1100 S-26	Long Term Efficacy of i.v. and i.a. PRRT using ⁹⁰Y or ¹⁷⁷Lu in Patients with NET Dr Jaroslaw Cwikla, Radiology and Diagnostic Imaging, Postgraduate Medical Centre and Central Clinical Hospital, Warsaw, Poland

ICRT 2013

8th International Conference on Radiopharmaceutical Therapy
Manila, Philippines
17 – 21 November 2013

Sofitel Philippine Plaza Manila, Philippines

DAY 3: TUESDAY, 19 NOVEMBER 2013

(continued)

0915 – 1100	ORAL PRESENTATIONS (Mindoro Room, Lobby Level)
Session Chairs	<ol style="list-style-type: none"> 1. Dr Vincent Peter Magboo, Nuclear Medicine, St. Luke's Medical Center, Quezon City, Philippines 2. Dr Partha S Choudhury, Nuclear Medicine, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India
0915 – 0930	<p>Development of A New [140Nd]-Porphyrin Complex as A Possible Tumor Imaging Agent Dr Mohammad Reza Aboudzadeh Roais, Nuclear Medicine, Agricultural, Medical and Industrial Research School, Karaj, Iran</p>
0930 – 0945	<p>Five Year Experience of Strontium-90 Irradiation for Treatment of Post-Operative Conjunctival Squamous Cell Carcinoma Prof Raihan Hussain, Nuclear Cardiology, Institute of Nuclear Medicine and Ultrasound, Dhaka, Bangladesh</p>
0945 – 1000	<p>Prospective Study of Skeletal Related Events (SREs) Incidence in Patients whom Radionuclide Therapy was added for Bone Metastases and Primary Tumor's Treatment Dr Nigora Rasulova, Nuclear Medicine, Republic Specialized Center of Surgery, Tashkent, Uzbekistan</p>
1000 – 1015	<p>Development of New Potential Multiple Myeloma Theragnostic Agents Dr Juan Pablo Gambini, Centro de Medicina Nuclear, Hospital de Clinicas, Montevideo, Uruguay</p>
1015 – 1030	<p>Customization of 90Y- SIR Sphere Delivery Set: Technical Modifications in Our Institution Leading to Improved Radiation Safety and Logistics Dr Ashish Kumar Jha, Nuclear Medicine & Molecular Imaging, Tata Memorial Hospital, Mumbai, India</p>
1030 – 1045	<p>Radiosynoviorthesis (RSO) in Joints Less Frequently Affected with Arthropathy after the Failure of Previous Treatment Dr Marika Vereb, Nuklearmedizin, Klinikum Kassel, Kassel, Germany</p>
1045 – 1100	<p>188Re-Zoledronic Acid: First-In-Man Study Ms Kochetova Tatiana, Radionuclide Therapy, Medical Radiology Research Center, Obninsk, Russia</p>
1100 – 1130	COFFEE & TEA BREAK / TRADE EXHIBITION / POSTER VIEWING (Pre-Function Area / Visayas Ballroom, Lobby Level)

ICRT 2013

8th International Conference on Radiopharmaceutical Therapy
Manila, Philippines
17 – 21 November 2013

Sofitel Philippine Plaza Manila, Philippines

DAY 3: TUESDAY, 19 NOVEMBER 2013

(continued)

1100 – 1130	POSTER PRESENTATIONS (Pre-Function Area / Visayas Ballroom, Lobby Level)
Session Coordinator	Dr Marie Rhiamar Sauler-Gomez, Radiology / Section of Nuclear Medicine, De La Salle University Medical Center, Cavite, Cavite
P-29	Role of Dual Point 18F-FDG PET/CT Imaging in Assessment of Micrometastases in Breast Cancer Patients MK Srivastava, et al (India)
P-30	Radionuclide Therapy Modalities: Local Experience in Nuclear Medicine Department of MRCCC – SHS ID Mulyanto, et al (Indonesia)
P-31	Case Study: First Experience in I-131 MIBG Palliative Therapy for Refractory Neuroblastoma Patients R Yudistiro, et al (Indonesia)
P-32	The Benefits of Adjuvant 131I Therapy for Differentiated Thyroid Carcinoma with Elevated Thyroglobulin and Negative 131I Whole body Scan L Herawati Diah, et al (Indonesia)
P-33	In Vivo SPECT Imaging and Biological Evaluation of 198,199Au-labeled Graphene Oxide Nanoflakes as Therapeutic Agents Y Fazaeli, et al (Iran)
P-34	Bone Lesion Score – A Predictor of Success of Radionuclide Therapy in Skeletal Metastasis G Jameel, et al (Pakistan)
P-35	Patient Characteristics and Outcomes of Radioiodine Therapy in Differentiated Thyroid Cancer with Ineffective TSH-Stimulation: A Case Series AR Dewi, et al (Indonesia)
P-36	Nuclear Medicine - Ethical Issues in Current Practices S Fatima, et al (Pakistan)
P-37	Value of Tl-201 Imaging in Predicting Therapeutic I-131 Uptake in Patients with Thyroglobulin-Positive But I-131 Scan Negative in Differentiated Thyroid Cancer D Tumapon, et al (Philippines)
P-38	PNRI Pioneering Local Production of Molybdenum-99/Techetium-99m (Mo-99/Tc-99m) Generators for Nuclear Medicine Centers in the Philippines A Bulos, et al (Philippines)
P-39	Development of A Novel Porphyrin Complex As An Imaging Agent: [67Ga]-3,4 Dimethoxylated Porphyrin Y Fazaeli, et al (Iran)
P-40	Nanopurification and Quality Control of [64Cu] CuCl2 by Amino Functionalized Fe3O4 Magnetic Nano-Particles Yousef Fazaeli, et al (Iran)
P-41	Radioiodine Therapy in Differentiated Thyroid Carcinoma – Long Term Follow-Up M Hoque, et al (Bangladesh)
P-42	Radiosynthesis, Quality Control and Biological Evaluation Of [111In] 5, 10, 15, 20-Tetra Phenyl Porphyrin Complex in Rats Bearing Breast Tumors As A Possible Imaging/PDT Agent Yousef Fazaeli (Iran)

ICRT 2013

8th International Conference on Radiopharmaceutical Therapy

Manila, Philippines
17 – 21 November 2013

Sofitel Philippine Plaza Manila, Philippines

DAY 3: TUESDAY, 19 NOVEMBER 2013

(continued)

1130 – 1305	SCIENTIFIC SESSION 8: NEUROENDOCRINE TUMOURS II, LYMPHOMA & MISCELLANEOUS (Luzon Ballroom, Lobby Level)
Session Chairs	<ol style="list-style-type: none"> 1. Prof Hans Biersack, Nuclear Medicine, University Hospital Bonn, Bonn, Germany 2. Dr Charity Viado-Gorospe, Philippines
1130 – 1150 S-27	68Ga-DOTATOC PET/CT in Patients with Carcinoma of Unknown Primary of Neuroendocrine Origin: Impact on Patient Management Prof Omar Alonso, Nuclear Medicine, Clinical Hospital, University of Uruguay, Montevideo, Uruguay
1150 – 1210 S-28	Sr-89 Bremsstrahlung SPECT Imaging Using SPECT/CT System in Bone Metastases for Theranostics Strategy Prof Hiroshi Toyama, Radiology, Fujita Health University, Toyoake, Japan
1210 – 1230	PET Monitoring in Treatment Response Dr Greg Wiseman, Nuclear Medicine / Radiology, Mayo Clinic, Minnesota, USA
1230 – 1250 S-30	First-Line Outpatient Radioimmunotherapy of Follicular Non-Hodgkin Lymphoma With ¹³¹I-Rituximab in 100 Patients Followed Up to 5 Years Prof Harvey Turner, Nuclear Medicine, Fremantle Hospital, Fremantle, Australia
1250 – 1305 S-31	Selection for PRRT in Neuroendocrine Tumours: Which Patients Should We Treat and Which Radionuclide Should We Use? Dr Shaunak Navalkissoor, Nuclear Medicine, Royal Free London NHS Foundation Trust, London, United Kingdom
1305 – 1400	LUNCH SYMPOSIUM (SPONSORED BY GE HEALTHCARE) (Luzon Ballroom, Lobby Level)
Session Chairs	<ol style="list-style-type: none"> 1. Dr Sze Ting Lee, Nuclear Medicine & Centre for PET, Austin Health, Victoria, Australia 2. Dr Maria Lourdes Taylan, Nuclear Medicine, University of St. Thomas Hospital, Manila, Philippines
1315 – 1345 S-32	A Vision Beyond Mammography Dr Antonio C. Garcia, Nuclear Medicine, Manila Doctors Hospital, Manila, Philippines
1400 – 1515	SCIENTIFIC SESSION 9: PROSTATE CANCER (Luzon Ballroom, Lobby Level)
Session Chairs	<ol style="list-style-type: none"> 1. Dr Sze Ting Lee, Nuclear Medicine & Centre for PET, Austin Health, Victoria, Australia 2. Dr Jose Eduardo Rondain, Nuclear Medicine, Makati Medical Center, Makati, Philippines
1400 – 1425 S-33	THERANOSTICS of Prostate Cancer – An Outstanding Opportunity for Nuclear Medicine Prof Richard P Baum, THERANOSTICS Center for Molecular Imaging and Therapy, Zentralklinik Bad Berka, Bad Berka, Germany
1425 – 1450 S-34	Radionuclide Therapy of Refractory Prostate and Breast Cancer Bone Metastases – Improved Survival Prof Hans Biersack, Nuclear Medicine, University Hospital Bonn, Bonn, Germany
1450 – 1515 S-35	Present Status of Radioimmunotherapy of Castrate-Resistant Prostate Cancer with ¹⁷⁷Lu-J591 mAb (ATL101) Prof Jean-Francois Chatal, Arronax Cyclotron, GIP Arronax, Nantes-Saint-Herblain, France

ICRT 2013

8th International Conference on Radiopharmaceutical Therapy

Manila, Philippines
17 – 21 November 2013

Sofitel Philippine Plaza Manila, Philippines

DAY 3: TUESDAY, 19 NOVEMBER 2013

(continued)

1515 – 1545	COFFEE & TEA BREAK / TRADE EXHIBITION / POSTER VIEWING (Pre-Function Area / Visayas Ballroom, Lobby Level)
1515 – 1545	POSTER PRESENTATIONS (Pre-Function Area / Visayas Ballroom, Lobby Level)
Session Coordinator	Dr Wenceslao Lauderer, Philippines
P-43	[64Cu]-DOTA-PR81 for PET Applications, The Production and Quality Control B Alirezapour, et al (Iran)
P-44	Value Of Thyroglobulin Measurement in Treatment and Follow Up of Patients with Follicular Differentiated Thyroid Cancer SR Zakavi (Iran)
P-45	Treatment Planning in Radionuclide Therapy H Rajabi (Iran)
P-46	3-Benzyl-3-Hydroxy-1,5-Dimethyl-1,3-Dihydro-Indol-2-One Labeled Gallium-67&68 as Potential Anticancer Agents M Ghandi, et al (Iran)
P-47	Withholding Radioactive Iodine Therapy in Thyroid Cancer Patients – A Drawback H Caldito, et al (Philippines)
P-48	Evaluation of Pharmacokinetics of 188Re-KHEDP and 99mTc-HDP in Human M Smolyarchuk, et al (Russia)
P-49	Evaluation of 188Re-KHEDP (Phosphoren) for Palliative Treatment in Patients with Bone Metastases V Krylov, et al (Russia)
P-50	Determining Differences in Whole Body Radio-iodine Clearance Using Dose Rate Monitoring in Patients Undergoing High-Dose Radioactive Iodine Therapy: A Single Institution Experience A Sunga, et al (Philippines)
P-51	Activity in Urine Following 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy I Vito, et al (United Kingdom)
P-52	Clinical Results of Combined Therapy of Painful Multiple Skeletal Metastases By Samarium-153 Oxabifore Administration and Pamidronate Injection D Arybzhonov, et al (Kazakhstan)
P-53	Introducing I-131 MIBG Therapy in Pakistan, Steps Taken to Administer First Therapy in A Patient Having Metastatic Pheochromocytoma S Butt, et al (Pakistan)
P-54	AHCC - Impact on The Immunological System on Patients With Disseminated Neuroendocrine Tumors (NETs) After Treatment with The Radioisotope Preparation (90Y-DOTA-TATE) – An Initial Report N Szalus, et al (Poland)
P-55	Follicular Thyroid Cancer Presenting with Skull Metastases without Uptake of Radioiodine : A Case Report A Elliyanti (Indonesia)
P-56	High Vs. Low Dose Radio-Iodine Therapy for Initial Remnant Ablation of Post-Thyroidectomised Patients with Differentiated Thyroid Cancer: A Meta-Analysis J Mendoza, et al (Philippines)

Page 12 of 16

Please note that the programme is correct at time of update and is subject to change without prior notice

ICRT 2013

8th International Conference on Radiopharmaceutical Therapy

Manila, Philippines
17 – 21 November 2013

Sofitel Philippine Plaza Manila, Philippines

DAY 3: TUESDAY, 19 NOVEMBER 2013

(continued)

1545 – 1705	SCIENTIFIC SESSION 10: ARTHRITIS & RADIOSYNOVECTOMY (Luzon Ballroom, Lobby Level)
Session Chairs	<ol style="list-style-type: none"> 1. Dr Knut Liepe, Nuclear Medicine, GH Kassel, Kassel, Germany 2. Dr Juan Javier Lichauco, Philippines
1545 – 1610	Radiation Synovectomy: Overview
S-36	Prof Gynter Moedder, German Centre for Radiosynoviorthesis, Cologne, Germany
1610 – 1630	Recent Advances in the Management of Inflammatory Arthritis
S-37	A/Prof Michael L Tee, Physiology / Internal Medicine-Rheumatology, University of the Philippines College of Medicine, Manila, Philippines
1630 – 1645	Current Status of Radiosynovectomy in India – Problems & Solutions
S-38	Prof Birendra Kishore Das, Nuclear Medicine, Utkal Institute of Medical Sciences, Bhubaneswar, India
1645 – 1705	Clinical Aspects of Radiosynovectomy: An Update Dr Knut Liepe, Nuclear Medicine, GH Kassel, Kassel, Germany
1830 – 2200	OENOPHILOUS DINNER (Casa Roces) *Transport will be available from 1745 onwards at Hotel Lobby
2200	END OF DAY 3



ICRT 2013

8th International Conference on Radiopharmaceutical Therapy
Manila, Philippines
17 – 21 November 2013

Sofitel Philippine Plaza Manila, Philippines

DAY 4: WEDNESDAY, 20 NOVEMBER 2013

0900 – 1100	SCIENTIFIC SESSION 11: NEW THERAPIES (Luzon Ballroom, Lobby Level)
Session Chairs	<ol style="list-style-type: none"> 1. Prof Irene Virgolini, Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria 2. Dr Priscilla Caguioa, Philippines
0900 – 0925	RIT & EBRT in Lymphoma
S-39	Dr Michael Tomblyn, Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, USA
0925 – 0950	Boron Neutron Captute Therapy (BNCT) of Cancer: A New Type of Radionuclide Therapy
S-40	Prof Jun Hatazawa, Nuclear Medicine, Osaka University, Suita, Japan
0950 – 1015	The Alpha Emitter Alphasarin®: The Treatment of Bone Metastases
S-41	Dr Knut Liepe, Nuclear Medicine, GH Kassel, Kassel, Germany
1010 – 1035	Current and Future IAEA Programs on Radionuclide Therapy
S-42	Prof Adriano Duatti, Nuclear Applications, IAEA, Vienna, Austria
1035 – 1100	Somatostatin Theranostics Beyond Neuroendocrine Tumours
S-43	A/Prof Michael Hofman, Medicine, University of Melbourne, Melbourne, Australia
1100 – 1120	COFFEE & TEA BREAK / TRADE EXHIBITION / POSTER VIEWING (Pre-Function Area / Visayas Ballroom, Lobby Level)
1100 – 1120	POSTER PRESENTATIONS (Pre-Function Area / Visayas Ballroom, Lobby Level)
P-57	Heterogeneity Analysis of [18F]-FDG Uptake in Differentiating Between Metastatic and Inflammatory Lymph Nodes in Adenocarcinoma of The Lung: Comparison with Other Parameters and Its Clinical Application H Budiawan, et al (Korea)
P-58	Radiation Dose Estimates of Technologists in The Positron Emission Tomography (PET) Center At The St. Luke's Medical Center J M Dela Cruz (Philippines)
P-59	Role of Myocardial Perfusion Imaging in Acute Coronary Syndrome Dr Imran Abdullah (Pakistan)
P-60	Role of SPECT-CT in Radiotherapy S Sergieva, et al (Bulgaria)
P-61	The Association of HIV And Skeletal Metastases in Breast Cancer Masha Maharaj, et al (South Africa)
P-62	Tc-99m MIBI Scintigraphy as an Early Predictor of Radioiodine Treatment Response in DTC G Gunawan, et al (Indonesia)
P-63	SNOLL (Sentinel Lymph Node Biopsy and Radioguided Occult Lesion Localisation) in Early Breast Carcinoma – Two Years of Experience in Slovakia L Kaliska, et al (Slovakia)
P-64	Breast Cancer and Autoimmune Thyroiditis: Does the Sodium Iodide Symporter Play A Role? Jefferson R. Pagsisihan, et al (South Korea)
P-65	Novel Method for Cyclotron Production of 45Ti M Aboudzadeh, et al (Iran)

ICRT 2013

8th International Conference on Radiopharmaceutical Therapy
Manila, Philippines
17 – 21 November 2013

Sofitel Philippine Plaza Manila, Philippines

DAY 4: WEDNESDAY, 20 NOVEMBER 2013

(continued)

P-66	Benign Lymphadenopathies on FDG PET/CT: Castleman's Disease, Kikuchi-Fujimoto's Disease and Reactive Lymph Node Hyperplasia Jamilla Cecilia L. Gomez, et al (Philippines)
P-67	Outcome of Radioiodine Therapy in Benign Nodular Non-Toxic Goiter. A Preliminary Study Karina Michaela Dela Cruz, et al (Philippines)
P-68	Pleuro-peritoneal Communication Detected by Technetium 99m-tagged Macroaggregated Albumin (MAA) Radionuclide Peritoneal Scintigraphy in a Chronic Kidney Disease Patient on Peritoneal Dialysis: A Case Report Carla Mari M. Macaisa, et al (Philippines)
P-69	Pre-clinical Dosimetry and Prognosis of Safety and Effectiveness of Radiopharmaceuticals 188Re-zoledronic Acid Volozynev L.V, et al (Russia)
P-70	The Role of 99mTc Hydroxydiphosphonate (HDP) Scintimammography in the Diagnosis of Breast Cancer Chris Eduarte, et al (Philippines)
1120 – 1300	SCIENTIFIC SESSION 12: LIVER THERAPY & MISCELLANEOUS (Luzon Ballroom, Lobby Level)
Session Chairs	1. Dr Butch Magsombol, Nuclear Medicine & PET, Singapore General Hospital, Singapore 2. Dr Samuel Ang, Philippines
1120 – 1150 S-45	Overview of Y-90 SIRT and Dosimetric Considerations – SGH Experience Dr David Ng, Nuclear Medicine & PET, Singapore General Hospital, Singapore
1150 – 1210 S-46	3D Personalized Monte Carlo Dosimetry for Treatment Planning in 90Y-Microspheres Therapy: Absorbed Dose and Biological Effective Dose Considerations Ms Alice Petitguillaume, Internal Dosimetry, Institute of Radiation Protection and Nuclear Safety (IRSN), Fontenay-Aux-Roses, France
1210 – 1230 S-47	Y-90 Microsphere Treatment of Hepatic Neuroendocrine Metastases Dr James Warrington, Nuclear Medicine, London Health Sciences Centre, London, Canada
1230 – 1250 S-13	Imaging of Drug Resistant TB Decoded Prof Mike Sathekge, South Africa
1250 – 1300 S-48	Radionuclide Clinical Trials Prof John Buscombe, Nuclear Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom
1300 – 1400	LUNCH / TRADE EXHIBITION (Pre-Function Area / Visayas Ballroom, Lobby Level)



ICRT 2013

8th International Conference on Radiopharmaceutical Therapy

Manila, Philippines
17 – 21 November 2013

Sofitel Philippine Plaza Manila, Philippines

DAY 4: WEDNESDAY, 20 NOVEMBER 2013

(continued)

1400 – 1540	SCIENTIFIC SESSION 13: NUCLEAR MEDICINE – TODAY & TOMORROW (Luzon Ballroom, Lobby Level)
Session Chairs	<ol style="list-style-type: none"> 1. Prof Richard P Baum, THERANOSTICS Center for Molecular Imaging and Therapy, Zentralklinik Bad Berka, Bad Berka, Germany 2. Dr Emerita Barrenechea, Nuclear Medicine, Veterans Memorial Medical Center, Quezon City, Philippines
1400 – 1430 S-44	Tribute Lecture: Development Experience of Re-188-HDD Lipiodol for Liver Cancer Therapy Prof Jae Min Jeong, Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea
1430 – 1450 S-49	A Statistician's Fond Remembrance of Ajit Padhy Prof Janez Stare, Biostatistics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
1450 – 1515 S-50	Nuclear Medicine – I Have Seen It All Prof Yasuhito Sasaki, Clinical Research Center, Shonankamakura General Hospital, Kamakura, Japan
1515 – 1540 S-51	Nuclear Medicine – The Future Prof Irene Virgolini, Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria
1540 – 1600	COFFEE & TEA BREAK / TRADE EXHIBITION (Pre-Function Area / Visayas Ballroom, Lobby Level)
1600 – 1700	WARMTH MEMBERS' ASSEMBLY ALL MEMBERS OF WARMTH TO ATTEND THE MEETING (Luzon Ballroom, Lobby Level)
1700 – 1730	CLOSING CEREMONY
1730	END OF DAY 4

DAY 5: THURSDAY, 21 NOVEMBER 2013

	SIGHT-SEEING TOUR
	END OF DAY 5



Preparations for ICRT 2013 in Manila, last meeting with Ajit Padhy





WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009


(WORLD ASSOCIATION OF RADIOPHARMACEUTICAL & MOLECULAR THERAPY)




8th INTERNATIONAL
CONFERENCE ON
RADIOPHARMACEUTICAL THERAPY
(ICRT 2013)

NOVEMBER 17-21, 2013

MANILA PHILIPPINES


















9th ICRT-2014, Cancun, Mexico





WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009



Pre-congress course

Coral Gallery
Hotel Fiesta Americana Coral Beach

Tuesday, 26th

08:00 – 08:30 Registration

08:30 – 09:00 Welcome

Diagnosis and therapy of NET

09:00 – 09:30 Peptide Receptor Radionuclide Therapy (PRRT) of Neuroendocrine Tumors – A Paradigm for THERANOSTICS and Personalized Nuclear Medicine.
Richard P. Baum

09:30 – 10:00 Theranostics of receptor targeted therapy in solid tumors.
Andrew Scott

10:00 – 10:30 SPECT-CT Imaging of NETs re-invented.
John Buscombe

11:00 – 11:30 Coffee break / Exhibit hall

Diagnosis of Inflammation and Thyroid cancer

11:30 – 12:00 New Gallium labelled radiopharmaceuticals in Inflammation /infection?
Mike Sathecke

12:00 - 12:30 New approaches to image thyroid cancer with radiolabelled peptides and antibodies.
Alberto Signore

12:30 – 13:00 ¹³¹I-therapy in differentiated thyroid cancer – new proposal of patient management.
Alicia Hubalewska

13:00 – 13:30 New guidelines for thyroid cancer therapy?
Markus Luster


13:30 – 14:00 Lunch



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009



Xcaret Room - Cancun Center

13:30 – 14:45 International Round Table Discussion on Translation
of Therapeutic Nuclear Oncology
(WFNMB/WARMTH/IAEA) – Focus on Lu-177 Therapy
Chair: *Andrew Scott & Paul Roach*
Invited Panel: *R. Baum, H. Turner, M. Sathekge, D. Paez*
(IAEA), *J. Langford (ANSTO)*

14:45 – 15:30 **Oral presentations from WARMTH Grantees**
(15 minutes each)
Chair: *Sze Ting Lee & Emerita Barrenechea*

*Early radioiodine ablation post thyroidectomy with recombinant
TSH(rTSH) stimulation and its impact on performance status
versus thyroxine abstinence protocol in differentiated thyroid
carcinoma: initial results of a randomized prospective clinical
trial

Partha Choudhary

*The role of Tc-99m-EDDA/HYNIC-TOC somatostatin receptor
scintigraphy in selecting thyroid cancer patients with negative
I-131 scan and rising thyroglobulin for peptide radioreceptor
therapy: preliminary results

Marina Vlaajkovic

*A pilot study on post-SIRT survival among patients with
hepatocellular carcinoma: a single institution experience
Eric Cruz

15:30 Announcement of next ICRT & Closing
Virgolini & R. Baum

**Exclusively sponsored by ANSTO & NTP*

Wednesday, 27th



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009



Xcaret Room - Cancun Center

WARMTH Program

Chairman: Richard Baum

Wednesday, 27th

08:30 Registration

09:05 – 09:15 Welcome Remarks & Candle Lighting Ceremony
Prof. R Baum

Practical Aspects of Radionuclide Therapy

Chair: John Buscombe & Richard Baum

09:15 – 09:45 Integrating Radium -223 Therapy in a Multi-
Disciplinary Care Setting: The MD Anderson Experience
Prof Homer Macapinlac (USA)

09:45 – 10:15 PRRT
Prof Irene Virgolini (Austria)


10:15 – 10:45 Radioimmunotherapy
Prof Harvey Turner (Australia)

10:45 – 11:15 Rhenium 188 Lipiodol therapy in inoperable liver
cancers and metastatic liver lesions
Dr. Ajit Shinto (India)

11:15 – 11:45 Coffee Break

11:45 – 12:45 Work – in – progress session (10 minute talks by
leaders in the field – to stimulate discussion of the
latest developments & encourage airing of problems,
with aim to audience participation to contribute to
solution)
Chair: *Irene Virgolini & Harvey Turner*
Prof. Richard Baum (Germany), Prof. Harvey Turner
(Australia), Prof. Andrew Scott (Australia), Prof. Mike Sathekge
(South Africa)

12:45 – 13:30 Lunch and networking











10th ICRT-2015, Innsbruck, Austria

Congress-President: Irene Virgolini

WARMTH
WORLD ASSOCIATION OF RADIOPHARMACEUTICAL & MOLECULAR THERAPY

ICRT-2015, May 4-8th
10th INTERNATIONAL CONFERENCE ON RADIOPHARMACEUTICAL THERAPY

HOST: Medical University of Innsbruck, Austria

MEDIZINISCHE UNIVERSITÄT INNSBRUCK

CONTACT ICRT 2015: innsbruck@i-med.ac.at, www.nuklearmedizin-innsbruck.com





WARMTH

WORLD ASSOCIATION OF RADIOPHARMACEUTICAL & MOLECULAR THERAPY

Registration No. 5/944634 • Registered under the Societies Registration Act of 1860 in New Delhi, India



MEDIZINISCHE
UNIVERSITÄT
INNSBRUCK

10th International Conference on Radiopharmaceutical Therapy Innsbruck, Austria, 3 – 8 May 2015

OPENING CEREMONY

Kaiser Leopold-Saal, Theological Faculty of the University of Innsbruck

Ensemble Giocoso: Luca Sorcočević / bearb. Vlado Sunco: Sinfonie Nr. 3

Welcome Address **Irene J Virgolini**, Congress President, ICRT 2015

Opening Remarks **Richard P Baum**, President, WARMTH

Welcome Address **Helga Fritsch**, Rector, Medical University Innsbruck

Ensemble Giocoso: Yann Tiersen / arr. A. Pauly: L'Après-Midi

WARMTH Candle Lighting Ceremony (all Governing Body Members)

Ensemble Giocoso: Ron Goodwin / arr. A. Pauly: Miss Marple Theme.

Video Presentation in memoriam **Ajit K Padhy** (Patricia Bernal)

Ensemble Giocoso: Michael Praetorius / arr. A. Pauly: 4 Tänze aus Terpsichore

Presentation of the **WARMTH Lifetime Achievement Award** to **Georg Riccabona**,
Professor emeritus, Department of Nuclear Medicine, Innsbruck (Laudatio: Irene J. Virgolini)

Ensemble Giocoso: Raffaele Calace: Serenata Malinconica

Manuela Cirilli, CERN, Switzerland: "CERN and Large Hadron Collider (LHC):
From Physics to Medicine"

Ensemble Giocoso: Evaristo Felice Dall'Abaco: Concerto a piu' 'Instrumenti.

DELEGATES FOR THE ICRT 2015 AT INNSBRUCK COME FROM 47 COUNTRIES



10th International Conference on Radiopharmaceutical Therapy

Innsbruck, Austria, 3 – 8 May 2015
Hotel „Grauer Bär“

Day 1, SUNDAY, 3 May 2015 10. Tiroler Nuklearmedizinkongress 2015

0900 – 1100	REGISTRATION for Pre-Congress Symposium
0900 – 1800	REGISTRATION for ICRT 2015
1100 – 1300	PRE-CONFERENCE INTERNATIONAL SYMPOSIUM ON NUCLEAR CARDIOLOGY Auditorium, Hotel Grauer Bär, Lobby Level
Session Chairs	1. Serge Askienazy, Paris, France 2. Gert Klug, Innsbruck, Austria
1100 – 1115	Cardiac CT – State of the Art and Future Perspectives
PC-01	Gudrun Feuchtnner, Innsbruck, Austria
1115 – 1135	Cardiac Nuclear Medicine – State of the Art and Future Perspectives
PC-02	Markus Schwaiger, Munich, Germany
1135 – 1145	Quantifying Reverse Perfusion in Endothelial Dysfunction Using 82Rubidium PET/CT
PC-03	Abdul Jalil Nordin, Fathinul Fikri Ahmad Saad, Pietro Muto, Irene Virgolini; Serdang, Malaysia
1145 – 1200	Clinical Impact of Cardiac Imaging
PC-04	Gert Klug, Innsbruck, Austria
1200 – 1215	Combined 3D and I-123 mIBG IGDT of Ganglionated Plexus for Catheter Ablation of Atrial Fibrillation
PC-05	Serge Askienazy, Paris, France
1215 – 1230	Nuclear Cardiology in the Daily Routine of the Cardiologist – Relevant Clinical Case Reports
PC-06	Christian Uprimny, Innsbruck, Austria
1230 – 1245	The Role of Delayed Imaging in 18F-FDG PET/CT Myocardial Viability Study
PC-07	Moses Modiselle, Nozipho Nyakale, Mike Sathekge; Pretoria, South Africa
1245 – 1300	The Evolving Role of Hybrid & Multimodality Imaging in Nuclear Cardiology
PC-08	Qaisar Siraj, Kuwait City, Kuwait
1300 – 1400	LUNCH Restaurant Hotel “Grauer Bär”, Lobby Level
1400 – 1630	PRE-CONFERENCE INTERNATIONAL SYMPOSIUM ON NUCLEAR NEUROLOGY Auditorium, Hotel Grauer Bär, Lobby Level
Session Chairs	3. Irene Virgolini, Innsbruck, Austria 4. Elke Gizewski, Innsbruck, Austria
1400 – 1420	Neuroradiology – State of the Art
PC-09	Elke Gizewski, Innsbruck, Austria
1420 – 1440	Nuclear Medicine Imaging of Brain Tumors – State of the Art
PC-10	Tatjana Traub-Weidinger, Vienna, Austria
1440 – 1500	Nuclear Medicine Imaging of EPMS - Morbus Parkinson
PC-11	Christoph Scherfler, Innsbruck, Austria
1500 – 1520	Nuclear Medicine Imaging of Alzheimer’s Disease
PC-12	Robert Pichler, Linz, Austria
1520 – 1540	Radioguided Brain Surgery – Project HORIZON-2020
PC-13	Chiara Maria Grana, Milan, Italy
1540 – 1600	Epilepsy – State of the Art
PC-14	Eveline Donnemiller, Innsbruck, Austria
1600 – 1615	Cerebral Glucose Hypometabolism in Tick-Borne Encephalitis, a Pilot Study in 10 Patients
PC-15	Anelia Dietmann, Daniel Putzer, Ronny Beer, Raimund Helbok, Bettina Pfausler, Abdul Jalil Nordin, Irene Virgolini, Astrid E. Grams, Erich Schmutzhard; Innsbruck, Austria
1615 – 1630	18F-DOPA in Brain Tumors Under Proton Therapy
PC-16	Franca Chierichetti, Trento, Italy
1630 – 1900	COFFEE & TEA BREAK / MEET THE INDUSTRY Hotel “Grauer Bär”, Pre-Function Area / Lobby Level

10th International Conference on Radiopharmaceutical Therapy

Innsbruck, Austria, 3 – 8 May 2015
Hotel „Grauer Bär“

1930 – 2100	OPENING CEREMONY Kaiser Leopold-Saal, Theological Faculty of the University of Innsbruck
	Welcome Address Irene J Virgolini , Congress President, ICRT 2015
	Opening Remarks Richard P Baum , President, WARMTH
	Welcome Address Helga Fritsch , Rector, Medical University Innsbruck
	Mandolin Orchestra "GIOCOSO" (Christoph Artner)
	WARMTH Candle Lighting Ceremony (all Governing Body Members)
	Video Presentation in memoriam Ajit K Padhy (Patricia Bernal)
	Presentation of the WARMTH Lifetime Achievement Award to Georg Riccabona , Professor emeritus, Department of Nuclear Medicine, Innsbruck (Laudatio: Irene J. Virgolini)
	Manuela Cirilli , CERN, Switzerland: "CERN and Large Hadron Collider (LHC): From Physics to Medicine"
2100 - 2400	WELCOME RECEPTION - CONGRESS DINNER Restaurant Hotel "Grauer Bär", Lobby Level
2400	END OF DAY 1

DAY 2: MONDAY, 4 MAY 2015

0800 – 1800	REGISTRATION
0830 – 1030	SCIENTIFIC SESSION 1: THYROID DISEASES I Conference Room, Lobby Level
Session Chairs	1. Stanley Goldsmith , New York, United States 2. Seyed Rasoul Zakavi , Mashhad, Iran
0830 – 0845 S1-01	Radioiodine Therapy of Hyperthyroidism Seyed Rasoul Zakavi, Mashhad, Iran
0845 – 0900 S1-02	Magnesium Deficiency in Benign Thyroid Disorders Roy Moncayo, Viktoria Plaschke, Martina Leitner, Stephanie Pfab, Lorenza Scarpa; Innsbruck, Austria
0900 – 0915 S1-03	Prevalence of Normal TSH Levels in European Patients With Thyroid Autonomy Detected by Thyroid Scintigraphy Giorgio Treglia, Pierpaolo Trimboli, Frederik Anton Verburg, Luca Giovannella; Bellinzona, Switzerland
0915 – 0930 S1-04	Efficacy of Fixed High Dose (30 mCi) Iodine-131 Therapy for Solitary Toxic Thyroid Nodule Khalid Bashir Makhdomi, Nairobi, Kenya
0930 – 0945 S1-05	Effectiveness of Excluding Thyroid Cancer in Patients Referred to Radioiodine Therapy For Benign Thyroid Diseases: A 9-Year Follow-Up Cohort Study Maria H. Listewnik, Maria Chosia, Hanna Piwowarska-Bilska, Krystyna Jasiakiewicz, Barbara Zaborek, Piotr Zorga, Bozena Birkenfeld; Szczecin, Poland
0945 – 1000 S1-06	Management of Paediatric Thyroid Carcinoma Monica A. Rossleigh, Sydney, Australia
1000 – 1015 S1-07	Radioiodine Therapy of Juvenile Differentiated Thyroid Cancer Jasna Mihailovic, Sremska Kamenica, Serbia

10th International Conference on Radiopharmaceutical Therapy

Innsbruck, Austria, 3 – 8 May 2015
Hotel „Grauer Bär“

1015 – 1030 **Read the Small Letters of the Guidelines for Ablation Therapy and Apply Them to the Patients. Size Does not Always Matter**
S1-08 Savvas Frangos, Nicosia, Cyprus

1030 – 1100 COFFEE & TEA BREAK / INDUSTRY EXHIBITION
Pre-Function Area / Lobby Level

1100 – 1300 SCIENTIFIC SESSION 2: THYROID DISEASES II

Conference Room, Lobby Level

Session Chairs	1. Emerita Andres-Barrenechea, Quezon City, Philippines 2. Roy Moncayo-Naveda, Innsbruck, Austria
1100 – 1115 S2-01	Oncological Therapy of Radioiodine Negative Thyroid Cancer Markus Raderer, Vienna, Austria
1115 – 1130 S2-02	The Anti-VEGF Agent Lenvatinib: A New Promising Molecule for Progressive Radioiodine-Refractory Differentiated Thyroid Cancer Christian Pirich, Salzburg, Austria
1130 – 1145 S2-03	The Efficacy of Radioactive Iodine Therapy for Insular Thyroid Carcinomas Emerita Andres-Barrenechea, Emelyn Gail Caverte; Quezon City, Philippines
1145 – 1205 S2-04 S2-05	Somatostatin Receptor Therapy of Radioiodine-Negative Thyroid Cancer Patients – Project HORIZON-2020 Proteasome Inhibitor Therapy with Bortezomib of Dedifferentiated, Radioiodine Negative and Somatostatin Receptor Negative Thyroid Cancer Margarida Rodrigues, Daniel Putzer, Sabine Buxbaum, Wolfgang Eisterer, Irene Virgolini; Innsbruck, Austria
1205 – 1215 S2-06	Peptide Receptor Radionuclide Therapy (PRRT) of Metastatic, Progressive, Treatment-refractory Medullary Thyroid Cancer Using ¹⁷⁷Lu and ⁹⁰Y-labeled Octreotide Analogs Ameya D. Puranik, Harshad R. Kulkarni, Aviral Singh, Richard P. Baum; Bad Berka, Germany
1215 – 1225 S2-07	Risk of Disease Recurrence in Patients with DTC with Postoperative Thyroglobulin<1ng/mL Sofia Vaz, Ines P. Carvalho, Rita Sousa, Margarida Vieira, Angelo Silva, Deolinda Madureira, Susana Esteves, Edward Limbert, Teresa C. Ferreira, Lucilia Salgado; Lisbon, Portugal
1225 – 1240 S2-08	Recombinant TSH in the Management of DTC : What Has Been Achieved & Where Do We Go From Here Partha S. Choudhury, Delhi, India
1240 – 1250 S2-09	Radioiodine Ablation with rTSH in Differentiated Thyroid Cancer – SKM Experience Yasir Majeed, Saima Riaz, Humayun Bashir, Aamna Hassan, M. Khalid Nawaz; Lahore, Pakistan
1250 – 1300 S2-10	¹³¹I SPECT-CT Scintigraphy in the Management of Patients with DTC Sonya Sergieva, Sofia, Bulgaria

1300 – 1400 LUNCH
Restaurant Hotel “Grauer Bär”, Lobby Level

1400 - 1530 SCIENTIFIC SESSION 3: RADIOPHARMACY

Conference Room, Lobby Level

Session Chairs	1. Renata Mikołajczak, Otwock, Poland 2. Clemens Decristoforo, Innsbruck, Austria
1400 – 1415 S3-01	Radiopeptides Targeting G-Protein Coupled Receptors in Cancer: From Bench to Bed Helmuth R. Maecke, Freiburg, Germany
1415 – 1430 S3-02	Targeted Molecular Imaging and Therapy of Chemokine Receptor-4 Expression in Cancer Patients Hans-Juergen P. Wester, Ken Herrmann, Margret Schottelius, Katrin Philipp-Abbrederis, Theresa Osl, Andreas Poschenrieder, Andreas Buck, Horst Kessler, Richard B. Baum, Carlos Gerngross, Michael Lassmann, Herrmann Einsele, Stefan Knop, Markus Schwaiger, Ulrich Keller; Munich, Germany

10th International Conference on Radiopharmaceutical Therapy

Innsbruck, Austria, 3 – 8 May 2015

Hotel „Grauer Bär“

1430 – 1440 S3-03	Preclinical Application of 47Sc-Folate – Pilot Study in Tumor-Bearing Mice Cristina Müller, Katharina Domnanich, Klaudia Siwowska, Ulli Köster, Andreas Türlér, Roger Schibli, Nicholas van der Meulen; Villigen, Switzerland
1440 – 1450 S3-04	PSMA Targeting Iron Oxide Nanoparticles for PET/MR Dual Modal Imaging Jae Min Jeong, Seoul, Republic of Korea
1450 – 1500 S3-05	Cyclic Minigastrin Radiolabelled with Lu-177: Preclinical Evaluation of a Kit Formulation for Clinical Use Christine Rangger, Dariusz Pawlak, Lajos Balogh, Zita Pöstényi, Renata Mikolajczak, Elisabeth von Guggenberg; Innsbruck, Austria
1500 – 1515 S3-06	18F-Labelled F3 Derivatives Targeting Cancer and Tumour Endothelial Cells Phoebe Y.H. Lam, Katherine A. Vallis, Oxford, United Kingdom
1515 – 1530 S3-07	From Preclinical Development to a Multicentre Clinical Trial: 111In-CP04 Targeting CCK2-Receptors for Personalized Diagnosis and Therapy of Patients with Medullary Thyroid Carcinoma Clemens Decristoforo, Dariusz Pawlak, Christine Rangger, Piotr Garnuszek, Petra Kolec-Peitl, Katja Zaletel, Thea Maina-Nock, Helmut Maecke, Paola Erba, Renata Mikolajczak, Georg Göbel, Alicja Hubalewska-Dydejczyk; Innsbruck, Austria
1530 – 1600	COFFEE & TEA BREAK / INDUSTRY EXHIBITION Pre-Function Area / Lobby Level
1600 – 1730	SCIENTIFIC SESSION 4: MEDICAL PHYSICS / RADIATION PROTECTION Conference Room, Lobby Level
Session Chairs	1. Kalevi Kairemo, Helsinki, Finland 2. Thomas Beyer, Vienna, Austria
1600 – 1615 S4-01	Molecular Imaging – Part 1. Bernd Pichler, Tübingen, Germany
1615 – 1630 S4-02	Molecular Imaging – Part 2. Thomas Beyer, Vienna, Austria
1630 – 1640 S4-03	Image Segmentation for Personalized Dosimetry in Radionuclide Therapy: A Semi-Automatic Workflow Matching a Reference Phantom to the Individual Patient Anatomy Matthias Blaickner, Harshad Kulkarni, Stefan Wiessalla, Christiane Schuchard, Richard Baum; Vienna, Austria
1640 – 1700 S4-04 S4-05 S4-06	Lu-177 BPAMD for Treatment of Skeletal Metastases in Prostate Cancer: First Dosimetric Results Biodistribution and Dosimetry of Lu-177 PSMA for Therapy of Metastatic Prostate Cancer: First Results Peptide Receptor Radionuclide Therapy Using Lu-177 HA DOTATATE and Lu-177 DOTATOC in the Same Patient: Comparison of Biokinetics and Dosimetry Christiane Schuchardt, Stefan Wiessalla, Harshad Kulkarni, Frank Rösch, Mostafa Shahinfar, Hans-Jürgen Wester, Richard P. Baum; Bad Berka, Germany
1700 – 1715 S4-07	Dose Escalation Study with 188Re-Zoledronic Acid in Patients with Painful Bone Metastases Tatiana Kochetova, Valeriy Krylov, Lev Volosnev; Obninsk, Russian Federation
1715 – 1730 S4-08	Applications of PET/CT in External Beam Radiation Therapy Dose Planning Kalevi Kairemo, Helsinki, Finland
AGENDA	1800 – 2400 WARMTH GOVERNING BODY MEETING (Governing Body Members only)
2000 – 2400	WARMTH CONGRESS DINNER Restaurant Hotel “Grauer Bär”, Lobby Level
2400	END OF DAY 2

10th International Conference on Radiopharmaceutical Therapy

Innsbruck, Austria, 3 – 8 May 2015

Hotel „Grauer Bär“

DAY 3, TUESDAY, 5 MAY 2015

0800 – 1800 REGISTRATION	
0830 – 1030	SCIENTIFIC SESSION 5: PROSTATE CANCER / BONE PAIN PALLIATION Conference Room, Lobby Level
	<div>0830 – 1300 Meeting of the “TRANSCAN Study Group” Hotel “Schwarzer Adler”</div>
Session Chairs	1. Richard Baum, Bad Berka, Germany 2. Mike Sathekge, Pretoria, South Africa
0830 – 0845 S5-01	Therapy of Prostate Cancer – an Overview. Wolfgang Horninger, Innsbruck, Austria
0845 – 0900 S5-02	THERANOSTICS of Prostate Cancer (PRLT) Using Ga-68 and Lu-177 Labeled PSMA Small Molecule – a New Horizon for Nuclear Medicine. Richard P. Baum, Harshad Kulkarni, Christiane Schuchardt, Aviral Singh, M. Weineisen, Margret Schottelius, Hans-Jürgen Wester; Bad Berka, Germany
0900 – 0915 S5-03	68Ga-PSMA PET/CT: Paradigm Shift in the Management of Prostate Cancer. Mike Sathekge, Pretoria, South Africa
0915 – 0930 S5-04	The Role of PET Imaging with 68Ga-PSMA and 18F-Choline in Recurrent Prostate Cancer Patients Francesco Ceci; Bologna, Italy
0930 – 0945 S5-05	Gamma Imaging in Patients Following 223Ra / XOFIGO. Kalevi Kairemo, Helsinki, Finland
0945 – 1000 S5-06	Gallium 68 PSMA PET CT Scans in Recurrent Prostate Cancer Ishita Sen, Vineet Pant, Abhinav Singhal, Sanjay Gogoi; New Delhi, India
1000 – 1015 S5-07	The Relation Between Bone Pain Response and Skeletal Metastases in Cancer Patients Receiving 153Samarium-EDTMP Therapy Mai Elzahry, Helmut Sinzinger, Mohamed Gaber, Waleed Diab; Qena, Egypt
1015 – 1030 S5-08	Diagnosis and Follow-up of Recurring and Metastatic Prostate Cancer by Ga-68 PSMA PET/CT Harshad Kulkarni, Hans-Jürgen Wester, Richard P. Baum; Bad Berka, Germany
1030 – 1100	COFFEE & TEA BREAK / INDUSTRY EXHIBITION Pre-Function Area / Lobby Level
1100 – 1230	SCIENTIFIC SESSION 6: RADIOSYNOVECTOMY Conference Room, Lobby Level
Session Chairs	1. Knut Liepe, Frankfurt, Germany 2. Suresh Srivastava, New York, USA
1100 – 1115 S6-01	Radiosynovectomy - State of the Art 2015, Part 1 Gynter Mödder, Renate Mödder-Reese; Köln, Germany
1115 – 1130 S6-02	Radiosynovectomy - State of the Art 2015, Part 2 Knut Liepe, Frankfurt, Germany
1130 – 1140 S6-03	Homogeneous Sn-117m Colloid – A Novel Radiosynovectomy Agent Nigel Stevenson, Jimmy Lattimer, Kimberly Seltling, Gilbert Gonzales, Cynthia Doerr, Alison Bendele, Jaime Simon, Suresh Srivastava; Columbia, United States
1140 – 1150 S6-04	Radiosynoviorthesis (RSO) of 17 Sacroiliac Joints with 186 Rhenium Colloid: 4-Years Outcomes Marika Vereb, Lucia Kaliska, Knut Liepe; Kassel, Germany
1150 – 1200 S6-05	Management of Conjunctival Squamous Cell Carcinoma by Strontium-90 Irradiation – A Seven Year Experience Raihan Hussain, Sadia Sultana, Rahima Perveen, Khokon Kumar Nath; Dhaka, Bangladesh
1200 – 1210 S6-06	Synovectomy with 153-Samarium Hydroxyapatite in Haemophilic Arthropathy Jose Ulisses Calegario, Davi Hage, Mariana Sayago; Brasilia, Brazil
1210 – 1220 S6-07	Bremsstrahlung SPECT-CT for Localization of Inadvertent Extra Articular Injection Qaisar Siraj, Al-Banna Anwar, Noora Bin Essa; Kuwait City, Kuwait

10th International Conference on Radiopharmaceutical Therapy

Innsbruck, Austria, 3 – 8 May 2015

Hotel „Grauer Bär“

1220 – 1230 S6-08	Response to Radiosynovectomy for Hemophilic Arthropathy (Medium- sized joints) to Rhenium-86 Colloid and to Yttrium-90 for Larger Joints Emerita Andres-Barrenechea, Quezon City, Philippines	
1230 – 1430	LUNCH Restaurant Hotel “Grauer Bär”, Lobby Level	1230 – 1430 Meeting of the “188Re LIPIODOL Study Group”
1430 – 1600	SCIENTIFIC SESSION 7: LIVER CANCER / METASTASES Conference Room, Lobby Level	
Session Chairs	1. Ajit S. Shinto, Coimbatore, India 2. Richard Baum, Bad Berka, Germany	
1430 – 1445 S7-01	Re 188 Lipiodol Intra Arterial Treatment of Inoperable Hepatic Cancer and Liver Metastases Ajit S. Shinto, Coimbatore, India	
1445 – 1500 S7-02	Percutaneous Ablation Therapy – State of the Art Réto Bale, Innsbruck, Austria	
1500 – 1510 S7-03	Selective Internal Radiation Therapy (SIRT) in Hepatic Metastases from Uveal Melanoma. Treatment Response in Comparison to Transarterial Chemoembolization with Fotemustin Heying Duan, Alexander Haug, Fredrik Waneck, Martin Funovics, Gundula Berzaczky, Christoph Höller, Martha Hoffmann; Vienna, Austria	
1510 – 1520 S7-04	Yttrium-90 Intra-Arterial Radioembolization Therapy of Unresectable Intrahepatic Cholangiocarcinoma: 5-Year Experience at a Single Center Hanna Sviridenka, Cinzia Pettinato, Fabio Monari, Francesco Ceci, Cristina Mosconi, Elena Tabacchi, Silvia Sanfilippo, Cristina Nanni, Eleonora Giampalma, Rita Golfieri, Aviral Singh, Stefano Fanti; Bologna, Italy	
1520 – 1530 S7-05	In Situ Vaccination: The Synergistic Roles of Immunotherapy and Radiobioconjugate Targetted Therapy Daya Hazra, Ajai Shukla, Nirmal Painuly, Praveen Tyagi, Padmamalika Hazra; New Delhi, India	
1530 – 1540 S7-06	Personalized Dosimetry with Intensification Using 90Y-Loaded Glass Microsphere Radioembolization Induces Prolonged Overall Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis Etienne Garin, Yan Rolland, Sophie Laffont, Julien Edeline, Eveline Boucher; Rennes, France	
1540 – 1550 S7-07	18F-FDG PET-CT for Detection of Local Recurrence in Patients of HCC Post TACE Muhammad Numair Younis, Hamid Naseer, Khuram Shafiq Khan, Ahmad Qureshy, Irfan Ullah Khan, Abubaker Shahid; Lahore, Pakistan	
1550 – 1600 S7-08	Personalized Dosimetry Techniques in Y-90 SIR-Spheres Radioembolization-Singapore General Hospital Experience. Butch Magsombol, Singapore	
1600 – 1800	COFFEE & TEA BREAK / INDUSTRY EXHIBITION / SCIENTIFIC POSTER SESSIONS Pre-Function Area /Lobby Level	
	SCIENTIFIC POSTER SESSION 1: THYROID Conference Room, Lobby Level	
Session Chairs	1. Raihan Hussain, Dhaka, Bangladesh 2. Patricia Bernal-Trujillo, Bogota, Colombia 3. Jasna Mihailovic, Sremska Kamenica, Serbia	
P1-01	Blood Neutrophil-to-Lymphocyte Ratio Correlates With Tumor Prognosis in Patients with Papillary Thyroid Cancer Ze Meng, Peiyong Li, Ming Zhang, Yan Cao, Xiaofei Liang; Shanghai, China	
P1-02	Enhance Retention of Radioiodine in Thyroid Cancer Cells and Non-Thyroid Cancer Cells by PAMAM-Ag+ Peiyong Li, Yan Cao, Ze Meng; Shanghai, China	

10th International Conference on Radiopharmaceutical Therapy

Innsbruck, Austria, 3 – 8 May 2015

Hotel „Grauer Bär“

P1-03	Thyroid Carcinoma Detected by Incidental 18F-FDG Uptake in a Patient with Progressive Cerebellar Syndrome – a Case Report Alexander Kroiss, Christian Uprimny, Sabine Buxbaum, Roy Moncayo, Irene Virgolini; Innsbruck, Austria
P1-04	Prognostic Value of Thyroid Volume Changes in Hyperthyroidism Response to Radioiodine Therapy (A Preliminary Report) Narjess Ayati, Seyed Rasoul Zakavi; Mashhad, Iran
P1-05	Did Standard Activities of Radio-Iodine 131I Useful in the Treatment of Multiple Bone Metastasis from Differentiated Thyroid Carcinoma Kaouthar Chatti, Nouha Essabbah, Hamza Regaieg, Tarek Kamoun, Raja Sfar, Manel Nourira, Maha Ben Fredj, Najla Ayachi, Mohsen Guezguez, Habib Essabbah; Sousse, Tunisia
P1-06	Nonthyroidal Malignancies in Patients with Differentiated Thyroid Carcinoma Zvezdana Rajkovic, Ivana Pavkovic, Pedj Kovacevic; Sarajevo, Bosnia and Herzegovina
P1-07	Carum Carvi Ingestion May Increase TSH Level in Patients with Thyroid Cancer Seyed Rasoul Zakavi, Seyed Maryam Naghibi, Mohamad Ramezani, Narjess Ayati; Mashhad, Iran
P1-08	Incidental Thyroid Carcinoma: Should Surgery or Radioiodine Therapy be the Initial Management for Graves' Disease with Multinodular Goitre? Alex Khoo Cheen Hoe, Fadzilah Hamzah, Shueh Lin Lim, Mohamed Ali Abdul Khader; Penang, Malaysia
P1-09	Tailoring Therapy for Benign Thyroid Disease in Private Practice Masha Maharaj, Durban, South Africa
P1-10	Low Expression of Sodium Iodide Symporter and TSH-R in Cases of Papillary Thyroid Carcinoma with Mutant B-Raf Through the Role of TGF-β: It's Implication in the Management of Papillary Thyroid Carcinoma Budi Darmawan, Bandung, Indonesia
P1-11	Clinical Outcome of Patients with Recurrent Well Differentiated Thyroid Carcinoma Faria Nasreen, Nurun Nahar, Sadia Sultana; Dhaka, Bangladesh
P1-12	Salivary Gland Malignancy as a Late Complication of Radioiodine Therapy Lutfun Nisa, Nurun Nahar, Raihan Hussain, Sadia Sultana, Faria Nasreen, Zeenat Jabin; Dhaka, Bangladesh
P1-13	Prescription of Iodine-131 (131I) for Treatment of Differentiated Thyroid Carcinoma (DTC) – What Changed in 10 Years: A Retrospective Analysis Rita Sousa, Teresa C. Ferreira, Sofia Vaz, Ines P. Carvalho, Angelo Silva, Pedro Ratao, Ana Daniel, Lucilia Salgado; Lisbon, Portugal
P1-14	Psycho – Social Aspects of Thyroid Cancer Patients in Bangladesh Zeenat Jabin, Fatima Begum, Tanjina Nawshin; Dhaka, Bangladesh
P1-15	Test of 24-Hour 131-I Uptake in Patients with Autonomous Follicular Toxic Adenoma and Multinodular Toxic Goiter with Disseminated Autonomy; Impact of the Salt Iodination and the Possible Influence on the Radioiodine Therapy Planning Ana Ugrinska, Daniela Miladinova; Skopje, Macedonia
P1-16	Incidence of Second Primary Malignancy in Patients Treated With Ablative I131 Doses. Mariela Agolti, Martin Rettore, Rocio Brezán, Maria Celeste Fernández; Paraná, Argentina
P1-17	A Case of Basedow-Graves Thyrotoxicosis Associated With the Follicular Variant of Papillary Carcinoma Iulia Andreea Chiriac, Raluca Mihaela Mititelu, Roxana Irina Rosca, Andrei Liviu Goldstein, Catalin Victor Mazilu, Daniela Neamtu; Bucharest, Romania
P1-18	Comparison of Post Operative 99mTc Perthechnetate Scan and Post Ablative 131I Scan for the Management of Differentiated Thyroid Carcinoma Shankar Kumar Biswas, Shaila Sharmin, Fatema Sultana Haque, Mohana Hossain, Tania Sultana, Afroza Akhter, Rubina Begum, Farhana Rahman, Sadia Hossain, Rawna Afrin, Mazharul Islam, Sanowar Hossain; Dhaka, Bangladesh
P1-19	Do All Patients With Raised Thyroglobulin Need Treatment in TENIS Syndrome? Kanhaiyalal Agrawal, Bhagwant Rai Mittal, Chinmoy Kumar Biswal, Rohit Kumar Phulsunga, Rajender Basher, Ashwani Sood, Anish Bhattacharya; Chandigarh, India
P1-20	Recurrent Differentiated Thyroid Cancer: Analysis of Factors and Causes Ganna Grushka, Natalia Luhovicka, Olga Astapryeva, Olga Paskevych; Kharkiv, Ukraine

10th International Conference on Radiopharmaceutical Therapy

Innsbruck, Austria, 3 – 8 May 2015

Hotel „Grauer Bär“

P1-21	Effect of Single Dose of Radioiodine Therapy on Volume Reduction of Thyroid Gland in Hyperthyroidism Shamrukh Khan, Faridul Alam, Fatima Begum; Dhaka, Bangladesh
P1-22	Clinical Outcome of Radioiodine Therapy in Adolescent Hyperthyroidism: Single Centre Experience Teik Hin Tan, Boon Nang Lee, Siti Zarina Amir Hassan; Putrajaya, Malaysia
P1-23	Serum Thyroglobulin Kinetics as the Predictor of Differentiated Thyroid Carcinoma Treatment Outcome Ayu Rosemeilia Dewi, Budi Darmawan, Basuki Hidayat, A Hussein S. Kartamihardja, Trias Nugraha, Johan S. Masjhur; Bandung, Indonesia
P1-24	Correlation Between Serum Tg-on and Persistent Disease in Patients with Well Differentiated Thyroid Carcinoma Budy Darmawan, Febby Hutomo, Johan S Masjhur ; Bandung, Indonesia
P1-25	Incremental Value of Regional SPECT-CT While Performing Whole Body I-131 Scan of the Patients Suffering from Differentiated Thyroid Cancer----Its Impact on Clinical Decision Making Soumendranath Ray, Jayanta Das, Manoj Shaw; Kolkata, India

1600 – 1800	SCIENTIFIC POSTER SESSION 2: PERSONALIZED MEDICINE: PRRT, PROSTATE CANCER Conference Room, Lobby Level
Session Chairs	<ol style="list-style-type: none"> 1. Hans-Jürgen Biersack, Bonn, Germany 2. Stefano Fanti, Bologna, Italy 3. Sze Ting Lee, Melbourne, Australia
P2-01	The First MIBG Therapy in the Philippines Patricia Bautista, Jonas Francisco Santiago; Metro Manila, Philippines
P2-02	Experience and Results of 38 Patients After 177Lu-Octreotate Therapy in the Federal Capital of Brazil Gabriela Lobo, Janaina Souto, Flavia Marciano, Gustavo Gomes, Marcelo Gomes, Dalton Anjos, Joao Arratia, Rodrigo Furtado, Roberta Araujo, Jose Ulysses Calegare, Enio Gomes; Brasilia, Brazil
P2-03	Response Time Pattern (Delayed Response) after PRRT with [177Lu-DOTA]-D-Phe1-Tyr3-Octreotide (177Lu-DOTATOC) Richard P. Baum, Karin Niepsch, Cees van Echteld; Bad Berka, Germany
P2-04	Uptake of 68Ga-DOTA-Conjugated Peptides in Uncinate Process of Pancreas----Characteristics and Clinical Significance Amrita Kasat, Zoe Zhang, Xuexian Yan; Singapore
P2-05	68Ga-DOTANOC PET/CT Imaging in Detection of Primary Site in Patients with Metastatic Neuroendocrine Tumours of Unknown Origin and its Impact on Clinical Decision Making: Experience from a Tertiary Care Centre in India Ankur Pruthi, Promila Pankaj, Ritu Verma, Harsh Mahajan; New Delhi, India
P2-06	Peptide Receptor Radionuclide Therapy Proves to be Safe and Immediately Efficient in Elderly Patients with Symptomatic Neuroendocrine Tumors Heying Duan, Alexander Haug, Stephan Witoszynski, Markus Raderer, Martha Hoffmann; Vienna, Austria
P2-07	Complementary Role of Somatostatin Receptor Scintigraphy and Positron Emission Tomography Using F-18 FDG in Selection of the Patients with TENIS Syndrome for PRRT Marina Vlajkovic, Milena Rajic, Milos Stevic, Radan Dzodic, Emil Matovina, Vera Artiko, Milovan Matovic; Nis, Serbia
P2-08	Atypical Bronchial Carcinoid: Different Approaches Llanos Geraldo Roig, Dorota Kendler, Sabine Buxbaum, Irene Virgolini; Innsbruck, Austria
P2-09	Response of Urothelial Carcinoma to Peptide Receptor Radionuclide Therapy (PRRT) Lorenza Scarpa, Margarida Rodrigues, Dorota Kendler, Sabine Buxbaum, Daniel Putzer, Michael Gabriel, Günther Gastl, Irene Virgolini; Innsbruck, Austria

10th International Conference on Radiopharmaceutical Therapy
Innsbruck, Austria, 3 – 8 May 2015
Hotel „Grauer Bär“

P2-10	Strontium-89 Chloride in the Palliative Treatment of Patients with Painful Skeletal Metastases Ljiljana Jaukovic, Sanja Dugonjic, Zoran Jankovic, Dragan Pucar; Belgrade, Serbia
P2-11	Cu-64 PSMA PET in Prostate Cancer Siroos Mirzaei, Charlotte Sonneck-Koenne, Peter Knoll; Vienna, Austria
P2-12	Lactate Dehydrogenase (LDH) as Predictive Factor of the Pain Free Syndrome Duration after Radionuclide Bone Metastases Treatment in Patients with Breast Cancer Nigora Rasulova, Dauranbek Arybzhonov, Vladimir Lyubshin, Gayrat Arifhodjaev, Yulia Shakirova, Valery Krylov; Tashkent, Uzbekistan
P2-13	Therapy with 89-Sr in Painful Bone Metastasis Due to Breast Cancer Raluca Mititelu, Iulia Chiriac, Catalin Mazilu, Sorin Mititelu, Carmen Tipar; Bucharest, Romania
P2-14	Detection of Bladder Neck Recurrence with Ga68 PSMA PET CT Scans in Post Prostatectomy Patients of Carcinoma Prostate Vineet Pant, Ishita Sen, Abhinav Singhal; Gurgaon, India
P2-15	68Ga-PSMA Uptake of Pulmonary Metastases in Patients of Carcinoma Prostate: Not a Reliable Tool in Isolation Vineet Pant, Ishita Sen, Abhinav Singhal; Gurgaon, India
P2-16	First Experience of Ra 223 Dichloride Therapy in Latvia Antra Berzina, Kirils Kravcovs, Ginta Lace; Riga, Latvia
P2-17	Incremental Role of 68Ga-PSMA PET CT Over 18 F FDG PET CT in Imaging of Primary Renal Cell Carcinoma and Evaluation of Its Metastases Vineet Pant, Ishita Sen, Abhinav Singhal; Gurgaon, India

1600 – 1800	SCIENTIFIC POSTER SESSION 3: RADIOPHARMACY / PHYSICS / IGDT / Miscellaneous Conference Room, Lobby Level
Session Chairs	1. Jae Min Jeong, Seoul, Korea 2. Elisabeth von Guggenberg, Innsbruck, Austria 3. Butch Magsombol, Singapore
P3-01	Labeled Graphene Oxide Nanostructures: Novel Therapeutic Agents Seyed Yousef Fazaeli Hoseini Nezhad, Karaj, Iran
P3-02	Porphyrin Complexes of 111In: Possible Imaging/PDT Agents Seyed Yousef Fazaeli Hoseini Nezhad, Ali Sattari; Karaj, Iran
P3-03	Radio Synthesis and Preclinical Dosimetric Estimation of [111In] 5, 10, 15, 20-tetra Phenyl Porphyrin Complex as a Possible Imaging/PDT Agent Seyed Yousef Fazaeli Hoseini Nezhad, Saeed Shanehsazzadeh, Afsaneh Lahooti, Amirreza Jalilian; Karaj, Iran
P3-04	Production, Quality Control and Application of 62Zn/ 62Cu Radio Isotope Generator in Iran Seyed Yousef Fazaeli Hoseini Nezhad, Karaj, Iran
P3-05	Production of 103Pd via (n,alpha)-Reaction and Its Separation by Spontaneous Electrodeposition Imtiaz Abbasi, Islamabad, Pakistan
P3-06	Production of Glass-Based Microsphere Labeled with 90Y and 198Au for Treatment of Liver Cancer Hosein Poorbaygi, Shahab Sheibani, Reza Naghdi, Aliakbar Habibpanah, Elham Mohagheghpoor; Tehran, Iran
P3-07	Preparation of 32P Labeled Albumin Particles for Internal Radiotherapy of Refractory Solid Tumors Shahnaz Tolooee, Hosein Poorbaygi, Shahab Sheibani, Mohammad Mazidi, Mahasti Amoui; Tehran, Iran
P3-08	99mTc-Colloidal Rhenium Sulphide: Influence of Different Generator's Eluates on Fluctuations in Radiochemical Purity Aljosa Stankovic, Dragana Milakovic, Zvezdana Rajkova; Banja Luka, Bosnia and Herzegovina
P3-09	Development of Radiopharmaceutical Based on Heat-Sensitive Polymer and 153Sm for Local Therapy Vladimir Duflet, Nikolay Bolbit, Tatyana Altyinnikova; Obninsk, Russian Federation
P3-10	Preparation of Radioresistant Therapeutic Radiopharmaceutical ¹³¹I-MIBG Vitaliy Pozdeev, Yuriy Kuptsov; Obninsk, Russian Federation

10th International Conference on Radiopharmaceutical Therapy

Innsbruck, Austria, 3 – 8 May 2015

Hotel „Grauer Bär“

P3-11	Our Approach to Development of Safety System for Monitoring and Prevention of Unauthorized Desertion of the "Restricted Area" by Patients Treated With High Doses of Radionuclide Therapy Milovan Matovic, Marija Jeremic, Slobodan Jankovic, Miroslav Ravlic, Marina Vlajkovic; Kragujevac, Serbia
	MISCELLANEOUS
P3-12	A Pilot Study on Post-SIRT Survival Among Patients with Hepatocellular Carcinoma: A Single Institution Experience Eric B. Cruz, Quezon City, Philippines
P3-13	The Rare Case of Extraneural Metastasis of Cerebellar Medulloblastoma Detected by 18-F-FDG PET/CT Lucia Kaliska, Martin Spurny, Marika Vereb, Pavol Bician; Banska Bystrica, Slovakia
P3-14	Metabolic Volumetric Parameters in Prediction of Outcome after Chemo-Radiotherapy in Nasopharyngeal Carcinoma Archi Agrawal, Venkatesh Rangarajan, Sarbani Laskar, Harish V, Nilendu Purandare, Sneha Shah, Ashish Jha; Mumbai, India
P3-15	FDG PET-CT - One Stop Test for Patients with Breast Cancer Recurrence Sadaf Jabeen, Saima Riaz, Humayun Bashir, Imran Khalid Niazi; Lahore, Pakistan
P3-16	PET-CT in the Evaluation of Primary Liver Carcinoma; Local Experience Muhammad Numair Younis, Hamid Naseer, Afshan Ashfaq, Ahmad Qureshy, Misbah Masood, Abubaker Shahid; Lahore, Pakistan
P3-17	Tumour Polypeptide Specific Antigen (TPS) Serology in Cancer Management Padmamalika Hazra, Daya Hazra, Gita Jaiswal; Agra, India
1800	Panorama Cable Car to Innsbruck's Mountain Peak "Hafelekar"
1830 – 2400	WARMTH CONGRESS DINNER Restaurant "Seegrube"
2400	END OF DAY 3

DAY 4, WEDNESDAY, 6 MAY 2015

0800 – 1800	REGISTRATION
0830 – 1030	SCIENTIFIC SESSION 8: PRRT Conference Room, Lobby Level
Session Chairs	<ol style="list-style-type: none"> 1. John Buscombe, Cambridge, UK 2. Harvey Turner, Murdoch, Australia
0830 – 0845 S8-01	The LUPPET STUDY: 177Lu-Dota-Peptide Radionuclide Therapy in FDG PET Positive/Negative Patients. A Metabolism Guided Personalized Medicine for Gastroenteropancreatic Neuroendocrine Tumors Giovanni Paganelli; Meldola, Italy
0845 – 0900 S8-02	From Molecular Imaging Using PET/CT to Personalized Therapy – 16 Years of THERANOSTICS Experience in Neuroendocrine Tumors at the Bad Berka NET Center of Excellence? Harshad R. Kulkarni, Richard P. Baum; Bad Berka, Germany
0900 – 0915 S8-03	Results of Dosimetry-Based PRRT (DOTA-THER). Annibale Versari, Reggio Emilia, Italy.
0915 – 0930 S8-04	CONTROL-NETS; An Evidence Base for Radiosensitizing Chemotherapeutic PRRT of Advanced GEP-NETS. Harvey Turner, Murdoch, Australia

10th International Conference on Radiopharmaceutical Therapy

Innsbruck, Austria, 3 – 8 May 2015

Hotel „Grauer Bär“

0930 – 0945 S8-05	A Retrospective Comparison Between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in Patients with Extra-adrenal Paraganglioma for Planning PRRT Alexander Kroiss, Christian Uprimny, Clemens Decristoforo, Andreas Frech, Lydia Posch, Rudolf Wolfgang Gasser, Claudia Goetsch, Barry Lynn Shulkin, Georg Mathias Sprinzl, Christoph Url, Rupert Prommegger, Gustav Fraedrich, Irenel Virgolini; Innsbruck, Austria
0945 – 1000 S8-06	Severe Haematological Complications Associated with PRRT: 15 Years of Experience at Bad Berka Aviral Singh, Harshad Kulkarni, Karin Niepsch, Richard P. Baum; Bad Berka, Germany
1000 – 1015 S8-07	Comparison of 68Ga-DOTATATE and 68Ga-DOTATOC Uptake in Primary Gastroenteropancreatic Neuroendocrine Tumor, Metastases and Normal Liver Tissue in the Same Patient Mila Todorovic-Tirnanic, Milan Gajic, Richard P. Baum; Belgrade, Serbia
1015 – 1030 S8-08	Future of Peptide Receptor Radionuclide Therapy (PRRT). Lisa Bodei; Milano, Italy

1030 – 1100 **COFFEE & TEA BREAK / INDUSTRY EXHIBITION**
Pre-Function Area / Lobby Level

1100 – 1300	SCIENTIFIC SESSION 9: QUALITY OF LIFE Conference Room, Lobby Level
Session Chairs	<ol style="list-style-type: none"> 1. Savvas Frangos, Limassol, Cyprus 2. Carlos Libhaber, Johannesburg, South Africa
1100 – 1115 S9-01	Current Status of Quality of Life Thinking - the Systematic Incorporation of the Patient Perspective into Research and Practice Eva Gamper; Innsbruck, Austria
1115 – 1130 S9-02	Patient Hierarchy of Needs William Claxton, Singapore
1130 – 1145 S9-03	Patient Education for Those Seeking Peptide Receptor Radionuclide Therapy (PRRT) Josh Mailman; Stanford, United States
1145 – 1200 S9-04	Tumor Response and Health-Related Quality of Life Predict Survival After PRRT in NET Patients Margarida Rodrigues, Bernhard Nilica, Sabine Buxbaum, Eva Maria Gamper, Christian Uprimny, Irene Virgolini; Innsbruck, Austria
1200 – 1210 S9-05	Quality of Life: Patient Response After 1st Treatment (PRRT) Ivy Mateo-Vito, Rebelidad Leshen, Helena McMeekin, Shaanak Navalkisoor; London, United Kingdom
1210 – 1220 S9-06	Symptoms Referred by Patients with Differentiated Thyroid Carcinoma During Preparation for Radioiodine Treatment Sofia Vaz, Rita Sousa, Teresa C. Ferreira, Angelo Silva, Ines P. Carvalho, Pedro Ratao, Ana Daniel, Lucilia Salgado; Lisbon, Portugal
1220 – 1230 S9-07	Relation of Thyroid Hormone Status with Severity of Depressive Illness Mohammad Mizanul Hasan, Chaman Afroz Chowdhury, Mohammad Sayadul Islam Mullick; Dhaka, Bangladesh
1230 – 1245 S9-08	Self-reported Bone Pain in Patients Treated with Radium 223: An Example of Web-based Home-Monitoring Sanja Kresic, Eva Maria Gamper, Sabine Buxbaum, Visnja Kenjic, Margarida Rodrigues, Bernhard Nilica, Bernhard Holzner, Irene Virgolini; Innsbruck, Austria
1245 – 1300 S9-09	Obesity and the Heart Carlos D. Libhaber, Johannesburg, South Africa
1300 – 1400	LUNCH Restaurant Hotel "Grauer Bär", Lobby Level <div> 1300 – 1400 Meeting of the "FDG-NET Study Group" </div>

10th International Conference on Radiopharmaceutical Therapy

Innsbruck, Austria, 3 – 8 May 2015

Hotel „Grauer Bär“

1400 – 1530	SCIENTIFIC SESSION 10: PERSONALIZED MEDICINE / THERANOSTICS
	Conference Room, Lobby Level
Session Chairs	1. Suresh Srivastava, New York, USA 2. Partha Sarathi Choudhury, Delhi, India
1400 – 1415 S10-01	Update 2015: WHERE WE ARE HEADING? The Beginnings, Evolution, and Current Status of "Theranostics" Suresh C. Srivastava, New York, USA
1415 – 1430 S10-02	Validation of a Cassette Based Fully Automated Synthesis of ¹⁷⁷Lu-PSMA617 Clemens Decristoforo, Dominik Summer, Alexander Wurzer, Roland Haubner, Irene Virgolini, Elisabeth von Guggenberg; Innsbruck, Austria
1430 – 1445 S10-03	Production and Application of ⁴⁴Sc Towards Clinical PET Imaging of Cancer Christiaan Vermeulen, Cristina Müller, Katharina Domnanich, Aviral Singh, Richard Baum, Andreas Türler, Roger Schibli, Nicholas van der Meulen; Villigen, Switzerland
1445 – 1500 S10-04	cGMP Conform Synthesis of [⁶⁸Ga]NODAGA-RGD with a Remote Controlled Synthesis Unit and Initial Clinical Data Roland Haubner, Armin Finkenstedt, Armin Stegmayr, Christian Mair, Christine Rangger, Heinz Zoller, Irene Virgolini; Innsbruck, Austria
1500 – 1510 S10-05	Clinical Usefulness of ¹⁸F-Sodium Fluoride and ¹⁸F-FDG PET/CT Cocktail in the Management of Oncology Patients Nozipho Nyakale, Andrei Iagaru, Sam Gambhir, Alfred Ankrah, Mike Sathekge; Pretoria, South Africa
1510 – 1520 S10-06	Comparison of ER, PR and HER 2 /neu Receptor Positivity with the Incidence of Bone Metastasis and Treatment Response in Follow-up Bone Scans in Breast Cancer Soumendranath Ray, Jayanta Das, Subir Sinha; Kolkata, India
1520 – 1530 S10-07	Variable CT Appearance and Ga-68 PSMA Uptake of Bone Metastases in Carcinoma Prostate Abhinav Singhal, Vineet Pant, Ishita Sen; Gurgaon, India
1530 – 1600	COFFEE & TEA BREAK / INDUSTRY EXHIBITION
	Pre-Function Area / Lobby Level
1600 – 1800	SCIENTIFIC SESSION 11: IMAGE-GUIDED THERAPY
	Conference Room, Lobby Level
Session Chairs	1. Cornelis A. Hoefnagel, Amsterdam, The Netherlands 2. Pietro Muto, Naples, Italy
1600 – 1615 S11-01	Radionuclide Therapy: Image-Guided or –Unguided Cornelis A. Hoefnagel, Amsterdam, The Netherlands
1615 – 1630 S11-02	A Retrospective Comparison Between ⁶⁸Ga-DOTA-TOC PET/CT and ¹²³I-MIBG SPECT/CT in Patients with Extra-adrenal Paraganglioma for Pretherapeutic Staging Alexander Kroiss, Christian Uprimny, Barry Lynn Shulkin, Andreas Frech, Rudolf Wolfgang Gasser, Christoph Url, Kurt Gautsch, Ruth Madleitner, Bernhard Nilica, Georg Mathias Sprinzi, Gustav Fraedrich, Irene Virgolini; Innsbruck, Austria
1630 – 1645 S11-03	⁶⁸Ga-DOTA-NOC PET/CT for the Diagnosis of Adrenal Gland Neoplasms Compared to ¹³¹I-MIBG: Preliminary Study Xiao-Cheng Yao, Chun Zhang, Le-le Zhang, Guo-Qiang Shao, Feng Wang; Nanjing, China
1645 – 1700 S11-04	Radionuclide Guided Surgery - Preliminary Experience Mairah Razi, Humayun Bashir, Abid Qudus Qazi, Amina Iqbal Khan, Asad Hayat, Aamna Hassan; Lahore, Pakistan
1700 – 1715 S11-05	First Human Diagnostic Application of Scandium-44 Highlights a Path Towards THERANOSTICS with Scandium-47 in Somatostatin Receptor Expressing Tumors Aviral Singh, Richard P. Baum, Ingo Klette, Nick van der Meulen, Cristina Müller, Andreas Türler, Roger Schibli; Bad Berka, Germany



WARMTH
WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY
FOUNDED 2009

10th International Conference on Radiopharmaceutical Therapy

Innsbruck, Austria, 3 – 8 May 2015
Hotel „Grauer Bär“

1715 – 1730 S11-06	Characterisation of Neuroendocrine Tumors with 68Ga-DOTANOC PET/CT and 18F- FDG PET/CT: A Comparison with Histopathology Rakesh Kumar, Punit Sharma, Niraj Naswa, C.S. Bal; New Delhi, India
1730 – 1745 S11-07	Role of 18F-FDG PET/CT in Predicting Pathologic Response to Neoadjuvant Chemo Radiotherapy and Survival in Patients of Non Metastatic Esophageal and Gastro-Esophageal Junction Carcinoma Ankur Pruthi, Sameer Taywade, Partha Sarathi Choudhury; New Delhi, India
1745 – 1800 S11-08	Lu-177 Labeled DOTAGA-PSMA Small Molecules for Theranostics of Metastasized Castrate-Resistant Prostate Cancer: Initial Clinical Results Harshad Kulkarni, Martina Weineisen, Christiane Schuchardt, Ingo Klette, Hans-Jürgen Wester, Richard P. Baum; Bad Berka, Germany

2000 – 2400	WARMTH KEY NOTE LECTURE & GALA DINNER Dresscode: red dresses for the ladies or your national dress if you prefer, black jackets and red ties for the men
	Ignasi Carrio, Barcelona, Spain: Personalized Nuclear Medicine
	Restaurant “Villa Blanka”
2400	END OF DAY 4


DAY 5: THURSDAY, 7 MAY 2015

0930 – 1100	0800 – 0930 WARMTH MEMBERS ASSEMBLY Hotel “Grauer Bär”, Conference Room, Lobby Level
	CLOSING CEREMONY Hotel “Grauer Bär”, Conference Room, Lobby Level
	HIGHLIGHT LECTURE Stanley J. Goldsmith, NY, USA: “My Dear Old Friend Radioiodine: From Status Quo to Status Go”
	PRESENTATION OF BEST ORAL AND BEST POSTER AWARDS Irene Virgolini, Congress President
	Concluding Remarks Richard P Baum, President, WARMTH Suresh Srivastava, President-Elect, WARMTH Partha S. Choudhury, Congress President ICRT 2016 PRESENTATION OF ICRT 2016, November 13-17
1100 – 2000	SIGHT-SEEING TOUR
2000 – 2400	TYROLEAN EVENING “Postkutschhof”, Axams Austrian Waltz and Polka Dancing Party
2400	END OF DAY 5



In the pre-field of organising the ICRT-2015 in Tyrol, Ajit Padhy had visited Innsbruck several times, including a visit in 2011 when we started to discuss the possibility of conducting an ICRT in Innsbruck Downtown - or somewhere else in the province of Tyrol. Ajit Padhy came with a delegation of staff members from the General Hospital of Singapore to the Innsbruck Medical University for training in PRRT. Ajit Padhy was always very found of the Tyrolean Alps as well as the good climate the province of Tyrol has to offer throughout the whole year. We were discussing whether we should conduct the ICRT in spring or in autumn, - unfortunately we could not finish the discussion due to his sudden demise in August 2013. The ICRT was after his sudden demise in 2013 planned to take place in May 2015 in Innsbruck.
















11th ICRT-2016, Kerala, India

Congress-President: Partha Choudhury





“The 11th ICRT was held on 13th-17th November 2016 in India. The four day meeting which was hosted by Rajiv Gandhi Cancer Institute & Research Centre Delhi in the city of Kochi in Kerala which is one of the sought after tourist destinations in the country and popularly known as “God’s own country”. The theme of the meeting was “From controversies to consensus” in radiopharmaceutical therapy.

The conference highlighted the following objectives :

- 1. To evaluate the current status of Nuclear Medicine in general and radionuclide therapy and molecular imaging in particular.*
- 2. To disseminate the concept of Theragnostics in the management of disease using molecular imaging as a premier diagnostic tool to aid therapy.*
- 3. To exchange information on the current advances in the field between scientists from developed and developing countries.*
- 4. To interact with the user groups like Internists, oncologists, rheumatologists, paediatricians, orthopaedicians and surgeons.*
- 5. To bring them the most important information in the field of radionuclide therapy.*
- 6. To define future directions of this speciality*

The major emphasis of the meeting was to involve the end users and stakeholders of therapeutic Nuclear Medicine, to enhance awareness and to sell this technology to our clinical colleagues. The entire range of Theragnostics in the field of Nuclear Medicine was covered including basic sciences, instrumentation, radiobiology, radiopharmaceuticals dosimetry and molecular imaging in the form of plenary lectures, oral and poster presentations, interactive sessions and audiovisual presentations. The Prof Ajit Padhy memorial oration in the memory of our founder was also introduced during this meeting and was delivered by Prof Hossein Jadvar. The scientific sessions organized throughout the meeting truly reflected WARMTH’s mission fulfilling the goal of providing the best care for our patients. The meeting concluded with a full day boat excursion in the famous “backwaters” of Kerala where we also celebrated the “oenophiles” afternoon with wines from all around the world brought in by our members from their respective countries along with the sumptuous Indian cuisine.” (Partha Choudhury, November 2019)



DAY 1, SUNDAY, 13 NOVEMBER 2016

PRE - CONGRESS SYMPOSIUM

12:00 - 13:35		SENTINEL NODE BIOPSY
Chairpersons		Sze Ting Lee B R Mittal
12.00-12.20	Sentinel Node Biopsy in Head & Neck Cancer: A Surgeon's Perspective	Mony A Kuriakose
12:25-12:45	How to Perform H & N Sentinel Node Scintigraphy	P. Shanmuga Sundaram
12:50-13:10	Recent Advances in Tracers and Techniques in SLNB Detection	Gopinath Gnanasegaran
13:15-13:30	Video Presentation on SNB Procedure & Interaction of Delegates with Experts	D.K.Vijaykumar/P. Shanmuga Sundaram
13:30-13:35	Discussion	
13:35 – 14:15		Lunch Break

14:15-18:00		PET-CT SYMPOSIUM
Chairpersons		Venkatesh Rangarajan John Buscombe
14:15-14:35	New PET Tracers	Anil Mishra
15:05-15:25	PET-CT in Infection and Inflammation	Rakesh Kumar
15:30-15:50	18F-Fluoride PET- CT: Game Changer	Fahad Marafi
15:50-16:00		Tea / Coffee Break
Chairpersons		Vikram Lele Nicola Mulholland
16:05-16:25	PET & Radiotherapy Planning	Sze Ting Lee
16:30-16:50	PET scan imaging to guide therapy in Oncology	Greg Wiseman
16:55-17:15	Revisiting enigma of glioma recurrence with simultaneous PET-MRI	Amarnath Jena
17:20-17:40	Non-Radioisotopic Imaging in Radionuclide Therapy	Soumen Ray
17:40-18:00	PET-CT in Cardiovascular diseases	Pietro Muto

18:30-20:30		INAUGURATION
18:30-19:15	Inaugural Ceremony ICRT 2016	
19:15-20:15	1st Ajit Padhy Memorial Oration	
Chairpersons		Suresh Srivastava (President WARMTH) Partha Choudhury (Secretary WARMTH)
19:15-19:25	Welcome & Introduction regarding Ajit Padhy oration	Suresh Srivastava
19:25-19:35	In the memory of our beloved predecessor, the Late Ajit Padhy, M.D.	Emerita Andres Barrenechea
19:35-20:15	Recent Advances in Prostate Cancer Theragnostics	Hossein Jadvar
20:30-23:00		INAUGURAL DINNER

DAY 2, MONDAY, 14 NOVEMBER 2016

8:30-11:00			SCIENTIFIC SESSION: THYROID DISEASES - BENIGN & MALIGNANT THYROID DISEASE
Chairpersons			Kumar Kallur Knut Liepe Batoool Albaloooshi
8:30-8:50	Updated Guidelines in Hyperthyroidism	Emerita Barrenechea	
8:50-9:10	Challenges in the Management of Advanced Thyroid Cancer: A Surgeon's Perspective	Ajay K Dewan	
9:10-9:30	Challenging Issues of Radioiodine Therapy of Differentiated Thyroid Cancer including Iodine Refractory Cases	Henry Bom	
9:30-9:50	TENIS: Multifaceted Considerations for a Rational Management	Sandip Basu	
9:50-10:10	Management of Paediatric Thyroid Disease	Isabel Roca	
10:10-10:30	Comparison of ETA & ATA guidelines in the management of thyroid cancer.	Archi Agarwal	
10:30-10:40	13-Cis-Retinoic Acid therapy in combination with Recombinant Human Thyrotropin for Treatment of Dedifferentiated Thyroid Cancer: A Pilot Study	Ashish Gambhir et al	
10:40-10:50	Development of a web application to calculate maximum safe dose of I-131 in high risk patients with Differentiated Thyroid Carcinoma	Mariela Agolti et al	
10:50-11:00	Tea / Coffee Break		

11:10 – 13:00			SCIENTIFIC SESSION: LIVER CANCER
Chairpersons			Ajay Dewan Patricia Bernal
11:10-11:30	Overview of Treatment of liver Tumors	Butch Magsambol	
11:30-11:50	Radio-Embolisation of Liver Metastases and HCC	Nicola Mulholland	
11:50-12:10	An insight into the treatment of liver cancer with indigenous I-131 labelled Lipiodol : Indian experience:	Kumar Kallur	
12:10-12:30	SIRFLOX: New Option for Treatment of Liver Metastasis in Colorectal Tumours	R V Parameswaran	
12:30-12:50	PET/MRI and PET/CT Imaging and Dosimetry in Liver -Selective Internal Radiation Therapy with Y-90 Microspheres: Which Approach is Better?	Karin Knesaurek	
12:50-13:00	Novel non-iodinated radiopaque microbeads that can be labeled with 188rhenium, for trans-arterial radio-embolization (TARE) of liver tumors	Vijay Harish Somasundaram et al	

13:00 - 13:50			LUNCHEON SYMPOSIUM: (SERENE LLC)
Chairpersons			Suresh Srivastava
13:00-13:15	Worldwide Status of Radiosynoviorthesis and the Opportunity for a New Tin-117m Colloid	Knut Liepe	
13:15-13:30	Multicentre Canadian Study to Measure the Safety and Efficacy of Radiosynoviorthesis (RSO)	Phil Cohen	
13:30-13:45	Update on tin-117m RSO canine osteoarthritis trial	Cynthia Doerr	

13:50-15:30			SCIENTIFIC SESSION: RADIOPHARMACY
Chairpersons			Anil Mishra



Harvey Turner		
13:50-14:10	Development of Indigenous Radiopharmaceuticals for Therapy	Sharmila Bannerjee
14:10-14:30	The Development of Re-188-based Radiopharmaceuticals in India with Special Reference to TARE	Madhava B.Mallia
14:30-14:50	Recent Basic Researches on Targeted Radionuclide Therapy in Japan	Seigo Kinuya
14:50-15:10	Rhenium Isotopes as Potential Therapy Agents Relevant to the Sodium Iodine Symporter (NIS) and the Role of Dosimetry in Translational Research	Lefteris Livieratos
15:10-15:30	Production & evaluation of Ac-225 & novel PET Radionuclides	Cathy Cutler
15:30-15:45	Tea / Coffee Break	

15:45 – 18:20		SCIENTIFIC SESSION: MEDICAL PHYSICS / RADIATION PROTECTION/DOSIMTERY
Chairpersons		Karin Knesaurek Emerita Barrenechea
15:45-16:05	Radiation Protection in Radionuclide Therapy? How much is too much	Venkatesh Rangarajan
16:05-16:25	The Regulatory norms in use of Recent Therapeutic Radionuclides.	Pankaj Tandon
16:25-16:45	Radiation Safety in Targeted Alpha Therapy	Jeffery R Jones
16:45-17:05	Clinicians' Perspective of Dosimetry in Radionuclide Therapy: Challenges & Practicality	Vikram Lele
17:05-17:25	Dose Recording: Science and Practicalities	Daniel McCool
17:25-18:00	Safety & Security of Radionuclide Therapy Sources : A RUSI project	SobhanVinjamuri, Margaret Hills, Cristina Variale
18:00-18:20	Radiosynovectomy : State of the art 2016	Gynter Modder

19:00-20:15		DINNER SYMPOSIUM (IBA Molecular)
Meet the experts		Gynter Modder
Speakers		Alejandro Otero Gynter Modder
20:15-23:00	GALA DINNER (IBA SPONSORED)	



DAY 3, TUESDAY, 15 NOVEMBER 2016

8:30 – 10:10		SCIENTIFIC SESSION: PROSTATE CANCER 1
Chairpersons		Hossein Jadvar Birendra K Das
8:30-8:50	Overview of management of Prostate Cancer	GINIL KUMAR
8:50-9:10	Metabolic Radiotracers to Image Prostate Cancer	Fahad Marafi
9:10-9:40	Precision Medicine at its best: PSMA Radioligand Therapy (PRLT) of End-stage Prostate Cancer Patients Selected by Ga-68 PSMA PET/CT	Aviral Singh on behalf of Richard Baum
9:40-10:10	Panel Discussion: Management Strategy in CRPC	Moderator : Kalevi Kairemo Panelists : GINIL KUMAR, Aviral Singh, Vineet Pant K.Pavitrnan
10:10-10:25	Tea / Coffee Break	

10:25 – 11:35		SCIENTIFIC SESSION: PROSTATE CANCER II
Chairpersons		Sudhir Rawal Seigo Kinuya
10:25-10:45	Practical Aspects of Setting up a Regional Radium Service	John Buscombe
10:45-11:05	Radium-223: Clinical and Dosimetry Aspects	Knut Liepe
11:05-11:35	Theragnostics & Combination Therapy in CRPC patients	Irene Virgolini

11:35 – 13:00		SCIENTIFIC SESSION: RHENIUM SYMPOSIUM
Chairpersons		Irene Virgolini Mike Sathekge
11:35-11:55	Re 188 Liver Cancer Therapy: What we have Learned so far	Mathew Cherian
11:55-12:10	Re-188 HEDP Therapy	Knut Liepe
12:10- 12:25	Re 188 Zoledronic Acid Therapy for Skeletal Metastases	Lev Tatiana
12:25-12:40	Re 188 Skin Patch Therapy	Jaya Shukla
12:40-13:00	Available Re-188 Generator old Kits as well as Relative Dosimetry	Ajit Shinto
1300-1345	Lunch Break	

13:45-15:25		SCIENTIFIC SESSION: THERAGNOSTICS - CONTROVERSIES TO CONSENSUS & ACCEPTANCE
Chairpersons		Suresh Srivastava Jamshed Bomanji
13:45-14:15	The Conception, Evolution, and Promotion of the Game-Changer Paradigm of 'Theragnostics' at Brookhaven National Laboratory	Suresh Srivastava
14:15-14:55	Radionuclide Therapy Debate :Can Radionuclide Therapies be used as First Line Therapy in Cancers?	
	For	Venkatesh Rangarajan



	Against	Batool Albalooshi
14:55-15:25	Panel Discussion - Mission, Passion, & Confusion in Radionuclide Therapies	Panelists Henry Bom, John Buscombe, B.R Mittal, Fahad Marafi Moderators : Gopinath Gnanasegaran; Suresh Srivastava
15:25-15:35	Tea / Coffee Break	

15:35 – 17:15		SCIENTIFIC SESSION: MISCELLANEOUS
Chairpersons		Niklaus G Schaefer Sandip Basu
15:35-15:55	The Role of Nuclear Medicine and TB Therapy	Mike Sathekge
15:55-16:15	Radioimmunotherapy as First-line Outpatient Treatment of Follicular Non-Hodgkins Lymphoma	Harvey Turner
16:15-16:35	Paediatric Radionuclide Therapy	Jamshed Bomanji
16:35-16:55	Introducing Conversion Electron Therapy for the Treatment of Metastatic Prostate and Breast Cancer	Suresh Srivastava
16:55-17:15	Recent developments on the production of therapeutic Radionuclides in India	Sudipta Chakraborty

17:15-18:00		SCIENTIFIC SESSION (ORAL PRESENTATION)
Chairpersons		Butch Magsombol Soumendranath Ray
17:15-17:25	¹⁷⁷ Lu-PSMA-617 radioligand therapy of metastatic castration resistant prostate cancer: update on the Bad Berka experience	Aviral Singh
17:25-17:35	Radium (Ra-223) dichloride therapy of the symptomatic bone metastases in patients with castration-resistant prostate cancer, one institution experience, preliminary results.	Lucia Kaliska
17:35-17:45	The Initial Chilean Experience with ⁶⁸ Ga/ ¹⁷⁷ Lu-PSMA in Castration Resistant Prostate Cancer	Horacio Amaral
17:45-17:55	PSMA Radioligand Therapy of Metastatic Prostate Cancer Using Lu-177 PSMA I&T and Lu-177 PSMA-617: Comparison of biodistribution and dosimetry	Christiane Schuchardt

18:00-20:00	GOVERNING BODY MEETING
20:00-23:00	DINNER



DAY 4, WEDNESDAY, 16 NOVEMBER 2016

08:30 – 1100		SCIENTIFIC SESSION: PRRT
Chairpersons		Jun Hatazawa Arun Malhotra
08:30-09:00	20 Years of THERANOSTICS Experience in Neuroendocrine Tumors – Past, Present, and Future of Peptide Receptor Radionuclide Therapy (PRRT)	Aviral Singh on behalf of Richard Baum
09:00-09:20	FDG and 68Ga-SSTR PET in the Follow up of Patients treated by PRRT: Where we are Today?	Bernhard Nilica
09:20-09:40	Radionuclide Therapy Combination with Immunotherapy	Niklaus G. Schaefer
09:40-10:00	Sequencing and Combination of Chemo/Biological Therapy with Lutetium-177-Octreotate PRRT of NETs	Harvey Turner
10:00-10:20	Neuroendocrine Tumours and PRRT: Overview of Recent Trials and Outcomes	Shaunak Navalkisoor
10:20-10:50	Panel Discussion : Finer practice points in PRRT	Panelist : Ullas Batra, Sobhan Vinjamuri, Harvey Turner, Shaunak Navalkisoor Moderator : Sandip Basu
10:50-11:00	Tea / Coffee Break	

11:00 – 13:00		SCIENTIFIC SESSION: DEVELOPMENT AND INTRODUCTION OF RADIONUCLIDE THERAPY : REGIONAL & WORLD WIDE CHALLENGES
Chairpersons		Suresh Srivastava Partha Choudhury
11:00-11:20	Asia: Role of Asian School of Nuclear Medicine in Promoting Radionuclide Therapy: What is stopping us from being the Best	Jun Hatazawa
11:20-11:40	USA: Hurdles in Implementing Newer Techniques & Therapies in Nuclear Medicine	Hossein Jadvar
11:40-12:00	Europe/UK: Is Evidence Based Approach a Hurdle in Radionuclide Therapies	Gopinath Gnanasegaran
12:00-12:20	AFRICA: Manpower or Money-power Hurdles in Implementing Therapies	Mike Sathekge
12:20-12:40	What does it take to Successfully Navigate a Career as the CEO of SNMMI, and help establish the new Therapy Center of Excellence within this Society”	Hossein Jadvar
12:40-13:00	Discussion: Different Needs in Different Countries: HOW WARMTH CAN SUPPORT?	Speakers & Audience
13:00-13:30	Lunch	

13:30 – 15:00		SCIENTIFIC SESSION 1: WORLD THERAGNOSTIC ACADEMY(WTA)
Chairpersons		Gopinath Gnanasegaran Irene Virgolini
13:30-13:50	Targeted Radionuclide Therapy : Radiation Safety by Design	Jeffery R Jones
13:50-14:20	Demonstration & discussion on Ga DOTA PSMA & Lu DOTA PSMA labelling, its trouble-shooting & how to perform Lu DOTA & PSMA Therapies	Vineet Pant



14:20-14:40	TARE: Indications & How to Perform: A Video Presentation by Interventional Radiologist	Dilip Kumar M.P
14:40-15:00	Re188 microspheres for SIRT of liver tumors- First hand experience of an Indigenous preparation	B R Mittal
15:00-15:15	Tea / Coffee Break	

15:30 – 15:50		SCIENTIFIC SESSION 2: WORLD THERAGNOSTIC ACADEMY(WTA) Patient Information & Management of Side Effects, and Complications Related to Radionuclide Therapies	
Chairpersons		Fahad Marafi Kalevi Kairemo	
15:30-15:50	Patient Outreach: Engaging the Patient Community	Josh Mailman	
16:00 – 17:30		MANAGEMENT OF SIDE EFFECTS AND COMPLICATIONS RELATED TO RADIONUCLIDE THERAPIES	
16:00-16:15	Benign & Malignant Thyroid Diseases	Emerita Barrenechea	
16:20-16:35	Radiosynovectomy	Knut Liepe	
16:40-16:55	PRRT	Masha Maharaj	
17:00-17:15	Re-188-Liver Cancer Therapy	Dilip Kumar M.P	
17:15-17:30	Bone Pain Palliation	Suresh Srivastava	

17:30-18:15		SCIENTIFIC SESSION (ORAL PRESENTATION)	
Chairpersons		Andrew Hilson Ana Ungriska	
17:30-17:40	NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with ¹⁷⁷ Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis	Maribel Lopera Sierra	
17:40-17:50	Clinical Application of SPECT-CT somatostatin-receptor scintigraphy in some neuroendocrine tumors (NETs) with rare localization	Sonya Sergieva	
17:50-18:00	Production and characteristics of a novel Sn-117m particulate suspension for application in human and veterinary radiosynoviorthesis	Nigel R Stevenson	
18:00-18:10	Role of SPECT-CT with ^{99m} Tc-Tektrotyd in the management of NETs	Sonya Sergieva	
18:10-18:20	Outcome of therapy of lymphatic filariasis documented by lymphoscintigraphy	Birendra Kishore Das	

19:00-23:00	MEMBER'S ASSEMBLY & CLOSING FOLLOWED BY DINNER
--------------------	---

DAY 5, THURSDAY, 17 NOVEMBER 2016

FUN DAY

09:00	Leave hotel after Breakfast for Back Water Cruise
12:00-17:00	Back Water Cruise in House Boat
	Lunch & Wine tasting from different countries in Boat (Oenophilus Afternoon)
17:30	Start returning to Kochi (2.5 hrs drive) in coach
19:30 Onwards	Free time with Dinner in Hotel : Time to network & unwind


















12th ICRT-2017, Vienna, Austria

Congress-President: Irene Virgolini



ICRT 2017 : 19th -20th Oct 2017
Vienna Austria
Venue : IAEA Headquarters Vienna



Details will be soon available at WARMTH website :
www.warmth.org

Complementary registration for WARMTH members





12th International Conference on Radiopharmaceutical Therapy

Vienna, 19 – 20 October 2017

IAEA, Vienna International Center, VIC, AUSTRIA

DAY 1, THURSDAY, OCTOBER 19, 2017

0800 – 0930 REGISTRATION for ICRT 2017 and Security Check at the IAEA Main Entrance, VIC-Center, Vienna

1000 – 1200 OPENING CEREMONY

Mandolin Orchestra "GIOCO SO"

Welcome Address

Suresh Srivastava, President, WARMTH

Opening Remarks

Irene Virgolini, President-elect, WARMTH

Welcome Address

Diana Paez, IAEA, Division Head Nuclear Medicine

May Abdel-Wahab, IAEA, Head Department of Human Health

Mandolin Orchestra "GIOCO SO"

WARMTH Candle Lighting Ceremony

Ajit Padhy Oration

Stanley J. Goldsmith, Cornell Medical Center, USA

"Searching for the Magic Bullet: History of Targeted Radionuclide Therapy"

Mandolin Orchestra "GIOCO SO"

1200 – 1300 LUNCH AT THE IAEA

1300 – 1500 SCIENTIFIC SESSION 1: THERAGNOSTICS, THE SOUL OF WARMTH: TARGETED RADIONUCLIDE THERAPY OF CANCER AND OTHER DISEASES (MODERATOR: SURESH SRIVASTAVA, BROOKHAVEN, USA)

1300 – 1320
1/1

Suresh Srivastava (USA)

The Conception, Development, and Promotion of the Novel Paradigm of "Theranostics" at Brookhaven National Laboratory

1325 – 1340
2/1

Mathew Thakur (USA)

⁶⁴Cu/⁶⁷Cu Theragnostics for Urothelial Malignancies

1340 – 1400
3/1

Gilbert Gonzales (USA)

Nuclear Medical Applications of ^{117m}Sn

1400 – 1420
4/1

Nigel Stevenson (USA)

Manufacturing and Characteristics of ^{117m}Sn

1420 – 1440
5/1

Cynthia Doerr (USA)

Animal Trials with HTC (Homogeneous ^{117m}Sn Colloid)

1440 – 1500
6/1

Discussion



12th International Conference on
Radiopharmaceutical Therapy
Vienna, 19 – 20 October 2017
IAEA, Vienna International Center, VIC, AUSTRIA

1500 – 1530 COFFEE & TEA BREAK

1530 – 1800 **SCIENTIFIC SESSION 2: THERAPEUTIC NUCLEAR ONCOLOGY / SYNERGISTIC CHEMO-IMMUNO-THERA(G)NOSTICS / ROUND TABLE DISCUSSION (MODERATOR: HARVEY TURNER, PERTH, AUSTRALIA)**

1530 – 1545 1/2	Nat Lenzo (Australia) Tumour-Targeted Molecular Radionuclide Therapy; Public and Private Outpatient Theragnostics
1545 – 1600 2/2	Katherine Vallis (United Kingdom) Experimental Radiotherapeutics; Joining Forces with Oncologists
1600 – 1615 3/2	Adeola Ayoola (Australia) Dual Specialty Training; The Oncology-Nuclear Medicine Nexus
1615 – 1630 4/2	Murali Kesavan (Australia) Haematologic Oncology; Myelotoxicity of Combination Therapies
1630 – 1645 5/2	Phillipe Calais (Australia) Individualised Patient Dosimetry and Radiation Safety of Outpatient Therapy
1645 – 1800 6/2	Round Table Discussion: Therapeutic Nuclear Oncology; Global Collaboration and Harmonization (Moderator: Harvey Turner) Panel: Irene Virgolini (WARMTH), Richard Baum (WARMTH), Sze-Ting Lee (WFNMB), Diana Paez (IAEA), Katherine Vallis (CRUK/MRC Oxford Institute Oncology), Nat Lenzo (Theranostics Australia)

END OF DAY 1





12th International Conference on
Radiopharmaceutical Therapy
Vienna, 19 – 20 October 2017
IAEA, Vienna International Center, VIC, AUSTRIA

DAY 2, FRIDAY, OCTOBER 20, 2017

0800 – 0900 **REGISTRATION for ICRT 2017 and Security Check at the IAEA Main Entrance**

0900 – 1105 **SCIENTIFIC SESSION 3: PROSTATE CANCER:
PSMA-LIGAND-RADIONUCLIDE THERAPY (PLRT) – WHAT DO WE
KNOW AND WHAT IS NEW? (MODERATOR: RICHARD BAUM, BAD
BERKA, GERMANY)**

0900 – 0930 1/3	Cristina Müller (Switzerland) Prostate Cancer Theragnostics – New Radioisotopes for Imaging and Therapy
0930 – 1000 2/3	Hans J. Wester (Germany) Radiohybrid Tracers: A Changer for PSMA Theragnostics
1000 – 1030 3/3	Frederik Giesel (Germany) Diagnosis of Prostate Cancer using F-18 labeled PSMA and its Impact for Patient Management
1030 – 1100 4/3	Richard P Baum (Germany) Lu-177 PLRT of Metastatic Prostate Cancer: The Bad Berka Experience in over 650 Treatments since 2013
1100 – 1105	Kalevi Kairemo (Finland) "Web-based Patient Monitoring During 177Lu-PSMA617 Treatment"

1105 – 1130 **COFFEE & TEA BREAK**

1130 – 1300 **SCIENTIFIC SESSION 4: THYROID CANCER – QUO VADIS?
(MODERATOR: PARTHA CHOUDHARY, NEW DELHI, INDIA)**

1130 – 1200 1/4	Jasna Mihailovic (Serbia) Current Status of Differentiated Thyroid Carcinoma
1200 – 1215 2/4	Zehra Ozcan (Turkey) Ablative therapy with RAI in low risk papillary thyroid cancer: Low dose or no dose?
1215 – 1230 3/4	Partha Choudhury (India) Recombinant TSH in the Management of Differentiated Thyroid Carcinoma
1230 – 1245 4/4	Alexander Kroiss (Austria) Role of PET-CT in the Management of Thyroid Cancer
1245 – 1300 5/4	Margarida Rodrigues (Austria) Management of Radioiodine Refractory Thyroid Cancer



12th International Conference on
Radiopharmaceutical Therapy
Vienna, 19 – 20 October 2017
IAEA, Vienna International Center, VIC, AUSTRIA

1300 – 1400

LUNCH AT THE IAEA

1400 – 1530

**SCIENTIFIC SESSION 5: LIVER-DIRECTED THERAPY AND PRRT
(MODERATOR: ALEXANDER HAUG, VIENNA, AUSTRIA)**

1400 – 1420
1/5

Klemens Scheidhauer (Germany)
PRRT of Neuroendocrine Tumors: Results of the NETTER-1 Trial

1420 – 1440
2/5

Hojjat Ahmadzadehfard (Germany)
Radioembolization of Liver Tumors: Technical Aspects and Results of Prospective Randomized Trials

1440 – 1500
3/5

Alexander Haug (Austria)
Radioembolization of Liver Metastases from NET, CCC and Melanoma

1500 – 1520
4/5

Cathy Cutler (USA)
The Department of Energy has been a Key Player in Nuclear Medicine and its Tri-Lab Efforts are now to Produce ²²⁵Ac

1530 – 1600

COFFEE & TEA BREAK

1600 – 1700

**SCIENTIFIC SESSION 6: FUTURE ASPECTS OF COLLABORATION OF
WARMTH WITH OTHER ORGANISATIONS/SOCIETIES – ROUND
TABLE DISCUSSION (MODERATOR: IRENE VIRGOLINI, INNSBRUCK,
AUSTRIA)**

1700 – 1800

WARMTH MEMBERS ASSEMBLY

1800 – 1830

CLOSING CEREMONY


Concluding Remarks
Presentation of ICRT 2018, Melbourne, Australia
Presentation of ISRT 2018, Helsinki, Finland
Presentation of ICRT 2019, Nanjing, China
Presentation of Life Achievement Award

Irene Virgolini
Sze Ting Lee
Kalevi Kairemo
Feng Wang

END OF DAY 2

















13th ICRT-2018, Melbourne, Australia





Friday 20 April		WARMTH ICRT	Room 220	
0900 - 1030	Pre-congress Plenary	Asian Nuclear Medicine Academic Forum (ANMAF) Opening Ceremony ANMAF Highlight Country – Prof Raihan Hussain Opening Keynote Lecture - Prof Andrew Scott		
1030 - 1100	Morning Tea - Foyer			
1100 - 1115	ICRT Opening Ceremony	Chairs: Prof Irene Virgolini & Prof Harvey Turner		
		Prof Irene Virgolini & Past Presidents of WARMTH		
1115 - 1230	ICRT Session 1: Theranostic Nuclear Oncology Colloquium	Complementary roles of medical oncologist and nuclear physician in clinical practice of theranostic nuclear oncology: engagement and collaboration. Prof J Harvey Turner (AUS) Prof Eva Segalov (AUS) Prof Richard P Baum (DEU) Prof Katherine Vallis (GBR) A/Prof Nat P Lenzo (AUS) Prof Francesco Giammarile (AUT)		
1230 - 1330	LUNCH – Foyer			
1330 - 1500	ICRT Session 2: Prostate Cancer Theranostics	Chairs: Prof Richard Baum & Prof Hans-Jürgen Wester		
		Introduction and current state of Theranostics of prostate cancer	Prof Richard Baum (DEU)	10 minutes
		Radiohybrids, an innovative and valuable new tracer concepts exemplified on PSMA inhibitors	Prof Hans-Jürgen Wester (DEU)	20 minutes
		Meeting the Challenges of Randomised Multi-Centre Clinical Trials: Experience from PSMA Imaging & Theranostics in Australia	Prof Michael Hofman (AUS)	20 minutes
		Ac-225 PSMA and survival in advanced prostate cancer	Prof Mike Sathekge (ZAR)	20 minutes
		New radioisotopes for Theranostics of prostate cancer	Dr Aviral Singh (DEU)	20 minutes
1500 - 1530	Afternoon Tea – Foyer			
1530 - 1630	ICRT Session 3: Liver- Directed Therapy	Chairs: Dr Butch Magsombol & Dr Ajit Shinto		
		¹⁸⁸ Re-Lipiodol as a cost effective, safe and efficacious treatment for inoperable HCC: 5 years’ experience	Dr Ajit Shinto (IND)	25 minutes
		Intra-arterial PRRT of neuroendocrine liver metastases (NELM): experience in over 50 patients and long term follow-up	Dr Aviral Singh (DEU)	25 minutes



1630 - 1730	WARMTH Member Assembly - Room 220
1800 - 1900	12 th Congress of the WFNMB Opening Ceremony – Plenary Hall 2
1900 - 2100	WFNMB 2018 Welcome Reception & Cocktail – MCEC Exhibition Hall













14th ICRT-2019 Nanjing, China

Congress-President: Feng Wang



Congress Venue ICRT- 2019 Nanjing





LETTER OF INVITATION

Dear Colleague,

On behalf of the ICRT Organizing Committee and the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH), it is with great pleasure that we sincerely invite you to attend the 14th International Conference on Radiopharmaceutical Therapy (ICRT), to be held in Nanjing from 21st August to 24th August, 2019.

In the last few decades, Nuclear Medicine has made significant changes and progress and attracted great interests in novel radiopharmaceutical therapy and its clinical translation. ICRT is one of the major scientific events organized in the field of radiopharmaceutical therapy and has turned into a prestigious annual global conference.

The ICRT 2019 will continue to provide an international platform for thought-provoking communication and information-sharing in novel and advanced radiopharmaceutical and molecular therapy, as well as promoting its clinical translation. The social programs of the ICRT 2019 will also provide many events for participants to experience the deep culture of China in Nanjing which is recognized as one of the Four Great Ancient Capitals of China.

We sincerely invite you to join us to make this congress remarkable and contribute to the continuous success of WARMTH which aims to provide the best treatment and care for our patients.

To ensure that you receive regular updates please refer to the ICRT 2019 conference website (www.theragnostics-nj.com) as further details regarding the Conference are announced.

We look forward to welcoming you in Nanjing in August 2019.

Warmest Regards,

Prof. Irene Virgolini
President, WARMTH
Director, Department of Nuclear Medicine
Medical University of Innsbruck
Innsbruck, Austria



Prof. Feng Wang
President, ICRT 2019
Director, Department of Nuclear Medicine
Nanjing Medical University
Nanjing, China





SCHEDULE OF ICRT 2019 PROGRAMME

August 21 st (Wednesday)	Hotel Lobby (1 st Floor)	Room 723 (7 th Floor)	
08:00-17:00	Registration		
17:30-18:30		The WARMTH EB and GB Meeting	
18:30-21:00		Welcome Reception (Baihua Hall)	
August 22 nd (Thursday)	Nanjing Hall (5 th Floor)	Zhonghua Hall A (5 th Floor)	Room 736 (7 th Floor)
08:30-09:30	Opening Ceremony (Nanjing Hall)		
09:30-10:00	Small Concert (outside Nanjing Hall)		
10:00-10:20	Coffee & Tea Break		
10:20-12:00	Session 1: Theragnostics in Neuroendocrine Tumors	Session 2: Summit and Workshop on Biomarker and Nuclear Medicine	Session 3: Cardiovascular and Cerebrovascular Diseases
12:00-12:20			
12:30-13:40	Session 4: The state-of-the-art Targeted Radiotherapy in Asia / Lunch	Lunch	
14:00-16:00	Session 5: Prostate Cancer	Session 6: Seminar on the Clinical Management of NET	Session 7: Workshop on Nuclear Medicine QC and Clinical Nursing
16:00-16:20	Coffee & Tea Break		
16:20-17:40	Session 8: Thyroid Cancer	Session 6: Seminar on the Clinical Management of NET	
17:40-18:00			
18:00-20:00	Dinner		
August 23 rd (Friday)	Nanjing Hall (5 th Floor)	Zhonghua Hall A (5 th Floor)	Room 736 (7 th Floor)
08:00-10:00	Session 9: New Generation of Theragnostics	Session 10: Seminar on Digital PET/CT and PET/MRI/Global Summit of United Imaging	
10:00-10:20	Coffee & Tea Break		
10:20-11:40	Session 11: Hepatic Cellular Carcinoma Intervention	Session 10: Seminar on Digital PET/CT and PET/MRI/Global Summit of United Imaging	
11:40-11:50			
12:30-13:30	Session 12: The Impact of PSMA Based Theragnostics (Clinical Perspective)/Lunch	Lunch	
13:30-13:40			
14:00-14:30	Session 13: Molecular Probe and Transfections	Session 14: Seminar on Prostate cancer	Session 15: Young Investigator Award on Theragnostics
14:30-15:40			
15:40-16:00	Coffee & Tea Break		
16:00-16:40	Session 16: PSMA Probe and beyond PSMA	Session 14: Seminar on Prostate cancer	Session 15: Young Investigator Award on Theragnostics
16:40-17:20			
17:40-18:00			
18:00-22:00	Closing Ceremony & Gala Dinner (Baihua Hall)		
August 24 th (Saturday)	Room 723 (7 th Floor)	Room 736 (7 th Floor)	Conference room 3, Building 2, Nanjing First Hospital (9 th Floor)
08:30-09:00		Session 17: Workshop on Medical Residency Training	Session 19: The 7 th Training Course for Preparation and Quality Control of Radiopharmaceuticals
09:00-10:00	WARMTH Member Assembly Meeting		
10:00-10:10			
10:10-10:30		Coffee & Tea Break	
10:30-12:15	Lunch for Social and Cultural Communication	Session 18: Integration of Nuclear Medicine in the Yangtze River Delta	Session 19: The 7 th Training Course for Preparation and Quality Control of Radiopharmaceuticals
12:15-12:30			
12:30-14:00		Lunch	
14:00-18:00	Social and Cultural Communication	Session 20: Seminar on Nuclear Medicine Image Interpretation, The 37 th Image Interpretation in Jiangsu	



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

14th INTERNATIONAL CONFERENCE ON RADIOPHARMACEUTICAL THERAPY
& 19th NUCLEAR MEDICINE ACADEMIC CONFERENCE OF ANGIO-MEDICAL ASSOCIATION
第14届核医学学术大会暨19届核医学学术大会



Day 1: Wednesday, August 21st, 2019

DAILY PROGRAMME

Time	Event	Location
08:00–17:00	Registration	Hotel Lobby (1 st Floor)
17:30–18:30	The WARMTH EB and GB Meeting	Room 723 (7 th Floor)
18:30–21:00	Welcome Reception	Baihua Hall (2 nd Floor)

Day 2: Thursday, August 22nd, 2019

Location: Nanjing Hall (5th Floor)

Time	Speaker	Lecture Title
Opening Ceremony		
08:30–08:40		Opening Remarks
08:40–08:43	Irene Virgolini	Welcome Speech
08:43–08:46		WARMTH Candle Lighting Ceremony
08:46–09:06		WARMTH Lifetime Achievement Award to Professor Xiujie Liu
09:06–09:09	Mathew L. Thakur	Ajit Padhy Oration
09:09–09:12	Yingdong Zhang	Welcome Speech
09:12–09:15	Zhifang Chai	Welcome Speech
09:15–09:18	Amirreza Jalilian	Welcome Speech
09:18–09:21	Yaming Li	Welcome Speech
09:21–09:24	Gang Huang	Welcome Speech
09:24–09:27	Yonghong Wang	Welcome Speech
09:27–09:30		Launching Ceremony
09:30–10:00		Small Concert
10:00–10:20		Coffee & Tea Break

Session 1: Theragnostics in Neuroendocrine Tumors

Chairman: Irene Virgolini, Sean Yan, Yaming Li

Time	Speaker	Lecture Title
10:20–10:40	Irene Virgolini	PRRT overview: The status and the state-of-the-art
10:40–11:00	Margarida Rodrigues	Multicenter retrospective analysis of Ga-68-DOTA-TOC/TATE and F-18-FDG-PET/CT in neuroendocrine tumor patients re-treated with peptide receptor radionuclide therapy
11:00–11:20	Yaming Li	Impact of 18F-FDG PET/CT imaging on treatment of cancer
11:20–11:40	Hong Zhao	Surgical treatment strategy for MEN with liver metastasis
11:40–12:00	Jingjing Zhang	Peptide Receptor Radionuclide Therapy (PRRT) in Grade 3 (G3) Neuroendocrine Neoplasms (NEN): A Single Centre Experience
12:00–12:20	Duanmin Hu	The role of endoscopic ultrasound in pancreatic neuroendocrine tumors
12:30–13:30		Lunch

06/07



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

14th INTERNATIONAL CONFERENCE ON RADIOPHARMACEUTICAL THERAPY
A 14th NUCLEAR MEDICINE ACADEMIC CONFERENCE OF JANGSU MEDICAL ASSOCIATION
第14届核医学学术大会暨江苏省医学会核医学分会学术大会



Session 4: The State-of-the-art Targeted Radiotherapy In Asia

Chairman: Seigo Kinuya, Lin Li

Time	Speaker	Lecture Title
12:30–12:45	Partha Choudhary	The Theragnostics in India
12:45–13:00	Seigo Kinuya	Theranostics in Japan
13:00–13:15	Sean Yan	PRRT-main stream practice and experience in an Asian centre
13:15–13:30	Lin Li	Brief introduction: current status of nuclear medicine in China
13:30–13:40	Hongyong Cao	Satellite Meeting (Perioperative nutrition support in patients with gastric cancer)

Session 5: Prostate Cancer

Chairman: J Harvey Turner, Richard P. Baum

Time	Speaker	Lecture Title
14:00–14:20	Jing Wang	The clinic application of the 68Ga-PSMA PET imaging
14:20–14:40	J Harvey Turner	Theranostic outcomes in clinical oncology practice
14:40–15:00	Hojjat Ahmadzadehfar	617-Trial: retrospective multicentre analysis of castration refractory metastatic prostate cancer patients treated by 177Lu-PSMA-617
15:00–15:20	Masha Maharaj	A diagnostic and therapeutic approach to a patient with prostate cancer with special emphasis on radionuclide methods
15:20–15:40	Winnie Wing Chuen Lam	PSMA-based thera(g)nostics in prostate cancer, initial experience in Asian patients
15:40–16:00	Ali Cahid Civelek	Will PET-MRI take the place of PET/CT in prostate cancer
16:00–16:20		Coffee & Tea Break

Session 8: Thyroid Cancer

Chairman: Yansong Lin, Shuren Li

Time	Speaker	Lecture Title
16:20–16:40	Michael Kreissl	Radiiodine refractory differentiated thyroid cancer – Is there still an indication for radionuclide therapy?
16:40–17:00	Yansong Lin	Management of radioactive iodine refractory thyroid cancer
17:00–17:20	Libo Chen	Challenges and strategies on 131I treatment for differentiated thyroid carcinoma
17:20–17:40	Barbara Hertz	Dr Saul Hertz discovers the medical uses of radioiodine: challenges and legacy
17:40–18:00	Gang Qiu	Lung metastasis of thyroid cancer
18:00–20:00		Dinner



14th INTERNATIONAL CONFERENCE ON RADIOPHARMACEUTICAL THERAPY
 & 18th NUCLEAR MEDICINE ACADEMIC CONFERENCE OF JAPANESE MEDICAL ASSOCIATION
 第十四届国际核医学学术会议暨第18届日本医学协会核医学会议



Location: Zhonghua Hall A (5th Floor)

Session 2: Summit and Workshop on Biomarker and Nuclear Medicine

Chairman: Yinglu Guo, Shukui Wang

Time	Speaker	Lecture Title
10:20-10:40	Amirreza Jalilian	The role of IAEA in supporting member states on radiopharmaceutical sciences
10:40-11:00	Xiaoyuan Chen	Evans blue modified radionuclide therapeutics
11:00-11:20	Jinliang Xing	Mitochondrial DNA mutation: transformation of a novel tumor biomarker (线粒体DNA突变: 一种新型肿瘤标志物的转化研究)
11:20-11:40	Baixuan Xu	Translational researches on the targeted puncture of prostate cancer guided by 18F-PSMA PET/MR (18F-PSMA PET/MR引导下靶向穿刺前列腺癌的转化研究)
11:40-12:00	Shukui Wang	Screening, identification and application of novel tumor markers (新型肿瘤标志物的筛选鉴定及应用进展)
12:30-13:30		Lunch



08/09



14th INTERNATIONAL CONFERENCE ON RADIOPHARMACEUTICAL THERAPY
 & 10th NUCLEAR MEDICINE ACADEMIC CONFERENCE OF JIANGSU MEDICAL ASSOCIATION
 第十四届国际核医学学术会议暨江苏省医学会核医学分会第十次学术年会



Session 6: Seminar on the Clinical Management of NET

Chairman: Zhenyu Zhang, Yuhong Zhou

Time	Speaker	Lecture Title
14:00–14:20	Yuan Ji	Pathological progression of neuroendocrine neoplasms (神经内分泌肿瘤病理进展)
14:20–14:40	Weijia Fang	Research progress of neuroendocrine tumor in China (神经内分泌肿瘤中国学者研究进展)
14:40–15:00	Liming Jiang	2019 ENETS: Focus on imaging (2019 ENETS:聚焦影像学)
15:00–15:20	Junli Wu	Precision surgical treatment of pancreatic neuroendocrine neoplasms (胰腺神经内分泌肿瘤的精准外科治疗)
15:20–15:40	Yuhong Zhou	Advances in drug therapy for neuroendocrine tumors (神经内分泌肿瘤药物治疗进展)
15:40–16:00	Qiyun Tang	The role of endoscopic images in neuroendocrine neoplasms (内镜影像在神经内分泌肿瘤中的作用)
16:00–16:20		Coffee & Tea Break
16:20–16:40	Jingjing Zhang	20 years of PRRT experience (>6000 cycles) of a single center (Zentralklinik Bad Berka) – long-term outcome (Zentralklinik Bad Berka单中心PRRT治疗20年经验(>6000 cycles)-基于长期随访结果)
16:40–17:10	Wenbin Xu	Case discussion
17:10–17:40	Wenjia Liu	Case discussion
18:00–20:00		Dinner





WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

14th INTERNATIONAL CONFERENCE ON RADIOPHARMACEUTICAL THERAPY
& 18th NUCLEAR MEDICINE ACADEMIC CONFERENCE OF ANHUI MEDICAL ASSOCIATION
暨安徽省医学会第十五次核医学学术年会



Location: Room 736 (7th Floor)

Continuing Education:

Session 3: Cardiovascular and Cerebrovascular Diseases

Chairman: Yuetao Wang, Yihui Guan

Time	Speaker	Lecture Title
10:20–10:40	Dong Soo Lee	Brain theranostics
10:40–11:00	Yihui Guan	Advance of molecular imaging techniques in central nervous system
11:00–11:20	Yuetao Wang	Interpretation of 2018 CSNM/CSC guidelines for the clinical use of cardiac radionuclide imaging
11:20–11:40	Lei Wang	Value of right heart imaging in pulmonary hypertension
11:40–12:00	Bailing Hsu	The recent advance of myocardial imaging quantitation in nuclear cardiology
12:00–12:20	Xiaoqi Ding	A developing technique for advanced analysis of cerebral metabolism: Whole-brain 1H – magnetic resonance spectroscopic imaging

Session 7: Workshop on Nuclear Medicine QC and Clinical Nursing

Chairman: Shuguang Chen, Kaixiu Zhang

Time	Speaker	Lecture Title
14:00–14:15	Tay Young Soon	Current approaches in dosimetry method and treatment delivery for Neuroendocrine patients receiving radionuclide receptor therapy
14:15–14:30	Laurentia Arlany	radiation safety practices in radionuclide therapy
14:30–14:45	Josh Mailman	Theranostics in multidisciplinary care of oncology patients
14:45–15:00	Jingchen Jiang	Analysis of factors influencing myocardial metabolism imaging quality and countermeasures
15:00–15:15	Ning Li	¹³¹ I-labeled BSA–CuS nanoparticles for radiotherapy and photothermal therapy to anaplastic thyroid carcinoma
15:15–15:30	Dongdong Huang	Effect of tube voltage and current on quantitative calculation of PET
15:30–15:45	Wenrui Wang	SPECT quantitative analysis of coronary physiology: comparison with PET and application of SPECT in coronary microvascular dysfunction
15:45–16:00	Hong Qu	To observe angiogenesis of rheumatoid arthritis and antagonist angiogenesis treatment by ^{99m} Tc–3PRGD2 imaging

10/11



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

14th INTERNATIONAL CONFERENCE ON RADIOPHARMACEUTICAL THERAPY
A 19th NUCLEAR MEDICINE ACADEMIC CONFERENCE OF JAPANESE MEDICAL ASSOCIATION
第14回国際放射製剤療法学大会・第19回日本医学放射線学大会



Day 3: Friday, August 23rd, 2019

Location: Nanjing Hall (5th Floor)

Session 9: New Generation of Theragnostics

Chairman: Jun Hatazawa, Mingrong Zhang

Time	Speaker	Lecture Title
08:00–08:15	Richard P. Baum	Two decades of theranostics – looking back and moving forward
08:15–08:30	Jun Hatazawa	Possibility of Astatine-211 alpha particle therapy for intractable cancers combined with boron neutron capture therapy
08:30–08:45	Mingrong Zhang	211–At-labeled radiotracers: synthesis and preclinical evaluation
08:45–09:00	Ajit S. Shinto	Radioimmuno scintigraphy– biodistribution, pharmacokinetics and dosimetry in patients
09:00–09:15	Kalevi Kairemo	Phase I trial of Ra-223 and new NAFCIST response criteria in metastatic osteosarcoma
09:15–09:30	Knut Liepe	Radiosynovectomy in treatment of arthritis new guidelines for Radium-223
09:30–09:45	Kuangyu Shi	The potential of artificial intelligence in dosimetry-guided treatment
09:45–10:00	Xiaoqing Song	CIRC tumor theranostics and products
10:00–10:20		Coffee & Tea Break

Session 11: Hepatic Cellular Carcinoma Intervention

Chairman: David Ng, Sze Ting Lee

Time	Speaker	Lecture Title
10:20–10:40	Ajit S. Shinto	Rhenium project on liver cancer
10:40–11:00	David Chee Eng Ng	Y90 PET in SIRT
11:00–11:20	Sze Ting Lee	Molecular imaging of hypoxia in malignant diseases
11:20–11:40		Discussion
11:40–11:50	Peter Leitner	Satellite Meeting (Theranostics in a cyclotron radiopharmacy)
12:30–13:30		Lunch

Session 12: The Impact of PSMA Based Theragnostics (Clinical Perspective)

Chairman: Winnie Wing Chuen Lam, Bin Zhang

Time	Speaker	Lecture Title
12:30–12:45	Hongqian Guo	Perspective of urologist: Nanjing Drum Tower Hospital experience
12:45–13:00	Ruipeng Jia	Perspective of urologist: Nanjing First Hospital experience
13:00–13:15	Haiying Dong	Perspective of oncologist: Zhejiang Provincial People's Hospital
13:15–13:30	Beihe Wang	Introducing PSMA into multimodality management of prostate cancer in Fudan University Shanghai Cancer Center
13:30–13:40	Alexander Pironi	Satellite Meeting (ITM Isotopen Technologien M ü nchen AG)



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

14th INTERNATIONAL CONFERENCE ON RADIOPHARMACEUTICAL THERAPY
& 15th NUCLEAR MEDICINE ACADEMIC CONFERENCE OF JAHOSHI MEDICAL ASSOCIATION
第14届核医学学术大会 & 第15届核医学学术大会



Session 13: Molecular Probe and Translations

Chairman: Xiaohua Zhu, Min Yang

Time	Speaker	Lecture Title
14:00~14:20	Shuren Li	Molecular imaging of tumor angiogenesis by using radionuclides: the past, present and future
14:20~14:40	Andreas Tuerler	²²⁵ Ac and how to produce it
14:40~15:00	Min Yang	Brief Introduction of GLP-1 derivatives and application
15:00~15:20	Yang Chang Tong	⁹⁰ Y-nanoparticle for liver tumor
15:20~15:40	Xiaohua Zhu	Tumor immune microenvironment and FDG uptake
15:40~16:00		Coffee & Tea Break

Session 16: PSMA Probe and beyond PSMA

Chairman: Shaoli Song, Ling Qiu

Time	Speaker	Lecture Title
16:00~16:20	Shankar Vallhabjoshula	PSMA targeted radionuclide therapy with antibodies and peptides: the past and the future
16:20~16:40	Jolanta Kunikowska	PSMA beyond prostate cancer
16:40~17:00	Xiang Li	Prostate membrane antigen (PSMA) biomarker for prostate cancer imaging and beyond
17:00~17:20		Discussion

Location: Zhonghua Hall A (5th Floor)

Session 10: Seminar on Digital PET/CT and PET/MRI/Global Summit of United Imaging

Chairman: Xu Huang

Time	Speaker	Lecture Title
08:00~09:00		Welcome ceremony
09:00~09:30	Dian Xiong	United imaging healthcare digital PET-CT introduction
09:30~10:00	Feng Wang	uMI 780/uPMR 790 user experience
10:00~10:20		Coffee & Tea Break
10:20~10:50	Yingwen Wei	uPMR 790/uEXPLORER introduction
10:50~11:20	Chenwei Li	uMI clinical application
11:20~11:40	Hongdi Li	Summary
12:30~13:30		Lunch

12/13



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

14th INTERNATIONAL CONFERENCE ON RADIOPHARMACEUTICAL THERAPY
& 15th NUCLEAR MEDICINE ACADEMIC CONFERENCE OF ANHUI MEDICAL ASSOCIATION
第十四届国际核医学学术会议暨安徽省核医学学术会议



Session 14: Seminar on Prostate Cancer

Chairman: Zengjun Wang

Time	Speaker	Lecture Title
13:30–13:50		Satellite Meeting
14:00–14:20	Zengjun Wang/ Ruipeng Jia/ Feng Wang	Welcome speech
14:20–14:40	Marcus Hacker	Artificial intelligence in prostate cancer diagnostics (人工智能在前列腺癌诊断中的应用)
14:40–15:00	Haiying Dong	Application of chemotherapy in prostate cancer (化疗在前列腺癌中的应用)
15:00–15:20	Xuefeng Qiu	Postoperative pathologic changes of prostate cancer after neoad- juvant therapy (新辅助治疗对于前列腺癌术后病理变化的报告)
15:20–15:40	Lixin Hua	Mechanism and benefit of novel first-line endocrine therapy in patients with high-risk mHSPC (新型一线内分泌治疗方案治疗高危mHSPC患者的机制与获益)
15:40–16:00		Coffee & Tea Break
16:00–16:20	Yao Zhu	Iceberg or lighthouse: critical evaluation of PSMA imaging in prostate cancer (冰山或灯塔:PSMA成像在前列腺癌中的重要评估)
16:20–16:40	Ruipeng Jia	Application of PSMA in prostate cancer (PSMA在前列腺癌中的应用)
16:40–17:00		Discussion
17:00–17:20	Gong Cheng	MDT 1
17:20–17:40	Luwei Xu	MDT 2
17:40–18:00		Discussion and Summary



WARMTH
WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY
FOUNDED 2009

14th INTERNATIONAL CONFERENCE ON RADIOPHARMACEUTICAL THERAPY
& 19th NUCLEAR MEDICINE ACADEMY CONFERENCE OF JAPANESE MEDICAL ASSOCIATION
第14回核医学アカデミー国際会議と第19回日本医学放射線学会大会



Location: Room 736 (7th Floor)

Session 15: Young Investigator Award on Theragnostics

Chairman: Chunjing Yu, Cunzhi Lu

Time	Speaker	Lecture Title
14:30–14:40	Aviral Singh	First-in-human molecular imaging using Ga-68 labeled novel somatostatin receptor antagonist NODAGA-LM3 in paraganglioma patients
14:40–14:50	Chongyang Ding	The roles of positron emission tomography/computed tomography in predicting the prognosis of chimeric antigen receptor T cell therapy treated patients with diffuse large B cell lymphoma
14:50–15:00	Christiane Schuchardt	Peptide receptor radionuclide therapy using SSSTR-Antagonists: Biodistribution and dosimetry of Lu-177 DOTA-LM3 compared to Lu-177 DOTATOC
15:00–15:10	Gerardo dos Santos	18FAIF-PSMA-11 as a novel tracer for theragnostic and initial staging of high risk prostate cancer patients
15:10–15:20	Gianpaolo Di Santo	Preliminary clinical experience with three novel peptide based radiotracers: 68Ga-NeoBOMB1, 68Ga-NODAGA-RGD and 111In-CP04
15:20–15:30	Leszek Krollicki	Targeted alpha therapy of recurrent glioma tumors : clinical experience with 225Ac-Substance-P
15:30–15:40	Rakhee Vatsa	Radiolabeled RGD, an important theranostic ligand for targeting angiogenesis: Bench to bedside
15:40–16:00		Coffee & Tea Break
16:00–16:10	Sonya Sergieva	SPECT-CT with new 99mTc-PSMA-T4 tracer in patients with recurrent prostate cancer
16:10–16:20	Yeye Zhou	Prognostic value of baseline 18F-FDG PET/CT metabolic parameters in pediatric lymphoma
16:20–16:30	Yousef Fazaell	Radachlorin-Gallium-68 labeled pharmaceutical: a new theranostic agent for the integration of photodynamic therapy and nuclear imaging
16:30–16:40	Yu Zhang	Studies on upstream transcriptional regulators of EGFR during spinal cord development

18:00–22:00 Closing Ceremony & Gala Dinner

Location: Baihua Hall (2nd Floor)

14/15

Day 4: Saturday, August 24th, 2019

Location: Room 723 (7th Floor)


09:00–10:00 WARMTH Member Assembly Meeting

Location: Room 736 (7th Floor)

Session 17: Workshop on Medical Residency Training

Chairman: A Cahid. Civelek, Jun Tang

Time	Speaker	Lecture Title
08:30–08:50	Hebei Li	The standardized training of residents of nuclear medicine in China: what we are doing (中国核医学住院医师规范化培训:我们正在做什么)
08:50–09:10	Gengbiao Yuan	Standardized training and personal growth in nuclear medicine (核医学规培教育与个人成长)
09:10–09:30	Xiaofeng Li	Experience of standardized training for resident physicians in the United States (美国住院医师规范化培训的一点儿体会)
09:30–09:50	Yi Xu	Daily work of standardized training for resident doctors in radiology department (放射科住培生的一天)
09:50–10:10	Jun Tang	The current situation of Chinese standardized training of residents of NM and our counter measure (中国核医学住院医师规范化培训的现状和对策)
10:10–10:30		Coffee & Tea Break



14th INTERNATIONAL CONFERENCE ON RADIOPHARMACEUTICAL THERAPY
A 16th NUCLEAR MEDICINE ACADEMIC CONFERENCE OF JIANGSU MEDICAL ASSOCIATION
第14届国际核医学学术会议暨江苏省核医学学术年会



Session 18: Integration of Nuclear Medicine in the Yangtze River Delta

Chairman: Hui Wang, Shibiao Sang

Time	Speaker	Lecture Title
10:30~10:45	Hui Wang	Study on the clinical transformation of F18-PSMA (F18-PSMA的临床转化研究)
10:45~11:00	Huiqin Xu	Basic study and clinical transformation of 18f-fmiso PET/CT to evaluate the sodium glycididazole radiotherapy sensitization (18F-FMISO PET/CT评估甘氨酸双唑钠放疗增敏作用的基础研究及临 床转化)
11:00~11:15	Changjing Zuo	18F-FDG PET/CT and comprehensive imaging diagnosis of biliary tumor (胆系肿瘤18F-FDG PET/CT及综合影像诊断)
11:15~11:30	Minghua Du	Opportunities and challenges of nuclear medicine in jiangsu province (江苏核医学的机遇和挑战)
11:30~11:45	Hong Zhu	Quality control of PET/CT imaging (PET/CT成像质量控制)
11:45~12:00	Zhongke Huang	Reflect and experience of multidisciplinary cooperation in thyroid cancer (甲状腺癌多学科协作的思考与体会)
12:00~12:15	Hongyu Li	The current status of theranostic radiopharmaceuticals in China (中国诊疗一体化的放射性药物现状)
12:30~13:30		Lunch



Location: Conference Room 3, Building 2, Nanjing First Hospital

Session 19: The 7th Training Course for Preparation and Quality Control of Radiopharmaceuticals ---68Ga/177Lu Radiolabeling and Clinical Translation

Time	Speaker	Lecture Title
8:30-8:45	Donghui Pan	Elution technology of 68Ga/68Ga generator and its application in PET Imaging(锗镓发生器的淋洗工艺及在PET成像中的应用)
8:45-09:00	Wenyu Wu	Labelling principle and progress in the application of 177Lu radiopharmaceuticals(177Lu放射性药物标记原理及应用进展)
09:00-09:15	Shuangyu Li	Integrated solution for tumor diagnosis and treatment---modular labeling of 68Ga and 177Lu radiopharmaceuticals (肿瘤诊疗一体化解决方案---68Ga、177Lu放射性药物的模块化标记)
09:15-09:30	Coffee & Tea Break	
09:30-09:45	Pengjun Zhang	Ethical declaration process for clinical research of radiopharmaceuticals (放射性药物的临床研究伦理申报流程)
09:45-10:00	Shuyue Ai	Interpretation of clinical cases of 68Ga radiopharmaceutical with PET/CT and PET/MR (68Ga放射性药物PET/CT、PET/MR的临床病例解读)
10:00-10:15	Jieping Song	Image evaluation and efficacy prediction of PRRT with 177Lu-DO-TA-TATE treatment (177Lu-DOTA-TATE PRRT治疗的影像评估和疗效预测)
10:15-10:30	Coffee & Tea Break	
10:30-12:30	Fei Yu Pengjun Zhang	Radiolabeling and quality control of 68Ga radiopharmaceuticals (Practice course) 68Ga-DOTA-NOC、68Ga-PSMA-11的标记及质量控制(现场课)
	Wenyu Wu Ting Bu	Radiolabeling and quality control of 177Lu radiopharmaceuticals (Practice course) 177Lu-DOTA-TATE、177Lu-PSMA-I&T的标记及质量控制(现场课)
	Zhenyu Zhao Jieping Song	Visit and study nuclide treatment ward and PET/CT, PET/MR (核素治疗病房以及PET/CT、PET/MR的参观学习)
12:30-13:00	Lunch	

14th INTERNATIONAL CONFERENCE ON RADIOPHARMACEUTICAL THERAPY
& 15th NUCLEAR MEDICINE ACADEMIC CONFERENCE OF JIANGSU MEDICAL ASSOCIATION
江苏省医学会第十五次核医学学术会议



Session 20: Seminar on Nuclear Medicine Image Interpretation,
The 37th Imaging Interpretation in Jiangsu
Chairman: Lijun Tang

Time	Speaker	Lecture Title
14:00–14:25	Jinhua Zhao	The role of lymphoma PET/CT imaging in clinical decision making (淋巴瘤PET/CT显像在临床决策中的作用)
14:25–14:50	Chongyang Ding	Clinical application of 18F–FDG PET/CT in extranodal NK/T cell lymphoma (18F–FDG PET/CT 在结外NK/T细胞淋巴瘤中的临床应用)
14:50–15:15	Li Wang	Progress in the diagnosis and treatment of invasive B cell lymphoma (侵袭性B细胞淋巴瘤诊治进展)
15:15–15:30		Satellite Meeting
15:30–16:40		Image Interpretation I
16:40–16:50		Coffee & Tea Break
16:50–18:00		Image Interpretation II
18:00–22:00		Dinner



18/19



14th International Conference on Radiopharmaceutical Therapy
Nanjing, China, 21-24 AUG 2019

Best poster award

(Judges: Qaisar Hussain Siraj, Margarida Rodrigues, Butch Magsombol, Sonya Sergieva, Yang Chang Tong)

1	Xinyu Wang, Yaoqi Li, Donghui Pan, Junjie Yan, Lizhen Wang, Yuping Xu, and Min Yang Jiangsu Institute of Nuclear Medicine, CN Construction of Novel Ferritin-based Nanodrug and Preliminary Study For Anticancer Therapy
2	Yu Liu, Mingzhu Li, Yuping Xu, Yaoqi Li, Donghui Pan, Lizhen Wang, Junjie Yan, Xinyu Wang, Min Yang* Jiangsu Institute of Nuclear Medicine, CN Preliminary evaluation of GLP-1R PET in the diagnosis and risk stratification of pheochromocytoms
3	Masayuki Hanyu, Lin Xie, Kuan Hu, Zhimin Yang, Yiding Zhang, Hisashi Suzuki and Ming-Rong Zhang National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, JP Radiolabelling and evaluation of isoDGR derivative using radioactive cooper



最佳壁报奖:

Xinyu Wang
Yu Liu
Masayuki Hanyu



14th International Conference on Radiopharmaceutical Therapy
NanJing, China, 21-24 AUG 2019

Best oral award

(Judges: Irene Virgolini, Qaisar Hussain Siraj, Margarida Rodrigues, Butch Magsombol)

1	Rakhee Vatsa
	Post graduate Institute of Medical Education and Research, India
	Radiolabeled RGD, an important theranostic ligand for targeting angiogenesis: Bench to bedside
2	Leszek Krolicki
	Department of Nuclear Medicine, Medical University of Warsaw
	Targeted alpha therapy of recurrent glioma tumors : clinical experience with 225Ac-Substance-P, Poland
3	Christiane Schuchardt
	Theranostics center for molecular radiotherapy and molecular imaging (PET/CT), Germany
	Peptide receptor radionuclide therapy using SSTR-Antagonists: Biodistribution and dosimetry of Lu-177 DOTA-LM3 compared to Lu-177 DOTATOC



最佳汇报奖:

Rakhee
Vatsa
Leszek
Krolicki
Christiane
Schuchardt



Registration



The WARMTH EB and GB Meeting



Welcome Reception



Welcome Reception



Open Ceremony



Open Ceremony



Opening Ceremony



Opening Ceremony




Opening Ceremony




Opening Ceremony




Concert and Participants




Concert and Participants



Lecture




Lecture



Lecture



Certificate of Presentation



Poster Exhibition



Closing Ceremony



Poster Award Presentation



Oral Award Presentation



Recognition Award Presentation



Closing Ceremony



Closing Ceremony



MARMTH Member Assembly Meeting










15th ICRT-2020 Coxbazar, Bangladesh

Congress-President: Raihan Hussain



15th International Conference on Radiopharmaceutical Therapy (ICRT)

19-22 November 2020

Dhaka, Bangladesh

On behalf of ICRT 2020 Secretariat and Society of Nuclear Medicine Bangladesh (SNMB) it is a great pleasure to welcome you to the **15th International Conference on Radiopharmaceutical Therapy (ICRT)** of WARMTH in Dhaka, Bangladesh on 19-22 November, 2020 in conjunction with **25th (Silver Jubilee) National Conference of SNMB**.

This four days conference will bring together the leaders, physicians, scientists, healthcare professionals and others interested in the challenges related to nuclear medicine and molecular imaging. We assure you the highest level of scientific discussions relevant to research and policy making for promotion of radiopharmaceutical therapy.


This will also strengthen the collaboration among colleagues from all over the world, while having great dialogues, experiencing the cultural and culinary heritage in Dhaka as well as post conference sightseeing tours. Additionally you can also have an experience of world's longest sandy beach in Cox's Bazar.

Prof. Dr. Raihan Hussain
President ICRT 2020 & President, SNMB


Congress Secretariat
Room 1003, SNMB Office, NINMAS, BSMMU, Shahbag, Dhaka, Bangladesh
Web: www.snm-bd.org

Call for Abstract : Open - March 2020
Early Bird Registration : Open - March 2020

Prof. Dr. Faria Nasreen
Secretary ICRT 2020 & General Secretary, SNMB





For details, scan this QR code or visit
www.icrt2020.congressia.com



Venue: Intercontinental Dhaka

WELCOME TO THE LAND OF RIVERS & TALES



16th ICRT-2021 South America

Parana, Argentina

Congress President: Mariela Agolti?





17th ICRT-2022 Kyoto, Japan



**13th Congress of the
World Federation of
Nuclear Medicine and Biology**

13th CONGRESS OF
WORLD FEDERATION OF
Nuclear Medicine and Biology 2022 IN JAPAN

The 62nd Annual Scientific Meeting of the Japanese Society of Nuclear Medicine
The 42nd Annual Meeting of the Japanese Society of Nuclear Medicine Technology

Summarize the past half century and
discuss the next half century of WFNMB

September 7-11, 2022 **September 12-13, 2022**

Kyoto International Conference Center (ICC Kyoto) Kanazawa Art Hall

WORLD FEDERATION OF
NUCLEAR MEDICINE AND BIOLOGY




ISRT's and supported Symposia and Congresses of The WARMTH

		LOCATION	CONGRESS PRESIDENT
2008	9 th Asia Oceania Congress of Nuclear Medicine and Biology, October 2008	New Delhi, India	Ajit Padhy
2010	Singapore Radiological Society & College of Radiologists 19 th Scientific Meeting, February 2010	Singapore	Ajit Padhy
2011	Singapore Nuclear Medicine Update, March 2011	Singapore	Ajit Padhy Antony Goh
2011	WARMTH International Workshop on Radionuclide Therapy & Kuwait Society of Nuclear Medicine, March 2011	Kuwait	Abdelhamid Elgazzar Ajit Padhy
2011	1 st World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy (PRRNT), June 2011	Bad Berka, Germany	Richard Baum
2013	National Symposium in Routine Clinical Practice, March 2013	Yangon, Myanmar	Kyin Myint, Ajit Padhy
2013	South Indian Society of Nuclear Medicine	Coimbatore, India	Ajit Padhy
2015	11 th AOCNMB and 54 th Autumn Meeting of the Korean Society of Nuclear Medicine	Jeju Island Korea	Henri Bom
2015	1 st World Rhenium Congress	Coimbatore	Ajit Shinto
2016	Therapy Center of Excellence of the SNMMI	San Diego, USA	Suresh Srivastava
2017	2 nd World Rhenium Congress	Coimbatore, India	Ajit Shinto
2017	Therapy Center of Excellence of the SNMMI	Denver, USA	Suresh Srivastava
2018	Therapy Center of Excellence of the SNMMI	Philadelphia, USA	Dan Pryma
2018	22 nd Annual Scientific Meeting of the Indonesian Society of Nuclear Medicine	Bandung, Indonesia	Ayu Rosemeilia Dewi
2018	ISRT	Helsinki, Finland	Kairemo Kalevi
2019	ISRT + 3 rd Serbian Meeting on Hybrid Imaging and Molecular Therapy	Novi Sad, Serbia	Jasna Mihailovic
2019	20 Years Anniversary of Cyprus SNM	Limassol, Cyprus	Savvas Frangos
2020	ISRT + IPET (IAEA)	Vienna, Austria	Diana Paez Partha Choudhury



2008 New Delhi, India
October 31 – November 4
Asia Oceania Congress of Nuclear Medicine
and Biology







2010, Singapore Update

SINGAPORE RADIOLOGICAL SOCIETY & COLLEGE OF RADIOLOGISTS, SINGAPORE
19TH ANNUAL SCIENTIFIC MEETING

Incorporating
Singapore General Hospital Nuclear Medicine Update 2010
25 – 28 February 2010 • Holiday Inn Atrium, Singapore

Imaging & Therapy in the Era of Molecular Medicine

www.singaporeradiology2010.com

Organised by:

- Singapore Radiological Society
- College of Radiologists, Singapore
- Department of Nuclear Medicine & PET, Singapore General Hospital, SingHealth
- Singapore Society of Radiographers
- PGMI, SCH, PCMI, Postgraduate Medical Institute

In collaboration with:

- World Radiopharmaceutical Therapy Council
- Federation of Nuclear Medicine and Biology



WARMTH

**WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY**

FOUNDED 2009

SINGAPORE RADIOLOGICAL SOCIETY & COLLEGE OF RADIOLOGISTS, SINGAPORE

19TH ANNUAL SCIENTIFIC MEETING INCORPORATING SGH NUCLEAR MEDICINE UPDATE 2010

25–28 February 2010 • Holiday Inn Atrium, Singapore

DAY 1: THURSDAY, 25 FEBRUARY 2010

0830 – 0920	REGISTRATION	Foyer, Level 4
0920 – 0930	WELCOME ADDRESS	Atrium Ballroom, Level 4
0920 – 0925	Welcome Address Prof Ajit Padhy, Organising Chairman, SGH Nuclear Medicine Update 2010	
0925 – 0930	Welcome Address Dr David Ng, Scientific Co-Chairman, SGH Nuclear Medicine Update 2010	
0930 – 1000	PLENARY LECTURE 1 The Road to Molecular Imaging Prof A H Elgazzar, Nuclear Medicine, Kuwait University, Kuwait	Atrium Ballroom, Level 4
1000 – 1030	PLENARY LECTURE 2 The London Polonium Poisoning: Events and Medical Implications Prof Alan Perkins, Medical Physics, University of Nottingham, United Kingdom	Atrium Ballroom, Level 4
1030 – 1100	COFFEE / TEA/ TRADE EXHIBITION / POSTER VIEWING	Changi Room, Level 4
1100 – 1300	SCIENTIFIC SESSION 1: GENERAL NUCLEAR MEDICINE	Atrium Ballroom, Level 4
1100 – 1130	1. An Update on Molybdenum Supplies and Alternatives Prof Alan Perkins, Medical Physics, University of Nottingham, United Kingdom	
1130 – 1200	2. Lymphoscintigraphy Dr Indirani Elangovan, Nuclear Medicine & PET, Apollo Hospital, India	
1200 – 1230	3. Review of PET and Receptor Imaging Prof Adil Al-Nahhas, Nuclear Medicine, Imperial Healthcare Trust, Hammersmith Hospital, United Kingdom	
1230 – 1300	4. Radionuclide Imaging in Paget's Disease of Bone Dr Gopinath Gnanasegaran, Nuclear Medicine, Guys & St Thomas' Hospital NHS Foundation Trust, United Kingdom	
1300 – 1400	LUNCH / TRADE EXHIBITION / POSTER VIEWING	Changi Room, Level 4
1400 – 1600	SCIENTIFIC SESSION 2: NUCLEAR ENDOCRINOLOGY	Atrium Ballroom, Level 4
1400 – 1430	1. Ga-68 Labelled Radiopharmaceuticals for Molecular Imaging of Cancer Using PET / CT – Present State and Future Perspectives Prof Richard Baum, Center for PET/CT, Zentralklinik Bad Berka, Germany	
1430 – 1500	2. Treatment with Y-90 and Lu-177 Labelled Somatostatin Analogs Prof Irene Virgolini, Nuclear Medicine, Medical University of Innsbruck, Austria	
1500 – 1530	3. Gallium-68 vs MIBG in Neural Crest Tumours Prof Adil Al-Nahhas, Nuclear Medicine, Imperial Healthcare Trust, Hammersmith Hospital, United Kingdom	
1530 – 1600	4. Molecular Imaging and Radionuclide Therapy Quiz Dr Gopinath Gnanasegaran, Nuclear Medicine, Guys & St Thomas' Hospital NHS Foundation Trust, United Kingdom	
1600 – 1630	COFFEE / TEA/ TRADE EXHIBITION / POSTER VIEWING	Changi Room, Level 4
1630 – 1740	ORAL PRESENTATIONS: FREE PAPERS & YOUNG INVESTIGATORS AWARD	Atrium Ballroom, Level 4
1900 – 2000	WELCOME COCKTAIL	Open Terrace, Level 4
2000	END OF DAY 1	

Page 1 of 7

Please note that the programme is correct at time of update and is subject to change without prior notice



WARMTH

**WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY**

FOUNDED 2009

SINGAPORE RADIOLOGICAL SOCIETY & COLLEGE OF RADIOLOGISTS, SINGAPORE

19TH ANNUAL SCIENTIFIC MEETING INCORPORATING SGH NUCLEAR MEDICINE UPDATE 2010

25– 28 February 2010 • Holiday Inn Atrium, Singapore

DAY 2: FRIDAY, 26 FEBRUARY 2010

0800 – 0900	REGISTRATION	Foyer, Level 4
0900 – 0930	OPENING ADDRESS	Atrium Ballroom, Level 4
0900 – 0910	Welcome Address Prof Ajit Padhy, Organising Chairman, SRS & CRS 19th ASM	
0910 – 0920	Welcome Address Dr Winston Lim, President, Singapore Radiological Society	
0920 – 0930	Welcome Address Dr Tan Bien Soo, President, College of Radiologists, Singapore	
0930 – 1100	SCIENTIFIC SESSION 3 : BASIC SCIENCES - INSTRUMENTATION & RADIOPHARMACEUTICALS	Atrium Ballroom, Level 4
0930 – 1000	1. Recent Developments in Multi-modality Instrumentation Prof David Townsend, PET & SPECT Imaging Group, Singapore Biomed Imaging Consortium Biomedical Sciences Institutes, Singapore	
1000 – 1030	2. A Review of Small Field of View Gamma Cameras for Intra-Operative Imaging Prof Alan Perkins, Medical Physics, University of Nottingham, United Kingdom	
1030 – 1100	3. International Collaboration Opportunities Towards Quality and Safety in Radiology Dr Lawrence Lau, International Radiology Quality Network, Australia	
1100 – 1130	COFFEE / TEA/ TRADE EXHIBITION / POSTER VIEWING	Changi Room, Level 4
1130 – 1300	SCIENTIFIC SESSION 4 : CURRENT TRENDS IN IMAGE GUIDED THERAPY	Atrium Ballroom, Level 4
1130 – 1200	1. PET/ CT: Radiation Therapy Planning Tool Dr Rathan Subramaniam, Radiology, Neuroradiology & Nuclear Radiology, Boston University, USA	
1200 – 1230	2. Advances in Current Interventional Radiological Procedures Prof Rajan Dheeraj, Medical Imaging, University of Toronto, University Health Network , Canada	
1230 – 1300	3. IGRT in Clinical Practice Prof Bin S. Teh, Radiation Oncology, The Methodist Cancer Center, USA	
1300 – 1400	LUNCH / TRADE EXHIBITION / POSTER VIEWING	Changi Room, Level 4
SCIENTIFIC SESSION 5 & RADIOGRAPHERS' TRACK (CONCURRENT)		
1400 – 1600	SCIENTIFIC SESSION 5 : CURRENT TRENDS IN THE MANAGEMENT OF LUNG CANCER	Atrium Ballroom, Level 4
1400 – 1430	1. Mediastinal Staging with Endobronchial Ultrasound Dr Lee Pyng, Respiratory & Critical Care Medicine, Singapore General Hospital, Singapore	
1430 – 1500	2. PET / CT in Lung Cancer and Oncology Guidelines – Has it Become a Must? Prof Richard Baum, Center for PET/CT, Zentralklinik Bad Berka, Germany	
1500 – 1530	3. Recent Advances in Radiotherapy in Lung Cancer Prof Bin S. Teh, Radiation Oncology, The Methodist Cancer Center, USA	
1530 – 1600	4. Radiofrequency Ablation of Lung Tumours Dr Peter Goh, Radiology, Mount Elizabeth Hospital, Singapore	

Page 2 of 7

Please note that the programme is correct at time of update and is subject to change without prior notice



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

SINGAPORE RADIOLOGICAL SOCIETY & COLLEGE OF RADIOLOGISTS, SINGAPORE

19TH ANNUAL SCIENTIFIC MEETING INCORPORATING SGH NUCLEAR MEDICINE UPDATE 2010

25 – 28 February 2010 • Holiday Inn Atrium, Singapore

DAY 2: FRIDAY, 26 FEBRUARY 2010 (CONT'D)

1400 – 1600	RADIOGRAPHERS' TRACK SESSION 1 : DIAGNOSTIC IMAGING TECHNIQUES	Seletar Room 1 & 2 Level 3
1400 – 1405	Welcome Address Prof Ajit Padhy, Organising Chairman, SRS & CRS 19th ASM	
1405 – 1430	1. Basic Concepts of PET/CT Imaging Dr Butch Magsombol, Nuclear Medicine & PET, Singapore General Hospital, Singapore	
1430 – 1450	2. Current Trends and Future Perspectives in Nuclear Medicine and PET Imaging Mr S Somanesan, Nuclear Medicine & PET, Singapore General Hospital, Singapore	
1450 – 1510	3. Digital Archiving in Nuclear Medicine Mr Ramesh Misra, Medical Informatics, MOH Holdings, Singapore	
1510 – 1530	4. Intra-Arterial CTA using a Hybrid Angiography-CT System Mr Cornelio Gutierrez Padre, Diagnostic Radiology, Singapore General Hospital, Singapore	
1530 – 1545	5. Contrast-Enhanced Ultrasound of Focal Liver Lesions: Correlation with CT, MRI and Histopathological Findings Ms Ooi Chin Chin, Diagnostic Radiology, Singapore General Hospital, Singapore	
1545 – 1600	6. Development of Accredited Data Acquisition Protocols for Personalized Dosimetry in Therapeutic Nuclear Oncology Mr Antonio Lou, Nuclear Medicine, The University of Western Australia, Australia	
1600 – 1620	COFFEE / TEA / TRADE EXHIBITION / POSTER VIEWING	Changi Room, Level 4
SCIENTIFIC SESSION 6 & RADIOGRAPHERS' TRACK (CONCURRENT)		
1620 – 1720	SCIENTIFIC SESSION 6 : HEAD AND NECK MALIGNANCIES	Atrium Ballroom, Level 4
1620 – 1640	1. Diagnostic Imaging in Head and Neck Cancer Dr James Khoo, Oncologic Imaging, National Cancer Centre, Singapore	
1640 – 1700	2. Head & Neck PET/CT: A Metabolic Biomarker for Outcome Dr Rathana Subramaniam, Radiology, Neuroradiology & Nuclear Radiology, Boston University, USA	
1700 – 1720	3. Treatment Perspectives of Radioiodine Negative Thyroid Cancer Prof Irene Virgolini, Nuclear Medicine, Medical University of Innsbruck, Austria	
1620 – 1800	RADIOGRAPHERS' TRACK SESSION 2 : EDUCATION & TRAINING	Seletar Room 1 & 2 Level 3
1620 – 1640	1. Distance Assisted Training (DAT) for Radiographers: An Update Dr Orestes Monzon, Philippine Heart Center, Philippines	
1640 – 1700	2. Using Teaching and Learning to Build an Organisation of Leaders and an Environment of Growth Mr Gary Tan, Diagnostic Radiology, Singapore General Hospital, Singapore	
1700 – 1715	3. Imaging Paradigm: From CT/ MRI to Pet and the Future of Spect in Radiation Oncology Ms Ng Sze Yin, Radiation Oncology, National Cancer Center, Singapore	
1715 – 1730	4. Our Experience and New Technique Using the Robotic Assisted Arm Angiography System in Interventional Radiology Mr Peter Yang, Diagnostic Radiology, Singapore General Hospital, Singapore	
1730 – 1745	5. Diagnosis of Deep Venous Thrombosis as a Cause for Suspected Pulmonary Embolism: Can Indirect CT Venography Replace Lower Extremity Venous Sonography? – Analysis of Current Literature Mr Liang Chongri Jacky, Diagnostic Imaging, National University Healthcare System, Singapore	
1745 – 1800	6. Sonographic Appearances of Benign and Malignant Thyroid Nodules Mr Rafidah Abu Bakar, Diagnostic Radiology, Singapore General Hospital, Singapore	

Page 3 of 7

Please note that the programme is correct at time of update and is subject to change without prior notice



DAY 2: FRIDAY, 26 FEBRUARY 2010 (CONT'D)		
1730 – 1840	ORAL PRESENTATIONS: FREE PAPERS & YOUNG INVESTIGATORS AWARD	Seletar Room 3 Level 3
1800 – 1900	COCKTAIL RECEPTION	Open Terrace, Level 4
1900	WELCOME ADDRESS	Atrium Ballroom, Level 4
1915 – 1945	F Y KHOO LECTURE	Atrium Ballroom, Level 4
SESSION CHAIRPERSONS : PROF AJIT PADHY, NUCLEAR MEDICINE & PET, SINGAPORE GENERAL HOSPITAL, SINGAPORE		
Ectropy And Entropy – How Molecules Talking to Each Other Create The Fascination of Molecular Imaging Prof Richard Baum, Center for PET/CT, Zentralklinik Bad Berka, Germany		
1945	GALA DINNER	Atrium Ballroom, Level 4
2100	END OF DAY 2	





WARMTH

**WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY**

FOUNDED 2009

SINGAPORE RADIOLOGICAL SOCIETY & COLLEGE OF RADIOLOGISTS, SINGAPORE

19TH ANNUAL SCIENTIFIC MEETING INCORPORATING SGH NUCLEAR MEDICINE UPDATE 2010

25– 28 February 2010 • Holiday Inn Atrium, Singapore

DAY 3: SATURDAY, 27 FEBRUARY 2010

0800 – 0830	REGISTRATION	Foyer, Level 4
SCIENTIFIC SESSION 7 & NURSING TRACK (CONCURRENT)		
0830 – 1030	SCIENTIFIC SESSION 7 : HEPATIC MALIGNANCIES	Atrium Ballroom, Level 4
0830 – 0900	1. Overview of Current Clinical Trials In HCC Treatment A/Prof Pierce Chow, General Surgery, Singapore General Hospital, Singapore	
0900 – 0930	2. Imaging of Hepatocellular Carcinoma: An Update Dr Albert Low, Diagnostic Radiology, Singapore General Hospital, Singapore	
0930 – 1000	3. Update on the Use of Y-90 Microspheres in Liver Tumours: Our Experience Prof Adil Al-Nahhas, Nuclear Medicine, Imperial Healthcare Trust, Hammersmith Hospital, United Kingdom	
1000 – 1030	4. Treatment Strategies for HCC: Surgery, RFA vs TACE Prof Rajan Dheeraj, Medical Imaging, University of Toronto, Canada	
0830 – 1030	NURSING TRACK : NURSING CARE MANAGEMENT IN DIAGNOSTIC IMAGING & INTERVENTIONAL RADIOLOGY	Seletar Room 1 & 2 Level 3
0830 – 0900	1a. Overview of Nursing Management of Paediatric Patients Undergoing Radiology Procedures at KKWCH – Part 1 NM Tan Seok Gek, Diagnostic Imaging, KK Women's and Children's Hospital, Singapore	
	1b. Nursing Management of Placenta Accreta Patient at KKWCH – Part 2 SSN Malathy Subramaniam, Diagnostic Imaging, KK Women's and Children's Hospital, Singapore	
0900 – 0930	2. Nursing Management of Patient Going for RadioFrequency Ablation – Pre, During and Post Procedure SN Amy Lim, Diagnostic Radiology, Singapore General Hospital, Singapore	
0930 – 1000	3a. Nursing Management of Post Radiation Iodine Therapy – Part 1 NC Susila Perumal, Medical Oncology, Singapore General Hospital, Singapore	
	3b. Overview of Nuclear Medicine Imaging (MUGA and Bone Scan) – Part 2 NC Susila Perumal, Medical Oncology, Singapore General Hospital, Singapore	
1000 – 1030	4a. Role Expansion of Radiology Nurses NC Grace Choo, Diagnostic Radiology, Singapore General Hospital, Singapore	
	4b. Tube Care – Tan Tock Seng Experience NC June Chow, Diagnostic Imaging, Tan Tock Seng Hospital, Singapore	
1030 – 1100	COFFEE / TEA/ TRADE EXHIBITION / POSTER VIEWING	Changi Room, Level 4
SCIENTIFIC SESSION 8 & NURSING TRACK (CONCURRENT)		
1100 – 1300	SCIENTIFIC SESSION 8 : GASTROINTESTINAL IMAGING	Atrium Ballroom, Level 4
1100 – 1130	1. CT Colonography – Current Status and Future Promises Prof Ho Chia Sing, Medical Imaging, University of Toronto, Canada	
1130 – 1200	2. CT Colonography - Recent Advances and Future Prospects in Japan Dr Gen Iinuma, Diagnostic Radiology Division, National Cancer Center Hospital, Japan	
1200 – 1230	3. Colonography in National University Hospital (NUH), Singapore Dr Bertrand Ang, Diagnostic Imaging, National University Hospital, Singapore	
1230 – 1300	4. PET in Colonic Malignancies Dr Anthony Goh, Nuclear Medicine & PET, Singapore General Hospital, Singapore	

Page 5 of 7

Please note that the programme is correct at time of update and is subject to change without prior notice



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009



DAY 3: SATURDAY, 27 FEBRUARY 2010

1100 – 1300	NURSING TRACK : NURSING CARE MANAGEMENT IN DIAGNOSTIC IMAGING & INTERVENTIONAL RADIOLOGY	Seletar Room 1 & 2 Level 3
1100 – 1130	1. MRI Safety Aspect Mr Tan Tee Meng, Diagnostic Radiology, Singapore General Hospital, Singapore	
1130 – 1200	2. Current Trends in Nursing Management of Patient Undergoing Cardiac Catheterisation NC Wong Wei Yui, Cardiovascular Laboratory, Changi General Hospital, Singapore	
1200 – 1230	3. Mammography Intervention – Nursing Management SEN Zubaidah Manan, Diagnostic Radiology, Singapore General Hospital, Singapore	
1230 – 1300	4. Nursing Assistance in Stereotactic Mamotomy in NCC SSN Melanie Tan, Diagnostic Imaging, National Cancer Centre, Singapore	
1300 – 1400	LUNCH / TRADE EXHIBITION / POSTER VIEWING	Changi Room, Level 4
1400 – 1600	SCIENTIFIC SESSION 9 : BREAST CANCER	Atrium Ballroom, Level 4
1400 – 1430	1. Breast Cancer - A Surgeon's Point of View Dr Tan Yah Yuen, KK Breast Unit, KK Women's and Children's Hospital, Singapore	
1430 – 1500	2. Positron Emission Tomography in the Management of Breast Cancer Dr Sameer Khan, Radiology & PET/CT, Imperial College Healthcare Trust, Hammersmith Hospital, United Kingdom	
1500 – 1530	3. Radiation Therapy of Breast Cancer Dr Wong Fuh Yong, Radiation Oncology, National Cancer Centre, Singapore	
1530 – 1600	4. Provision of a MRI Service to a Busy Clinical Breast Service – Priorities , Technique and Lessons Learned Dr James Anderson, Diagnostic and Interventional Radiology, Division of Imaging Services, Royal Perth Hospital, Australia	
1600 – 1630	COFFEE / TEA/ TRADE EXHIBITION / POSTER VIEWING	Changi Room, Level 4
1630 – 1800	SCIENTIFIC SESSION 10 : LYMPHOMA	Atrium Ballroom, Level 4
1630 – 1700	1. Clinical Aspects of Lymphoma Dr Miriam Tao, Medical Oncology, National Cancer Centre, Singapore	
1700 – 1730	2. PET Staging in Lymphoma Dr Sameer Khan, Radiology & PET/CT, Imperial College Healthcare Trust, Hammersmith Hospital, United Kingdom	
1730 – 1800	3. The Importance of Quantitative Molecular Imaging – From MORE (Molecular Response) to PERCIST (PET Response Criteria in Solid Tumours) Prof Richard Baum, Center for PET/CT, Zentralklinik Bad Berka, Germany	
1800	END OF DAY 3	

Page 6 of 7

Please note that the programme is correct at time of update and is subject to change without prior notice



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009



DAY 4: SUNDAY, 28 FEBRUARY 2010

0800 – 0830	REGISTRATION	Foyer, Level 4
0830 – 1030	SCIENTIFIC SESSION 11 : CARDIAC IMAGING	Atrium Ballroom, Level 4
0830 – 0900	1. Current Technological Status of Cardiac CT and Clinical Implications Dr John Hoe, Medi-Rad Associates Pte Ltd, Singapore	
0900 – 0930	2. New Advances in Nuclear Cardiology Dr Felix Keng, Cardiology, National Heart Centre, Singapore	
0930 – 1000	3. Imaging of Myocardial Ischaemia Prof He Zuo Xiang, Department of Nuclear Medicine, Fu Wai Hospital & Cardiovascular Institute, China	
1000 – 1030	4. Cardiac MRI and its Applications to the Clinician Dr Lynette Teo, Diagnostic Imaging, National University Hospital, Singapore	
1030 – 1100	COFFEE / TEA / TRADE EXHIBITION / POSTER VIEWING	Changi Room, Level 4
1100 - 1300	SCIENTIFIC SESSION 12 : MUSCULOSKELETAL	Atrium Ballroom, Level 4
1100 – 1130	1. Radiosynovectomy in Haemophilias Dr Emerita Barrenechea, Nuclear Medicine and Research, Veterans Memorial Medical Center, Philippines	
1130 – 1200	2. Pathophysiology of Bone Infection and Radionuclide Imaging Prof A H Elgazzar, Nuclear Medicine, Kuwait University, Kuwait	
1200 – 1230	3. Current Status and Future Directions of Musculoskeletal Hybrid Imaging Dr Gopinath Gnanasegaran, Nuclear Medicine, Guys & St Thomas' Hospital NHS Foundation Trust, United Kingdom	
1230 – 1300	4. Orthopaedic Oncology – Postoperative Assessment Dr Kenneth Sheah, Radlink Diagnostic Imaging Pte Ltd, Singapore	
1300 – 1400	CLOSING	Atrium Ballroom, Level 4
1800	END OF DAY 4	



Page 7 of 7

Please note that the programme is correct at time of update and is subject to change without prior notice









2011, Singapore Update



SGH Nuclear Medicine Update 2011

In Collaboration With World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) & Nuclear Medicine Society (Singapore) (NMSS)

2 – 5 March 2011

Deck on 9, Block 6 Level 9, Singapore General Hospital





SGH Nuclear Medicine Update 2011

In Collaboration With World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) & Nuclear Medicine Society (Singapore) (NMSS)

2 – 5 March 2011

Deck on 9, Block 6 Level 9, Singapore General Hospital

DAY 1: WEDNESDAY, 2 MARCH 2011

0800 – 0900	REGISTRATION	
0900 – 0915	INAUGURATION	Deck on 9, B6L9
0915 – 1045	SCIENTIFIC SESSION 1: RADIOPHARMACEUTICALS AND INSTRUMENTATION	Deck on 9, B6L9
	Session Chairperson: 1. Mr S Somanesan, Nuclear Medicine & PET, Singapore General Hospital, Singapore	
0915 – 0945	Current Trends In Hybrid Imaging Prof David Townsend, PET & SPECT Imaging Group, Singapore Bioimaging Consortium Biomedical Sciences Institutes, Singapore	
0945 – 1015	Current Trends In Therapeutic Radiopharmaceuticals Dr Sidney Yu, Nuclear Medicine & PET, Singapore General Hospital, Singapore	
1015 – 1045	Development in Radiopharmaceutical Chemistry: Radioisotopes Beyond Tc-99m, F18 and I-131, Radiopharmaceuticals Beyond Tc-Kits, I-131 and F-18 FDG Dr Maung Maung Saw, Singapore	
1045 – 1115	COFFEE / TEA / TRADE EXHIBITION	
1115 – 1230	SCIENTIFIC SESSION 2: CORRELATIVE IMAGING-GENERAL	Deck on 9, B6L9
	Session Chairperson: 1. Dr Ong Seng Chuan, Nuclear Medicine and PET Centre, Mount Elizabeth Hospital, Singapore	
1115 – 1145	Basic Concepts Of Cross Sectional Anatomy For Nuclear Medicine Physicians Dr James Khoo, Oncologic Imaging, National Cancer Centre, Singapore	
1145 – 1215	Nuclear Medicine Techniques: Are We Following The Principles To Avoid Pitfalls? Prof A H Elgazzar, Faculty of Medicine, Kuwait University, Kuwait	
1215 – 1230	An Overview Of The Singapore National Electronic Health Records Mr Ramesh Misra, Clinical Transformation Services, Information Systems Division, MOH Holdings, Singapore	
1230 – 1300	POSTER VIEWING / JUDGING	Deck on 9, B6L9
1300 – 1400	LUNCH / TRADE EXHIBITION	Deck on 9, B6L9
1400 – 1600	SCIENTIFIC SESSION 3: MUSCULO-SKELETAL SYSTEM	Deck on 9, B6L9
	Session Chairperson: 1. Dr Arvind Sinha, Diagnostic Imaging, National University Hospital, Singapore 2. Prof Bozena Birkenfeld, Nuclear Medicine, Pomeranian Medical University, Poland	
1400 – 1430	Perils & Pitfalls Of Bone Mineral Densitometry Dr Manju Chandran, Endocrinology, Singapore General Hospital, Singapore	
1430 – 1500	Scintigraphically Under-Recognized Bone Diseases Prof A H Elgazzar, Faculty of Medicine, Kuwait University, Kuwait	
1500 – 1530	Role Of Multi-Slice SPECT/CT In Soft-Tissue Pathology And Osseous Impingement Syndromes Dr Gopinath Gnanasegaran, Nuclear Medicine, Guys & St Thomas' Hospital NHS Foundation Trust, United Kingdom	
1530 – 1600	Bone Scintigraphy In Pediatrics: Read With A Colleague Prof A H Elgazzar, Faculty of Medicine, Kuwait University, Kuwait	
1600 – 1615	COFFEE / TEA / TRADE EXHIBITION	Deck on 9, B6L9



SGH Nuclear Medicine Update 2011

In Collaboration With World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) & Nuclear Medicine Society (Singapore) (NMSS)


2 – 5 March 2011

Deck on 9, Block 6 Level 9, Singapore General Hospital

DAY 1: WEDNESDAY, 2 MARCH 2011 (CONT'D)

1615 – 1800	SCIENTIFIC SESSION 4: CLINICAL APPLICATIONS OF SPECT-CT & NM QUIZ	Deck on 9, B6L9
Session Chairpersons: 1. Dr Yong Wei Sean, Surgical Oncology, National Cancer Centre, Singapore 2. Dr Gopinath Gnanasegaran, Nuclear Medicine, Guys & St Thomas' Hospital NHS Foundation Trust, United Kingdom		
1615 – 1645	Improved Detection And Localisation Of Sentinel Nodes By SPECT/CT Dr C Hoefnagel, Diagnostic Oncology, The Netherlands Cancer Institute, The Netherlands	
1645 – 1715	Talk by Siemens Dr Beer, Germany	
1715 – 1800	Quiz: PET/CT – Science & Practice Dr Gopinath Gnanasegaran, Nuclear Medicine, Guys & St Thomas' Hospital NHS Foundation Trust, United Kingdom	
1800	END OF DAY 1	





SGH Nuclear Medicine Update 2011


In Collaboration With World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) & Nuclear Medicine Society (Singapore) (NMSS)

2 – 5 March 2011

Deck on 9, Block 6 Level 9, Singapore General Hospital

DAY 2: THURSDAY, 3 MARCH 2011

0800 – 0830	REGISTRATION	Deck on 9, B6L9
0830 – 0930	SCIENTIFIC SESSION 5: THYROID & NET	Deck on 9, B6L9
Session Chairpersons: 1. Dr Wong Wai Yin, Nuclear Medicine & PET, Singapore General Hospital, Singapore 2. A/Prof Marina Vlakovic, Center of Nuclear Medicine, Clinical Center Nis, Serbia		
0830 – 0850	Somatostatin Analogs In The Diagnosis And Treatment Of Radioiodine Negative Thyroid Cancer Patients. Treatment Perspectives In Somatostatin Receptor Negative Thyroid Carcinoma Prof Irene Virgolini, Nuclear Medicine, Medical University of Innsbruck, Austria	
0850 – 0910	The Role of rhTSH In The Treatment And Follow-Up Of Differentiated Thyroid Cancer A/Prof Knut Lieve, Nuclear Medicine, Klinikum Kassel, Germany	
0920 – 0930	Graves' Ophthalmopathy – A Perspective Dr Emerita Barrenechea, Nuclear Medicine, Veterans Memorial Medical Center, Philippines	
0930 – 1030	ORAL PRESENTATIONS	Deck on 9, B6L9
Session Chairpersons: 1. Dr Saabry Osmany, RadLink Diagnostic Imaging, Singapore 2. Dr Gopinath Gnanasegaran, Nuclear Medicine, Guys & St Thomas' Hospital NHS Foundation Trust, United Kingdom		
0930 – 0940	Significant Impact Of Mid Treatment 18f Fdg Pet-Ct As A Prognostic Indicator In The Management And Follow-Up Of Metastatic Breast Cancer Dr Partha Choudhury, Nuclear Medicine, Rajiv Gandhi Cancer Institute & Research Centre, India	
0940 – 0950	Early Response Assessment In Gastrointestinal Stromal Tumors With FDG PET Scan 24 Hours After A Single Dose Of Imatinib Dr Ajit Shinto, Nuclear Medicine and PET, Amala Institute of Medical Sciences, India	
0950 – 1000	Role Of 18F- FDG PET CECT In Hepatocellular Carcinoma Dr Vineet Pant, Nuclear Medicine and PET CT, Artemis Health Institute, India	
1000 – 1010	The Clinical Role Of 99mtc-EDDA-HYNIC-TOC Scan In Diagnosing And Staging Of Patients With Different Types Of Tumors With Somatostatin Receptor Expression A/Prof Marina Vlakovic, Center of Nuclear Medicine, Clinical Center Nis, Serbia	
1010 – 1020	Assessment Of F18-Fluoride Skeletal Positron Emission Tomography Scan In Detecting Osseous Metastasis: A Philippine Pilot Study In The Background Of Worldwide Technetium Shortage Dr Allan Jay Domingo, Nuclear Medicine and PET, St Lukes Medical Center, Philippines	
1020 – 1030	Myocardial Perfusion Imaging And Calcium Scoring As Coronary Artery Disease Predictors Dr Jamilla Gomez, Nuclear Medicine and PET, St Lukes Medical Center, Philippines	
1030 – 1100	COFFEE / TEA / TRADE EXHIBITION	Deck on 9, B6L9



SGH Nuclear Medicine Update 2011


In Collaboration With World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) & Nuclear Medicine Society (Singapore) (NMSS)

2 – 5 March 2011

Deck on 9, Block 6 Level 9, Singapore General Hospital

DAY 2: THURSDAY, 3 MARCH 2011 (CONT'D)

1100 – 1300	SCIENTIFIC SESSION 6: PET/CT GENERAL	Deck on 9, B6L9
	Session Chairpersons: 1. Dr John Buscombe, Nuclear Medicine, Addenbrooke's Hospital, United Kingdom	
1100 – 1130	PET Imaging In Oncology – Not Only FDG Prof Adil Al-Nahhas, Nuclear Medicine, Imperial College, United Kingdom	
1130 – 1200	Molecular Imaging Of Renal And Prostate Cancer Prof Andrew Scott, The Ludwig Institute for Cancer Research, Australia	
1200 – 1230	PET-CT Guided Fine Needle Aspiration And Biopsy A/Prof Rakesh Kumar, Nuclear Medicine & PET, All India Institute of Nuclear Medicine, India	
1230 – 1300	Increasing Imaging Accuracies And Specifications. An Illustration Of Techniques And Tracer Applications In Nuclear Diagnostics Dr Andrew Tan, Nuclear Medicine & PET, Singapore General Hospital, Singapore	
1300 – 1400	LUNCH / TRADE EXHIBITION	Deck on 9, B6L9
1400 – 1550	SCIENTIFIC SESSION 7: NEUROENDOCRINE TUMOURS	Deck on 9, B6L9
	Session Chairpersons: 1. Prof Adil Al-Nahhas, Nuclear Medicine, Imperial College, United Kingdom 2. Dr Anthony Goh, Nuclear Medicine & PET, Singapore General Hospital, Singapore	
1400 – 1430	Basics Of Receptor-Mediated Nuclear Medicine: Preparation, Quality Control And In Vitro Characterization Of Different Somatostatin Analogs Radiolabelled For Diagnosis And Therapy Prof Irene Virgolini, Nuclear Medicine, Medical University of Innsbruck, Austria	
1430 – 1500	Peptide Receptor Radionuclide Therapy (PRRT) Of Neuroendocrine Tumors: Basic Principles, Current State And Future Perspectives Prof Richard Baum, Center for PET/CT, Zentralklinik Bad Berka, Germany	
1500 – 1530	Peptide Receptor Target Therapy Using i.a. 90Y-DOTATATE, In Patients With Advance Progressive Liver Involvement Of Neuroendocrine Carcinoma (GEP-NET) Dr Jaroslaw Cwikla, Radiology and Diagnostic Imaging, Medical Centre for Postgraduate Education & Central Clinical Hospital of Ministry of Internal Affairs and Administration, Poland	
1530 – 1550	Dosimetry Models For Treatment Of Neuroendocrine Tumors With Radiolabelled Somatostatin Analogues Prof Bozena Birkenfeld, Nuclear Medicine, Pomeranian Medical University, Poland	
1550 – 1620	COFFEE / TEA / TRADE EXHIBITION	Deck on 9, B6L9
1620 – 1750	SCIENTIFIC SESSION 8: HEAD & NECK TUMORS	Deck on 9, B6L9
	Session Chairpersons: 1. Dr Fong Kam Weng, Radiation Oncology, National Cancer Centre, Singapore 2. A/Prof Ivan Ng, Neurosurgery (Skull Base & Neurovascular), National Neuroscience Institute, Singapore	
1620 – 1650	PET Neuro-Imaging Prof Naoyuki Watanabe, Japan	
1650 – 1720	FET PET In Brain Tumors Dr Bogdan Malkowski, Uniwersytet Mikołaja Kopernika, Poland	
1720 – 1750	Radiotherapy Treatment Planning & PET Prof Andrew Scott, The Ludwig Institute for Cancer Research, Australia	
1750	END OF DAY 2	



SGH Nuclear Medicine Update 2011

In Collaboration With World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) & Nuclear Medicine Society (Singapore) (NMSS)

2 – 5 March 2011


Deck on 9, Block 6 Level 9, Singapore General Hospital

DAY 3: FRIDAY, 4 MARCH 2011

0800 – 0830	REGISTRATION	Deck on 9, B6L9
0830 – 1030	SCIENTIFIC SESSION 9: GASTROINTESTINAL SYSTEM & LIVER	Deck on 9, B6L9
	Session Chairpersons: 1. Prof Pierce Chow, General Surgery, Singapore General Hospital, Singapore 2. Dr David Ng, Nuclear Medicine & PET, Singapore General Hospital, Singapore	
0830 – 0855	Nuclear Medicine And Gastrointestinal Tract Prof Alan Perkins, Nuclear Medicine / Medical Physics, University of Nottingham, Medical School, Queen's Medical Centre, United Kingdom	
0855 – 0920	Molecular Imaging Of Colorectal Carcinoma Dr Lee Sze Ting, The Ludwig Institute for Cancer Research, Australia	
0920 – 0945	Radiological And Clinical Efficacy Of Radioembolisation (RE) 188Re HSA-Microspheres, In Patients With Advance Primary Or Metastatic Liver Cancers Dr Jaroslaw Cwikla, Radiology and Diagnostic Imaging, Medical Centre for Postgraduate Education & Central Clinical Hospital of Ministry of Internal Affairs and Administration, Poland	
0945 – 1010	Clinical Use Of Re-188 A/Prof Knut Liepe, Nuclear Medicine, Klinikum Kassel, Germany	
1010 – 1030	Yttrium-90 Selective Internal Radiation Therapy For Inoperable Liver Tumors: SGH Experience Dr Kao Yung Hsiang, Nuclear Medicine & PET, Singapore General Hospital, Singapore	
1030 – 1100	COFFEE / TEA / TRADE EXHIBITION	Deck on 9, B6L9
	SCIENTIFIC SESSION 10 & SCIENTIFIC SESSION 11 (CONCURRENT)	
1100 – 1300	SCIENTIFIC SESSION 10: LYMPHOMA/ MISCELLANEOUS	Deck on 9, B6L9
	Session Chairpersons: 1. Dr Lim Soon Thye, Medical Oncology, National Cancer Centre, Singapore 2. Dr Lee Sze Ting, The Ludwig Institute for Cancer Research, Australia	
1100 – 1130	SPECT/CT In Radionuclide Tumour Imaging And Therapy Dr C Hoefnagel, Diagnostic Oncology, The Netherlands Cancer Institute, The Netherlands	
1130 – 1200	Interim PET In Lymphoma Dr Bogdan Malkowski, Uniwersytet Mikolaja Kopernika, Poland	
1200 – 1230	SPECT-CT In Endocrine Tumors Dr John Buscombe, Nuclear Medicine, Addenbrooke's Hospital, United Kingdom	
1230 – 1300	PET/CT Imaging Of Cutaneous Malignancy Dr Kok Tien Yue, Nuclear Medicine & PET, Singapore General Hospital, Singapore	
1100 – 1300	SCIENTIFIC SESSION 11: RADIOGRAPHERS' TRACK SESSION 1	LT, B6L9
	Moderator: 1. Dr Butch Magsombol, Nuclear Medicine & PET, Singapore General Hospital, Singapore Session Chairpersons: 1. Mr Philip Hoon, Nuclear Medicine & PET, Singapore General Hospital, Singapore 2. Mr Ho Hee Shen, School of Health Sciences, Nanyang Polytechnic, Singapore	
1100 – 1130	Commissioning, Accepting, And Integrating a TOF PET/CT Scanner Into Routine Practice Mr S Somanesan, Nuclear Medicine & PET, Singapore General Hospital, Singapore	
1130 – 1200	The ABC's of Setting Up a PET/CT Facility Mr Gabriel Lim, Nuclear Medicine & PET, Singapore General Hospital, Singapore	
1200 – 1230	My Journey with Discovery 690 Mr Muhammed Jai, Nuclear Medicine & PET, Singapore General Hospital, Singapore	

Page 5 of 7

Please note that the programme is correct at time of update and is subject to change without prior notice



SGH Nuclear Medicine Update 2011

In Collaboration With World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) & Nuclear Medicine Society (Singapore) (NMSS)

2 – 5 March 2011

Deck on 9, Block 6 Level 9, Singapore General Hospital

DAY 3: FRIDAY, 4 MARCH 2011 (CONT'D)

1230 – 1300	ORAL PRESENTATIONS (RADIOGRAPHERS' TRACK)	LT, B6L9
1230 – 1240	PET/CT In Head And Neck Radiotherapy – Comparison Of Gross Tumor Volumes Obtained Using Automated Versus Manual Methods Miss Anjana Ramkumar, Radiation Oncology & Imaging, Amrita Institute of Medical Sciences & Research Institute, India	
1240 – 1300	General Discussions	
1300 – 1400	LUNCH / TRADE EXHIBITION	Deck on 9, B6L9
	SCIENTIFIC SESSION 12 & SCIENTIFIC SESSION 13 (CONCURRENT)	
1400 – 1600	SCIENTIFIC SESSION 12: MISCELLANEOUS	Deck on 9, B6L9
	Session Chairpersons: 1. Dr Felix Sundram, Wijaya International and Sime Darby Medical Centres, Malaysia 2. A/Prof Terrance Chua, Cardiology, National Heart Centre, Singapore	
1400 – 1430	Low Dose PET/CT With ToF Technology In Clinical Oncology Dr C Hoefnagel, Diagnostic Oncology, The Netherlands Cancer Institute, The Netherlands	
1430 – 1500	PET Imaging Of Brown Fat And The Pathophysiology Of Obesity Prof Alan Perkins, Nuclear Medicine / Medical Physics, University of Nottingham, Medical School, Queen's Medical Centre, United Kingdom	
1500 – 1530	PET-CT In Infections And Inflammations A/Prof Rakesh Kumar, Nuclear Medicine & PET, All India Institute of Nuclear Medicine, India	
1530 – 1600	Rubidium-82 Myocardial Perfusion Imaging: A Review Dr Gilbert Keng, Singapore PET and Cardiac Imaging Centre Pte Ltd, Singapore	
1400 – 1600	SCIENTIFIC SESSION 13: RADIOGRAPHERS' TRACK SESSION 2	LT, B6L9
	Moderator: 1. Dr Butch Magsombol, Nuclear Medicine & PET, Singapore General Hospital, Singapore Session Chairpersons: 1. Ms Julitta Baum, Cardiology, Drei-Burgen-Klinik, Germany 2. Ms Tan Sai Geok, School of Health Sciences, Nanyang Polytechnic, Singapore	
1400 – 1430	PET Radiotracers Other Than FDG In Cancer Imaging Dr Sidney Yu, Nuclear Medicine & PET, Singapore General Hospital, Singapore	
1430 – 1500	Setting Up A PRRT Service In Singapore General Hospital Mr Elias Woodrow Elias, Nuclear Medicine & PET, Singapore General Hospital, Singapore	
1500 – 1530	Our Initial Experience With SPECT-CT Mr Lim Yew Yee, KK Women's & Children's Hospital, Singapore	
1530 – 1600	Discussions	
1600 – 1630	COFFEE / TEA / TRADE EXHIBITION	Deck on 9, B6L9
1900 – 2300	NUCLEAR MEDICINE SOCIETY (SINGAPORE) ORATION & GALA DINNER	Holiday Inn Atrium
	Session Chairpersons: 1. Dr David Ng, Nuclear Medicine & PET, Singapore General Hospital, Singapore 2. Dr Anthony Goh, Nuclear Medicine & PET, Singapore General Hospital, Singapore	
1900 – 1930	Molecular Complexity and Organisation – A Perspective Dr Aw Swee Eng, Nuclear Medicine & PET, Singapore General Hospital, Singapore	
1930 – 2300	GALA DINNER	Atrium Ballroom, Level 4
2300	END OF DAY 3	

Page 6 of 7

Please note that the programme is correct at time of update and is subject to change without prior notice



SGH Nuclear Medicine Update 2011

In Collaboration With World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) & Nuclear Medicine Society (Singapore) (NMSS)

2 – 5 March 2011

Deck on 9, Block 6 Level 9, Singapore General Hospital

DAY 4: SATURDAY, 5 MARCH 2011

0830 – 0900	REGISTRATION	Deck on 9, B6L9
0900 – 1030	SCIENTIFIC SESSION 14: RADIONUCLIDE THERAPY	Deck on 9, B6L9
	Session Chairpersons: 1. Dr Lai Hee Kit 2. Dr John Buscombe, Nuclear Medicine, Addenbrooke's Hospital, United Kingdom	
0900 – 0930	Radiosynovectomy In Bleeding Joints Dr Emerita Barrenechea, Nuclear Medicine, Veterans Memorial Medical Center, Philippines	
0930 – 1000	Clinical Aspects, Side Effects And Radiation Protection In Radiosynovectomy A/Prof Knut Liepe, Nuclear Medicine, Klinikum Kassel, Germany	
1000 – 1030	Radiosynovectomy Using P-32 Colloid: Experience In Argentina Dr Victoria Soria, Hosp. de Clinicas, Argentina	
1030 – 1100	COFFEE / TEA / TRADE EXHIBITION	Deck on 9, B6L9
1100 – 1300	SCIENTIFIC SESSION 15: RADIONUCLIDE THERAPY	Deck on 9, B6L9
	Session Chairpersons: 1. Dr Anthony Goh, Nuclear Medicine & PET, Singapore General Hospital, Singapore 2. Dr Ang Ee Sin, Nuclear Medicine & PET, Singapore General Hospital, Singapore	
1100 – 1130	RIT Of Lymphomas Dr John Buscombe, Nuclear Medicine, Addenbrooke's Hospital, United Kingdom	
1130 – 1200	THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers And PET/CT To Personalized Therapy Prof Richard Baum, Center for PET/CT, Zentralklinik Bad Berka, Germany	
1200 – 1230	Closing Address Prof Ajit Padhy, Scientific Chairman, SGH Nuclear Medicine Update 2011	
1230	END OF DAY 4	





2011, Kuwait

**WARMTH International Workshop on Radionuclide Therapy & Annual Conference
of Kuwait Society of Nuclear Medicine
March 28-30, 2011, Venue: Mövenpick Hotel & Resort Al Bida'a, Samiya**

PROGRAMME

27/3/2011 (Sunday)		
Arrival of Participants		
28/3/2011 (Monday)		
08:30-17:00	Registration	
08:30-09:30	Inauguration :	
Scientific Sessions - 28/3/2011 (Monday)		
09:30-11:00	Scientific Session-1	
	Thyroid diseases: 1	
	Chairpersons: Drs. Imnan Al-Shamneri / Prof. J.H. Turner	
09:30-10:00	Radioiodine Therapy of Differentiated Thyroid Cancer: An overview	Prof. J. Mihailovic (Serbia)
10:00-10:30	Determination of Maximum I-131 Prescribed activity for treatment of differentiated thyroid cancer: One day vs. Multi-day Dosimetry	Dr. Van Nostrand (USA)
10:30-11:00	Graves' Ophthalmopathy - A perspective	Dr. E. Barrenechea (Philippines)
11:00-11:30	Tea/Coffee Break	
11:30-01:30	Scientific Session-2	
	Thyroid diseases: 2	
	Chairpersons: Dr. Issa Loutfi / Dr. Isabel Roca	
11:00-11:30	I-124 PET/CT in the detection of Functioning Residual Thyroid Tissue and Metastases in Differentiated Thyroid Cancer	Dr. Van Nostrand (USA)
11:30-12:00	Somatostatin Analogs in the Diagnosis and Treatment of Radioiodine Negative Thyroid Cancer patients.	Prof. I. Virgolini (Austria)
12:00-12:30	General Recommendations in Management of Pediatrics Thyroid Carcinoma	Dr. Monica Rossleigh (Australia)
12:30-13:00	Reporting new clinical trials, basis of clinical trial design and harmonisation of regulatory guidelines for radionuclide therapy.	Prof. J.H. Turner (Australia)
13:30-14:30	Lunch Break	
14:30-16:30	Scientific Session-3	
	Neuroendocrine Tumours	
	Chairpersons: Naheel Al-Nafeesi / Dr. Shrikant Solao	
14:30-15:00	Preparation, quality control and in vitro characterization of different radiolabelled somatostatin analogs for diagnosis and therapy.	Prof. I. Virgolini (Austria)
15:00-15:30	Molecular imaging of Neuroendocrine Tumors based on SSTR PET/CT	Prof. R.P. Baum (Germany)
15:30-16:00	Dose planning in Peptide Receptor Radionuclide Therapy in Clinical Oncology Practice	Prof. Kalevi Kairemo (Finland)
16:00-16:15	Tea/Coffee Break	
16:15-17:00	Peptide Receptor Radionuclide Therapy (PRRT) of Neuroendocrine Tumors. Practical Procedure and Practice Guidelines	Prof. R.P. Baum (Germany)
17:00	End of Day-1	
29/3/2011 (Tuesday)		
09:00-10:30	Scientific Session-4	
	Pediatric Nuclear Medicine-1	
	Chairpersons: Dr. Mona Baker / Dr. M.A. Khader	
09:00-09:30	Application of SPECT/CT applications in Pediatric diseases	Dr. Isabel Roca (Spain)
09:30-10:00	Pin-hole Imaging	Prof. AH Elgazzar (Kuwait)
10:00-10:30	Imaging investigations in infants and children presenting with urinary tract infection	Dr. Monica Rossleigh (Australia)
10:30-11:00	Tea/Coffee Break	
11:00-13:00	Scientific Session-5	



Paediatric Nuclear Medicine-2

Chairpersons: Dr. Imman Al-Enizi/ Dr. Monica Rossleigh

11:00-11:30	Overview of Pediatric Oncology in Kuwait	Dr. Rakesh Mittal (Kuwait)
11:30-12:00	Guidelines/ Recommendations in the Management of Pediatric Malignancies	Dr. Monica Rossleigh (Australia)
12:00-12:30	Dose Selection for Pediatric Nuclear Medicine Procedures	Dr. Laila Ali (Kuwait)
12:30-13:00	Gastrointestinal Studies in Children	Dr. Isabel Roca (Spain)
13:00-14:30	Lunch Break	
14:30-16:00	Scientific Session-6	
	<i>Molecular Imaging</i>	
	Chairpersons: Prof. Azu Owunwanne / Prof. Kalevi Kairemo	
14:30-15:00	Molecular imaging of Lung Cancer : State of the Art in 2011	Prof. R.P. Baum (Germany)
15:00-15:30	Molecular Imaging of Breast Cancer	Prof. A.K. Padhy (Singapore)
15:30-16:00	The Importance of Quantitative Molecular PET/CT Imaging: from RECIST to PERCIST	Prof. R.P. Baum (Germany)
16:00	End of Day-2	

30/3/2011 (Wednesday)

09:00-10:30	Scientific Session-7	
	<i>Radiosynovectomy</i>	
	Chairpersons: Dr. Anwar Al-Banna / Dr. Marika Vereb	
09:00-09:30	Radionuclide treatment of bleeding joints in haemophiliacs	Dr. E.Barrenechea (Philippines)
09:30-10:00	Radiosynovectomy in Drug-resistant Rheumatoid Arthritis	Dr. Shrikant Solao (India)
10:00-10:30	Radiosynovectomy: Practical Demonstration	Drs. Barrenechea and Solao
10:00-10:30	Kuwait Experience in Radiosynovectomy	Dr.Anwar Al-Banna (Kuwait)
10:30-11:00	Tea/ Coffee break	
11:00-11:30	Scientific Session-8	
	<i>Miscellaneous</i>	
	Chairpersons: Dr. Mohammad Ghanem / Prof. AH Elgazzar	
11:00-11:30	PET/CT in Fever of Unknown Origin	Dr. Shrikant Solao (India)
11:30-12:00	Radioembolization with Y-90 therspheres: Kuwait Experience	Dr. Abdelredah Abbas (Kuwait)
12:00-12:30	Radioimmunotherapy of non-Hodgkin lymphoma with I-131 Rituximab	Prof. J.H. Turner (Australia)
12:30-13:00	Closing Remarks	Prof. AH Elgazzar (Kuwait) Prof. A.K. Padhy (WARMTH)











2011, Bad Berka, Germany

Congress-President: Richard Baum, Frank Rösch



**JOHANNES GUTENBERG
UNIVERSITÄT MAINZ**



Zentralklinik Bad Berka







PROGRAMME

**1st World Congress on Gallium-68 and
Peptide Receptor Radio Nuclide Therapy (PRRNT)**

THERANOSTICS – on the Way to Personalized Medicine

June 23 – 26, 2011

ORGANIZED BY

Prof. Dr. med. Richard P. Baum, Dept. of Nuclear Medicine –
Center for PET/CT, Zentralklinik Bad Berka, Germany

Prof. Dr. sc. nat. Frank Rösch, Institute of Nuclear Chemistry,
Johannes Gutenberg University Mainz, Germany

In collaboration with /under the auspices of








WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009





WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

Welcome Message

Dear Colleagues:

Since the decoding of the human genome a decade ago, medicine is rapidly moving toward a preventive and personalized mode focused on genetic and molecular diagnostics and targeted, individualized therapies.

THERANOSTICS is the emerging field of molecular targeting of vectors which can be used for both therapies and diagnosis, when modified accordingly. This term was specifically used in the context of certain radiopharmaceuticals, so that the same pharmaceutical (e.g., a peptide) when labeled with a positron emitter, can be used for diagnosis using PET/CT, and when labeled with a beta emitter, may be used for therapy of a particular disease, targeted specifically by that radiopharmaceutical. The importance of THERANOSTICS is that it takes into account personalized management of disease. THERANOSTICS embodies both molecular and personalized medicine.

The 1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT) is co-organized by the Department of Nuclear Medicine/ PET Center, Zentralklinik Bad Berka and the Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, Germany. Target audience include chemists, physicians, and investigators dealing with generators, PET radiochemistry as well as molecular imaging and radionuclide therapy.

The congress plans to both educate and to offer a unique forum for high level scientific discussions on the recent developments in the exciting field of THERANOSTICS.

A special focus is the rapidly developing research and clinical application of Ga-68 and other generator-produced PET radioisotopes, new PET radiopharmaceuticals as well as PRRNT.

THERANOSTICS – on the Way to Personalized Medicine 3

For Ga-68 radiopharmaceutical chemistry, this World Congress intends to reflect the first decade of the renaissance of Ge-68/Ga-68 radionuclide generators. The last 10 years of commercially available ionic generators have stimulated both systematic chemical research and clinical applications of promising tracers.

Outstanding speakers from all over the world will be giving their fascinating insights into their research and clinical work, creating new ideas and concepts on the way to personalized medicine. Within the next decade, further and rapid developments may be expected.

A considerable number of companies are participating in the Trade Exhibition, presenting the latest technological developments in generator technology and Ga-68 modules, devices and labeling strategies.

In addition, a "Hands-on Training Course" on Ge-68/Ga-68 generators, for learning the practical principles of Ge-68/Ga-68 radionuclide generator elution for all types of today's available commercial systems, for eluate post-processing and Ga-68 labeling procedures as well as for product purification, combined with those of analogue Y-90 and Lu-177 chemistry, is offered (for a

limited number of participants) on June 27-28, 2011 at the Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, Germany. In addition, this Training Course – as well as the World Congress itself, realizes the idea of transferring novel technologies to the member states of the IAEA, thus contributing to the concept of translating Ge-68/Ga-68 generators and PRRNT all over the world.

Looking forward to seeing you in Bad Berka!

Prof. Dr. med. Richard P. Baum

Prof. Dr. sc. nat. Frank Rösch

Thursday, June 23, 2011 – Pre-Congress Symposium



Molecular Imaging and Treatment Options in NET Patients

14:00 Clinical Value of Ga-68 Imaging V. Prasad (Berlin, Germany)

14:20 Ga-68 Labeling-Generators & Synthesis Modules K. Zhernosekov (Villigen, Switzerland)

14:40 ITG iQS® Ga-68 Fluidic Labeling Module J. Jernström (Garching, Germany)

Coffee Break

15:10 Treatment Options for NET Patients D. Hörsch (Bad Berka, Germany)

15:30 Multimodality Radiopeptide Therapy of NET J.H. Turner (Fremantle, Australia)

15:50 Challenges in Production of Therapeutic Isotopes M. Harfensteller (Garching, Germany)

Location:

Zentralklinik Bad Berka – Lecture Hall
(Hörsaal, 1st floor at main entrance of the hospital)
Robert-Koch-Allee 9, 99437 Bad Berka, Germany



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

Friday, June 24, 2011 – Scientific Programme

07:30	Registration (also possible on Thursday, 17–19 hrs p.m.)
08:15	Opening Ceremony Chairpersons: Richard P. Baum, Bad Berka (Germany); Frank Rösch, Mainz (Germany) Opening Remarks → Local Representatives (Zentralklinik Bad Berka, Rhön-Klinikum AG) Martin Bosch, Norbert Presselt → International Atomic Energy Agency (IAEA) Uday Bhonsle → World Federation of Nuclear Medicine and Biology (WFNMB) Enrique Estrada Lobato → World Association for Radionuclide and Molecular Therapy (WARMTH) Ajit Kumar Padhy → European Association of Nuclear Medicine (EANM) Wolfram H. Knapp → Center for Molecular Imaging Innovation and Translation (CMIIT) Henry Van Brocklin → Deutsche Gesellschaft für Nuklearmedizin (DGN) Hans-Jürgen Biersack Opening Lecture O-01 Ge-68/Ga-68 Generators – Past, Present and Future Frank Rösch, Mainz (Germany)
09:30 – 10:00	Coffee/Tea/Opening of Trade Exhibition/Poster Viewing

16 1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRT)

10:00 – 11:20	SCIENTIFIC SESSION 1 Ge-68/Ga-68 Generators, Post-processing and Modules Chairpersons: Bengt Langström, Uppsala (Sweden); Richard P. Baum, Bad Berka (Germany)
10:00	O-02 Pro and Cons – Some Thoughts Around Technology for Routine Production of Ga-68 Tracers Bengt Langström, Uppsala (Sweden)
10:20	O-03 Overview and Perspectives on Automation Strategies in Ga-68 Radiopharmaceutical Production Stefano Boschi, Bologna (Italy)
10:40	O-04 Post-processing via Cation Exchange Cartridges: Versatile Options Frank Rösch, Mainz (Germany)
	Free Oral Papers
11:00	O-05 Automated Preparation Method for Ga-68 DOTATATE Using Anion-exchange Prepurification of the Ge-68/Ga-68 Generator Eluate Geerd-J. Meyer, Hannover (Germany)
11:10	O-06 Ge-68/Ga-68 Labeling System for Efficient and Cost Effective Labeling of Radiopharmaceuticals Jussi Jernstroem, Munich (Germany)



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

Friday, June 24, 2011 – Scientific Programme

11:20 – 12:30		SCIENTIFIC SESSION 2
		Gallium Chemistry: Ligands
		Chairpersons: Clemens Decristoforo, Innsbruck (Austria); Helmut Mäcke, Freiburg (Germany)
11:20	O-07	Gallium-68 Labeled Annexin for Apoptosis Imaging Alfons Verbruggen, Leuven (Belgium)
11:40	O-08	Ga-68 PET for Infection Imaging, Inflammation and Other Indications Vijay Kumar, Sydney (Australia)
12:00	O-09	Development of Ga-68 Labeled Amino Acids and Nitroimidazole Derivatives Jae Min Jeong, Seoul (South Korea)
		Free Oral Papers
12:10	O-10	PET Imaging Using Ga-68 Labeled Somatostatin Antagonists is Influenced by the Choice of the Chelator Melpomeni Fani, Freiburg (Germany)
12:20	O-11	A Novel Ga-68 Labeled Pteric Acid-based PET Tracer for Tumor Imaging via the Folate Receptor Berit Kühle, Mainz (Germany)
12:30 – 14:00		Lunch/Visit of Trade Exhibition/Poster Viewing

18 1st World Congress on Gallium-68 and Peptide Receptor Radio-Nuclear Therapy (PARRT)

14:00 – 15:10		SCIENTIFIC SESSION 3
		Gallium Chemistry: Peptidic Tracers
		Chairpersons: Otto C. Boerman, Nijmegen (The Netherlands); Alfons Verbruggen, Leuven (Belgium)
14:00	O-12	Ga-68 Labeled Peptides Targeting G-protein Coupled Receptors: Agonists versus Antagonists Helmut Mäcke, Freiburg (Germany)
14:20	O-13	Ga-68 Labeled Nanoparticles, Peptides and Phage Display Selected Peptides for PET Imaging of Cancer Cathy Cutler, Columbia (USA)
		Free Oral Papers
14:40	O-14	Molecular Imaging of HER2 Expression in Breast Cancer Using Ga-68-NOTA-Anti-HER2 Nanobodies Catarina Xavier, Brussels (Belgium)
14:50	O-15	Radiolabeling and Biodistribution of Ga-68-AMBA in ZR75-1 Human Breast Cancer Tumors Aureli Prignon, Paris (France)
15:00	O-16	Design, Synthesis and Preclinical Evaluation of Ga(III)-DOTA-modified Ranatensin Analogues for SPECT/PET Imaging Anil K. Mishra, Delhi (India)

TERANOSTICS – on the Way to Personalized Medicine 19



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

Friday, June 24, 2011 – Scientific Programme

15:10 – 16:30

SCIENTIFIC SESSION 4

New Ga-68 Pharmaceuticals: Chemistry and Pre-clinical Evaluation

Chairpersons: Cathy Cutler, Columbia (USA); Geerd-J. Meyer, Hannover (Germany)

15:10

O-17

Pretargeted Immuno-PET of Colorectal Cancer with Bispecific Antibodies

Otto C. Boerman, Nijmegen (The Netherlands)

15:30

O-18

Ga-68 Labeled PET Tracers for Studying Pathophysiological Properties of the P-glycoprotein

Oliver Thews, Halle (Germany)

15:50

O-19

Click Cyclized Ga-68 Labeled alpha MSH Peptides for Imaging Medulloblastoma

Michael K. Schultz, Iowa City (USA)

Free Oral Papers

16:10

O-20

In vivo Comparison of Ga-68 and In-111 labeled Affibody Molecule Analogues

Irina Velikyan, Uppsala (Sweden)

16:20

O-21

Novel DOTA-Neurotensin Analogue and Ga-68 PET Imaging of Neurotensin Receptor-positive Tumors in Mice

Anne Gruaz-Guyon, Paris (France)

16:30 – 17:00

Coffee / Tea / Visit of Trade Exhibition / Poster Viewing

20 1st World Congress on Gallium-68 and Peptide Receptor Radio-Nuclide Therapy (PRINT)

17:00 – 18:30

SCIENTIFIC SESSION 5

Lu-177, Y-90: Production, Chemistry and Pre-clinical Evaluation

Chairpersons: Konstantin Zheronosekov, Bern (Switzerland); Maung Maung Saw, Singapore

17:00

O-22

Radiometals for Therapeutic Application: Availability and Future Prospects

Marc Harfensteller, Munich (Germany)

17:20

O-23

Lu-177-BPAMD and Ga-68-BPAMD: THERANOSTICS for Bone Metastases

Marco Fellner, Mainz (Germany)

17:40

O-24

Radiolabeled GRPR-Antagonists: New Promising Tools for the Diagnosis and Therapy of GRPR-positive Tumors

Theodosia Maina, Athens (Greece)

Free Oral Papers

18:00

O-25

Lu-177/Y-90 - Intermediate Affinity Monoclonal Antibodies Targeting EGFR and HER2/c-neu: Preparation and Preclinical Evaluation

Denis R. Beckford Vera, Rez (Czech Republic)

18:10

O-26

Automated and cGMP-consistent Synthesis of Lu-177 and Ga-68 Labeled Peptides

Clemens Decristoforo, Innsbruck (Austria)

18:20 End of Sessions

18:45 Busses Leaving from Zentralklinik Bad Berka to Schloss Ettersburg

19:30 Welcome Reception at Schloss Ettersburg

THEANOSTICS – on the Way to Personalized Medicine 21



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

Saturday, June 25, 2011 – Scientific Programme

07:30		Registration
08:00 – 10:00		SCIENTIFIC SESSION 6 Ga-68 Imaging in Clinical Practice – Worldwide Experience Chairpersons: Wolfram H. Knapp, Hannover (Germany); Wolfgang Weber, Freiburg (Germany)
08:00	O-27	The European Experience Gabriele Pöpperl, Stuttgart (Germany)
08:15	O-28	The Indian Experience Vikram Lele, New Delhi (India)
08:30	O-29	The Latin American Experience Horacio Amaral, Santiago de Chile (Chile)
08:45	O-30	The Australian Experience Tim Akhurst, Melbourne (Australia)
09:00	O-31	The Singapore Experience Ajit Kumar Padhy, Singapore
09:15	O-32	The First American Experience Eric H. Liu, Nashville (USA)
09:30	O-33	The Mexican Experience & Rest of the World Enrique Estrada Lobato, Mexico City (Mexico)
09:45		Round Table with Session Lecturers
10:00 – 10:30		Coffee/Tea/Visit of Trade Exhibition/Poster Viewing

22 1st World Congress on Gallium-68 and Peptide Receptor Radio Nuclide Therapy (PRAWT)

10:30 – 12:30		SCIENTIFIC SESSION 7 Novel Clinical Applications of Ga-68 Labeled Tracers Chairpersons: Jaroslaw Cwikla, Warsaw (Poland); Irene Virgolini, Innsbruck (Austria)
10:30	O-34	Combined PET/MR Imaging for Ga-68 Labeled Tracers: A Case Study for Ga-68 DOTATOC in Meningioma Patients Thomas Beyer, Tübingen (Germany)
10:45	O-35	PET/CT-Guided FNAC Biopsy (Metabolic FNAC/Biopsy) Using Automated Robotic Arm Rakesh Kumar, New Delhi (India)
11:00	O-36	Ventilation/Perfusion Scans Using Ga-68 Labeled Tracers Jörg Kotzerke, Dresden (Germany)
11:15	O-37	Radioguided Surgery in Neuroendocrine Tumors Using Ga-68 Labeled Somatostatin Analogues. A Pilot Study Daniel Kämmerer, Bad Berka (Germany)
11:30	O-38	Somatostatin Receptor PET vs. its PET Competitors in the Diagnosis and Management Strategy of Patients with Neuroendocrine Tumors (NET), According to the Clinical Context and the Type of NET Jean-Noël Talbot, Paris (France)
11:45	O-39	Glucagon-like Peptide-1 (GLP-1) Receptor-PET Imaging using Ga-68 Labelled GLP-1 Analogues Damian Wild, Freiburg (Germany)

THE RANOSTICS – on the Way to Personalized Medicine 23



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

Saturday, June 25, 2011 – Scientific Programme

Free Oral Papers		
12:00	O-40	Performance of DOTATOC PET/CT for the Detection of Insulinomas in Adults Francoise Montravers, Paris (France)
12:10	O-41	Automated Synthesis of Ga-68 Exendin-4 for PET Imaging of Beta Cell Activity in Diabetes Mellitus Mario De Decker, Fremantle (Australia)
12:20	O-42	Role of Ga-68 DOTA-SMS-R PET/CT in the Detection of Cardiac Metastases in Patients with Neuroendocrine Tumors Vikas Prasad, Bad Berka (Germany)
12:30 – 14:00	Lunch / Visit of Trade Exhibition / Poster Viewing	

24 14th World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRT)

14:00 – 16:00	SCIENTIFIC SESSION 8 PRRT – The European Experience Chairpersons: Helmut Mäcke, Freiburg (Germany); Jean-Claude Reubi, Bern (Switzerland)	
14:00	O-43	Milestones in Preclinical Applications and Future Developments Regarding Somatostatin Analogues Marion deJong, Rotterdam (The Netherlands)
14:15	O-44	PRRT with Lu-177[DOTA,Tyr3]Octreotate Dik Kwekkeboom, Rotterdam (The Netherlands)
14:25	O-45	The Swiss Experience Jan Müller-Brand, Basel (Switzerland)
14:35	O-46	The Milano Experience Lisa Bodei, Milano (Italy)
14:45	O-47	The German Experience Dieter Hörsch, Bad Berka (Germany)
14:55	O-48	The Austrian Experience Irene Virgolini, Innsbruck (Austria)
15:05	O-49	The UK Experience John Buscombe, Cambridge (United Kingdom)
15:15	O-50	The Polish Experience Jolanta Kunikowska, Warsaw (Poland)
15:25	O-51	COST Action BM0607 on Targeted Radionuclide Therapy (TRNT), Oct 2007 – Oct 2011 Marion deJong, Rotterdam (The Netherlands)
15:35	Round Table with Session Lecturers	
16:00 – 16:30	Coffee/Tea / Visit of Trade Exhibition / Poster Viewing	

Theranostics – on the Way to Personalized Medicine 25



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

Saturday, June 25, 2011 – Scientific Programme

16:30-18:40		SCIENTIFIC SESSION 9 Dosimetry and Radiation Protection Chairpersons: Ignasi Carrio, Barcelona (Spain); Michael Lassmann, Würzburg (Germany)
16:30	O-52	Bad Berka Dose Protocol (BBDP) – Results in 350 Patients with a Routinely Applicable Protocol for Dosimetry in PRRNT Christiane Schuchardt, Bad Berka (Germany)
16:45	O-53	4D SPECT/CT Acquisition for 3D Dose Calculation and Dose Planning in Lu-177 Peptide Receptor Radionuclide Therapy Kalevi Kairemo, Helsinki (Finland)
17:00	O-54	Dosimetry Assessment in Y-90 Peptide Targeted Radiotherapy: Y-86 and Y-90 Imaging Stephan Walrand, Brussels (Belgium)
17:15	O-55	Renal Protection and Toxicity Related to Peptide Receptor Radionuclide Therapy (PRRNT) of Neuroendocrine Tumor Vikas Prasad, Bad Berka (Germany)
17:30	O-56	Radiation Protection Issues in PRRNT and Results of the ORAMED Project Arndt Rimpler, Berlin, Germany
17:45	O-57	Lu-177 Octreotate in GEP-NET: Outcome with Special Regard to Tumor Grade and Bone Metastases Samer Ezziddin, Bonn (Germany)

26 1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT)

		Free Oral Papers Chairpersons: Annare Ellmann, Cape Town (South Africa); Henry VanBrooklin, San Francisco (USA)
18:00	O-58	Does the Addition of Gelofusin in the Renal Protection of Patients Undergoing PRRNT Make a Difference? Paul Maltby, Liverpool (United Kingdom)
18:10	O-59	The Possibility to Use Peptide Receptor Radionuclide Therapy as a Neoadjuvant Therapy in Patients with Inoperable Neuroendocrine Tumors (NETs) Anna Sowa-Staszczak, Krakow (Poland)
18:20	O-60	Ga-68-DOTA-Somatostatin Analogues PET in Neuroendocrine Tumors: First Year Experience in Turkey Emre Demirci, Istanbul (Turkey)
18:30	O-61	PET Lung Ventilation/Perfusion Imaging Using Gallium-68 Labeled Aerosol and Gallium-68 Labeled Macroaggregated Albumin (MAA) Stephan-Johann Ament, Mainz (Germany)

18:40 End of sessions

19:00 Busses leaving from Zentralklinik Bad Berka to Rittergut München

19:30 Midsummer Night at Rittergut München

TERANOSTICS – on the Way to Personalized Medicine 27



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

Sunday, June 26, 2011 – Scientific Programme

08:00		Registration
08:30–11:00		SCIENTIFIC Session 10 Current State of NET Therapy and PRRNT - Worldwide Experience Chairpersons: Hans-Jürgen Biersack, Bonn (Germany); Ajit Kumar Padhy, Singapore
08:30	O-62	A Schema of Therapeutic Options for Neuroendocrine Tumors and the Value of Biomarkers Thomas O'Dorisio, Iowa City (USA)
08:45	O-63	Systemic Therapy of Neuroendocrine Tumors in 2011 and in the Future Edward M. Wolin, Los Angeles (USA)
09:00	O-64	Australian Experience of Radiopeptide Therapy of NET J. Harvey Turner, Fremantle (Australia)
09:15	O-65	Neuroendocrine Tumor Treatment with Somatostatin Analog Peptides Labeled with Radionuclides: Latin-American Pioneer Experience Horacio Amaral, Santiago de Chile (Chile)
09:30	O-66	PRRNT - The Indian Experience Chandra Sekhar Bal, New Delhi (India)
09:45	O-67	The US Experience in Providing PRRNT in Children, Adolescents and Adults Sue O'Dorisio, Iowa City (USA)

28 1st World Congress on Gallium-68 and Peptide Receptor Radio Nuclide Therapy (PRRNT)

		Free Oral Papers Chairpersons: John Buscombe, Cambridge (United Kingdom), Eric H. Liu, Nashville (USA)
10:00	O-68	Ga-68 DOTATOC vs. Ga-68 DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors Thorsten D. Poeppel, Essen (Germany)
10:10	O-69	Comparison of Lesion Detection and Characterisation in Patients with Neuroendocrine Tumors Using DOTATOC-PET in Correlation with Contrast-enhanced MRI and Contrast-enhanced CT Frederik L. Giesel, Heidelberg (Germany)
10:20	O-70	Diagnostic Impact of Ga-68 DOTA-TATE PET/CT Imaging in the Detection of Recurrent or Metastatic Medullary Thyroid Carcinoma and Elevated Calcitonin Levels Anar Aliyev, Istanbul (Turkey)
10:30	O-71	Comparison of Ga-68 Somatostatin Analogues, F-18 DOPA and F-18 FDG PET/CT in Patients with Recurrent Medullary Thyroid Carcinoma: Also Ferrari does not Always Win! Giorgio Treglia, Rome (Italy)
10:40	O-72	Comparison of Positron Emission Tomography with Ga-68 DOTA-TATE and F-18 FDG in Neuroendocrine Tumors Sabire Yilmaz, Istanbul (Turkey)
10:50	O-73	PRRNT with Lu-177 DOTATATE for GEP-NET – Initial Results in Brazil Aron J. Beller, Sao Paulo (Brazil)
11:00–11:30		Coffee/Tea/Visit of Trade Exhibition / Poster Viewing

THE RANOSTICS – on the Way to Personalized Medicine 29



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

Sunday, June 26, 2011 – Scientific Programme

11:30 – 13:30

SCIENTIFIC SESSION 11

Novel Clinical Approaches for PRRNT of Neuroendocrine Tumors

Chairpersons: Carlos Libhaber, Cape Town (South Africa), Edward M. Wolin, Los Angeles (USA)

11:30

O-74

Effect of Peptide Receptor Radionuclide Therapy with TANDEM Isotopes-Y-90/Lu-177 DOTA-TATE in Patients with Disseminated Neuroendocrine Tumors

Jolanta Kunikowska, Warsaw (Poland)

11:45

O-75

PRRT Combined with Chemotherapy and Kinase Inhibitors

J. Harvey Turner, Fremantle (Australia)

12:00

O-76

TACE and SIRT Combined with PRRT or Intra-arterial PRRT

Alexander Petrovitch, Bad Berka (Germany)

12:15

O-77

Intra-arterial Bi-213-DOTATOC Alpha-Peptide Therapy in Patients with Neuroendocrine Tumors Refractory to Beta-radiation

Clemens Kratochwil, Heidelberg (Germany)

12:30

O-78

Intra-arterial PRRNT Using Y-90 DOTATATE – The Warsaw Experience

Jaroslav Cwikla, Warsaw (Poland)

12:45

O-79

Engineered Bacteria for Cancer Theranostics

Jung-Joon Min, Chonnam (South Korea)

30 1st World Congress on Gallium-68 and Peptide Receptor Radio Nuclide Therapy (PRRNT)

13:00 – 14:15

SCIENTIFIC SESSION 12

New Horizons & Future Developments

Chairpersons: Baljinder Singh, Chandigarh (India); Frank Rösch, Mainz (Germany)

O-80

Old and New Peptide Receptor Targets in Cancer: Future Directions

Jean-Claude Reubi, Bern (Switzerland)

O-81

Novel Targets for Peptide Receptor Based Imaging and Therapy

Wolfgang Weber, Freiburg (Germany)

Closing Lecture (Including Highlights)

O-82

THERANOSTICS – Where do we go from here?

Richard P. Baum, Bad Berka (Germany)

14:15

Closing Remarks

14:30 Farewell Barbeque

16:00 Busses leaving from Zentralklinik Bad Berka to Mainz (Post-Congress)

THERANOSTICS – on the Way to Personalized Medicine 31





2013, Symposium on Medicine in Routine Clinical Practice Yangon, Myanmar











WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

AOCNMB 2015

October 31 - November 4, 2015
Jeju, Korea

11th Asia Oceania Congress of Nuclear Medicine and Biology
54th Annual Autumn Meeting of the Korean Society of Nuclear Medicine

*From Globalization to Localization
Young Leadership*

Registration is now OPEN !!

<http://www.aocnmb2015.com>

Program

Plenary Speaker

- Ren-Shyan Liu (President, FASMI)
- Hossein Jadvar (President, SNM)
- Valerie Lewington (Educational Chair, EANM)
- Richard Baum (President, WARMTH)
- Andrew Scott (President, WFNM)
- Nagara Tamaki (Hokkaido University, Japan)
- Thomas Pascual (IAEA)

Joint Symposium

- Hybrid Imaging
- Optimization of Radioiodine Therapy for Thyroid Cancer
- Clinical Translation of Molecular Imaging
- Current Advances in Molecular Imaging
- Future of Targeted Radionuclide Therapy
- PET GMP
- Future of Cardiovascular Imaging
- Imaging for Non-coronary Heart Disease

Continuing Education

- Molecular Imaging
- CT Reading
- Nuclear Chemistry
- Pediatric Nuclear Medicine

Issues & Current Topics

- Regional Leadership
- I-131 Therapy for Thyroid Cancer
- Introduction on ARSNM (Arab Society of Nuclear Medicine)
- PET Oncology
- Radiation Safety
- Radionuclide Therapy
- General Nuclear Medicine
- Pediatric Nuclear Medicine
- Radiopharmaceuticals

Special Lecture Hee Seung Borm (President, AOCNMB), Dong Soo Lee (Seoul National University, Korea)

Highlight Lecture June-Key Chung (Seoul National University, Korea)

Honorary Fellow Lecture Yong Whoo Bahk (Sungae Hospital, Korea)

Secretariat | AOCNMB 2015


8F Saehan Bldg.106, Namdaemun-ro 356-gil, Seocho-gu, Seoul, 137-888, Korea
Tel. +82 70 8887 7996 Fax. +82 303 3441 7996 E-mail. aocnmb2015@gmail.com



AOCNMB 2015

11th Asia Oceania Congress of Nuclear Medicine and Biology
54th Annual Autumn Meeting of the Korean Society of Nuclear Medicine

October 31 - November 4, 2015 ICC Jeju, Korea



Scientific Program

Home > Program > Scientific Program

Invitation

Organizing Committee

Program

- Program at a Glance
- Scientific Program
- Speakers Information
- Social Program

Congress Information

- General Information
- Venue

Registration

Call for Abstracts

ANMB Examination

Sponsorship & Exhibition

- Sponsorship
- Exhibition

Accommodation & Tour

- Accommodation
- Tour

Information

- Jeju, Korea
- Transportation
- Visa
- General Information

News & Notice

Daily Overview

Oct 31 (Sat)	Nov 1 (Sun)	Nov 2 (Mon)	Nov 3 (Tue)	Nov 4 (Wed)
October 31 (Sat), 2015				
Joint Symposium 1. Hybrid Imaging - Co-organized by IEEE NPSS Seoul Chapter Research Trends in PET Instrumentation <i>Jung Yeol Yeom (School of Biomedical Engineering, Korea University, Korea)</i> A Multi-Modality Imaging System for Laparoscopic Sentinel Lymph Node Dissection <i>Seong Jong Hong (Departments of Senior Healthcare and Radiological Science, Eulji University, Korea)</i> Oncologic Application of Parallel PET-MRI <i>Ilhan Lim (Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), Korea)</i> Multimodal Image Fusion <i>Hiroshi Watabe (Cyclotron and Radioisotope Center, Tohoku University, Japan)</i>		09:00 - 11:00 Tamna Hall (5F)		
WARMTH Symposium Session 1. Established Radionuclide Therapies: Practical Aspects and New Development (I) Radioactive Iodine Therapy for Hyperthyroidism-an Update <i>Emerita Andres-Barrenechea (Department of Nuclear Medicine, St. Luke's Medical Center, Philippines)</i> Radioliodine Therapy - Thyroid Cancer <i>Partha S Choudhury (Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India)</i> Radionuclide Therapy of Bone Metastases (Pain Palliation) <i>Ajit S Shinto (Department of Nuclear Medicine, Kovai Medical Center and Hospital, India)</i> Radioembolization of Hepatocellular Carcinoma using Y-90 Labeled Microspheres <i>Jae-Gol Choe (Department of Nuclear Medicine, Korea University Anam Hospital, Korea)</i>		09:15 - 10:55 Halla Hall (3F)		
Continuing Education 1. Molecular Imaging Basic Concepts for Molecular Biology <i>Hyewon Youn (Department of Nuclear Medicine, Seoul National University Hospital, Korea)</i> Molecular Imaging with Reporter Gene Expression <i>Yong Hyun Jeon (Department of Nuclear Medicine, Kyungpook National University, Korea)</i> Molecular Imaging for Cell Tracking <i>Yong Jin Lee (Molecular Imaging Research Center, Korea Institute of Radiological & Medical Sciences, Korea)</i> Molecular Imaging for Biomolecules <i>Kwangil Kim (Molecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences, Korea)</i> Overview of Multimodal Imaging <i>Jin Su Kim (Molecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences, Korea)</i>		09:00 - 11:00 Room 401 (4F)		
Free Paper 1		09:00 - 11:00 Samda A (3F)		
Current Issues 1. PET Oncology Clinical PET beyond 18F-FDG in Taiwan <i>Ruoh-Fang Yen (National Taiwan University Hospital, Taiwan)</i> Applications of PET/CT in External Beam Radiation Therapy Dose Planning		09:00 - 11:00 Samda B (3F)		










The WARMTH and The SNMMI

Ajit Padhy has been able to forge an alliance with the SNMMI and, henceforth, The WARMTH was able to join SNMMI in organizing one Annual SNMMI-WARMTH Symposium on Radionuclide Therapy in conjunction with the Annual Meeting of the SNMMI. Under The WARMTH President Suresh Srivastava, who also was the President of the Therapy Center of Excellence of The SNMMI, the collaboration was established.



“During 2013 and 2014, we cosponsored a number of joint WARMTH-SNMMI Continuing Medical Education (CME) sessions, during both SNMMI Mid-Winter and the Annual Meetings, and those were quite a success. In addition, our participation in the Categorical Seminars on Theragnostics at the 2015 Annual SNMMI Meeting in Baltimore and this year’s Annual Meeting in San Diego 2016 “Theragnostics Beyond Neuroendocrine Tumors: Novel Applications of Targeted Radionuclide Therapy in Malignant and Nonmalignant Conditions”) was unique and very successful. The sponsoring Council/Center/Committees were the New SNMMI Therapy Center of Excellence, Pediatric Imaging Council, Correlative Imaging Council, and The WARMTH. The twenty or so Co-Organizers / Moderators / Speakers for this session included Irene Virgolini, Patricia Bernal, Emerita Barrenechea, and me from The WARMTH side. Also, earlier in the year, we had participated in the SNMMI Mid-Winter Meeting in Orlando, Florida, during the last week of January, where we had been able to organize three CME sessions with the cosponsorship of The WARMTH. The meeting rooms have generally been full, and for many of these our cosponsored sessions, I have been told that they were some of the best-attended sessions within the SNMMI Meetings. These have been great beginnings for us in terms of the collaboration between The WARMTH and SNMMI, and hopefully, this would definitely flourish and continue to prevail.” (Suresh Srivastava, 2016)



2016, SNMMI Annual Meeting, San Diego, USA

[Back to Schedule](#)

CAT8: 'Theragnostics' Beyond Neuroendocrine Tumors: Novel Applications of Targeted Radionuclide Therapy in Malignant and Nonmalignant Conditions

Saturday, June 11
8:00 AM–4:00 PM

Location: 30DE (San Diego Convention Ctr)

Education: Categorical

Sponsored by: Therapy Center of Excellence

CME: 6.50

ACPE: 6.50 [0210-0000-016-529-L04-P]

VOICE A+: 6.50

CAMPEP: 6.50

Educational Objectives

Upon completion of this activity, the participant will be able to:

1. Describe the basic principles of the 'Theragnostics' paradigm, and its usefulness for optimizing of radiopharmaceutical therapies in benign and malignant conditions
2. Describe the differences, advantages and disadvantages for various therapies, radionuclides, and targeting techniques
3. List novel techniques and new trends in treatment, including combination therapies utilizing radiopharmaceuticals
4. Generate a plan to update and improve the clinical protocols being used at their centers/institutions/hospitals based on the latest updates and knowledge gained
5. Craft a plan to introduce new alternate therapies in their hospitals
6. Identify the features of pediatric thyroid cancer that characterize pediatric patients who may most benefit from I-131 radioiodine therapy.
7. Describe the current use of I-131 MIBG for treating neuroblastoma in this population
8. Discuss the investigational use of Ra-223 radionuclide therapy for skeletal metastatic disease in young adults



9. Discuss the potential pediatric indications for using Y-90 and Lu-177 radiolabeled peptides to treat pediatric neuroendocrine tumors, including neuroblastoma

Presentations

8:00 AM - 8:40 AM

Alpha Endoradiotherapy of Osseous Metastatic Prostate Cancer
Hossein Jadvar, MD, PhD, MPH, MBA, FACNM

8:40 AM - 9:20 AM

The Conception, Evolution, and Development of the Relatively New Paradigm of 'Theranostics' at Brookhaven National Laboratory
Suresh C. Srivastava, PhD

9:20 AM - 9:50 AM

Radiopharmaceutical Treatment Planning in the Era of Theragnostics
George Sgouros, PhD

9:50 AM - 10:20 AM

Induction and Maintenance Therapies with TRT – A New Paradigm for Treatments with Radiopharmaceuticals
AJB (Sandy) McEwan, MD

10:20 AM - 10:35 AM

BREAK

10:35 AM - 11:10 AM

Radiiodine (I-131) Therapy for Thyroid Cancer
Douglas Van Nostrand, MD

11:10 AM - 11:45 AM

Using MIBG for Staging and Assessing Response to Therapy
Susan E. Sharp, MD

11:45 AM - 12:15 PM

I-131 MIBG Therapy of Neuroblastoma
Suzanne Shusterman, MD

12:15 PM - 1:15 PM

LUNCH

1:15 PM - 1:45 PM

Moving Beyond Single Agent Radiopharmaceutical Therapy: Prospects and Considerations for Combination Therapies
Daniel Pryma, MD

1:45 PM - 2:15 PM

Radioimmunotherapy for Lymphoma
Arif Sheikh, MD, ABNM, CBNC, ABIM

2:15 PM - 2:30 PM

BREAK

2:30 PM - 3:00 PM

Liver-Directed Theragnostics
Ghassan Elias El-Haddad, MD

3:00 PM - 3:30 PM

Theranostics for Certain Non-NET's: Brain Tumors, Urothelial Cell Cancer, and crPCA Treatment with Antiandrogens
Irene J. Virgolini, MD

3:30 PM - 4:00 PM

Radiosynovectomy for the Treatment of Joints and Various Arthritides: Involvement of Nuclear Medicine in Rheumatology and Orthopedics
Emerita A. Barreñechea, MD

Session Leaders

Organizer: Daniel Pryma, MD; Suresh C. Srivastava, PhD; Erik Mittra, MD, PhD; Irene J. Virgolini, MD; Frederick D. Grant, MD

Moderator: Amol M. Takalkar, MD, MS, MBA, FACNM; Patricia Isabel Bernal Trujillo, MD; Ruth Lim, MD; Suresh C. Srivastava, PhD





2017, SNMMI Annual Meeting, Denver, USA

Dear Friends,

As you all know, the Annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), during June 10-14, 2017 in Denver, Colorado, is planning to hold a unique CME session entitled *"Involving Theragnostics in the Areas of Orthopedics and Rheumatology: Targeted Radionuclide Therapy in Various non-malignant Arthritic and Joint Diseases"*. It will primarily be focused on RSO (Radiosynovectomy) procedures. This course will be sponsored by the new SNMMI Therapy Center of Excellence (TxCoE), and co-sponsored by the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). Clinical trials and centers that are developing and advancing RSO and RSO isotopes will be the focus of this CME course.

As you have been informed earlier, we have developed a tentative agenda as follows, and I hope that you would participate in this unique and prestigious course. The session will be held on Wednesday June 14; 9:45 AM – 11:15 AM, and the details will be as follows:

Knut Liepe, MD: "Global experience with radioisotopes used for RSO";
9:45 AM – 10:10 AM.
Nigel Stevenson, Ph.D: "Characteristics and comparison of RSO isotopes including Sn-117m"; 10:10 AM – 10:25 AM.
Jim Lattimer DVM: "U.S. experience using new isotope Sn-117m homogeneous colloid for RSO in canines with OA"; 10:25 AM – 10:50 AM.
Eric Turcotte MD: "Canadian clinical trial experience using Re-186 and Y-90 in RSO of human arthritides"; 10:50 – 11:15 AM.

Please let me know, possibly by return e-mail, if you would be interested in participating within this CME session. I must finalize the program and submit it by Tuesday, Jan. 10.

Hopefully, I will receive a positive answer from you all within this time frame.


Thanks and best regards,

Suresh
Suresh Srivastava, Ph.D.
Senior Medical Scientist
Brookhaven National Laboratory
Upton, NY 11973
USA






**SNM
MI** SOCIETY OF
NUCLEAR MEDICINE
AND MOLECULAR IMAGING
ANNUAL MEETING
WWW.SNMMI.ORG/AM2017





2018 SNMMI Annual Meeting, Philadelphia, USA



SNMMI SOCIETY OF
NUCLEAR MEDICINE
AND MOLECULAR IMAGING
ANNUAL MEETING

SNMMI ANNUAL MEETING

June 23 – 26, 2018 > Philadelphia, PA > www.snmmi.org/AM2018

IN THIS ISSUE

Get Social

View the great line-up of networking and special events.

Session Highlights

Get a sample of sessions from the 10 available tracks.

See Who's Exhibiting

More than 160 companies are expected in the exhibit hall.

[Preview Magazine > Issue 2](#)



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009



CAT 3: PSMA Radioligand Therapy (PRLT) of End-Stage Prostate Cancer Patients Selected by PSMA PET/CT. The Power of Precision Oncology



Favorites

12 Likes



Notes

DATE & TIME

Saturday, June 23, 2018

7:30am - 3:00pm (EDT)

114 Michael A. Nutter Theatre (Pennsylvania Convention Center)

DESCRIPTION

Sponsored by: Therapy Center of Excellence

CME: 6.00

ACPE: 6.00

VOICE A+: 6.00

CAMPEP: 6.00

Educational Objectives

Upon completion of this activity, the participant will be able to:

1. Identify the relevance of PSMA molecule.
2. Name the current therapeutic strategies for end-stage prostate cancer.
3. Examine targeting PSMA for theranostics of prostate cancer.
4. Discuss the role of PSMA PET/CT in selection of patients and follow-up / therapeutic response assessment.
5. Summarize the developments of PSMA ligands.
6. Discuss the state-of-the-art clinical utility of PSMA radioligand therapy using beta- and alpha-emitting radionuclides.

Presentations

7:30 AM - 8:15 AM

PSMA Radioligand Therapy (PRLT) of Prostate Cancer patients selected by 68Ga-PSMA

Vivek Narayan, MD, MS

8:15 AM - 9:00 AM

PRLT of Early and Advanced Metastatic Prostate Cancer: A Single Center Experience in over 250 Patients

Richard P. Baum, MD, PhD

9:00 AM - 9:45 AM

Meeting the Challenges of Randomized Multi-Centre Clinical Trials: Experience from PSMA Imaging & Therapy in Australia

Michael S. Hofman, MBBS

9:45 AM - 10:00 AM

Morning Break

10:00 AM - 10:45 AM

Overview of PSMA Ligands (68Ga and 18F labeled)

Hans Juergen Wester, PhD

10:45 AM - 11:15 AM

Ga-68 Radiopharmaceuticals for Prostate Imaging: Synthesis and Regulatory Considerations

Roger Slavik, PhD

11:15 AM - 11:30 AM

Morning Panel Discussion

Richard P. Baum, MD, PhD; Michael S. Hofman, MBBS; Hans Juergen Wester, PhD; Roger Slavik, PhD

11:30 AM - 12:30 PM

Lunch Break



CAT 3: PSMA Radioligand Therapy (PRLT) of End-Stage Prostate Cancer Patients Selected by PSMA PET/CT. The Power of Precision Oncology

12:30 PM - 1:00 PM

The Role of Dosimetry in PRLT and Perspectives on new Radioisotopes for Theranostics

Harshad R. Kulkarni, MD

1:00 PM - 1:30 PM

Clinical Trials with F-18 Labeled PSMA Tracers

Steven Rowe, M.D.,Ph.D.

1:30 PM - 2:00 PM

South African Experience Using Ac-223 PSMA for Alpha-Radiation Treatment of Prostate Cancer

Machaba Michael Sathekge, MD, PhD

2:00 PM - 2:15 PM

Afternoon Break

2:15 PM - 2:45 PM

Future Considerations and Combinations for PRLT Therapy

Irene J. Virgolini, MD

2:45 PM - 3:00 PM

Afternoon Panel Discussion

Harshad R. Kulkarni, MD; Steven Rowe, M.D.,Ph.D.; Machaba Michael Sathekge, MD, PhD; Irene J. Virgolini, MD

Session Leaders

Organizer: Richard P. Baum, MD, PhD; Josh Mailman, MBA; Irene J. Virgolini, MD

Moderator: Richard P. Baum, MD, PhD; Michael S. Hofman, MBBS; Irene J. Virgolini, MD

FACULTY

	Baum, MD, PhD, Richard Zentralklinik Bad Berka	Speaker
	Hofman, MBBS, Michael Peter MacCallum Cancer Institute	Speaker
	Kulkarni, MD, Harshad Zentralklinik Bad Berka	Speaker
	Mailman, MBA, Josh NorCal CardNET Community	Speaker
	Narayan, MD, MS, Vivek The Hospital of the University of Pennsylvania	Speaker
	Rowe, M.D.,Ph.D., Steven Johns Hopkins	Speaker
	Sathekge, MD, PhD, Machaba University of Pretoria	Speaker
	Slavik, PhD, Roger UCLA Biomedical Cyclotron Facility	Speaker
	Virgolini, MD, Irene Medical University of Innsbruck, Department of Nuclear Medicine	Speaker
	Wester, PhD, Hans Technische Universität München	Speaker

SCHEDULE BY TRACK


Oncology and Therapy




SCHEDULE FILTERS

Categorical











2019, SNMMI Annual Meeting Anaheim, California USA





2018, Bandung, Indonesia





Dr. Ayu Rosemeilia Dewi
Chairman

22nd Annual Scientific Meeting of Indonesian Society of Nuclear Medicine (ISNM) – Indonesian Society of Nuclear Medicine and Biology (ISNMB) – National Nuclear Energy Agency Republik of Indonesia (BATAN) in conjunction with International Symposium of Nuclear Science and Application for Human Health was held in 14 – 16 September 2018 at Crowne Plaza Hotel Bandung, West Java.

It was a 3 days conference, 1 day parallel workshops and 2 days parallel symposiums with total 8 International Speakers, 30 National Speakers, 349 participants. At the first day, we held 6 parallel workshops with total 192 participants. The workshops were Nuclear Cardiology and Nuclear Oncology Workshop (I and II) for Nuclear Medicine Physician and Resident; Radiation Protection Workshop (III) for Physician, Medical Physicist, Pharmacist, Nurse, Radiographer and Student; QC of Ga-68 Labelling Workshop (IV) for Pharmacist, Nursing Care Workshop (V) for Nurse, QC of NM Equipment and Calibration Workshop (VI) for Radiographer and Medical Physicist. To end the first day, we held welcome dinner with special traditional Sundanese song and dance.

At the second and third day, we held 6 clinical and 5 pre-clinical symposiums. We also held free paper presentation of 44 abstracts (6 oral presentation and 38 poster presentation) from 6 countries. The conference was officially opened by “Angklung (Sundanese Traditional Music Tool) shake” by the President ISNM-ISNMB (Dr. Eko Purnomo), Head of BATAN (Prof. Djarot Wisnubroto), Head of National Nuclear Energy Regulatory Agency of Indonesia - BAPETEN (Prof. Jazi Eko istiyanto), IAEA representative (Dr. Thomas NB Pascual), President of ARCCNM (Prof. Henry Bom), AOSNM representative (Prof. Hussein S. Kartamihardja), AOFNMB representative (Prof. Johan S. Masjhur), WARMTH representative (Prof. Qaisar Hussain Siraj). There was also a great moment of signing of the MoU between President **ISNM-ISNMB** and Head of BATAN for the Development of Nuclear Medicine in Indonesia. We also held a mini symposium of Indonesia NM Milestone, Strategy and It Role’s for NM Development in Indonesia which was delivered by 5 Speakers (ISNM, BATAN, BAPETEN, IAEA, Ministry of Health). It was continued with Focus Group Discussion led by Dr. Ryan Yudhistiro with ISNM-ISNMB representatives (Dr. Eko Purnomo, Prof. Johan S. Masjhur, Prof. Hussein S. Kartamihardja, Dr. Stepanus Massora, Dr. Febby Hutomo), BATAN (Nur Rahmah Hidayati - PTKMR), BAPETEN (Ishak - Director of FRZR), Ministry of Health (Dr. Andi Saguni - Director General of Health and Safety), Director of Legal Compliance and Inter-Institutional Relations of National Health Care Insurance (Dr. Bayu Wahyudi) which discussed the Development of Nuclear Medicine Strategy with the topic "Brighter Future of Indonesian Health Care by Nuclear Medicine". To end the second day, we held gala dinner with special traditional Sundanese dance and ice breaking moment.

We closed the third day with ‘the winner announcement of free paper presentation’ and it was decided that the next annual meeting would be held at Yogyakarta.







ISRT 2018, Helsinki, Finland

Congress-President: Kalevi Kairemo

"The Helsinki ISRT-2018 was arranged because the last full ICRT was arranged in 2016 in Cochin, Kerala, India in 2016. In 2017 and 2018, WARMTH Conferences were one day events both in Vienna (EANMC) and Melbourne (WFNMB). This ISRT-2018 Conference was held in downtown Helsinki in Paasitorni Congress Center in November 18-20, 2018. This three day event had 151 registered participants from 53 countries, and from the WARMTHs perspective it did not make any deficit nor any profit. IAEA supported travel of 20 participants from developing countries to this conference. Minister of Health Pirkko Mattila gave an opening speech the Conference, followed by a Candle light ceremony (picture).

City of Helsinki and Mayor of Helsinki (Health Section Sanna Vesikansa) arranged a reception in the City Hall. I had arranged a private Tram transportation to the City hall and after that a city sightseeing tour by the same tram.

There was an extensive program for a three day event, consisting of 20 posters and 41 oral presentations in 9 sessions (attachment). The abstracts were all published in World Journal of Nuclear Medicine.

Multiple high quality presentations were given, but the most important presentation was the 45-min Ajit Padhy Oration entitled "New Insights in Theranostics" was given by Steven M. Larson from Memorial Sloan-Kettering Cancer Center, New York (h-index 118, more than 700 publications).

There was a special Nuclear Cardiology Session, arranged by Juhani Knuuti. He also got the Lifetime Achievement Award from WARMTH (h-index 75, more than 500 publications). A specific nuclear oncology/ oncology session was organized by the University of Texas MD Anderson Cancer Center. A session dedicated Radiation Biology and Hazards was arranged by Seigo Kinuya (JPN) and Bennett S. Greenspan (USA), SIRT session by Aviral Singh (GER) and Patrick Flamen (BEL), NET session by Irene Virgolini (AUT), PSMA session by Richard P. Baum (GER), and Alpha emitter -session by Jean-Francois Chatal (FRA) and Oyvind Bruland (NOR). The Thyroid session was organized by Mark Tulchinsky (USA), Ilya Sleptsov (RUS) and Raihan Hussein (BGL).

One of the achievements in the Helsinki ISRT-2018 was the "Theragnostics Day Proclamation" which also was published in World Journal of Nuclear Medicine (WJNM 2019; 18: 212). Additionally, the collaborations between SNMMI, WFNMB, IAEA and WARMTH were discussed intensively." (Kalevi Kairemo, November 2019)



International Symposium on Radiopharmaceutical Therapy Helsinki, 18-20 November 2018

DAY 1, SUNDAY, NOVEMBER 18, 2018

- | | |
|----------------------|---|
| 13.00 – 18.30 | REGISTRATION for ISRT 2018 |
| 14.00 – 16.00 | SCIENTIFIC SESSION 1: NUCLEAR CARDIOLOGY
Moderators: Juhani Knuuti, Turku, Finland and Pietro Muto, Naples, Italy |
| 14.00 – 14.30 O1 | Revolution in cardiac imaging: Quantitative perfusion, inflammation and hybrid imaging Juhani Knuuti, Turku, Finland |
| 14.30 – 15.00 O4 | Novel therapies of cardiac regeneration. How imaging can help in diagnosis, targeting and monitoring? Seppo Ylä-Herttuala, Kuopio, Finland |
| 15.00 – 15.30 O2 | Imaging innervation. Finally clinical applications? Albert Flotats, Barcelona, Spain |
| 15.30 – 16.00 O3 | Gauging cardiac repair, regeneration and inflammation with new molecular probes James Thackeray, Hannover, Germany |
| 16.00 – 16.30 | COFFEE & TEA BREAK |
| 16.30 – 18.45 | SCIENTIFIC SESSION 2: NEW TRENDS IN ONCOLOGY AND PRECISION MEDICINE.
Moderators: Vivek Subbiah , MDACC, Houston, TX, USA and Homer Macapinlac , MDACC, Houston, TX, USA |
| 16.30 – 16.55 O5 | Personalized medicine and precision oncology , Vivek Subbiah, Investigational Cancer Therapeutics, UT MD Anderson Cancer Center |
| 16.55 – 17.20 O6 | Precision oncology in rare tumors: adopting the orphans , Roman Groisberg, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA |
| 17.20 – 17.45 O7 | Optimizing patient selection for phase 1 clinical trials: lessons from targeted therapy and immunotherapy drug development , Shiraj Sen, Drug Development, Sarah Cannon Research Institute at HealthOne; Denver, CO, USA |



17.45 – 18.20 O8 **Target discovery for precision oncology using large public databases**, Jason Roszik, Department of Genomic Medicine, UT MD Anderson Cancer Center

18.20 – 18.45 O12 **Re-188 Lipiodol Liver Cancer Project – an update on current status**, Ajit Shinto, Coimbatore, India

WARMTH CONGRESS DINNER 1

19.30 – 22.30 Restaurant Meripaviljonki

DAY 2, MONDAY, NOVEMBER 19, 2018

08.00 – 18.00 REGISTRATION for ISRT 2018

09.00 – 11.00 OPENING CEREMONY

Welcome Address Partha Choudhury, President-Elect, WARMTH

Opening Remarks Kalevi Kairemo, Congress President, ISRT-2018, WARMTH

Welcome Address Pirkko Mattila, Minister of Health, Finland

WARMTH Candle Lighting Ceremony WARMTH Board Members

AJIT PADHY ORATION Steven M. Larson, MSKCC, NY, USA

O10 **"New Insights in Theragnostics"**

presenter Andrew M. Scott, Melbourne, Australia

11.00 – 11.30 COFFEE & TEA BREAK

11.30 – 13.00 SCIENTIFIC SESSION 3: RADIOEMBOLISATION AND LIVER THERAPIES

Moderators: Patrick Flamen, Brussels, Belgium and Aviral Singh, Bad Berka, Germany

- 11.30 – 11.55 O11 **Personalized SIRT based on predictive dosimetry, regional functional reserve measurement and molecular imaging**, Patrick Flamen, Jules Bordet Institute, Brussels, Belgium
- 11.55 – 12.20 O9 **Oncolytic viruses**, Akseli Hemminki, University of Helsinki
- 12.20 – 12.40 O13 **Biologic dosimetry in SIRT**, Katherine Vallis, University of Oxford, UK
- 12.40 – 13.00 O14 **Intra-arterial PRRT of SSTR-expressing liver tumors**, Aviral Singh, Bad Berka, Germany
- Posters:** P1 *The quantitative analysis of post-selective internal radiation therapy (SIRT) ⁹⁰Y microspheres PET/CT in hepatocellular carcinoma in comparison with ^{99m}Tc-labelled macroaggregated albumin (MAA) planar and SPECT/CT*, Ngoc Ha Le, Tran Hung Dao Hospital, Ho Chi Minh City, Vietnam
- 13.00 – 14.00 LUNCH AT THE CONGRESS CENTER PAASITORNI**
- 14.00 – 16.00 SCIENTIFIC SESSION 4: NEW RADIONUCLIDE THERAPIES / RADIATION HAZARDS/ SAFETY ISSUES**
Moderators: Seigo Kinuya, Kanazawa, Japan and Kazuko Ohno, Fukushima, Japan
- 14.00 – 14.30 O15 **Boron neutron capture therapy and world's first accelerator-based BNCT facility at Southern Tohoku General Hospital**, Yoshihiro Takai, Southern Tohoku BNCT Research Center, Japan
- 14.30 – 15.00 O16 **What did we learn from the Fukushima accident?** Ohtsura Niwa, Radiation Effects Research Foundation, Hiroshima/ Nagasaki, Japan
- 15.00 – 15.30 O17 **Regulatory nuclear safety aspects, Linear No-Threshold Hypothesis of risk from low-level radiation exposure**, Bennett S Greenspan, Society of Nuclear Medicine and Molecular Imaging, USA
- PANEL-discussion: Regulatory/ nuclear safety aspects**
Moderators: Seigo Kinuya, Kazuko Ohno and Bennet S Greenspan
- Posters:** P2 *Establishment of incident reporting programme and lesson learnt in unsealed radionuclide therapy*, Noreen Marwat, Nuclear Medicine Oncology and Radiotherapy Institute, Pakistan

- P3 ***Practices across Pakistan how medical emergency is handled in case of patients who has undergone unsealed radionuclide therapy***, Noreen Marwat, Nuclear Medicine Oncology and Radiotherapy Institute, Pakistan
- 16.00 – 16.30 COFFEE & TEA BREAK**
- 16.30 – 18.15 SCIENTIFIC SESSION 5: PROSTATE CANCER: PSMA RADIOLIGAND THERAPY (PRLT) – WHAT DO WE KNOW AND WHAT IS NEW?**
 Moderator: Richard P. Baum, Bad Berka, Germany
- 16.30 – 16.45 O18 **Introduction to PRLT**, Richard P. Baum
- 16.45 – 17.00 O19 **Dosimetry following Lu-177 PSMA radioligand therapy and an insight into novel radionuclides for theranostics of prostate cancer**, Aviral Singh, Bad Berka, Germany
- 17.00 – 17.15 O20 **Dosimetry in PSMA radioligand therapy of metastasized prostate cancer using Lu-177 PSMA I&T and Lu-177 PSMA-617** Christiane Schuchardt, Bad Berka, Germany
- 17.15 – 17.45 O21 **PSMA targeting and therapy trials in Australia**, Andrew M. Scott, Melbourne, Australia
- 17.45 – 18.00 O22 **Ac-225- and Bi-213- PSMA-617 radioligand therapy in patients with castration resistant prostate cancer**, Mike Sathekge, Pretoria, South Africa
- 18.00 – 18.15 O23 **[¹⁸F]AIF-PSMA-HBED-CC and ¹⁷⁷Lu-PSMA-617 as a potential theragnostic tandem and comparison with 68Ga-PSMA-HBED-CC in high-risk prostate cancer patients at initial staging**, Omar Alonso, CUDIM, Montevideo, Uruguay
- Posters: P4 ***¹⁷⁷Lutetium-prostate-specific membrane antigen radionuclide treatment of lymph node metastatic prostate cancer with PSA recurrence: A cohort study***, Finn Edler von Eyben, Odense, Denmark
- P5 ***Dosimetry in Molecular Radiotherapy - Bad Berka Experience***, Christiane Schuchardt, Bad Berka, Germany
- P6 ***Web-Monitoring Tool for ¹⁷⁷Lutetium-PSMA Treatments in Prostate Cancer Patients***, Kalevi Kairemo, Helsinki, Finland



18.25 *Tram transportation to the City Hall in front of the Scandic Paasi hotel (Hakaniemi Square stop 0252)*

WARMTH CONGRESS DINNER 2

19.00 – 20.30 **CITY HALL of Helsinki, Mayor Reception**

20.45 -21.45 *Tram transportation from the City Hall (Market Square stop) to the Scandic Paasi hotel (Hakaniemi Square) including sightseeing in Helsinki*

DAY 3, TUESDAY, NOVEMBER 20, 2018

08.00 – 08.45 REGISTRATION for ISRT 2018

8.45 – 11.00 SCIENTIFIC SESSION 6: THYROID CANCER – QUO VADIS?
Moderators: Mark Tulchinsky, PA; USA & Raihan Hussain, Dhaka, Bangladesh

Debating Controversies in Radioiodine Imaging and Therapy of Thyroid Cancer

8.45 – 9.00 O24 **Introduction-thyroid cancer management,** Mark Tulchinsky, Hershey, PA, USA

9.00 – 9.15 O25 **Total vs. subtotal thyroidectomy. East, West , what's the best?**
Ilya V. Sleptsov, St. Petersburg, Russia

9.15 – 9.30 O26 **Dosimetric approach of thyroid cancer,** Henry Bom, Chonnam, South Korea

9.30 – 9.45 O27 **Management of I-131 refractory thyroid cancer: a multimodality approach,** Partha Choudhury, New Delhi, India

9.45 – 9.55 O28 **Prevalence of genetic duet and its influence on the prognosis of differentiated papillary thyroid carcinoma patients,** Sanjana Ballal, New Delhi, India

9.55 – 10.00 O29 **Comments -thyroid cancer management,** Raihan Hussain, Dhaka, Bangladesh

Panel discussion: Moderator Mark Tulchinsky

Panelists: Raihan Hussain, Henry Bom, Partha Choudhury and Ilya Sleptsov, St. Petersburg, Russia

10.05 – 10.30	"Radioiodine Imaging Before, After, Both or Neither ... and How?"
10.30 – 10.55	"Controversies in Radioiodine Side-Effects: Confusion About Salivary Damage and Secondary Malignancy"
Posters: P7	<i>Antithyroglobulin antibody as a marker of successful ablation therapy in differentiated thyroid cancer</i> , Ayu Rosemeilia Dewi, Universitas Padjadjaran, Indonesia
P8	<i>Importance of isolated raised thyroglobulin antibody in follow up and management of differentiated thyroid cancer</i> , Ray Soumendranath, Tata Medical Center, Kolkata, India
P9	<i>Contribution of manual fusion in thyroid cancer whole body study with I-131. Case Report</i> , Mariela Agolti, Parana, Argentina
P10	<i>Contribution of manual fusion in thyroid cancer whole body study with I-131</i> , Mariela Agolti, Parana, Argentina
11.00 – 11.10	Lifetime Achievement Awards & Group Photo Irene Virgolini, President, WARMTH & Kalevi Kairemo
11.10 – 11.30	COFFEE & TEA BREAK
11.30 – 13.00	SCIENTIFIC SESSION 7: PEPTIDE RECEPTOR/ NEW THERAPIES Moderator: Irene Virgolini, Innsbruck, Austria
11.30 – 11.45 O30	Value of FDG in NET: importance of dual tracer imaging , Margarida Rodrigues Radischat, Innsbruck, Austria
11.45– 12.00 O31	Value of Re-PRRT in NET , Anna Yordanova, Bonn, Germany
12.00– 12.15 O32	PRRT in G3-NEN , Aviral Singh, Bad Berka, Germany
12.15– 12.35 O33	New peptides for PRRT in Non-NETs , Irene Virgolini, Innsbruck, Austria
12.35– 12.50 O34	Long-term side effects and quality of life, patients view Josh Mailman, San Francisco, USA

- 12.50– 12.58 O35 **A correlation between c-Fos expression and radioiodine in breast cancer cell lines**, Aisyah Eliyanti, Andalas University/ Dr.M.Djamil Hospital, Indonesia
- Posters:** P11 ***First ex-vivo experience with I- radiation and radioguided surgery technique in meningioma and neuroendocrine patients***, Chiara Maria Grana, European Institute of Oncology, Milan, Italy
- P12 ***Lutetium-labelled DOTA-TOC and radionuclide therapy (PRRT) in China: First Experience***, Feng Wang, Nanjing, China
- P13 ***Developing neuropeptide Y (NPY) nanoconstructs as potential theranostic agents***, Irfan Ullah Khan, Institute of Nuclear Medicine & Oncology, Lahore, Pakistan
- 13.00 – 14.00 LUNCH AT THE CONGRESS CENTER PAASITORNI**
- 14.00 – 16.00 SCIENTIFIC SESSION 8: NEW ALPHA- THERAPIES**
 Moderators: Oyvind Bruland, Oslo, Norway and Roy Larsen, Oslo, Norway
- 14.00– 14.30 O36 **Predicting the future of Alpha: clinical indications and radioisotopes of choice?** Jean-Francois Chatal, Arronax, Nantes, France
- 14.30– 14.50 O37 **Radiometabolic therapy with ²²³Ra-dichloride: the European Institute of Oncology experience**, Chiara Maria Grana, European Institute of Oncology, Milan, Italy
- 14.50– 15.10 O38 **Ra-223 in osteosarcoma –Ph I-trial**, Vivek Subbiah, MD Anderson Cancer Center, USA
- 15.10– 15.30 O39 **Ra-224 labelled biodegradable carbonate microparticles (Radspherin[®]) to combat microscopical residual peritoneal carcinomatosis**, Tina Bønsdorf, Oncoinvent AS, Oslo, Norway
- 15.30– 15.50 O40 **“Dual-alpha” - an expanding technology for development of targeted alpha therapies**, Asta Juzeniene, Norwegian Radium Hospital, Oslo, Norway
- Posters:** P14 ***Clinical case of benefit due to deviation in Ra-223 treatment schedule***, Tatiana Kochetova, MRRC, Obninsk, Russia



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

- P15 ***Personalized molecular imaging with bone scintigraphy, NaF-PET, and FDG-PET for evaluation of osteosarcoma response to Radium-223***, Kalevi Kairemo, Houston, TX, USA
- P16 ***Treatment response evaluation in soft-tissue osteosarcoma metastases using fluoride-18 (¹⁸F)-PET/CT radiomics analysis for ²²³Ra-therapy***, Kalevi Kairemo, Houston, TX, USA
- P17 ***Substantiation of an individual therapeutic dose of ¹⁵³Sm-oxabiphor for the treatment of bone metastases***, Ganna Grushka, Grigorev Institute for Medical Radiology, Ukraine
- P18 ***Radionuclide therapy for bone pain palliation in anemic patients: role of erythropoietin***, Sukanta Barai, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
- P19 ***¹⁸F-fluoroethyltyrosine PET/CT: the European Institute of Oncology experience in brain tumors***, Chiara Maria Grana, European Institute of Oncology, Milan, Italy
- P20 ***Pharmaceutical development of the therapeutic radiopharmaceutical based on α -emitting Sm-153 in heat-sensitive carrier for brachytherapy of tumors of various locations***, NM Tolbit, Karpov Institute, Obninsk, Russia

15.50 – 16.20 COFFEE & TEA BREAK

16.20 – 17.00

SCIENTIFIC SESSION 9: FUTURE ASPECTS OF COLLABORATION OF WARMTH, IAEA AND WFNMB – ROUND TABLE DISCUSSION
Moderator: Irene Virgolini, Innsbruck, Austria

WARMTH perspective, Partha Choudhury, President-Elect

IAEA Perspective, NN, Vienna

WFNMB perspective, Andrew M. Scott, Melbourne, Australia

SNMMI perspective, Bennett Greenspan, USA

O41 Presentation of ICRT 2019, Feng Wang, Nanjing, China

O42 Closing remarks, Kalevi Kairemo




Candle Lighting Ceremony 19.11.2018 in Helsinki. Minister Pirkko Mattila(FIN), Kairemo (FIN), Baum (GER), Mailman (USA), Singh (IND/GER) and Hussein (BGL).



City of Helsinki Reception 19.11.2018 (City Hall). Deputy Mayor Sanna Vesikansa speaking (left), tram transportation and sightseeing (Kairemo as tour guide, right).

Group photo 20.11.2018







2019, Novi Sad, Serbia



This Meeting is under the auspices of
EANM and WARMTH

5th International Meeting on Molecular Imaging and Molecular Therapy 3rd Serbian Meeting on Hybrid Imaging and Molecular Therapy with International Participation

Updates in Nuclear Medicine – Diagnosis, Treatment & Beyond

March 8-9, 2019 Novi Sad



Venue

Amphitheatre of the Faculty of Medicine, Department of Pharmacy
Organizers: Faculty of Medicine & Serbian Society of Nuclear medicine





Dear colleagues and guests,

It is my great pleasure to welcome you to the city of Novi Sad to attend the 5th International Meeting on Molecular Imaging and Molecular Therapy and the 3rd Serbian Symposium on Hybrid Imaging and Molecular Therapy with International Participation, entitled *Updates in Nuclear Medicine – Diagnosis, Treatment & Beyond*. As in previous years, the Symposium is organized by the Medical Faculty of Novi Sad and the Serbian Society of Nuclear Medicine under the auspices of the EANM and WARMTH.

During previous meetings, we gathered together nuclear medicine physicians, chemists, physicists, technologists and those interested in nuclear medicine science from many countries all over the world. We had over 300 participants from 20 different countries.

Considering the fact that this is our 5th congress and that our team is now quite experienced in organizing events like this, you can expect an even better and enriched scientific and cultural program than before.

Nuclear medicine has changed in the recent years. It enables us to scan and treat patients with new techniques and radiopharmaceuticals, improving compliance and effectiveness of treatment and patient clinical outcome.

The scientific program has been designed to cover a wide range of nuclear imaging modalities and therapies. The conference is designed to be of interest for experts in the fields of nuclear medicine, oncology, neurology, urology, cardiology and endocrinology. Additionally, this meeting is intriguing and challenging for young nuclear medicine specialists as well as residents. Different specialties are invited to evaluate and learn about the role of nuclear medicine theragnostics-imaging to diagnose and treat the disease and management beyond initial diagnosis.

As the host city, Novi Sad isn't nicknamed the "Athens of Serbia" without a reason: its history as a vibrant, creative city continues nowadays is based on its established art galleries, enriched musical scene and a vibe that's more generally liberal than that of other Serbian cities. Recently Novi Sad received two prestigious recognitions, a 2019' European Youth Capital and 2012' European Capital of Culture.

This meeting is a great opportunity for you to communicate with colleagues from different countries all over the world. I am sure it will result in creative exchanges of ideas and future collaboration.

We are looking forward to welcoming you in our beautiful city of Novi Sad.

Yours Sincerely

Prof. Jasna Mihailović, MD, PhD

President of Serbian Society of Nuclear Medicine

Chairman, Organizing Committee



Organizing Committee

Prof Jasna Mihailovic, PhD, MD, President of Serbian Nuclear Medicine Society
 Prof Snezana Brkic, PhD, MD, Dean of the Medical Faculty of Novi Sad
 Vanja Cimbalevic, MD; Jelena Roganovic, MD
 Nina Klicov, Chief Technician; Marko Vasiljevic, Technician

Scientific Committee

Dr Aida Afgan, MD, Serbia
 Prof Boris Ajdinovic, MD, PhD, Serbia
 Prof Vera Artiko, MD, PhD, Serbia
 Prof Amela Begic, MD, PhD, Bosnia and Herzegovina
 Dr Paolo Castellucci, MD, Italy
 Assoc Prof Sabina Dizdarevic, MD, PhD, UK
 Prof Kemal Dizdarevic, MD, PhD, Bosnia and Herzegovina
 Prof Samer Ezziddin, MD, PhD, Germany
 Prof Stefano Fanti, MD, PhD, Italy
 Snezana Golubovic, MD, MSc Pharm, Serbia
 Prof Slobodan Ilic, MD, PhD, Serbia
 Prof Diwakar Jain, MD, PhD, USA
 Dr Pavel Krzhivitskiy, MD, MSc, Russian Federation
 Assoc Prof Ronan Killeen, MD, PhD, Ireland
 Asst Prof Alan Klitzke, MD, PhD, USA
 Prof Milovan Matovic, MD, PhD, Serbia
 Prof Ljiljana Mijatovic, MD, PhD, Serbia
 Prof Danijela Miladinova, MD, PhD, Republic of Macedonia
 Prof Jasna Mihailovic, MD, PhD, Serbia
 Prof Vladimir Obradovic, MD, PhD, Serbia
 Assoc Prof Dragan Pucar, MD, PhD, Serbia
 Prof Milena Rajic, MD, PhD, Serbia
 Prof Zvezdana Rajkovic, MD, PhD, RS, Bosnia and Herzegovina
 Dr Raluca Mititelu, MD, PhD, Romania
 Prof Daria Ryzhkhova, MD, PhD, Russian Federation
 Dr Aleksandar Simic, MD, Serbia
 Dr Qaisar Siraj, MD, PhD, Kuwait
 Prof Dragana Sobic-Saranovic, MD, PhD, Serbia
 Prof Viacheslav Sukhov, MD, PhD, Russian Federation
 Prof Irene Virgolini, MD, PhD, Austria
 Research Prof Sanja Vranjes-Djuric, PhD, Serbia
 Prof Jean-Noel Talbot, MD, PhD, France
 Prof Marina Vlajkovic, MD, PhD, Serbia
 Prof Katja Zaletel, MD, PhD, Slovenia
 Assoc Prof Radmila Zeravica, MD, PhD, Serbia

Honorary Committee

Prof Zoran Milosevic, PhD, Provincial Secretary for Higher Education and Scientific Research
 Prof Zoran Gojkovic, MD, PhD, Minister of Health of the province of Vojvodina
 Milos Vucevic, Mayor of the City of Novi Sad

General information

Early registration fee is EUR120 and is available until January 20, 2019; one-day registration fee is EUR30 (includes access to the sessions, coffee breaks with refreshments, and lunch on Saturday); late registration after January 20 is EUR 180, on-site registration is EUR 300. The registration fee includes congress material, coffee breaks, lunch, and dinners on Friday and Saturday. Registration is available on the next webpage <http://www.panacomp-kongresi.net/events/>

Hotel accommodation may be done individually or via *Panacomp* agency, also on the webpage of the Symposium. There you can find all information about the Symposium.

Abstracts (250 words) in English should be submitted until January 20, 2019 to jasnam61@gmail.com. Accepted abstracts will be published in the *Book of Abstracts*. During the gala dinner, the prize amounting EUR 100 will be awarded for the best oral presentation given by the residents-in training. The official language of the Meeting is English. The Symposium is under the auspices of the EANM and will be accredited from the national CME authority.

Friday March 8, 2017

13.30-14.00 Registration

14.00-16.00 Session: Theragnostics in Endocrine Diseases I
Moderators: Klitzke, Ruzhkova

14.00-14.20

Stefano Fanti, Italy

Different Tracers in Staging and Restaging Prostate Cancer

14.20-14.40

Ana Ugrinska, Republic of Macedonia

Nuclear Medicine Imaging of Prostate Cancer

14.40-15.00

Jean Noel Talbot, France

Parathyroid Imaging in Nuclear Medicine

15.00-15.20

Paolo Castellucci, Italy

The Use of DOTA Peptides and DOPA in NET

15.20-15.40

Raluca Mititelu, Romania

Radionuclide Bone Pain Palliation in Prostate Cancer

15.40-16.00 Discussion

16.00-16.20 Coffee break

16.20-18.00 Session: Theragnostics in Endocrine Diseases II – Part 1: Imaging
Moderators: Sukhov, Ajdinovic

16.20-16.40

Daria Ryzhkhova, Russian Federation

18 F-DOPA PET-CT Diagnostic of Medular Carcinoma

16.40-17.00

Natasa Pryulovic-Bunovic, Serbia

Multimodal Imaging in Breast Cancer – Current and Future Aspects

17.00-17.20

Daniela Miladinova, Republic of Macedonia

Whole Body SPECT vs. Planar Bone Imaging in Patients with Prostate and Breast Cancer

17.20-17.40

Pavel Krzhivitskiy, Russian Federation

SPECT-CT Visualization of Sentinel Lymph Nodes in Women with Cervical Cancer: Is it Important for Radiotherapy Planning

17.40-18.00 Discussion

19.00 Social Program

Saturday, March 9

8.30-9.50 Session: Thyroid Gland – Imaging and Therapy

Moderators: Fanti, Zaletel

8.30-8.50

Jasna Mihailovic, Serbia

The New Theragnostic Paradigm on Thyroid Cancer

8.50-9.10

Milovan Matovic, Serbia

Development and Realization of Automatic System for ¹³¹I Capsule Filling for Diagnosis and Therapy
 Purpose: Our Solution.

9.10-9.30

Katja Zaletel

The Role of Radioiodine in Graves' Disease Management

9.30-9.50 Discussion

9.50-10.00 Coffee break

10.00-12.00 Session: Theragnostics in Endocrine Diseases II – Part 2: Imaging and Therapy

Moderators: Majstorov, Begic

10.00-10.20

Irene Virgolini, Austria

Dual Tracer Imaging in NET

10.20-10.40

Marina Vlajkovic, Serbia

Theranostics in High-Risk- Children Neuroblastoma -Achievements and Concerns

10.40-11.00

Alan Klitzke, USA

177-Lu-Dotatate Therapy in Management of Neuroendocrine Tumors

11.00-11.20

Viacheslav Sukhov, Russian Federation

Comparison of F18 and Ga68 PSMA as Theranostics Pair-Agents to Lu177

11.20-11.40

Samer Ezziddin, Germany

PSMA PRLT-Augmented Treatment by Individualized Protocol, Tandem Alpha-Beta PRLT
 and Co-Medications

11.40-12.00 Discussion

12.00-12.20 Coffee break

12.20-14.00 Session: Theragnostics in CNS Diseases

Moderators: Virgolini, Ugrinska

12.20-12.40

Ronan Killeen, Ireland

Clinical Applications of FDG PET CT Brain in Oncology and Beyond

12.40-13.00

Sabina Dizdarevic, UK

Dementia Functional Imaging: How to Complete the Diagnostic Puzzle?

13.00-13.20

Kemal Dizdarevic, Bosnia and Herzegovina

Radionuclide Theragnostics for Neurosurgery

13.20-13.40

Leposava Brajkovic, Serbia

FDG-PET in Presurgical Evaluation of Focal Epilepsy

13.40-14.00 Discussion

14.00-14.45 Lunch

14.45-16.25 Session: Nuclear Medicine in Cardiopulmonal Diseases

Moderators: Ezzidin, Miladinova

14.45 – 15.05

Amela Begic, Bosnia and Herzegovina

Ventilation/Perfusion Tomography - V/P SPECT in Detection of Cardiopulmonary Diseases- Clinical Application

15.05-15.25

Diwakar Jain, USA

Cardiotoxicity of Cancer Chemotherapy: Early Detection, Treatment and Prevention

15.25-15.45

Qaisar Siraj, Kuwait

Multimodality Cardiac Imaging in the Diagnosis of CAD

15.45-16.05

Venjamin Majstorov, Republic of Macedonia

Myocardial Perfusion Findings in Patients with Systemic Lupus Erythematosus

16.05 – 16.25 Discussion

16.25-16.40 Coffee break

16.40-17.40 Oral Presentations: Residents In-Training

Moderators: Dizdarevic, Majstorov, Mihailovic

17.40-18.40 Hall A-Physicians' Poster Presentations:

Moderators: Ilincic, Zeravica

17.40-18.40 Hall B-Technologists' Poster Presentations:

Moderators: Klicov, Đorđević

18.40-18.55 Final Test and Meeting Evaluation

18.55 Closing the Meeting


20.30 Dinner at Hotel PARK

Residents In-Training Award





2019-ISRT Limassol, Cyprus



20 YEARS
Cyprus Society of Nuclear Medicine

6-10 November 2019
Atlantica Miramare Hotel
Limassol, Cyprus



Under the auspices





INVITATION

The Cyprus Society of Nuclear Medicine (CySNM) was formed in 1999 in Nicosia. Founding members were nuclear medicine specialists, medical physicists, nuclear medicine technologists and other doctors (cardiologists, oncologists) with a special interest in nuclear medicine. The first president was Dr. Savvas Frangos. The society has developed and become a member of the European Association of Nuclear Medicine and the World Federation of Nuclear Medicine and Biology. The current president is Dr. Ourania (Rena) Demetriadou.

Over the last two decades a lot of scientific work has been achieved. Nuclear Medicine has developed in terms of both imaging and therapy and is now a well-respected specialty within Cypriot medicine. The Cyprus Society of Nuclear Medicine is looking forward to celebrating its 20th birthday with all those friends and colleagues who have contributed to the society's success. We strongly believe that the best way to achieve that is through the organization of an "Anniversary Conference".

This would not just be a standard nuclear medicine conference. Though Cyprus is a small country we have had a big impact in the world of nuclear medicine and we wish to share our birthday with all our good friends worldwide. We are thankful to those world class leaders in nuclear medicine who have accepted our invitation and come here to Cyprus to share this special time with us. We will structure the meeting such that there will not only be exciting and learned lectures but there will be plenty of time for interaction and discussion including lively debates on controversies concerning nuclear medicine and its application.

We are particularly proud to give a special platform for young scientists to present their work, on the future of nuclear medicine, and the conference is open for abstracts submissions. If accepted this work will be presented in poster form and the accepted abstracts will be published in a special edition of a medical journal about Nuclear Medicine and thus be automatically cited in the Pubmed.

In addition to the program for clinicians and scientists there will be a high quality program for technologists covering the latest information concerning high quality nuclear medicine imaging including SPECT/CT and PET/CT. There will be the opportunity to discuss how we can modify our practices to provide safer and more effective imaging for our patients.

Do not forget that Cyprus is an amazing place to visit with over 5000 years of history and unique food, wonderful people and a mild climate. Attendance at this 20th birthday conference can easily be combined with a few extra days so you can really enjoy your trip.

So come and join us for an extra special conference, listen to the best lecturers in nuclear medicine, and enjoy all that this wonderful island has to offer as you share with us a very special 20th birthday.

Dr. Rena Demetriadou, President of CySNM

Dr. Savvas Frangos, Chair Scientific Committee



20 YEARS CYPRUS SOCIETY OF NUCLEAR MEDICINE Anniversary Conference Atlantica Miramare Hotel

SPEAKERS

Francesco Giammarile, IAEA
Dong Soo Lee, Korea
Irene Virgolini, Austria
Wim Oyen, The Netherlands
John Buscombe, UK
Andrew Scott, Australia
Arturo Chiti, Italy
Johannes Czernin, USA
Gregory Wiseman, USA
Pushan Bharadwaj, Singapore
Richard Baum, Germany
Iulia Andreea Chiriac, Romania
Jelena Šaponjski, Serbia
Evanthia Giannoula, Greece

Sobhan Vinjamuri, UK
Hossein Jadvar, USA
Partha Choudhury, India
Marcel Stokkel, The Netherlands
Ioannis Iakovou, Greece
Jean-Noël Talbot, France
Demetris Andreopoulos, Cyprus
Panos Papanastasopoulos, Cyprus
Marilena Theodorou, Cyprus
Panayiotis Economides, Cyprus
Vasilis Constantinides, Cyprus
Stasinos Theodorou, Cyprus
Agathoclis Agathocleous, Cyprus
John Koutsikos, Greece

PROGRAM

WEDNESDAY 6 NOVEMBER

- 19:00-19:45 Opening Remarks
Savvas Frangos, Chair of the Scientific Committee
Rena Demetriadou, President of CySNM
John Buscombe on behalf of the Speakers
Officials
Honorary memberships and acknowledge of contribution
- 19:45-20:15 Opening Lecture
Tumor Markers Imaging
Andrew Scott
- 20:15-22:30 Welcome reception



THURSDAY 7 NOVEMBER

08:30-10:30 Session 1 Brain and Radiotherapy Chairpersons: Andreas Fotopoulos, Wim Oyen

- 08:30-09:00 Brain SPECT and FDG PET
Dong Soo Lee
- 09:00-09:30 Imaging and Therapy of Brain Tumors
Andrew Scott
- 09:30-10:00 Is PET/CT adding on value in Radiotherapy planning ?
Marilena Theodorou
- 10:00-10:30 PET/CT in Radiotherapy
Wim Oyen
- 10:30-11:00 *Coffee Break*

11:00-13:00 Session 2 In memory of Ajit Padhy: How can we promote Nuclear Medicine? Coordinator: Savvas Frangos

- The role of the Organisations**
- 11:00-11:15 Dong Soo Lee, President of WFNMB
- 11:15-11:30 Irene Virgolini, President of WARMTH
- 11:30-11:45 Wim Oyen, President of EANM
- 11:45-12:00 Francesco Giammarile, IAEA
- The role of Journals**
- 12:00-12:15 Johannes Czernin, Editor in Chief JNM
- 12:15-12:30 Arturo Chiti, Editor in Chief EJNMMI
- The Situation in Countries**
- Traditional Countries: UK*
- 12:30-12:40 John Buscombe, President BNMS
- Small Countries: Cyprus, Greece*
- 12:40-12:50 Rena Demetriadou, President CySNM
- 12:50-13:00 John Koutsikos, President HSNMMI
- 13:00-14:30 *Lunch and poster walk*

14:30-16:00 Session 3 Bones Chairpersons: Francesco Giammarile, Arturo Chiti

- 14:30-15:00 F18 FDG PET/CT in Osteomyelitis
Sobhan Vinjamuri
- 15:00-15:30 Radiosynoviorthesis an old new (attractive) person
Ioannis Iakovou
- 15:30-16:00 Sodium Fluoride PET/CT: Clinical experience
Sobhan Vinjamuri
- 16:00-16:30 *Coffee Break*

16:30-18:00 Session 4 Miscellaneous Chairpersons: Ioannis Iakovou, Sobhan Vinjamuri

- 16:30-17:00 FDG PET in breast cancer staging. Where are we now
Marcel Stokkel
- 17:00-17:30 Advanced imaging in lung cancer: applications of radiomics and artificial intelligence.
Arturo Chiti
- 17:30-18:00 Cancer Immunotherapy: Where are We Headed with Imaging Treatment
Response Criteria
Hossein Jadvar





WARMTH
 WORLD ASSOCIATION
 OF RADIOPHARMACEUTICAL
 AND MOLECULAR THERAPY
 FOUNDED 2009

**FRIDAY
 8 NOVEMBER**

09:00-10:30 Session 5 Lymphomas

Chairpersons: Diogenis Kyprianou, Ioannis Iakovou

- 09:00-09:30 Lymphomas: The Hematologists View
Agathoclis Agathocleous
- 09:30-10:00 Lymphoma Treatment Response Assessment
Gregory Wiseman
- 10:00-10:30 Radiomics as a tool to asses response to immunotherapy in refractory HL.
Arturo Chiti
- 10:30-11:00 *Coffee Break*

11:00-13:00 Session 6 Thyroid

Chairpersons: John Koutsikos, Alexis Vrachimis

- 11:00-11:30 Thyroid Nodules
Panayiotis Economides
- 11:30-12:00 Extent of Surgery
Vasilis Constantinides
- 12:00-12:30 Radioiodine Therapy in Thyroid Cancer
Gregory Wiseman
- 12:30-13:00 New guidelines effect in everyday practice of DTC patients follow up
Ioannis Iakovou
- 13:00-14:30 *Lunch and poster walk*



14:30-16:00 Session 7 Cardiac

Chairpersons: Jean-Noel Talbot, Raluca Mititelu

- 14:30-15:00 What are the questions to be answer for Cardiologists?
Stasinos Theodorou
- 15:00-15:30 Myocardial perfusion imaging: why do we need PET?
Pushan Bharadwaj
- 15:30-16:00 Nuclear viability imaging: current evidence base
Pushan Bharadwaj
- 16:00-16:30 *Coffee Break*



16:30-18:00 Session 8 Miscellaneous

Chairpersons: Pushan Bharadwaj, Partha Choudhury

- 16:30-16:50 Fluorine-18-choline PET/CT for parathyroid imaging
Jean-Noel Talbot
- 16:50-17:10 Approach to treatment and its optimization in primary and metastatic hepatic malignancies
Partha Choudhury
- 17:10-17:30 Fluorine-18-choline PET/CT in oncology (non-prostate indications)
Jean-Noel Talbot
- 17:30-18:00 Imaging atheroma with PET
John Buscombe



SATURDAY 9 NOVEMBER

08:30-10:00 Session 9 Neuroendocrine Tumors

Chairpersons: Marcel Stokkel, Vera Artiko

- 08:30-09:00 Neuroendocrine Tumors: The medical oncologist View
Panos Papanastasopoulos
- 09:00-09:30 Importance of Dual Tracer Imaging in NETs
Irene Virgolini
- 09:30-10:00 Advancing Personalized Nuclear Medicine: Past, Present and Future of Peptide Receptor Radionuclide Therapy (PRRT) of neuroendocrine tumors
Richard Baum
- 10:00-10:30 *Coffee Break*



10:30-12:30 Session 10 Prostate

Chairpersons: Alexis Vrachimis, Richard Baum

- 10:30-11:00 Clinical Management of Prostate Cancer
Demetris Andreopoulos
- 11:00-11:30 Non-PSMA PET of Prostate Cancer: Is There a Role?
Hossein Jadvar
- 11:30-12:00 Is a place for Ra-223 therapy in the era of PSMA?
John Buscombe
- 12:00-12:30 The role of nuclear medicine in prostate cancer imaging and treatment including image guided surgery.
Marcel Stokkel



SUNDAY 10 NOVEMBER

08:30-10:30 Session 11 Prostate

Chairpersons: Irene Virgolini, Hossein Jadvar

- 08:30-09:15 PSMA targeted theragnostics: From bench to Bedside
Johannes Czernin
- 09:15-10:00 The Power of Precision Oncology: From Innovation to Implementation using PSMA Radioligand Therapy (PRLT) of prostate cancer
Richard Baum
- 10:00-10:30 *Coffee Break*



10:30-12:00 Session 12 Can we predict the future?

Chairpersons: Arturo Chiti, Nicolas Eftychiou

- 10:30-11:00 The Future of Nuclear Medicine,
Johannes Czernin, USA
- 11:00-12:00 Vision of Nuclear Medicine through the eyes of young Specialists
- 11:00-11:15 Evanthia Giannoula, Greece
- 11:15-11:30 Jelena Šaponjski, Serbia
- 11:30-11:45 Iulia Andreea Chiriac, Romania
- 11:45-12:00 Discussion



12:00-13:30 Session 13 Closing Ceremony

- 12:00-13:00 Highlight lecture
Savvas Frangos
- 13:00-13:30 Closing and Award ceremony
Rena Demetriadou, Savvas Frangos





Salomi Tavern



Agios Epiktitos Tavern



EUSTOLIOS HOUSE

This building, excavated around 1938, was originally thought to be a palace.

Its earliest phase dates to the early Roman period but it was drastically altered during the 3rd and 4th centuries AD. The building complex we see today is the result of extensive remodeling during the last few years of rule of the emperor Theodosius II (AD 408-450 AD).

It follows the usual Roman peristyle type of private base architecture and the rooms can be divided into three clusters or groups.

The first group, situated around this sign, is the first one one meets when entering the complex. This is the northern area, having a main entrance (1) and forecourt (2), around which are preserved the north and south rooms which were used as a service area (15, 16) for storage.

The floor has a short welcoming inscription (A):

ENTER TO THY
GOOD FORTUNE
AND MAY THY COMING BLESS
THIS HOUSE

This forecourt leads to the vestibule (3) of the central section of the building and is situated at a slightly higher level. This vestibule leads onto the forecourt with a central courtyard atrium (4), complete with garden, fountain and pool (5). Colonnaded porticoes (6,7,8) which also have mosaic floors, surround the courtyard. The most significant preserved mosaic floors are found around the peristyle courtyard, reception areas and general purpose rooms (9, 10, 11, 12).



Kourion Amphitheatre



UNESCO Lofou Village



Dinner in Kamerones Tavern





Other Meetings where WARMTH Friends find Each Other

5th THERANOSTICS World Congress 2019
MARCH 1 - 3, 2019
THE SHILLA JEJU HOTEL, JEJU, KOREA

A Gate to the Future of Theranostics

1 st Germany Bad Nierke	2 nd India Chandigarh	3 rd USA Baltimore	4 th Australia Melbourne	5 th Korea Jeju
---------------------------------------	-------------------------------------	----------------------------------	--	-------------------------------

www.theranostics2019.org



Organized by: Korean Association for Nuclear Medicine Promotion (KANUPROM), The Korean Society of Nuclear Medicine (KSNM), The Korean Academy of Science and Technology

Logos: KANUPROM, KSNM, The Korean Academy of Science and Technology, University of Bonn Hospitals & Clinics

PRELIMINARY SCIENTIFIC PROGRAM – CURRENT LIST OF CONFIRMED SPEAKERS AND TOPICS
2nd World Congress on Ga-68 (Generators and Novel Radiopharmaceuticals), Molecular Imaging (PET/CT), Targeted Radionuclide Therapy, and Dosimetry (SWC-2013): On the Way to Personalized Medicine
February 28 - March 2, 2013
Chandigarh, India
1st ANNOUNCEMENT



Annual ENETS Barcelona, Spain





WARMTH Scientific Projects

1. Liver-Targeted Therapy

^{188}Re -Lipiodol Project (Ajit Shinto, Coimbatore, India)

2. Thyroid Diseases

Radioiodine Therapy for Differentiated Thyroid Carcinoma (Sabina Dizdarevic, Sussex, UK)

3. PRRT

Retrospective WARMTH Study: Multicenter Analysis of ^{68}Ga -Somatostatin Receptor and ^{18}F -FDG-PET/CT (Dual-Tracer Imaging) in Neuroendocrine Tumor Patients Treated With Peptide Receptor Radionuclide Therapy (Margarida Rodrigues, Innsbruck, Austria)

4. PRLT

Retrospective Multicentre Analysis of Castration Refractory Metastatic Prostate Cancer Patients Treated by ^{177}Lu -PSMA-617 (Hojjat Ahmadzadehfard, Bonn, Germany)

National Investigators Global Harmonization of Theranostics of Cancer of Prostate (NiGHTCAP) (Harvey Turner, Perth, Australia)

Salvage Radiotherapy with or without ^{177}Lu -PSMA Radionuclide Treatment for Lymph Node Metastatic Prostate Cancer: A Randomized Phase 2 Trial (Finn von Eyben, Helsinki, Finland)

Combination Treatment ^{223}Ra / ^{177}Lu -PSMA617 (Irene Virgolini, Innsbruck, Austria, Sabina Dizdarevic, Sussex, UK)



CLINICAL INVESTIGATION

Liver

INTRA-ARTERIAL RHENIUM-188 LIPIODOL IN THE TREATMENT OF INOPERABLE HEPATOCELLULAR CARCINOMA: RESULTS OF AN IAEA-SPONSORED MULTINATION STUDY

PATRICIA BERNAL, M.D.,* JEAN-LUC RAOUL, M.D., Ph.D.,[†] GAJ VIDMAR, Ph.D.,[‡]
ERDENECHIMEG SEREEGOTOV, M.D.,[§] FELIX X. SUNDAM, M.D.,^{||} AJAY KUMAR, M.D.,[¶]
JAE MIN JEONG, M.D., Ph.D.,** PAWANA PUSUWAN, M.D.,^{††} CHAITANYA DIVGI, M.D., Ph.D.,^{‡‡§§}
PAT ZANZONICO, M.D., Ph.D.,^{¶¶} JANEZ STARE, M.D., Ph.D.,[‡] JOHN BUSCOMBE, M.D.,^{|||} CHAU TRINH THI
MINH, M.D.,^{¶¶} MAUNG MAUNG SAW, Ph.D.,^{||} SHAOLIANG CHEN, M.D.,*** RUBEN OGBAC, M.D.,^{†††}
AND AJIT K. PADHY, M.D.^{||†††}

*Fundacion Santa Fe De Bogota, Bogota, Colombia; [†]Centre Régional de Lutte Contre le Cancer, Centre Eugène Marquis, University of Rennes, Rennes, France; [‡]IBMI, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; [§]First State Central Clinic, National Medical University of Mongolia, Ulaanbaatar, Mongolia; ^{||}Singapore General Hospital, Singapore; [¶]All India Institute of Medical Sciences, New Delhi, India; **Seoul National University Hospital, Seoul, South Korea; ^{††}Siriraj Hospital, Mahidol University, Bangkok, Thailand; ^{‡‡}Memorial Sloan-Kettering Cancer Center, New York, NY; ^{§§}Division of Nuclear Medicine & Clinical Molecular Imaging, University of Pennsylvania, Philadelphia, PA; ^{|||}Royal Free Hospital, London, United Kingdom; ^{¶¶}Cho Ray Hospital, Ho Chi Minh City, Vietnam; ***Zhongshan Hospital, Fudan University, Shanghai, China; ^{†††}St. Luke's Medical Centre, Quezon City, Philippines; and ^{||†††}International Atomic Energy Agency, Vienna, Austria

Purpose: Intra-arterial injections (IAI) of ¹³¹I-lipiodol is effective in treating hepatocellular carcinoma patients, but is expensive and requires a 7-day hospitalization in a radioprotection room. ¹⁸⁸Re is inexpensive, requires no patient isolation, and can be used with lipiodol.

Methods and Materials: This International Atomic Energy Agency–sponsored phase II trial aimed to assess the safety and the efficacy of a radioconjugate ¹⁸⁸Re + lipiodol (¹⁸⁸Re-Lip) in a large cohort of hepatocellular carcinoma patients from developing countries. A scout dose is used to determine the maximal tolerated dose (lungs <12 Gy, normal liver <30 Gy, bone marrow <1.5 Gy) and then the delivery of the calculated activity. Efficacy was assessed using response evaluation criteria in solid tumor (RECIST) and alpha-feto-protein (αFP) levels and severe adverse events were graded using the Common Toxicity Criteria of the National Cancer Institute scale v2.0.

Results: The trial included 185 patients from eight countries. The procedure was feasible in all participating centers. One treatment was given to 134 patients; 42, 8, and 1 received two, three, and four injections, respectively. The injected activity during the first treatment was 100 mCi. Tolerance was excellent. We observed three complete responses and 19 partial responses (22% of evaluable patients, 95% confidence interval 16–35%); 1- and 2-year survivals were 46% and 23%. Some factors affected survival: country of origin, existence of a cirrhosis, Cancer of the Liver Italian Program score, tumor dose, absence of progression, and posttreatment decrease in αFP level.


Conclusions: IAI of ¹⁸⁸Re-Lip in developing countries is feasible, safe, cost-effective, and deserves a phase III trial. © 2007 Elsevier Inc.

Hepatocellular carcinoma, Radiolabeled lipiodol, ¹⁸⁸Rhenium, Internal radiotherapy.

Results: Efficacy

SURVIVAL

- Median follow up period: 455 days
- Median Survival: 256 days
- Estimated survival at:
 - 3 months : 93%
 - 6 months : 60%
 - 1 year : 46%
 - 2 years : 23%



***Estimated population survival curve
with 95% confidence interval.***

•Bernal P, Raoul JL, Vidmar G, et al. Intra-arterial Rhenium-188 Lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multi-nation study. Int J Radiat Oncol Biol Phys. 2007; 69:1448-55

•Bernal P, Raoul J-L, Stare J, et al. IAEA-sponsored multi-nation study of Intra-arterial Rhenium-188 Lipiodol in the treatment of inoperable hepatocellular carcinoma: Results with special emphasis on prognostic value of dosimetric study. Seminars in Nucl Med, March, 2008



1. Liver-Targeted Therapy with ^{188}Re -(AHDD) Lipiodol

The WARMTH Multicenter Study on liver cancer therapy using ^{188}Re -(AHDD) Lipiodol was the first multicenter project initiated by Ajit Padhy while he was still in charge of the Division of Nuclear Medicine at the IAEA .



This WARMTH multicenter project is an excellent example for the successful implementation of Nuclear Medicine therapy in developing countries. First data were published in the Int. J Radiation Oncology Bio. Phys., 2007;69:1448-1455 by Patricia Bernal et al. During the South Indian Society Meeting of Nuclear Medicine August 16-18, 2013 in Coimbatore, India, Ajit Padhy empowered the liver-targeted therapy. Following the sudden demise of Ajit Padhy on August 22, 2013 after his return to Singapore, the project had already found its roots in the developing countries. Following the discussions in Manila during the ICRT-2013, Ajit Shinto from Coimbatore, took over The WARMTH ^{188}Re -Lipiodol-Project. The first World Rhenium Congress was subsequently held in 2015 in Coimbatore, India, and was significantly supported also by the IAEA. A 2nd World Congress followed in August 2017. During the meetings in Coimbatore, extensive practical education was done for participants from mostly developing countries. These actions were part of The WARMTH's WTA.






WARMTH
WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY
FOUNDED 2009

SAVE THE DATE
AUGUST 16th To 18th



**19th Annual Conference of
Society of Nuclear Medicine India, - Southern Chapter
Coimbatore**

**Targeted
Therapy
in Oncology**



Venue : Koval Medical Center and Hospital, Coimbatore





WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

August 18
Sunday



8:00 AM Workshop

NEURO-ENDOCRINE TUMOURS

9:00 AM Surgical options in NET
Dr. Senthil

9:30 AM MEDICAL Oncology role in NET
Dr. Sudhakar Natarajan

9:45 AM PRRT - AIIMS experience and Lowdose, fractionated Rx
Dr. Bal.C.S

10:15 AM Kit formulation for Diagnosis and Therapy
Dr. Sharmila Banerjee

10:30 AM Non NET – PRRT / cocktail Rx
Dr. Renata Mikolajczak

10:50 AM  Coffee break

LATEST ADVANCES

11:15 AM PET-CT based interventions
Dr. Mittal.B.R

11:35 AM PRRT -State of the art
Prof. Irene Virgolini

11:55 AM PET MRI initial experience
Dr. Uma Ravishankar

12:15 PM Targeted therapy
Dr. Christian Behrenbruch

12:35 PM PET – MRI in Paediatrics
Dr. James Warrington

12:55 PM Technological update by PHILIPS

Dr. Paul Vannan

Dr. Mohan Prasad
Dr. L.V.Krishnamoorthy
Dr. Karthiges

Dr. Ajit Shinto

Dr. Kavitha Reddy
Dr. Maharajan
Dr. Kumaresan



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

August 17
Saturday



8:00 AM Workshop

HCC (Session 1)

9:00 AM Surgeon's perspective
Dr. Senthilnathan.P

9:20 AM Medical Oncologist-overview of treatment modalities
Dr. Sivanesan

9:40 AM Transarterial therapies for HCC and techniques
Dr. Mathew Cherian

10:00 AM Dosimetric Considerations in Radioconjugate Therapy
of HCC
Dr. Magsombol Butch Maulion

10:25 AM Y90 in metastatic and colorectal / Breast Ca
Dr. James Warrington

10:50 AM



Coffee break

HCC (Session 1)

11:05 AM 188W/188Re generator and therapeutic applications
Prof. Ashutosh Dash

11:20 AM Re188 Lipiodol Treatment of HCC: A perspective
Dr. Ajit Padhy

11:45 AM Labelling procedure for Re Lipiodol and re formulation
Dr. Jae Min Jeong

12:05 PM Setting up a Re Lipiodol facility
Dr. Muang Muang Saw

12:25 PM The mongolian experience in liver cancer therapy
Dr. Sereegotov

12:45 PM I-131 Lipiodol therapy and experience
Dr. Kallur.K.G

1:00 PM



Lunch break



Dr. N.Sudhakar



Dr. Nagaraj M
Dr. Suresh V
Dr. Paul Vannan



Dr. N.Kuppurajan



Dr. Karthikeyan
Dr. Vimalakannan
Dr. Subash John



On behalf of the Dept of Nuclear Medicine and Therapy, KMCH, Coimbatore and WARMTH (World Association Of Radionuclide And Molecular Therapy), I am pleased to invite you to the very First World Rhenium 188 Congress and Workshop. As a unique trait, the Symposium focuses exclusively on Re-188 based imaging, therapy, pre clinical research, existing clinical applications, on the recent advances in Re radiometal coordination chemistry, and on the new applications of Re radiometal-containing molecules in pre-clinical and clinical imaging and radiotherapy.

The Congress, is intended for chemists, physicists, technologists, physicians and all scientists and clinicians interested in Re-188 based translational research and current state-of-the-art molecular imaging and radionuclide therapy. The re-emergence in enthusiasm for Re-188 use over the last several years can be ascribed to several factors, some of which promise an increasing role for Re-188 as a tool in both diagnostic and therapeutic applications such as theranostics. The term "theranostics" symbolizes the inseparability of diagnosis and therapy and has a profound effect personalized disease management. (Ajit Shinto, 2015)

Ajit Shinto, Coimbatore, India, pointed out the following needs for the Rhenium-Project:

*„Subsidized generator, regular availability (ITG)
Training and help in setting up the Radio-pharmacy
IR proctor, dosimetry and kits
Standardized criteria for treatment-uniform data
Multiple centers in India and other developing countries
Encourage any other dept to start.
Also enable other therapies like
-Bone pain palliation therapy
-Intravascular brachytherapy
-RSV, skin patch therapy
-V-DMSA Therapy“*






WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009




Re world
Rhenium
congress

AUGUST 14 - 15, 2017

KOVAI MEDICAL CENTER & HOSPITAL, INDIA

'RE'-INVENTING RHENIUM 188

**'TARE'-ING DOWN THE BARRIERS
FOR LIVER CANCER THERAPY**



CALL FOR ABSTRACTS
OPEN FROM
SEP 15th 2016

**KOVAI MEDICAL CENTER
AND HOSPITAL**

Dept. of Nuclear Medicine, PET CT and Therapy
Avinashi Road, Coimbatore - 641 014, India.
Phone: 0422 4323800 - 802, 3083800



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009



Re world
Rhenium
congress



First World Rhenium - 188 Congress (11th-13th Sep 2015)

REGISTRATION OPENS 8:00 am onwards

Day 1: Rhenium-188 Radiopharmaceuticals - 08:30 am - 05:00 pm

Tungsten-188/Rhenium-188 generator technology, New developments : 08:30 am - 10:30 am

CHAIR PERSONS: DR. PHILIP BLOWER, DR. ROGIER LANGE

Bernard Ponsard: "Production of W-188/Re-188 in the BR2 High-Flux Reactor" and "Securing the Supply of Medical Radioisotopes (25 mins)

Richard Henkelman: ITG (25 mins)

Philippe van Putt: Design of Re-188 generator considering diverse source of W-188 (25 mins)

Ashutosh Dash: 188-W/188-Re generators using low specific activity 188-W: Possible path forward (BARC) (25 mins)

10:30 am - 11:00 am TEA/COFFEE

11:00 am - 11:45 am - OPENING CEREMONY

Basics of Re chemistry and radiopharmaceutical development 12:00 Noon - 02:00 pm

CHAIR PERSONS: DR. SZE TING LEE, DR. HARVEY TURNER

Phil Blower: Chemistry and labeling methods for preparing Re-188 radiopharmaceuticals (12:00 pm - 12:30 pm)

M R A Pillai: Re-188 radiopharmaceuticals: Products having potential to move from bench to bedside (12:30 pm - 01:00 pm)

Advances in Re chemistry focused on development of new therapeutic agents

1. *Sharmila B:* Re DEDTC (BARC) (01:00 pm - 01:20 pm)

2. *Tatiana:* 188 Re Based Radiopharmaceuticals for Treatment Bone metastases: Comparative Data. (01:20 pm - 01:40 pm)

3. *Chih Hsien:* Translating Research of Re-188-liposome for Cancer Therapy: From Bench to Bed (01:40 pm - 02:00 pm)

02:00 pm - 03:05 pm LUNCH

RADIOPHARMACY, DOSIMETRY AND REGULATORY ASPECTS: 03:00 pm - 05:30 pm

CHAIR PERSONS: DR. SURESH S, BERNARD PONSARD

Harvey Turner: Important issues for establishing radiopharmacy and handling of Re-188 (20 mins)



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009



Re world
Rhenium
congress



Pedro: Quantitative measurements of Re-188 activity (20 mins)

Knut Liepe: Dosimetry for Re based microsphere, synovectomy and pain palliation therapy (20 mins)

Pankaj Tandon: Regulatory aspects for starting a Re 188 programme (20 mins)

Venkatesh Ranganathan: Issues for starting a Re programme (TMH) (20 mins)

Rogier Lange: Influence of carrier concentration and of varying the process variables on the product quality of Re Rp's (20 mins)

Pedro: Quantitative Imaging and Dosimetry Calculations for use in 188Re Radionuclide Therapies. (20 mins)

INFORMAL BANQUET - "LUNGI DANCE" THE KOVAI CARNIVAL

DAY 2: Interventional technologies using Rhenium-188 – Liver cancer and restenosis therapy

08.00 am - 10:00 am generator and wet chemistry demonstrations

LIVER CANCER AND Re-188 Lipiodol 10:00 am - 01:15 pm

CHAIR PERSONS: DR. RICHARD BAUM, DR. SHARATH PUTTA

Vivekanandan Shanmugham: Liver cancer: clinical treatment algorithms (10:00 am - 10:20 am)

Mathew Chanin: Basics of interventional radiology treatment of HCC (TACE and TARE) (10:20 am - 10:45 am)

Harvey Turner: Radioconjugate options for TARE and their comparison. (10:45 am - 11:05 am)

Patricia Bernal: Initial human studies with Re Lipiodol (11:05 am - 11:25 pm)

Arun Malhotra: The AIIMS experience (11:25 am to 11:40 am)

CHAIR PERSONS: DR. FELIX SUNDARAM, DR. SZE TING LEE

Eric Cruz: Trans-arterial 188Re-HDD-Lipiodol Therapy for Inoperable Liver Malignancy: Initial Philippine Experience (11:40 am - 12:00 Noon)

Jeong: AHDD kit for liver cancer Rx (12:00 Noon - 12:20 pm)

Knut Liepe: Re-188 Microspheres experience (12:20 pm - 12:45 pm)

Lepareur: Re Lipiodol SSS radiochemistry bio-distribution and pharmacokinetics and clinical results (12:45 pm - 01:10 pm)

Dr. Ajit Shanta: Summing up and WARMTH Rhenium project (01:10 pm - 01:20 pm)



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009



Re world
Rhenium
congress



01:20 pm - 02:30 pm LUNCH

BRACHYTHERAPY AND RESEARCH SESSION : 02:30 pm - 05:30 pm

CHAIR PERSONS: DR. EMERITA B, DR. RICHARD BAUM

Joachim Kropp: Endovascular brachytherapy - coronary and peripheral (02:30 pm - 03:20 pm)

Research Paper presentations (03:20 pm - 05:30 pm) Each 12 mins

1. Pedro: Characterization of Re-188 emissions for SPECT quantification in radionuclide therapy
2. Anupam: **A novel 188Re analogue of 131I-mIBG with affinity for Nor-epinephrine transporter (NET)**
3. Aswathi K: In vivo dosimetry with various Re 188 Lipiodol agents
4. Pedro: Accuracy of quantitative Re-188 imaging using a small animal SPECT/CT
5. Rakhee: Re-188 labeled stannous chloride particles for radiation synovectomy: In-house preparation
6. Surlapta: Is 90Y an alternative to 188Re in Indian Context? A Comparative Feasibility Assessment
7. Indira U: Preparation/QC of Re 188 Sn colloids and V-DMSA
8. Radhakrishnan FR: Preparation/QC of Re 188 Sn V-DMSA
9. Tatiana: The first data of absorbed doses of 188Re-Zoledronic acid in humans with bone metastases
10. Priya Bhasari: Preparation and quality control of Re-188-EDTMP for bone pain palliation
11. Bagher Aziz: Improvement of the Rhenium Radiopharmaceuticals in IRAN
12. Rubel C: **Studies on reproducibility of post elution concentration of 188Re using single DEAE cellulose anion exchanger column**
13. Aswathi: Freeze dried HEDP (1-HYDROXYETHANE 1, 1-DIPHOSPHONIC ACID) kit for the preparation of 188Re-HEDP: In house development and clinical evaluation

FORMAL BANQUET: With WARMTH, IAEA and THE GET PADHIED orations.



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009



Re world
Rhenium
congress



DAY3: Key clinical applications using rhenium-188 radiopharmaceuticals

DEMO LABELLING OF RSV,HEDP, AHDD, SSS AND NITRIDO 08:00 am - 10:00 am

SYNOVECTOMY AND SKIN THERAPY 10:00 am - 12:45 pm

CHAIR PERSONS: DR.RICHARD BAUM, DR.MRA PILLAI

Knut Liepe: Comparison with other agents for synovectomy and clinical experience (10:00 am - 10:40 am)

Shamim: Re188 colloid in Radiosynovectomy AIIMS (10:40 am - 11:00 am)

Stepchenkov: Re-188 generators produced at SSC RF - IPPE for radioisotope therapy (11:00 am - 11:25 am)

Anun Malhotra: Re-188 radio labelled skin patch for treatment of BCC(Basal Cell Ca) (11:25 am - 11:45 am)

Praya: Overview of Re based radiopharmaceutical work at PGIMER (11:45 am - 12:10 pm)

Chris Adams: Re-188 P-2045 based therapy for lung cancers (12:10 pm - 12:40 pm)

12:45 pm - 01:45 pm LUNCH

BONE PAIN PALLIATION THERAPY

CHAIR PERSONS: DR.SACHDEVA, DR.PANKAJ DOUGALL

Knut Liepe: Comparison with other agents for pain palliation (01:45 pm - 02:10 pm)

Rogier Lange: Development of GMP grade Re-188-HEDP and clinical benefit for treatment of bone metastases (02:10 pm - 02:35 pm)

Liu Xing Dong: Rhenium-188-HEDP in the palliative treatment of bone metastases (02:35 pm - 03:00 pm)

Tatiana: Re-188 Zoledronic acid therapy (03:00 pm - 03:25 pm)

Suresh Srivastava: Closing remarks and Introducing Tin-117m for Conversion Electron Therapy of Liver Cancer (03:25 pm - 03:55 pm)

CLOSING CEREMONY 04:00 pm - 04:15 pm



2015, 1st World Rhenium Congress and World Theragnostic Academy WTA Coimbatore, India

- Faculty from over 30 countries and delegates from 35-40 countries.
- 4 New centers in India have started HCC therapy.
- We helped the 1st State Hospital of Mongolia to start their ^{188}Re -therapy programme.
- 2 other centers are doing advanced research on ^{188}Re -based HCC therapies
- PRC of China is starting a phase 2B trial on HEDP radiotherapy.
- We are collaborating with Kings College London for the global research challenge to develop ^{188}Re -based PSMA and V DMSA therapy and even for thyroid cancer.
- Standardization of dosimetric protocols. (Ajit Shinto)

2017, 2nd World Rhenium Congress and World Theragnostic Academy WTA Coimbatore, India

"We had the 1st ever completely dedicated Rhenium supplement published by IJNMR for which Prof Baum served as the guest editor.

We continue to support and training to the 6 centers in India. BARC has started producing DEDC/Tin Colloid/HEDP kits.

We have standardised the dosimetric protocol and are in the process of a MIRD pamphlet as well as a guideline publication in EJNM.

Just finished training NMP from South Africa to start Re programme and they have placed the order for the generator.

Have received applications from Myanmar and Colombia to help establish their Re programmes.

After 2 WRC, 2015 and 2017, the 3rd WRC next year in China 2019." (Ajit Shinto)



WARMTH





WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009



KMCH
Research Foundation

K	M
C	H






KMCH
 Research Foundation

K	M
C	H


Re 188 HEDP for skeletal pain palliation



Re 188 P2045

Doses of > 100 mCi per patient, but toxicity is an issue esp pre treated, low baseline counts and widespread marrow mets. Now 30-40 mCi in repeated doses are better tolerated .

Lu 177 DOTA-TATE




2. Thyroid Diseases

The theragnostic approach in personalised medicine is not a new one. A perfect example of an personalized theragnostic approach which has been established over the last 60 years is shown in this Fig. In the patient the post-therapeutic radioiodine scan showed intensive uptake in the lungs, identifying the lung metastases, which disappeared 6 months after radioiodine therapy.

Thyroid cancer may occur through rapid growth, evidenced by a cold nodule on the thyroid scan. The theragnostic approach of differentiated thyroid cancer consists of radical thyroid surgery followed by high dose radioiodine therapy and life-long thyroid hormone substitution therapy. With radioiodine treatment the 10 year survival of patients with thyroid cancer is more than 90% as long as the tumour is radioiodine-positive. However, when the tumor becomes radioiodine-negative – as tested by follow-up scintigraphy – the prognosis of thyroid cancer becomes very bad.



“Theranostic” Approach in Thyroid Cancer My Dear Old Friend Radioiodine – ^{131}I



^{131}I -Post-Therapy Scan
at 76 hrs, Tg 49 µg/l



^{131}I -Follow-up Scan after
6 months, Tg 3.7 µg/l




Treatment Strategy:

- Radical Thyroidectomy
- High-dose ^{131}I -Therapy
- Thyroid Hormone Substitution

10-Year-Survival

Durante et al. J Clin Endocrinol Metab. 2006



Nuclear Medicine Department, Medical University Innsbruck



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

DIZDAREVIC S¹, TULCHINSKY M²,
MCCREADY VR¹, MIHAILOVIC J³, VINJAMURI S⁴,
BUSCOMBE JR⁵, LEE ST^{6,7}, FRANGOS S⁸,
SATHEKGE M⁹, SIRAJ Q¹⁰, CHOUDHURY P¹¹, BOM H¹²,
FRANCESCHI M¹³, UGRINSKA A¹⁴,
PAEZ D¹⁵, HUSSAIN R¹⁶, MAILMAN J¹⁷,
LUSTER M¹⁸, VIRGOLINI I¹⁹,
ON BEHALF OF THE WARMTH THYROID GROUP



¹Department of Imaging and Nuclear Medicine, Brighton and Sussex University Hospitals NHS Trust, Brighton and Sussex Medical School, Royal Sussex County Hospital, Brighton, UK, ²Radiology Department, Nuclear Medicine Section, Penn State University, Milton S. Hershey Medical Center, USA, ³Department of Nuclear Medicine, Oncology Institute of Vojvodina, Sremska Kamenica, University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia, ⁴Department of Nuclear Medicine, Royal Liverpool University Hospital, Liverpool, ⁵Department of Nuclear

Medicine, Cambridge University Hospitals, Cambridge, UK, ⁶Department of Molecular Imaging and Therapy, Austin Health, Melbourne, ⁷Olivia Newton-John Cancer Research Institute, Heidelberg, Australia School of Cancer Medicine, La Trobe University, Heidelberg, Australia, ⁸Department of Nuclear

Medicine, Bank of Cyprus Oncology Center, Nicosia, Cyprus, ⁹Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa, ¹⁰Department of Nuclear Medicine, Farwania Hospital, Kuwait, ¹¹Department of Nuclear Medicine, Rajiv Gandhi

Cancer Institute and Research Centre, Delhi, India, ¹²Department of Nuclear Medicine, Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM), Chonnam National University Medical School, Gwangju, South Korea, ¹³Department of Oncology and Nuclear Medicine, Sestre Milosrdnice, UHC, Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia, Faculty of Medicine, University of Osijek, Osijek, Croatia, ¹⁴Institute of Pathophysiology and

Nuclear Medicine, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia, ¹⁵Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, International Atomic Energy Agency, Vienna, Austria, ¹⁶Nuclear

Medicine and Molecular Imaging, Apollo Hospitals Dhaka, Society of Nuclear Medicine, Bangladesh (SNMB), ¹⁷World Association of Radiopharmaceutical and Molecular Therapy (WARMTH), Oakland, CA, USA, ¹⁸Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany, ¹⁹Department of Nuclear Medicine, Medical University of Innsbruck, Austria

¹⁰Department of Nuclear Medicine, Farwania Hospital, Kuwait, ¹¹Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India, ¹²Department of Nuclear Medicine, Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM), Chonnam National University Medical School, Gwangju, South Korea, ¹³Department of Oncology and Nuclear Medicine, Sestre Milosrdnice, UHC, Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia, Faculty of Medicine, University of Osijek, Osijek, Croatia, ¹⁴Institute of Pathophysiology and

Nuclear Medicine, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia, ¹⁵Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, International Atomic Energy Agency, Vienna, Austria, ¹⁶Nuclear

Medicine and Molecular Imaging, Apollo Hospitals Dhaka, Society of Nuclear Medicine, Bangladesh (SNMB), ¹⁷World Association of Radiopharmaceutical and Molecular Therapy (WARMTH), Oakland, CA, USA, ¹⁸Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany, ¹⁹Department of Nuclear Medicine, Medical University of Innsbruck, Austria

¹⁰Department of Nuclear Medicine, Farwania Hospital, Kuwait, ¹¹Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India, ¹²Department of Nuclear Medicine, Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM), Chonnam National University Medical School, Gwangju, South Korea, ¹³Department of Oncology and Nuclear Medicine, Sestre Milosrdnice, UHC, Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia, Faculty of Medicine, University of Osijek, Osijek, Croatia, ¹⁴Institute of Pathophysiology and

Nuclear Medicine, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia, ¹⁵Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, International Atomic Energy Agency, Vienna, Austria, ¹⁶Nuclear

Medicine and Molecular Imaging, Apollo Hospitals Dhaka, Society of Nuclear Medicine, Bangladesh (SNMB), ¹⁷World Association of Radiopharmaceutical and Molecular Therapy (WARMTH), Oakland, CA, USA, ¹⁸Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany, ¹⁹Department of Nuclear Medicine, Medical University of Innsbruck, Austria

¹⁰Department of Nuclear Medicine, Farwania Hospital, Kuwait, ¹¹Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India, ¹²Department of Nuclear Medicine, Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM), Chonnam National University Medical School, Gwangju, South Korea, ¹³Department of Oncology and Nuclear Medicine, Sestre Milosrdnice, UHC, Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia, Faculty of Medicine, University of Osijek, Osijek, Croatia, ¹⁴Institute of Pathophysiology and

Nuclear Medicine, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia, ¹⁵Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, International Atomic Energy Agency, Vienna, Austria, ¹⁶Nuclear

Medicine and Molecular Imaging, Apollo Hospitals Dhaka, Society of Nuclear Medicine, Bangladesh (SNMB), ¹⁷World Association of Radiopharmaceutical and Molecular Therapy (WARMTH), Oakland, CA, USA, ¹⁸Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany, ¹⁹Department of Nuclear Medicine, Medical University of Innsbruck, Austria

¹⁰Department of Nuclear Medicine, Farwania Hospital, Kuwait, ¹¹Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India, ¹²Department of Nuclear Medicine, Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM), Chonnam National University Medical School, Gwangju, South Korea, ¹³Department of Oncology and Nuclear Medicine, Sestre Milosrdnice, UHC, Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia, Faculty of Medicine, University of Osijek, Osijek, Croatia, ¹⁴Institute of Pathophysiology and

Nuclear Medicine, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia, ¹⁵Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, International Atomic Energy Agency, Vienna, Austria, ¹⁶Nuclear

Medicine and Molecular Imaging, Apollo Hospitals Dhaka, Society of Nuclear Medicine, Bangladesh (SNMB), ¹⁷World Association of Radiopharmaceutical and Molecular Therapy (WARMTH), Oakland, CA, USA, ¹⁸Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany, ¹⁹Department of Nuclear Medicine, Medical University of Innsbruck, Austria

¹⁰Department of Nuclear Medicine, Farwania Hospital, Kuwait, ¹¹Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India, ¹²Department of Nuclear Medicine, Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM), Chonnam National University Medical School, Gwangju, South Korea, ¹³Department of Oncology and Nuclear Medicine, Sestre Milosrdnice, UHC, Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia, Faculty of Medicine, University of Osijek, Osijek, Croatia, ¹⁴Institute of Pathophysiology and

Nuclear Medicine, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia, ¹⁵Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, International Atomic Energy Agency, Vienna, Austria, ¹⁶Nuclear

Medicine and Molecular Imaging, Apollo Hospitals Dhaka, Society of Nuclear Medicine, Bangladesh (SNMB), ¹⁷World Association of Radiopharmaceutical and Molecular Therapy (WARMTH), Oakland, CA, USA, ¹⁸Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany, ¹⁹Department of Nuclear Medicine, Medical University of Innsbruck, Austria

The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma.

Dizdarevic S, Tulchinsky M, McCready VR, Mihailovic J, Vinjamuri S, Buscombe JR, Lee ST, Frangos S, Sathekge M, Siraj Q, Choudhury P, Bom H, Franceschi M, Ugrinska A, Paez D, Hussain R, Mailman J, Luster M, Virgolini I; WARMTH Thyroid Group.

World J Nucl Med. 2019 Apr-Jun;18(2):123-126.

The WARMTH will continue to optimize harmonization in the practice of RAI therapy globally and promote utilization of multidisciplinary teams of a specialist in thyroid cancer evaluation and management. The WARMTH will also encourage development of national or regional programs with a team of multidisciplinary thyroid cancer specialists in resource-constrained countries to provide the patients with a high-quality care and optimal outcomes.

Editorial

The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma

INTRODUCTION

The World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) is a worldwide nonprofit organization, which is dedicated to educating medical professionals in the use of radionuclide therapies based on the theragnostic principles and to harmonizing appropriate evidence-based practices worldwide.

Radionuclide therapy with radioiodine for thyroid conditions has been utilized for over 77 years since the first use of radioiodine (RAI) in a patient by Saul Hertz.^[1] Over the years, new radionuclides of iodine have been introduced, which have improved diagnostic imaging quality. However, the basic concept of using a radiopharmaceutical to interrogate its affinity for a molecular target, in this case the sodium-iodide symporter, and later use of a biosimilar or identical agent formulated to deliver a radiation-absorbed dose to achieve a therapeutic effect remains the most enduring example of an optimal theragnostic approach.^[2] Radiotheragnostic approach takes advantage of using a targeted radiopharmaceutical that demonstrates avidity to the disease-affected organ(s) or cells in an orderly manner. First, the avidity of the theragnostic radiopharmaceutical to the target is tested by administration of a diagnostic activity of the agent or its biosimilar analog labeled with the same or a radioisotope with optimal imaging characteristics. Second, the therapeutic activity of the theragnostic radiopharmaceutical is selected based on the information obtained from the diagnostic radiopharmaceutical, as well as taking into consideration ancillary diagnostic factors, such as other diagnostic imaging modalities, laboratory markers of the disease process as well as relevant physical and functional patients' characteristics. Since the introduction of RAI, there have been many attempts to discover and develop another "magic bullet" for diagnosis and therapy using a variety of radiopharmaceuticals that only recently began to bear fruit in cancer management.^[3]

There are many international guidelines addressing RAI therapy in the differentiated thyroid cancer (DTC), such as from the European Association of Nuclear Medicine (EANM),^[4] the Society of Nuclear Medicine and Molecular Imaging,^[5] the American Thyroid Association (ATA),^[6] as well as many national guidelines.

They all differ significantly in principles and recommendations, for example, European panelists suggested modifications to approximately one-third of ATA 2015 recommendations. Those varying perspectives stimulated continuing debates, and the stakeholders concede that additional research is needed to resolve discrepant recommendations and potentially improve patient outcomes.^[7] The WARMTH is a key stakeholder organization that is inherently enabled to facilitate a worldwide outreach to all professionals authorized in safe and effective administration of RAI therapy. Hence, in this introductory position statement, the WARMTH will channel its collective understanding of the first or initial RAI (iRAI) administration post total or near-total thyroidectomy for DTC and goals for the future investigations. The statement is also aimed to facilitate understanding of the key issues and homogenize the appropriate use of terminology in the memberships' countries of practice. The WARMTH will also seek to issue further position statements on the various key matters, including, but not limited to the need for preablation scans, the need for single-photon emission computed tomography-computed tomography (SPECT-CT) in addition to whole-body (WB) scans, the role of thyroglobulin (Tg) measurement, the use of hormone withdrawal versus recombinant human thyroid-stimulating hormone (rhTSH) stimulation, the role of fluorine-18-fluorodeoxyglucose-positron emission tomography-CT (¹⁸F-FDG-PET-CT), optimum treatment and follow-up regime, role of dosimetry, role of tyrosine kinase inhibitors, and when to discharge patients to community care.

RADIOACTIVE IODINE FOR DIFFERENTIATED THYROID CANCER

In patients with DTC, RAI WB and neck imaging can be used to evaluate residual postoperative benign thyroid remnant, detect residual disease in the postoperative bed and residual metastatic disease in the neck or distant sites, as well as identify recurrent disease following therapy.

The aims for RAI therapy include:^[6,8]

1. Remnant ablation
2. Adjuvant treatment
3. Treatment of known disease.



Dizdarevic, *et al.*: WARMTH position statement

The iRAI administration can be given to ablate residual benign thyroid tissue.^[9] This enables Tg test to be used for the detection of a residual DTC and/or for detection of a later recurrence. The adjuvant therapy is aimed at treating microscopic thyroid cancer that is presumed to be iodine avid. Its presence is usually signaled by elevated Tg in excess of what would be anticipated as solely the product of the remnant benign tissue that can be quantified on RAI uptake and scan. When pathology reveals positive surgical margins, it is given that microscopic tumor is left in the remnant thyroid tissue. Finally, therapy of metastatic disease is indicated when pretherapy RAI scan identifies a metastatic site or sites for RAI therapy, which can be administered using either empirical or dosimetric approaches. The above-described breakdown is not always possible in clinical practice as a significant uncertainty may remain at the time of iRAI administration. In such instances, it is most appropriate to qualify the therapy generically, as the “iRAI administration,” without committing to one of the three above-specified options.

In considering appropriateness for iRAI therapy, the EANM guidelines are viewed as more certain,^[4] while the 2015 ATA guidelines critiqued as being more ambiguous, which can lead to variable interpretation and greater practice variability.^[6] The UK national multidisciplinary guidelines^[10] indicate that the majority of patients with a DTC > 1 cm in diameter would need iRAI after total or near-total thyroidectomy. Patients with DTC of 1 cm or less with the low-risk characteristics can be treated with hemithyroidectomy and without RAI therapy according to the same document. The tumors between 1 and 4 cm would be considered for RAI therapy individually, based on the multiple risk variables.^[10] The WARMTH recognizes that tumor size and other clinic-pathologic characteristics are general indicators of risk status for DTC patients, but they are certainly rather simplistic and nonspecific. For example, each member of this writing panel treated primary DTC microcarcinoma with extensive metastases.^[11] While histopathological features are more sophisticated than size alone for risk characterization, they also lack the kind of specificity that could reliably differentiate between those patients who will do well without total thyroidectomy and/or iRAI therapy from those who would not. The molecular and genomic markers hold the greatest promise for accurate determination of an individual DTC patient prognosis and for enabling theragnostic iRAI treatment in the manner most aligned with precision medicine. Progressive approaches are now combining molecular-genomic features with clinicopathologic characteristics to produce novel indices through sophisticated computer-modeling approaches,^[12] which could soon make currently used systems that are based on the size and histopathology appear antiquated.

The WARMTH strongly supports guidelines that promulgate thyroidectomy performance by a qualified surgeon with a consistently high practice volume (20–25 thyroid surgeries per year or more),^[10] and postoperative management at centers with an established thyroid cancer multidisciplinary team. However, the WARMTH acknowledges that this practice may not yet be available in some resource-constrained regions and countries. It is encouraged that such multidisciplinary thyroid cancer teams, as well as access to a second opinion by a thyroid cancer histopathology specialist,^[13] are expeditiously developed worldwide.

Over the last decade, there has been a move toward a more dynamic risk-based approach to RAI therapy for DTC. Such risk stratification could be based on the multimodality information, including postthyroidectomy Tg measurements and appearances on neck ultrasonography, sometimes in lieu of using whole-body RAI imaging. There is a recent tendency to personalize iRAI therapy based on the limited and conflicting risk data obtained from observational studies.^[14] However, when there are > 16 different staging systems defining the risk, it proves difficult to have a homogeneous process to the selection of administered activity for the initial ¹³¹I treatment.^[14]

The conflict in administering higher activities that could increase chances of treating any potential microscopic metastases, as compared to lower activities, is that it may also increase the risk of subsequent malignant neoplasm (SMN) and salivary dysfunction, as well as (depending on local regulations) increase hospital costs and radiation protection of the staff. The two prospective trials, HiLo^[15] and ESTIMABL1,^[16] aimed to better understand differences in outcomes between administering lower and higher iRAI activity. There are also other prospective trials underway to evaluate clinical safety of omitting iRAI therapy under certain scenarios, for example, Iodine or Not (IoN) trial^[17] and ESTIMABL 2, as there are no published prospective trials with sufficiently long follow-up that could provide reliable basis for deciding whether it is better to withhold or administer iRAI therapy and if so, what would be the best activity. In this disease, which may often recur 10 to (in rare cases) 30 years later, the current trials with 5–10 years of follow-up may be of limited value.

The primary end point of the two prospective studies – HiLo and ESTIMABL1 – was iRAI administration efficiency.^[15,16] Success rates were similar for “low” (30 mCi/1.1 GBq) and “high” activity (100 mCi/3.7 GBq) of ¹³¹I. A statistically insignificant but higher rate of success was found in the higher RAI activity-treated group (90.2%) as compared to the lower activity group (84.3%) (both under rhTSH stimulation),



Dizdarevic, et al.: WARMTH position statement

supporting noninferiority of the lower activity.^[15] These outcomes could suggest that in general, the volume of residual thyroid tissue is small resulting in a high-absorbed dose even with low-administered activities. The 5-year outcomes of ESTIMABL1 trial have only recently been reported with a disease-free survival of 98%.^[18] However, the extent of disease or subsequent recurrences could not have been predicted by the risk stratification before iRAI therapy. In fact, it is uncertain from the information provided whether those patients would be recommended for iRAI therapy based on the 2015 ATA guidelines. At the same time, new evidence is growing in support of the RAI theragnostic approach to DTC,^[19] which bears a more logical point of view.

There is a general agreement for using higher activities in patients with a high risk of recurrence.^[4,6,10] The question, however, remains on whether lower activities or any treatment at all should be used in low-risk patients to reduce the frequency of SMN and other complications, as well as the length of hospital stay (a significant administrative hurdle in some countries with stricter regulations). There are conflicting reports with some suggesting increased risk of SMN, while others report on no change or even fewer malignancies after the RAI treatment.^[20]

Furthermore, nonthyroidal primary tumors (particularly breast cancer and hematological malignancies) are relatively common in patients with DTC and usually antecede the DTC.^[21] The individual variations in DNA repair efficiency after the radiation exposure are also a modifying factor to be borne in mind.^[22]

PATIENTS' AND BROAD MEDICAL STAKEHOLDERS' INVOLVEMENT

¹³¹I treatment has been the most enduring story of targeted radionuclide therapy and theragnostics. However, it is important to remember that with current access to information, patients are aware about risks of radiation exposure and, in particular, the possibility of SMN. A clear statement in layman terms that address the balance between benefits and the relative risks is required for providing the patient with actionable information. Informative studies on patient perceptions about and experience with radiotheragnostics are mostly lacking. The WARMTH will endeavor to develop the thyroid patients' forum to facilitate the exchange of their experiences with RAI treatments, their interactions with the health-care providers and sharing patients' life stories, as well as to allow for systematic surveying to provide feedback that could be invaluable in improving patients' future experience with RAI treatments. Patients' involvement should be a priority

for the Nuclear Medicine Community. The WARMTH is also committed to multidisciplinary decision-making and will endeavor to actively encourage engagement with surgeons, oncologists, endocrinologists, pathologists, nuclear medicine physicians, radiologists and other key members involved in the management of thyroid cancer patients.

SUMMARY

The WARMTH has the benefit of being a worldwide organization with experts in the development and use of radionuclides and radiopharmaceuticals around the globe. The effectiveness of ¹³¹I for treating DTC is well recognized. However, controversies on the optimal ¹³¹I treatment activity and specific indications continue, while the risk stratification has not been harmonized. The WARMTH will continue to optimize harmonization in the practice of RAI therapy globally and promote utilization of multidisciplinary teams of a specialist in thyroid cancer evaluation and management. The WARMTH will also encourage development of national or regional programs with a team of multidisciplinary thyroid cancer specialists in resource-constrained countries to provide the patients with a high-quality care and optimal outcomes.

In selecting patients for RAI therapy, demonstration of iodine avidity and cancer spread using RAI scintigraphy represents the core principle of radiotheragnostic approach that should guide personalized management instead of relying on less of a direct evidence for disease risk, such as the size of the primary tumor. The WARMTH will harness global resources of its member specialists to facilitate the development of prospective evidence on theragnostic approach to patients with DTC, who in the future may be risk stratified by an integrative risk index modeling, which combines genomic alterations with conventional staging systems.

**DIZDAREVIC S¹, TULCHINSKY M²,
MCCREARY VR¹, MIHAILOVIC J³, VINJAMURI S⁴,
BUSCOMBE JR⁵, LEE ST^{6,7}, FRANGOS S⁸,
SATHEKGE M⁹, SIRAJ Q¹⁰, CHOUDHURY P¹¹, BOM H¹²,
FRANCESCHI M¹³, UGRINSKA A¹⁴,
PAEZ D¹⁵, HUSSAIN R¹⁶, MAILMAN J¹⁷,
LUSTER M¹⁸, VIRGOLINI I¹⁹,
ON BEHALF OF THE WARMTH THYROID GROUP**

¹Department of Imaging and Nuclear Medicine, Brighton and Sussex University Hospitals NHS Trust, Brighton and Sussex Medical School, Royal Sussex County Hospital, Brighton, UK,


²Radiology Department, Nuclear Medicine Section, Penn State University, Milton S. Hershey Medical Center, USA, ³Department of Nuclear Medicine, Oncology Institute of Vojvodina, Sremska Kamenica, University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia, ⁴Department of Nuclear Medicine, Royal Liverpool University Hospital, Liverpool, ⁵Department of Nuclear

Medicine, Cambridge University Hospitals, Cambridge, UK, ⁶Department of Molecular Imaging and Therapy, Austin Health, Melbourne, ⁷Olivia Newton-John Cancer Research Institute, Heidelberg, Australia School of Cancer Medicine, La Trobe University, Heidelberg, Australia, ⁸Department of Nuclear Medicine, Bank of Cyprus Oncology Center, Nicosia, Cyprus, ⁹Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa, ¹⁰Department of Nuclear Medicine, Farwania Hospital, Kuwait, ¹¹Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India, ¹²Department of Nuclear Medicine, Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM), Chonnam National University Medical School, Gwangju, South Korea, ¹³Department of Oncology and Nuclear Medicine, Sestre Milosrdnice, UHC, Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia, Faculty of Medicine, University of Osijek, Osijek, Croatia, ¹⁴Institute of Pathophysiology and Nuclear Medicine, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia, ¹⁵Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, International Atomic Energy Agency, Vienna, Austria, ¹⁶Nuclear Medicine and Molecular Imaging, Apollo Hospitals Dhaka, Society of Nuclear Medicine, Bangladesh (SNMB), ¹⁷World Association of Radiopharmaceutical and Molecular Therapy (WARMTH), Oakland, CA, USA, ¹⁸Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany, ¹⁹Department of Nuclear Medicine, Medical University of Innsbruck, Austria

REFERENCES

- Hertz B. Dr. Saul Hertz discovers the medical uses of radioiodine (RAI). *J Radiol Oncol* 2018;2:3-54.
- Frangos S, Buscombe JR. Why should we be concerned about a "g"? *Eur J Nucl Med Mol Imaging* 2018;46:519.
- Jadvar H, Chen X, Cai W, Mahmood U. Radiotheranostics in cancer diagnosis and management. *Radiology* 2018;286:388-400.
- Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging* 2008;35:1941-59.
- Silberstein EB, Alavi A, Balon HR, Clarke SE, Divgi C, Gelfand MJ, et al. The SNMMI practice guideline for therapy of thyroid disease with ¹³¹I 3.0. *J Nucl Med* 2012;53:1633-51.
- Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* 2016;26:1-33.
- Luster M, Aktolun C, Amendoeira I, Barczyński M, Bible KC, Duntas LH, et al. European perspective on the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. *Proceedings of an interactive international symposium. Thyroid* 2018;29:7-26.
- Tulchinsky M, Binse I, Campenni A, Dizdarevic S, Giovannella L, Jong I, et al. Radioactive iodine therapy for differentiated thyroid cancer: Lessons from confronting controversial literature on risks for secondary malignancy. *J Nucl Med* 2018;59:723-5.
- Van Nostrand D. Selected controversies of radioiodine imaging and therapy in differentiated thyroid cancer. *Endocrinol Metab Clin North Am* 2017;46:783-93.
- Mitchell AL, Gandhi A, Scott-Coombes D, Perros P. Management of thyroid cancer: United kingdom national multidisciplinary guidelines. *J Laryngol Otol* 2016;130:S150-60.
- Mihailovic J, Stefanovic L, Stankovic R. Influence of initial treatment on the survival and recurrence in patients with differentiated thyroid microcarcinoma. *Clin Nucl Med* 2013;38:332-8.
- Cheng Q, Li X, Acharya CR, Hyslop T, Sosa JA. A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors. *Oncotarget* 2017;8:16690-703.
- Frangos S, Iakovou IP, Marlowe RJ, Eftychiou N, Patsali L, Vanezi A, et al. Difficulties in deciding whether to ablate patients with putatively "low-intermediate-risk" differentiated thyroid carcinoma: Do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study. *Eur J Nucl Med Mol Imaging* 2015;42:2045-55.
- Tuttle RM. Controversial issues in thyroid cancer management. *J Nucl Med* 2018;59:1187-94.
- Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. *N Engl J Med* 2012;366:1674-85.
- Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. *N Engl J Med* 2012;366:1663-73.
- Mallick U, Harmer C, Hackshaw A, Moss L; IoN Trial Management Group. Iodine or not (IoN) for low-risk differentiated thyroid cancer: The next UK national cancer research network randomised trial following HiLo. *Clin Oncol (R Coll Radiol)* 2012;24:159-61.
- Schlumberger M, Leboulleux S, Catargi B, Deandreis D, Zerdoud S, Bardet S, et al. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. *Lancet Diabetes Endocrinol* 2018;6:618-26.
- Avram AM, Rosculet N, Esfandiari NH, Gauger PG, Miller BS, Cohen M, et al. Differentiated thyroid cancer outcomes after surgery and activity-adjusted ¹³¹I theragnostics. *Clin Nucl Med* 2019;44:11-20.
- Yu CY, Saeed O, Goldberg AS, Farooq S, Fazelad R, Goldstein DP, et al. A systematic review and meta-analysis of subsequent malignant neoplasm risk after radioactive iodine treatment of thyroid cancer. *Thyroid* 2018. Doi:10.1089/thy.2018.0244.
- Hirsch D, Shohat T, Gorshtein A, Robenshtok E, Shimon I, Benbassat C, et al. Incidence of nonthyroidal primary malignancy and the association with (¹³¹I) treatment in patients with differentiated thyroid cancer. *Thyroid* 2016;26:1110-6.
- Brody AS, Guillerman RP. Don't let radiation scare trump patient care: 10 ways you can harm your patients by fear of radiation-induced cancer from diagnostic imaging. *Thorax* 2014;69:782-4.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online	
Website: www.wjnm.org	Quick Response Code 
DOI: 10.4103/wjnm.WJNM_117_18	


How to cite this article: Dizdarevic S, Tulchinsky M, McCreedy VR, Mihailovic J, Vinjamuri S, Buscombe JR, et al. The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma. *World J Nucl Med* 2019;18:123-6.

3. PRRT


Basic Principle

Peptide Receptor Radionuclide Therapy (PRRT)
Peptide Ligand Radionuclide Therapy (PLRT)

Diagnosis



Therapy



Peptide's Rap

You are a receptor / **antigen**,
I am a peptide / **ligand**,
I want to interact with you!
I want to be labelled,
smoothly radiolabelled to find you,
I want to be labelled,
roughly radiolabelled to kill you.
You are a receptor,
I am a peptide,
I love - and I hate you!


**Diagnosis and Therapy are Walking Together
on Radiopeptides' Avenue: "Theranostics"**
EDITORIAL: EJNMMI 2011 Apr;38(4):605-12
L. Mansi & L. Virgolini

Nuclear/Medicine Department, Medical University Innsbruck

I find the statement of Lisa Bodei, NY, USA „*Nowadays everybody wants to be the father of PRRT*“ quite interesting (September 5, 2019, International Virtual Conference on Theranostics, iViCT, IAEA).

Today PRRT, peptide receptor radionuclide therapy, is well established in patients with neuroendocrine tumors which express the somatostatin receptor. We give the radioactive peptide treatments usually fractionated, several weeks apart. The theragnostic approach includes a PET-scan before start of therapy and then in the follow-up. Dosimetry constitutes an essential step of the whole procedure in order to calculate normal organ and tumor doses to be able to estimate benefit and risk for the patient.

Example of a patient with NET who received several injections of radioactive peptides, somatostatin analogs labeled either with ^{90}Y or ^{177}Lu . This patient had liver metastases which disappeared completely after several therapy cycles.



Retrospective WARMTH Study: Multicenter Analysis of ^{68}Ga -Somatostatin Receptor and ^{18}F -FDG-PET/CT (Dual-Tracer Imaging) in Neuroendocrine Tumor Patients Treated With Peptide Receptor Radionuclide Therapy



Prof. Irene Virgolini

Director, Department of Nuclear Medicine
Medical University Innsbruck
Anichstraße 35, A-6020 Innsbruck
Tel: +43 (0)50 504-22651
Fax: +43 (0)50 504-22659
Email: irene.virgolini@i-med.ac.at
<http://nuklearmedizin-innsbruck.com>

Study Ongoing


Priv.-Doz. Margarida Rodrigues-Radishat

Medical University Innsbruck
Anichstraße 35, A-6020 Innsbruck
margarida.rodrigues-radischat@tirol-kliniken.at

Dr. Diana Paez


Section Head | Nuclear Medicine and Diagnostic Imaging Section | Division of Human Health | Department of Nuclear Sciences and Applications International Atomic Energy Agency | Vienna International Centre, PO Box 100, 1400 Vienna, Austria
Email: D.Paez@iaea.org

4. PRLT - PSMA Radioligand Therapy



A new area of theragnostics was opened only few years ago for prostate cancer that expresses PSMA, prostate specific membrane antigen. Nowadays we image the tumor by a ⁶⁸Ga-labelled PSMA ligand directed against PSMA. We inject the therapeutic radiopharmaceutical in several cycles and follow the patient by PET scan. Again, dosimetry is very important to calculate the normal organ and tumor doses, to predict how many cycles we would give to the patient.

^{68}Ga -PSMA-11 PET/CT in Prostate Cancer Treatment Monitoring after ^{177}Lu -PSMA-617 Therapy



Here is an example of a patient with lymph node metastases which disappeared after only two therapy cycles with prognostics, along with decrease of tumor marker.

Here is another example of shrinkage of lymph node metastases after ^{177}Lu -PSMA-treatment.



Prof. Dr. med. Hojjat Ahmadzadehfar, MSc
Head of the Therapy Section
Department of Nuclear Medicine
University Hospital Bonn



Retrospective Multicentre Analysis of Castration Refractory Metastatic Prostate Cancer Patients Treated by Lu- PSMA-617 617 trial

Hojjat **Ahmadzadehfar**¹, Kambiz Rahbar², Richard Baum³, Carolin Gerke¹, Clemens Kratochwil⁴, Harun Ilhan⁵, Mike Sathekge⁶, Levent Kabasakal⁷, Francisco Osvaldo Garcia-Perez⁸, Kalevi Kairemo⁹, Masha Maharaj¹⁰, Diana Paez¹¹, Irene Virgolini¹²

¹ Department of Nuclear Medicine, University Hospital Bonn

² Department of Nuclear Medicine, University Hospital Muenster

³ Center for Precision Radiomolecular Oncology, Bad Berka (ZBB)

⁴ Department of Nuclear Medicine, University Hospital Heidelberg

⁵ Department of Nuclear Medicine, LMU, University Hospital Munich

⁶ Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, South Africa

⁷ Department of Nuclear Medicine, Istanbul University, Istanbul, Turkey

⁸ Department of Nuclear Medicine and Molecular Imaging, Instituto Nacional de Cancerología Mexico City, Mexico

⁹ Docrates Cancer Center, Helsinki, Finland

¹⁰ Department of Nuclear Medicine, Imaging and Therapy Centre, Durban, KwaZulu-Natal, South Africa

¹¹ Nuclear Medicine and Diagnostic Imaging Section, Department of Nuclear Sciences and Applications, IAEA

¹² Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria

Study Ongoing



**J. Harvey
Turner**

Head of Department
Faculty of Health and
Medical Sciences, The
University of Western
Australia Department
of Nuclear Medicine,
Perth, WA Australia.

NIGHTCAP
NATIONAL INVESTIGATORS
GLOBAL HARMONIZATION OF
THERANOSTICS OF CANCER OF
PROSTATE

INAUGURAL INVESTIGATORS'
MEETING

presented at the WFNMB, April 2018,
Melbourne

A CO-ORDINATED, PROSPECTIVE,
INTERNATIONAL, STANDARDISED
PROTOCOL, AUDIT OF HARMONIZED
CLINICAL PRACTICE OF $^{68}\text{Ga}/^{177}\text{Lu}$ -PSMA
THERANOSTICS OF METASTATIC CASTRATE-
RESISTANT PROSTATE CANCER (mCRPC)

harvey.turner@health.wa.gov.au

Study Discussed

The LYM-Trial

Salvage radiotherapy with or without ^{177}Lu -PSMA radionuclide treatment for lymph node metastatic prostate cancer: a randomized phase 2 trial

Finn Edler von Eyben


Center for Tobacco Control Research,
Birkevej 17
5230 Odense M
Denmark.
finn113edler@mail.tele.dk

Participating hospitals


Seven hospitals participate in the trial:
IRST, Meldola, Italy, University hospital
in Innsbruck, Austria, University of
Ankara Medical Faculty, Turkey, and
Steve Biko Academic Hospital,
University of Pretoria, Pretoria, South
Africa.



Study Discussed



Combination Treatment ^{177}Lu -PSMA617 / ^{223}Ra



Nuclear Medicine Department, Medical University Innsbruck

Study Discussed



WARMTH

WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY

FOUNDED 2009

ISSN 1450-1147



World Journal of Nuclear Medicine

Volume 18 / Issue 3 / July-September 2019

www.wjnm.org



Published in collaboration with :
World Association of Radiopharmaceutical & Molecular Therapy (WARMTH)
Nuclear Medicine Society Singapore (NMSS)

Medknow

 Wolters Kluwer



WJNM

World Journal of Nuclear Medicine

- Official journal of The WARMTH
- Launched in Oct 2002 at the 8th WCNMB, Santiago, Chile
- Frequency of publication: quarterly

Founded by:

Ajit K. Padhy
Keith E Britton
Horacio Amaral
(President WFNMB 1998-2002)

Editors-in-Chief:

Keith Eric Britton
Ajit K. Padhy
John Buscombe
Qaisar Siraj

World Journal of Nuclear Medicine

Volume 1, Number 1, October 2002

Editorials

Keith E. Britton, Editor in Chief
World Journal of Nuclear Medicine 1

Horacio Amaral, President WFNMB
The World Journal of Nuclear Medicine, the second symbol of the WFNMB 2

Ajit K. Padhy, Executive Editor
Nuclear Medicine in the Developing Countries 3

Radionuclide Therapy

Sundram FX, Jeong J-M, Zanzonico P, Bernal P, Chau T, Onkhuudai P, Divgi C, Knapp FF (Russ) Jr., Buscombe J, Padhy AK
Trans-arterial Rhenium-188 Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma-An IAEA sponsored multi-centre phase I study 5

Hambye Anne-Sophie E, Dobbeleir Andre A, Vervae Ann M, and Kanapp Furn F. (Russ) Jr..
Image Quality with Rhenium-188 and Technetium-99m: Comparative Planar and SPECT Evaluation in a Phantom Study and Implications for Dosimetry 12

Olea Enrique, Pan Zhongyun, Parma EP, Pusuwan P, Riccabona G, Tian J-H, Obaldo J, Padhy AK
**IAEA Study Group on Palliative Treatment of Metastatic Bone Pain
Efficacy and Toxicity of Sm-153 EDTMP in the Palliative Treatment of Painful Bone Metastases 21**

In vivo Diagnostic

Bal CS, Padhy AK, Kumar A, Bahadur S
Comparison of Outcomes of Bone Scan, Clinical Judgement and other Imaging Modalities in the Pre-operative Assessment of Mandibular Invasion by Squamous Cell Carcinoma of Oral Cavity 29

Shen R, Liu X-J, Shi R, Tian Y, Wei H, Guo F, He Z-X
Evaluation of left ventricular function by Tc-99m MIBI/ F-18 FDG Gated Myocardial Tomography with Dual Isotope Simultaneous Acquisition 35

Singh AK, Varma J, Bhatnagar A.
Insulin-Augmented Thallium Myocardial Scintigraphy in Animals: First Results 41

Hoefnagel CA, Sivo-Prndelj F, Valdes Olmos RA.
Lymphoscintigraphy and Sentinel Node Procedures in Breast Carcinoma: Role, Techniques and Safety aspects 45

Nunez M, Vila R, Alonso O, Beretta M, Mut F
Scatter correction in Scintimammography with Tc-99m MIBI: Preliminary Results Using Phantom and Clinical Studies 55

Smith S, AL-Nahhas A, Vivian G
Value of I-123 MIBG as part of Multimodality Imaging in Screening Families with Multiple Endocrine Neoplasia Type 2A Syndrome 61

Lacie M, Cook G JR, Marsden PK, Fogelman I, Maissey MN.
A Comparative Study of F-18 FDG and C-11 Methionine PET in the evaluation of Brain Tumours 68

General articles

Britton KE, Granowska M
Cancer Find and Treat the Individual: The Nuclear Medicine Approach 75

Turner J. Harvey
A Global Perspective of Therapeutic Nuclear Medicine 80

Windows

Onkhuudai P, Erdenechimeg S.
Development of Nuclear Medicine in Mongolia 82

Thakur M., Rodrigues M.
International Society of Radiolabeled Blood Elements (ISORBE) 84

Obituary

Britton KE
Prof. Wolfgang Becker 85

IAEA Archives

Ganatra R.D.
The Future of Nuclear Medicine 86
World J Nucl Med 2002;1:1-88



WJNM Indexing

- **The journal is indexed with**

DOAJ

PubMed Central

- **Abstracting Partners**

Baidu Scholar

CNKI (China National Knowledge Infrastructure)

EBSCO Publishing's Electronic Databases

Ex Libris – Primo Central

Google Scholar

Hinari

Infotrieve

National Science Library

ProQuest

TdNet

Wanfang Data

Not indexed in Scopus and ISI (Institute of Scientific Information) for journal citation report (Impact Factor) yet



Journal Performance

	2018	2019
Reviewers	12-15	80
Number of Articles Submitted	119	60
Days to Suggest Reviewers	35.71 [4 , 51]	4.32 [0 , 24]
Days Taken by Reviewers	10.43 [2 , 21]	16.91 [0 , 41]
Days until Paper is Under Review	55.88	31.77
Articles Re-Reviewed	5	12
Days from First Submission to Acceptance	44.35 [3 , 177]	71.26 [23 , 132]

Future Planning

- Online AOP publication
- Encourage submissions and publication in WJNM
- Editorials and review articles
- Decrease the submission to acceptance period
- Increase the number of issues
- Scopus and ISI indexing

Editorial

Its goodbye from him

Time is one of the constants in our universe we are all tied to and indeed in nuclear medicine, we use time as a significant parameter of what we do. Radionuclides have a decay half-time which allows us to detect any gamma emissions. The time of decay for a radioisotope may be one of the factors that determine the radiation dose to a patient, one of the reasons that long half-life agents such as gallium-67 and thallium-201 have become less popular over time.

The use of time is essential in any physiological-based imaging, we are all used to the time activity curve of the renogram, but we also need time to allow for uptake of physiological agents and clearance of nonspecific activity for example in bone scintigraphy and of F-18 fluorodeoxyglucose in positron emission tomography (PET). Of course, we are also aware when time is short. We only have a finite time in which to inject a radiopharmaceutical to be of use. Therefore, in nuclear medicine, we become obsessed with time. In out PET-computed tomography, there are digital clocks measuring time in hours, minutes, and seconds. All are synchronized, and all are then linked to the master clock at the national physics laboratory. This is of course because much of our PET research involves precise timings, often to the second, for injection, blood samples, and imaging. This can result in us becoming a bit overzealous about time. I remember berating an internal medicine colleague who said they would be along in 10 min but took 13 min. I tried to explain how such tardiness could wipe out the results of a PET research study costing thousands of dollars. He just looked at me as though I was very weird.

The one thing we can depend on time (unless we are next to a black hole that is) is that it moves forward in a relentless, smooth, and predictable fashion. The human condition is that we are born, grow up, then get older and eventually die. It is said that we spend the first 25 years of our life wishing time ran faster than after that wishing time ran slower. I was looking at a picture taken in 1983 [Figure 1]. I am the rather gauky (yes thin!!!) looking medical student sitting next to Henry Wagner in the conference room of nuclear medicine at Johns Hopkins Hospital. It was here that I first met the magic of nuclear medicine. I could see how we could look into different physiological processes and gain an understanding of the pathophysiology of disease. Since then, time has brought us new techniques such as




Figure 1: The Editor in chief as a medical student sitting next to the great Prof. Henry Wagner in the reporting room, Nuclear Medicine, Johns Hopkins Hospital, in 1983

hybrid imaging and theranostics. There have been new radiopharmaceuticals such as In-111 pentetreotide, I-123 ioflupane, Ga-68 prostate-specific membrane antigen, and Ra-223. Nuclear medicine aided by the expanding role of PET, and radionuclide therapy continues to grow as a specialty worldwide and its future seems much more assured than it did in 1983.

There was a King of Denmark who was also King of England; his name in Danish was Knut and in English Canute. When he reigned 1000 years ago, he was considered the greatest king of his age. His empire took in what is now Scandinavia, the UK, Ireland, Iceland, and Northern France. His ships traveled to and traded with Arabs, the Russians, and North Americans. However, he was a wise king, and to prove his point he had his throne placed on a beach as the tide came in. His courtiers told him the sea would not dare to allow the tide to come in and wet his feet. Of course, it did and he made the point time and tide waits for no man (or woman).

So what is the point of this rambling editorial? Like Knut time has caught up with me. In the worst possible circumstances, I took over the editor in 2013 after the sudden death of Professor Ajit Padhy, the founding editor of the World Journal of Nuclear Medicine (WJNM). Ajit was a great friend to many of us and achieved so much in a life that was sadly too short. It was with a heavy heart I took on the role as editor in chief. During that time, the journal became an online journal with over 100,000 views per year. We increased from three issues a year to four issues a year. With the amazing support of the



Buscombe: Goodbye

World Association for Radionuclide Therapy (WARMTH), the journal has remained free to submit to, to view online and to have color images. This is now very rare. The publishers Medknow have worked hard to ensure the journal is published on time and in a highly professional way, this year changing the typescript so it is easier to read on line. Within a few weeks of publication, articles are on PubMed and with the free download, this means authors' work has an amazing worldwide audience. None of these achievements would have happened without the support of the publishers, my managing editor, Dr. Savvas Frangos, our regional editors, and the editorial board. The WJNM has been supported by the Presidents of WARMTH and Josh Mailman the WARMTH CEO. However, after 5 years, time has caught up with me. It is vital that a journal as important as the WJNM does not reflect the views of one person, and one of the best ways to ensure this is for there to be a change in editor in chief.

The WARMTH governing body has agreed to support the WJNM and has appointed Prof Qasir Siraj from Kuwait to be editor in chief of the WJNM from January 1, 2019. Qasir is an excellent choice and he has worked in both developing and developed countries in nuclear medicine. He has set up and run the Pakistan Journal of Nuclear Medicine, and this experience means that he will make an excellent job on the WJNM. There is still much to do, the most pressing being to

get the WJNM a citation index which is official. This will be the work for Qasir and the new team he will put in place.


With that I wish Qasir, your good selves, and the WJNM a wonderful future John Buscombe Editor in Chief, World Journal of Nuclear Medicine 2013–2018.

JOHN RICHARD BUSCOMBE

Department of Nuclear Medicine, Cambridge University Hospitals, Cambridge, UK.

E-mail: john.buscombe@addenbrookes.nhs.uk

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online	
Website: www.wjnm.org	Quick Response Code 
DOI: 10.4103/wjnm.WJNM_75_18	

How to cite this article: Buscombe JR. Its goodbye from him. World J Nucl Med 2018;17:211-2.

Acceptance/Rejection Rate: 2018

Total 119 Articles Submitted in 2018				
Article Type	Submitted	Accepted	Rejected	Under Review
Case Report	49	33 [67%]	16 [33%]	0 [0%]
Editorial	6	5 [83%]	1 [17%]	0 [0%]
Letter To Editor	1	0 [0%]	1 [100%]	0 [0%]
Original Article	58	36 [62%]	21 [36%]	1 [2%]
Review Article	5	4 [80%]	1 [20%]	0 [0%]
Total Decisions	118	78[66%]	40[34%]	
Total Articles	119	78[66%]	40[34%]	1[1%]




Editorial Board



Editorial

A message from the new editor-in-chief



It is my honour and privilege to write this introductory editorial on my appointment as the new Editor-in-Chief of the World Journal of Nuclear Medicine. The WJNM was founded by our good friend Professor Ajit Kumar Padhy, a bold visionary in nuclear medicine who dedicated his life to promoting nuclear medicine and radionuclide therapy worldwide, but in particular, devoted his time and energy towards expanding and promoting nuclear medicine in the developing countries. Ajit's phenomenal zeal and energy and his unrelenting efforts in realizing the high standards and goals he set for himself are well known amongst his peers. His tragic and untimely demise left the nuclear medicine community and those close to him (he had many friends in nuclear medicine worldwide), reeling with a huge sense of loss, but after the initial shock was over, the community readily rallied to his cause, all the more determined to take his mission forward. At this juncture, Prof John Buscombe took on the rein of the WJNM and steered it further up the ladder of success with the result that the journal has become well-established as a niche nuclear medicine publication. With John's retirement, the helm of the journal has passed on to me by the World Association of Radionuclide and Molecular Therapy (WARMTH).

As the Editor-in-Chief of the WJNM, I shall collaborate with my editorial team and publishers for delivering a high-quality publication, and endeavour to enhance the journal visibility, impact factor and popularity. One of my primary future goals is to encourage the younger nuclear medicine generation colleagues to support the journal. I also hope to introduce new and short case publications formats and engage active and dynamic nuclear medicine professionals in the journal


publication. These various measures shall unravel in the near future.

I am aware of the mantle of Editorship and am mindful of the great confidence and responsibility entrusted to me not only to maintain the current high standards but to realize the shared vision and the ambition of my colleagues to ensure a place for the journal amongst one of the leading publications in nuclear medicine. In this endeavour, I would solicit the support of the WARMTH membership and indeed the nuclear medicine professionals worldwide.

QAISAR HUSSAIN SIRAJ

Editor-in-Chief,
World Journal of Nuclear Medicine
E-mail: sirajqaisar@gmail.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online	
Website: www.wjnm.org	Quick Response Code 
DOI: 10.4103/wjnm.WJNM_109_18	

How to cite this article: Siraj QH. A message from the new editor-in-chief. World J Nucl Med 2019;18:1.

WJNM: Number of manuscripts per country 2018 & 2019

Country	Manuscripts Submitted
Australia	4
Austria	1
Belgium	2
Brazil	1
Canada	2
China	1
Denmark	1
Egypt	3
France	1
Germany	1
Ghana	1
Greece	2
India	33
Indonesia	1
Iran	16
Israel	1
Italy	1
Kenya	1
Kuwait	4
Macedonia	2
Malaysia	2
Mexico	1
Oman	2
Pakistan	5
Philippines	1
Saudi Arabia	3
South Africa	1
Spain	1
Thailand	2
Turkey	8
United Kingdom	1
United States	4
United_Kingdom	4
Uruguay	1
USA	4

Belgium	1
Canada	2
Germany	3
India	17
Iran	3
Israel	1
Italy	3
Kenya	1
Kuwait	3
Malaysia	1
Morocco	3
Pakistan	3
Puerto Rico	1
South Africa	1
Switzerland	1
Thailand	1
Turkey	1
United Arab Emirates	2
United States	13
USA	1

World Theragnostics Academy (WTA)

**“Targeted training for targeted therapy”
(drafted by Gopinath Gnanasegaran, UK in 2014)**

Syllabus (draft)

Contents

Module 1. Physics & radiation protection	3
Module 2. Radiopharmacy	4
Module 3. Clinical	5
Oncology: Thyroid cancer	
Neuroendocrine tumours	
Pheochromocytoma & paragangliomas	
Lymphomas	
Hepatocellular cancer	
Palliation of Bone metastases	
Benign disease	
Benign thyroid disease (Graves' disease, MNG, Autonomous nodules etc)	
Rheumatoid arthritis, Haemophilia	
Polycythemia	
Module 4. MCQ exam	
Module 5: Oral exam	
Certification	

Module 1: Physics and Radiation Protection

(Topics to be covered in the PowerPoint lectures)

a. Choice of radionuclide and their physical properties, production etc

b. Legislations and local rules

Environmental Regulations

Storage and use of radioactive substances

Radioactive waste: storage & disposal

Arrangements & management of radiation protection

Designated areas

Monitoring of patients and staff

Duties of employees and miscellaneous

c. Facilities and design of department for radionuclide therapy

Building design, equipment, staff training and experience

Preparation/dispensing

Administration/treatment rooms

Radiation risk assessment

Operational policies/work Instructions

Waiting areas for radioactive patients

d. Radiation protection:

Dose monitoring: staff radiation

Injection

Patient handling/transport

Staffing

Comforters /carers, parental and paediatric radiation protection

Potential risks to children from radioactive parents or vice versa

Establishing patients are not pregnant or breastfeeding before treatment

Duration of avoidance of pregnancy or fathering a child after radionuclide treatment

Contingency planning

Spillage of unsealed sources: Monitoring and decontamination

Clinical complications

Death of a patient following treatment

Waste disposal

e. Dosimetry: basic principles and applications

Module 2: Radiopharmacy

(Topics to be covered in the PowerPoint lectures)

Preparation and dispensing of radiopharmaceuticals
Laboratory design
Storage areas
Protective clothing
Contamination hazards: Airborne contamination and surface contamination
Quality assurance: Radionuclide concentration, purity
Record keeping
Reporting and investigation of incidents
Maladministration's and management

Radiopharmaceuticals:

Iodine-131 (^{131}I)
Indium-111 (^{111}In)
Yttrium-90 (^{90}Y)
Lutetium-177 (^{177}Lu)
Strontium-89 (^{89}Sr)
Rhenium-186 (^{186}Re)
Rhenium-188 (^{188}Re)
Samarium-153 (^{153}Sm)
Phosphorus-32 (^{32}P)
Erbium-169 (^{169}Er)
Alpha particles

Module 3: Clinical Applications

(Topics to be covered in the PowerPoint lectures)

Oncology:

Thyroid cancer: ^{131}I

Neuroendocrine Tumours: ^{131}I MIBG, ^{90}Y -DOTATOC, ^{177}Lu -DOTATATE....

Pheochromocytoma & Paragangliomas: ^{131}I MIBG

Radioimmunotherapy for Lymphomas: ^{90}Y -Zevalin, ^{131}I -Tositumomab

Hepatocellular Cancer: ^{131}I -Lipiodol/ ^{188}Re -Lipiodol, ^{90}Y -SIR-Spheres

Palliation of Bone Metastases: ^{153}Sm , ^{188}Re -Lipiodol, alpha-particles,

Clinical presentation: Epidemiology; Clinical presentation /Signs and symptoms; Diagnosis; Classification; Staging procedures

Pathology

Radiological imaging

Radionuclide imaging: SPECT

Radionuclide imaging: PET

Management: Surgical and non-surgical

Radionuclide Therapy

Introduction

Patient selection: Indications, contraindications etc

Principle

Radiopharmaceuticals

Patient preparation

Protocol and injected activity

Post therapy advice/radiation protection

Side effects/complications

Follow up

Management of Iodine non-avid thyroid cancer

Frequently asked questions

References

Module 3: Clinical Applications

(Topics to be covered in the PowerPoint lectures)

Benign Disease:

Thyroid Disease: ^{131}I

Radiosynovectomy: (Rheumatoid arthritis, Haemophilia) ^{186}Re , ^{169}Er , ^{32}P

Clinical presentation: Epidemiology; Clinical presentation /Signs and symptoms; Diagnosis; Classification; Staging procedures

Pathology

Radiological imaging

Radionuclide imaging: SPECT

Radionuclide imaging: PET

Management: Surgical and non-surgical

Radionuclide Therapy

Introduction

Patient selection: Indications, contraindications etc

Principle

Radiopharmaceuticals

Patient preparation

Protocol and injected activity

Post therapy advice/radiation protection

Side effects/complications

Follow up

Management of Iodine non-avid thyroid cancer

Frequently asked questions

References

Module 4: MCQ: 100-150 questions

Physics/radiation protection/legislation etc

Radiopharmacy

Clinical

Module 5: oral/viva-Case based discussions

8-10 stations or case scenarios

Physics/radiation protection/legislation etc

Radiopharmacy

Clinical



10th International Conference on Radiopharmaceutical Therapy

Innsbruck, Austria, 3 – 8 May 2015

Hotel „Grauer Bär“

DAY 6: FRIDAY, 8 MAY 2015

DEPARTURE except for participants of the WARMTH Theranostics Academy

WARMTH THERANOSTICS ACADEMY (WTA)

Location: Department of Nuclear Medicine, Medical University Innsbruck

WTA DEAN: Cornelis Hoefnagel, Amsterdam, The Netherlands
WTA Director: Gopinath Gnanasegaran, London, United Kingdom

0900 – 1100 Introduction into WTA

- 0900 – 0910 [Welcome Address](#)
Irene Virgolini, Innsbruck, Austria
- 0910 – 0920 [Welcome Address](#)
Richard Baum, Bad Berka, Germany
- 0920 – 0930 [Introduction into WTA Part1](#)
Cornelis Hoefnagel, Amsterdam, The Netherlands
- 0930 – 0940 [Introduction into WTA Part2](#)
Gopinath Gnanasegaran, London, United Kingdom
- 0940 – 1000 [Practice of Nuclear Nursing at the University of Innsbruck](#)
Martin Jeller
- 1000 – 1020 [Overview of Radiopharmacy at the University of Innsbruck](#)
Clemens Decristophoro
- 1020 – 1040 [Overview of Radiotechnologist Practice at the University of Innsbruck](#)
Angelika Hutter
- 1040 – 1100 [Overview of Nuclear Therapy at the University of Innsbruck](#)
Irene Virgolini

1100 – 1300 PRACTICAL TEACHING Group 1 (8 Students)
PRACTICAL TEACHING Group 2 (8 Students)
PRACTICAL TEACHING Group 3 (8 Students)

1300 – 1400 **LUNCH**
University Hospital

1400 – 1600 PRACTICAL TEACHING Group 1 (8 Students)
PRACTICAL TEACHING Group 2 (8 Students)
PRACTICAL TEACHING Group 3 (8 Students)

Page 14 of 15

Please note that the programme is correct at time of update and is subject to change without prior notice

10th International Conference on Radiopharmaceutical Therapy

Innsbruck, Austria, 3 – 8 May 2015
Hotel „Grauer Bär“

1600 – 1800

PRACTICAL TEACHING Group 1 (8 Students)
PRACTICAL TEACHING Group 2 (8 Students)
PRACTICAL TEACHING Group 3 (8 Students)

Local WTA Board

Hospitation of the Nuclear Therapy Ward (Chair: S. Buxbau)
Radiation Protection (Chair: C. Mair)
Nuclear Nursing Practice (Chair: M. Jeller)
Psychooncology / Quality of Life (Chair: E. Gamper)

Dosimetry / Medical Physics (Chair: B. Warwitz)
Hospitation of the Thyroid Outpatient Ward (Chair: R. Moncayo)
Technologist Practice (Chair: A. Hutter)

Radiopharmacy / Radiochemistry (Chair: C. Decristoforo)
Hospitation of the PET/CT-Center (Chair: A. Kroiss)



2000 – 2200

CERTIFICATIONS
WTA Dinner

2200

END OF DAY 6



Please note that the programme is correct at time of update and is subject to change without prior notice





Society of
Nuclear Medicine
India

SOUTHERN CHAPTER 2017

AUGUST 12 & 13, 2017



AUGUST 14 - 15, 2017



WTA
WORLD
THERANOSTICS
ACADEMY

AUGUST 15 & 16, 2017

Dear Colleagues,

On behalf of the Organizing Committee, it is my great pleasure to invite you to three consecutive meetings in August 2017, hosted by the Dept of Nuclear Medicine, KMCH in Coimbatore, India.

We start off with the 23rd Annual conference of Society of Nuclear Medicine India (Southern Chapter) 2017 to be held on 12th & 13th August 2017 followed by the ISCORN session, The 2nd World Rhenium Congress (14th & 15th August 2017) and then the WARMTH Theranostic academy(WTA) meeting(15th & 16th August 2017).

The WTA sessions are on dosimetry, Advances in Radiopharmacy, Radio immuno scintigraphy and RIT (In association with Society of Radiopharmaceutical Sciences : SRS)

The meeting will be over 5 days and will include oral presentations, poster presentations, invited lectures, panel discussions and quiz competitions. The aim of the meeting will be to serve as a platform for delegates to enrich their knowledge with the recent advancements in Diagnostic & Therapeutic Nuclear Medicine. The meeting will provide an opportunity to the Clinicians, Nuclear Medicine Physicians, Scientists and the Technologists to exchange valuable ideas and foster new collaborations. There is individual registration as well as all inclusive packages available for delegates to choose depending on their time and financial suitability.

I urge all colleagues in the field of Nuclear Medicine to consider attending this meeting. I look forward to seeing you and wish you a pleasant stay in Coimbatore!

Dr. Ajit Shinto,
Dr. Kamalashwaran.
Dept of Nuclear Medicine,
KMCH.



<http://www.worldrheniumcongress.org>



World Theranostic Academy

Aug 15th - 16th 2017

- WTA and SRS sponsored Radio immuno scintigraphy and RIT session - Aug 15th post lunch session (2:30-6:30 pm)
- WTA and SRS session on Advances in Radio-pharmacy and chemistry - Aug 16th Full day
- Scientific paper presentation 3-5 pm
- Special thyroid workshop in Association with API (TamilNadu and Pondicherry chapter)



<http://www.worldrheniumcongress.org>



WTA
WORLD
THERANOSTICS
ACADEMY
SINCE 2013

AUGUST 16 - 18, 2017

The WORLD THERANOSTIC ACADEMY (WTA) is the educational arm of WARMTH and is composed of faculty, instructional staff, and post graduate students who have been recognized by their peers for sustained, demonstrated teaching excellence. The Academy works to promote, recognize, and support teaching and learning excellence in the Nuclear Medicine community. We help faculty, staff, and students across the world update their knowledge by creating an informal channel for disbursement of knowledge without geographical barriers.

- > Share and find solutions to Nuclear medicine cases and scenarios.
- > Connect with other members of the Nuclear Medicine community.
- > Discover and participate in engaging discussions.

- Nuclear nephro- urology advances (ISCORN).
- Radio immuno scintigraphy and RIT (SRS).
- Radiopharmaceuticals ; new agents & development (SRS & ICNN).
- Theranostics: prostate, NET, Skeletal (WARMTH).

KOVAI MEDICAL CENTER AND HOSPITAL

Dept. of Nuclear Medicine, PET CT and Therapy
Avinashi Road, Coimbatore - 641 014, India.
Phone: 0422 4323800 - 802, 3083800





WARMTH
WORLD ASSOCIATION
OF RADIOPHARMACEUTICAL
AND MOLECULAR THERAPY
FOUNDED 2009

www.kmchhospitals.com



AUGUST 16 - 18, 2017




The Radiouclides in Nephrourology (RIN) group was formed in 1968 after an international symposium in Liège in 1967 devoted to this subject. The purpose of the group is to provide a forum for the exchange of the developments in radionuclide techniques in nephro-urology. It is now called International Scientific Committee on Radionuclide Nephro-urology



**SOCIETY OF
Radiopharmaceutical
Sciences**

The Society of Radiopharmaceutical Sciences (SRS) is an international society providing academic and intellectual support for radiopharmaceutical science. At the heart of all nuclear imaging, radiopharmaceutical science is the design, synthesis and evaluation of compounds containing suitable radionuclides that can be used in vivo to trace (follow) a particular physiological or biochemical phenomena.



Indian College of Nuclear Medicine

The Indian College of Nuclear Medicine (ICNM) is the academic wing of the Society of Nuclear Medicine (SNM), India. The college is fully devoted in academic activities to the promotion, practice and advancement of the science of Nuclear Medicine and related subjects including Health Physics, Radiobiology, Radio Pharmacy, Radioimmunoassay, medical electronics & Instrumentation and research using radiotracers.

The "World Association of Radiopharmaceutical and Molecular Therapy" (WARMTH) extends its activities throughout the world. WARMTH is the only worldwide organization founded to promote the use of radionuclide molecular therapy, and of the relatively novel paradigm of 'Theranostics.'



The WARMTH and the Patients



Josh Mailman, USA

Chief Operational Officer of WARMTH
President of the NorCal CarcíNET Community



Bill Claxton, Singapore

Co-Founder of the Carcinoid and Neuroendocrine Tumor Society Singapore
International Neuroendocrine Cancer Alliance



The WARMTH and the IAEA

Diana Paez

Nuclear Medicine Physician
Section Head | Nuclear Medicine and Diagnostic Imaging Section
Division of Human Health | Department of Nuclear Sciences and Applications

2019 International Virtual Conference on Theranostics (iViCT) IAEA, Vienna, Austria





Addenda – Links

Patricia Bernal : Video on Ajit Padhy Memorial

<https://vimeo.com/104608011>

Remigius Orjiukwu : Nuclear Therapy Song -

<https://warmth.org/about-us>

Raihan Hussain and Fariah, Video of ICRTs 2005-2020

Link on the Website of WARMTH



The Sponsors of The WARMTH



GE Healthcare



